<SEC-DOCUMENT>0001144204-16-111023.txt : 20160701
<SEC-HEADER>0001144204-16-111023.hdr.sgml : 20160701
<ACCEPTANCE-DATETIME>20160701075044
ACCESSION NUMBER:		0001144204-16-111023
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		8
FILED AS OF DATE:		20160701
DATE AS OF CHANGE:		20160701

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AYTU BIOSCIENCE, INC
		CENTRAL INDEX KEY:			0001385818
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				470883144
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-212100
		FILM NUMBER:		161744677

	BUSINESS ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 200
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112
		BUSINESS PHONE:		(720) 437-6580

	MAIL ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 200
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AYTU BIOSCIENCE, INC.
		DATE OF NAME CHANGE:	20150609

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Rosewind CORP
		DATE OF NAME CHANGE:	20070110
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>v443120_424b3.htm
<DESCRIPTION>PROSPECTUS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Filed pursuant to Rule 424(b)(3)</B></P>

<P STYLE="margin: 0; text-align: right"><B>Registration No. 333-212100</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tpg3.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>7,604,168 Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus relates to the sale or other disposition from
time to time of up to 7,604,168 shares of our common stock, $0.0001 par value per share, issued to and issuable upon the exercise
of warrants held by the selling stockholders named in this prospectus. We are not selling any shares of common stock under this
prospectus and will not receive any of the proceeds from the sale of shares of common stock by the selling stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling stockholders may sell or otherwise dispose of the
shares of common stock covered by this prospectus in a number of different ways and at varying prices. We provide more information
about how the selling stockholders may sell or otherwise dispose of their shares of common stock in the section entitled &ldquo;Plan
of Distribution&rdquo; on page 106. The selling shareholders will pay all brokerage fees and commissions and similar expenses.
We will pay all expenses (except brokerage fees and commissions and similar expenses) relating to the registration of the shares
with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is listed on the OTCQX Market operated by OTC
Markets Group, Inc. (or OTCQX) under the ticker symbol &ldquo;AYTU.&rdquo; On June 28, 2016, the last reported sale price of
our common stock on the OTCQX was $0.39.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investing in our common stock involves a high degree of risk.
You should review carefully the risks and uncertainties described under the heading &ldquo;Risk Factors&rdquo; beginning on page
8 of this prospectus, and under similar headings in any amendments or supplements to this prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus.
Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The date of this
prospectus is June 30, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus Summary</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Offering</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Special Note Regarding Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market for Common Stock</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend Policy</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling Stockholders</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan of Distribution</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">106</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Ownership of Certain Beneficial Owners and Managment</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">108</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Capital Stock</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Matters</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">112</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Experts</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">112</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where You Can Find More Information</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">112</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should rely only on the information contained in this prospectus,
as supplemented and amended. We have not, and the selling stockholders have not, authorized anyone to provide you with information
that is different. This prospectus may only be used where it is legal to sell these securities. The information in this prospectus
may only be accurate on the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We urge you to read carefully this prospectus, as supplemented
and amended, before deciding whether to invest in any of the common stock being offered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless the context indicates otherwise, as used in this prospectus,
the terms &ldquo;Aytu,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;our company&rdquo; and &ldquo;our business&rdquo;
refer to Aytu BioScience, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We own or have rights to various U.S. federal trademark registrations
and applications, and unregistered trademarks and servicemarks, including Zertane, Vyrix, RedoxSYS, MiOXSYS, Natesto, ProstaScint
and Luoxis. All other trade names, trademarks and service marks appearing in this prospectus are the property of their respective
owners. We have assumed that the reader understands that all such terms are source-indicating. Accordingly, such terms, when first
mentioned in this prospectus, appear with the trade name, trademark or service mark notice and then throughout the remainder of
this prospectus without trade name, trademark or service mark notices for convenience only and should not be construed as being
used in a descriptive or generic sense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_001"></A>PROSPECTUS SUMMARY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This summary highlights certain information about us and
this offering contained elsewhere in this prospectus. Because it is only a summary, it does not contain all of the information
that you should consider before investing in shares of our securities and it is qualified in its entirety by, and should be read
in conjunction with, the more detailed information appearing elsewhere in this prospectus. Before you decide to invest in our securities,
you should read the entire prospectus carefully, including &ldquo;Risk Factors&rdquo; beginning on page 8, and the financial statements
and related notes included in this prospectus.&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company Overview&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a commercial-stage specialty healthcare company focused
on acquiring, developing and commercializing novel products in the field of urology. We have multiple urology-focused products
on the market, and we seek to build a portfolio of novel therapeutics that serve large medical needs in the field of urology. We
are initially concentrating on prostate cancer, urinary tract infections, male sexual dysfunction and male infertility and plan
to expand into other urological indications for which there are significant medical needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We currently market ProstaScint&reg; (capromab pendetide), the
only radioimaging agent indicated to detect prostate specific membrane antigen, or PSMA, in the assessment and staging of prostate
cancer. ProstaScint is approved by the U.S. Food and Drug Administration, or FDA, for use in both newly diagnosed, high-risk prostate
cancer patients and patients with recurrent prostate cancer. We also market Primsol&reg; (trimethoprim hydrochloride) &mdash; the
only FDA-approved trimethoprim-only oral solution for urinary tract infections. We recently acquired exclusive U.S. rights to Natesto<SUP>TM</SUP>
(testosterone), a novel formulation of testosterone delivered via a discreet, easy-to-use nasal gel, and we plan to launch Natesto
in the United States with our direct sales force in July 2016. Natesto is FDA-approved for the treatment of hypogonadism (low testosterone)
in men and is the only testosterone replacement therapy, or TRT, delivered via a nasal gel. Natesto offers multiple advantages
over currently available TRTs and competes in a $2.4 billion market. Importantly, as Natesto is delivered via the nasal mucosa
and not to the skin, there is no risk of testosterone transference to others, a known potential side effect and black box warning
associated with all other topically applied TRTs, including the market leader AndroGel&reg;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have a focused pipeline, including MiOXSYS, a novel in vitro
diagnostic device that is currently CE marked (which enables it to be sold within the European Economic Area (see &ldquo;Business
&mdash; Foreign Regulatory Approval&rdquo;)) and for which we intend to initiate a final clinical study to enable FDA clearance
in the U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our MiOXSYS<SUP>TM</SUP> system is a novel, point-of-care semen
analysis system with the potential to become a standard of care in the diagnosis and management of male infertility. Male infertility
is a prevalent and underserved condition and oxidative stress is widely implicated in its pathophysiology. MiOXSYS was developed
from our core oxidation-reduction potential research platform known as RedoxSYS&reg;.We are advancing MiOXSYS toward FDA clearance
and believe we are adequately funded to complete the required clinical study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our late-stage therapeutic candidate is Zertane<SUP>TM</SUP>,
an oral therapeutic that has been studied for the treatment of premature ejaculation, or PE. PE is the most common sexual dysfunction
for which there is not an FDA-approved treatment and affects up to 23% of men in the U.S. and major European countries. Zertane,
which has demonstrated safety and efficacy in two European pivotal studies, has the potential to be the first oral therapeutic
approved in the United States for the treatment of PE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, we are actively looking to acquire additional
urology products, including existing products we believe can offer distinct commercial advantages. Our management team&rsquo;s
prior experience has involved identifying clinical assets that can be re-launched to increase value, with a focused commercial
infrastructure specializing in urology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>ProstaScint&reg; (capromab pendetide).</I> We became a commercial
stage company by virtue of our acquisition of ProstaScint in May 2015 and are generating sales of this FDA-approved prostate cancer
imaging agent. As prostate cancer is a condition commonly diagnosed and treated by urologists, ProstaScint complements our urology-focused
product portfolio and pipeline. Prostate cancer is the most common cancer among men in the United States, with an estimated 241,000
annual cases (as of 2012). Further, more than 2,200,000 men were alive with some history of prostate cancer in 2006, and over 30,000
U.S. men die each year from the disease. The effect of prostate cancer on healthcare economics is substantial, which makes the
need for accurate disease staging critical for treatment and management strategies. The U.S. market for the diagnosis and screening
of prostate cancer is expected to total $17.4 billion by 2017, a compound annual growth rate, or CAGR, of 7.5%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Natesto<SUP>TM</SUP> (testosterone).</I> On April 22, 2016,
we entered into an agreement to acquire the exclusive U.S. rights to Natesto<SUP>TM</SUP> (testosterone) nasal gel from Acerus
Pharmaceuticals Corporation, or Acerus, which rights we will acquire effective upon the expiration of the current licensee&rsquo;s
rights, expected to occur on June 30, 2016. Natesto is a patented, FDA-approved testosterone replacement therapy, or TRT, and is
the only nasally-administered formulation of testosterone available in the United States. Natesto is a discreet, easy-to-administer
nasal gel that may be appropriate for men with active lifestyles as Natesto is small, portable, Transportation Security Administration,
or TSA-compliant, and easy to use. Importantly, Natesto is not applied directly to the patient&rsquo;s skin as other topically
applied TRTs are. Rather, it is delivered directly into the nasal mucosa via a proprietary nasal applicator. Thus, Natesto does
not carry a black box warning related to testosterone transference to a man&rsquo;s female partner or children &mdash; as other
topically (primarily gels and solutions) administered TRTs do by virtue of their delivery directly onto the skin. We intend to
launch Natesto in the U.S. in July 2016 with our direct sales force, and we expect to position Natesto as the ideal treatment solution
for men with active, busy lifestyles who suffer from hypogonadism.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Primsol&reg; (trimethoprim solution).</I> On October 5, 2015,
we purchased Primsol from FSC Laboratories, Inc. Primsol is the only FDA-approved liquid formulation of trimethoprim, an antibiotic
that is well established in current guidelines for treating uncomplicated urinary tract infections, or UTIs. This differentiated
product is appropriate for UTI patients that have difficulty swallowing tablets, such as the elderly, and particularly for patients
that experience adverse reactions to sulfamethoxazole (&ldquo;sulfa&rdquo;). It is estimated that 150 million cases of urinary
tract infection occur annually worldwide, and the annual estimated incidence is 0.5 &ndash; 0.7/persons per year. Importantly,
there are more than 1 million catheter-associated UTIs in the U.S. alone. As many of these patients are elderly and unable to swallow
pills, an oral liquid formulation represents a convenient formulation for easier administration. The acquisition of Primsol added
a second established brand to our product portfolio. We expect to benefit from and continue to grow Primsol&rsquo;s established
base of prescribers, which already includes a significant proportion of urologists despite the fact that it has not been previously
marketed to these specialists. We can thus utilize the same sales channel as ProstaScint, leading to potential commercial synergies
and product growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>MiOXSYS.</I> MiOXSYS<SUP>TM</SUP> is a rapid in vitro diagnostic
semen analysis test used in the quantitative measurement of static oxidation reduction potential, or sORP, in human semen. MiOXSYS
is a recently CE marked system and is an accurate, easy to use, and fast infertility assessment tool. It is estimated that 72.4
million couples worldwide experience infertility problems. In the United States, approximately 10% of couples are defined as infertile.
Male infertility is responsible for between 40 &ndash; 50% of all infertility cases and affects approximately 7% of all men. Male
infertility is often unexplained (idiopathic), and this idiopathic infertility is frequently associated with levels of oxidative
stress in the semen. As such, having a rapid, easy-to-use diagnostic platform to measure oxidative stress should provide a practical
way for male infertility specialists to improve semen analysis and infertility assessments without having to refer patients to
outside clinical laboratories.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Male infertility is prevalent and underserved, and oxidative
stress is widely implicated in its pathophysiology. The global male infertility market is expected to grow to over $300 million
by 2020 with a CAGR of nearly 5% from 2014 to 2020. Oxidative stress is broadly implicated in the pathophysiology of male infertility,
yet very few diagnostic tools exist to effectively measure oxidative stress levels in men. However, antioxidants are widely available
and recommended to infertile men. With the introduction of the MiOXSYS System, we believe for the first time there will be an easy
and effective diagnostic tool to assess the degree of oxidative stress, sperm motility and morphology, and potentially enable the
monitoring of patients&rsquo; responses to antioxidant therapy as a treatment regimen for infertility. The MiOXSYS System received
CE marking in Europe in January 2016 and obtained Health Canada Class II Medical Device approval in March 2016. We expect to advance
MiOXSYS into clinical trials in the United States in order to enable 510(k) clearance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the MiOXSYS system, we are continuing to develop
the global market for the RedoxSYS System across a range of applications. Specifically, we have begun initial commercializing of
the RedoxSYS System for research use through distribution partners, primarily outside the U.S. In 2014, we received ISO 13485 certification,
demonstrating our compliance with global quality standards in medical device manufacturing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The technology underpinning the RedoxSYS and MiOXSYS systems
was developed by Luoxis Diagnostics, Inc. in the two years immediately preceding the merger between Luoxis, Vyrix Pharmaceuticals,
Inc., and us (under our former name of Rosewind Corporation) in April 2015. Upon the consummation of the merger, the RedoxSYS System
and MiOXSYS System became our assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Zertane.</I> The FDA has accepted an Investigational New
Drug, or IND, application for our product candidate Zertane for the treatment of premature ejaculation. However, depending on our
success in raising additional funds, we may decide to focus our capital resources on other strategies and not pursue clinical testing
of Zertane in the U.S. If we decide not to pursue clinical testing of Zertane, we will seek strategic options to maximize the value
of Zertane, inclusive of divestiture, out-licensing, and strategic commercial collaborations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The global premature ejaculation market is expected to reach
over $12 billion in annual sales by 2017, representing a CAGR of 4.1% from 2010. According to published analyses, PE is a highly
prevalent male sexual dysfunction affecting up to 23% of men worldwide. Based on internal market research and published reports,
we believe that PE is up to 1.5-times more prevalent than erectile dysfunction, or ED. Currently, there are no FDA-approved prescription
products in the United States to treat PE, and to our knowledge, only two other prescription products have been approved elsewhere
in the world. Treatment options for PE have traditionally included antidepressant drugs prescribed &ldquo;off label,&rdquo; topical
numbing medications, and cognitive behavior therapy or counseling, all of which have had limited effectiveness in treating the
disorder. PE therefore represents an area of significant unmet medical need.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Strategy&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Key elements of our strategy include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9642;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expand the commercialization of FDA-approved ProstaScint for the staging of both newly diagnosed high-risk and recurrent prostate cancer patients. We have begun commercializing ProstaScint in the U.S. and in key markets around the world. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9642;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Launch Natesto in the U.S. for the treatment of hypogonadism with our direct sales force. We expect to launch Natesto in July 2016 and target high-prescribing TRT prescribers with a primary emphasis on urologists and male health practitioners. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9642;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expand the commercialization of FDA-approved Primsol for the treatment of uncomplicated urinary tract infections. We are re-launching Primsol to urologists in the U.S. and in key markets around the world where appropriate. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9642;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Establish MiOXSYS as a leading in vitro diagnostic device in the assessment of male infertility. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9642;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquire additional marketed products and late-stage development assets within our core urology focus that can be efficiently marketed through our growing commercial organization. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9642;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Develop a pipeline of urology therapeutics, with a focus on identifying novel products with sufficient clinical proof of concept that require modest internal R&amp;D expense. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Future Products&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We plan to augment our core in-development and commercial assets
through efficient identification of complementary therapeutics, devices, and diagnostics related to urological disorders. We intend
to seek assets that are near commercial stage or already generating revenues. Further, we intend to seek to acquire products through
asset purchases, licensing, co-development, or collaborative commercial arrangements (co-promotions, co-marketing, etc.).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our management team has extensive experience across a wide range
of business development activities and have in-licensed or acquired products from large, mid-sized, and small enterprises in the
United States and abroad. Through an assertive product and business development approach, we expect that we will build a substantial
portfolio of complementary urology products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Developments&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October 5, 2015, we entered into and closed on an asset purchase
agreement with FSC Laboratories, Inc. (the &ldquo;Seller&rdquo;). Pursuant to the agreement, we purchased assets related to the
Seller&rsquo;s product known as Primsol&reg; (trimethoprim solution), including certain intellectual property and contracts, inventory,
work in process and all marketing and sales assets and materials related solely to Primsol (together, the &ldquo;Primsol Business&rdquo;),
and assumed certain of the Seller&rsquo;s liabilities, including those related to the sale and marketing of Primsol arising after
the closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We paid $500,000 at closing for the Primsol Business and paid
an additional $142,000 of which $102,000 went to inventory and $40,000 toward the Primsol Business, for the transfer of the Primsol-related
product inventory, which we now own. As agreed, we paid $500,000 on April 1, 2016, and also agreed to pay an additional $500,000
no later than June 30, 2016, and $250,000 no later than September 30, 2016 for a total purchase price of $1,892,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The agreement also provides that for a period of one year after
the closing the Seller will not directly or indirectly sell, market, promote, advertise or distribute anywhere in the world any
urinary tract anti-infective pharmaceutical or treatment product containing trimethoprim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October 8, 2015, we and Biovest International, Inc., or Biovest,
(whose contract manufacturing business is now known as Cell Culture Company, or C3) entered into a Master Services Agreement, pursuant
to which Biovest is to provide manufacturing services to us. The agreement provides that we may engage Biovest from time to time
to provide services in accordance with mutually agreed upon project addendums and purchase orders. We expect to use the agreement
from time to time for manufacturing services, including without limitation, the manufacturing, processing, quality control testing,
release or storage of our products. The agreement provides customary terms and conditions, including those for performance of services
by Biovest in compliance with project addendums, industry standards, regulatory standards and all applicable laws. Biovest will
be responsible for obtaining and maintaining all governmental approvals, at our expense, during the term of the agreement. The
agreement has a term of four years, provided that either party may terminate the agreement or any project addendum under the agreement
on 30 days written notice of a material breach under the agreement. In addition, we may terminate the agreement or any project
addendum under the agreement upon 180 days written notice for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In conjunction with entering into the agreement, we submitted
a work order to Biovest to provide us with active pharmaceutical ingredient for ProstaScint over at least a four-year period at
a total cost of $5,000,000, of which we paid $1,000,000 upon submission of the work order, an additional $500,000 on January 4,
2016 and an additional $500,000 on April 1, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 20, 2016, each of Joshua R. Disbrow, our Chief Executive
Officer, and Jarrett T. Disbrow, our Chief Operating Officer, purchased 153,846 shares of our common stock at a price of $0.65
per share, resulting in gross proceeds to us of $200,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 10, 2016, we completed the conversion of $4,125,000
in convertible notes and $143,000 of accrued interest. The notes were issued in financings that closed in July and August 2015.
Upon the conversion, we issued an aggregate of 7,879,096 shares common stock. An aggregate of $1,050,000 of principal of convertible
notes remains outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective April 11, 2016, our Board appointed Carl C. Dockery
as our first independent director. Mr. Dockery is a financial executive with 30 years of experience as an executive in the insurance
and reinsurance industry and more recently in 2006 as the founder and president of a registered investment advisory firm, Alpha
Advisors, LLC. For more information on Mr. Dockery, see &ldquo;Management.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 22, 2016, we entered into and closed a license and
supply agreement to acquire the exclusive U.S. rights to Natesto<SUP>TM</SUP> (testosterone) nasal gel from Acerus Pharmaceuticals
Corporation, or Acerus, which rights we will acquire effective upon the expiration of the current licensee&rsquo;s rights, expected
to occur on June 30, 2016. The licensee&rsquo;s term runs for the greater of eight years or until the expiry of the latest to expire
patent including claims covering Natesto and until the entry on the market of at least one AB-rated generic product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We paid Acerus an upfront fee of $2,000,000 upon execution of
the agreement. On September 5, 2016 we will pay an additional $2,000,000 (the &ldquo;Second Upfront&rdquo;). On January 1, 2017,
we will pay an additional $4,000,000 (the &ldquo;Third Upfront&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the upfront payments, we must make the following
one-time, non-refundable payments to Acerus within 45 days of the occurrence of the following event (provided that, the maximum
aggregate amount payable under such milestone payments will be $37,500,000):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9642;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2,500,000 if net sales during any four consecutive calendar quarter period equal or exceed $25,000,000 (the &ldquo;First Milestone&rdquo;);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9642;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$5,000,000 if net sales during any four consecutive calendar quarter period equal or exceed $50,000,000;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9642;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$7,500,000 if net sales during any four consecutive calendar quarter period equal or exceed $75,000,000;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9642;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$10,000,000 if net sales during any four consecutive calendar quarter period equal or exceed $100,000,000; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9642;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$12,500,000 if net sales during any four consecutive calendar quarter period equal or exceed $125,000,000.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also purchased an aggregate of 12,245,411 shares of Acerus
common stock for Cdn.$2,534,800 (approximately US$2,000,000), with a purchase price per share of Cdn.$0.207. We cannot dispose
of these shares until August 29, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the term of the agreement, we will purchase all of our
Natesto product need from Acerus. Each month we will provide Acerus with a two-year forecast of our product needs, the first three
months of which will be noncancelable. Pursuant to the agreement, we will pay Acerus a supply price per unit of the greater of
(i) 115% of Acerus&rsquo; cost of goods sold for Natesto, not to exceed a fixed ceiling price and (ii) 10% of the net selling price
for the first year of the agreement that increases to 16% in the second year and 25% in the third year of the agreement and remains
constant after that. Upon the expiration or invalidation of the last-to-expire (or be invalidated) Acerus patent covered by the
agreement, the supply price will be reduced to an amount equal to the sum of (A) 115% of the Acerus&rsquo; cost of goods sold (but
not to exceed the fixed ceiling price) and (B) 50% of the difference between the supply price and 115% of Acerus&rsquo; cost of
goods sold (but not exceed the fixed ceiling price); provided that the supply price will not be reduced to an amount lower than
115% of Acerus&rsquo; cost of goods (but not to exceed the fixed ceiling price).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the event of any termination of the agreement prior to the
date on which the Second Upfront, Third Upfront and/or First Milestone is otherwise payable, all of those amounts will, unless
otherwise paid prior to the effective date of termination, be payable on the effective termination date. Following the termination
date, any further milestone amounts will be payable to Acerus in accordance with the agreement, even if the milestone is met after
the termination date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the event of any termination of the license agreement prior
to the date on which the Second Upfront, Third Upfront and/or First Milestone is otherwise payable, all of those amounts will,
unless otherwise paid prior to the effective date of termination, be payable on the effective termination date. Following the termination
date, any further milestone amounts will be payable to Acerus in accordance with the agreement, even if the milestone is met after
the termination date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the agreement, we and Acerus are forming a cross-functional
transition team to ensure a fully-integrated and timely transition to us from Endo. We and Acerus also will form a joint marketing
committee to oversee brand marketing and overall planning related to Natesto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will be responsible for all aspects of managing the NDA and
complying with any regulatory or other legal obligations arising in connection therewith &mdash; excluding any additional safety
or (except as set out below with respect to a twice a day study) efficacy studies. Notwithstanding the foregoing, we will, in our
capacity as the holder of the NDA for Natesto, provide all assistance and cooperation as may reasonably be required by Acerus in
connection with the conduct of such safety or efficacy studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will be responsible for directly or indirectly manufacturing
Natesto subject to our obligation to purchase Natesto from Acerus, and Acerus&rsquo;s obligation to sell Natesto to us, as set
forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We agreed to undertake the cardiovascular postmarketing requirement,
or PMR, for Natesto; however, Acerus must reimburse us for all costs of such obligation, including any PMR trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the event that Acerus decides to dispose of any intellectual
property licensed to us under the agreement in any territory in the world (other than Brazil or the countries of the European Union),
Acerus must notify us and negotiate exclusively with us for a period of 60 days for an agreement to assign, transfer or license
such intellectual property to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may terminate the agreement at any time upon six months&rsquo;
notice, provided that we must make any milestone payment to Acerus that would otherwise become due during such six month period,
and may be responsible for the Second Upfront, Third Upfront and First Milestone payments as referenced above. Either Party may
terminate the agreement for material default or breach that remains uncured or the bankruptcy or insolvency of the other party.
Acerus may terminate the agreement upon six months&rsquo; notice if it determines that the reimbursable amounts in connection with
the cardiovascular PMR obligations would no longer make the agreement economically viable for Acerus, provided that it must pay
us all reimbursable amounts outstanding prior to such termination, and also fulfill any valid purchase orders submitted by us prior
to the effective date of termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 6, 2016, we completed a public offering of 18,750,000
shares of our common stock, par value $0.0001 per share, and warrants to purchase up to an aggregate of 20,799,250 shares of our
common stock at a combined public offering price of $0.40 per share and related warrant, including 2,049,250 warrants sold pursuant
to the partial exercise of the underwriters&rsquo; over-allotment option sold at a purchase price of $0.01 per warrant. As a part
of their compensation, the underwriters were also issued five-year warrants to purchase up to 1,312,500 shares, at an exercise
price of $0.50 per share. The offering resulted in net proceeds to us of approximately $6,700,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 5, 2016, as a result of the public offering, an aggregate
of $1,050,000 of principal and $78,000 of accrued interest on our convertible notes converted into an aggregate of 3,666,698 shares
of common stock and warrants to purchase 3,666,698 shares of common stock with an exercise price of $0.50 per share. In connection
with the conversion, we issued to the placement agents for the convertible note offering warrants to purchase an aggregate of approximately
270,772 shares of our common stock at an exercise price of $0.40 per share. These warrants are exercisable for five years from
the date of issuance of the related notes in July and August 2015. The warrants have a cashless exercise feature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We were incorporated as Rosewind Corporation on August 9, 2002
in the State of Colorado.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vyrix Pharmaceuticals, Inc., or Vyrix, was incorporated under
the laws of the State of Delaware on November 18, 2013 and was wholly owned by Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), or
Ampio, immediately prior to the completion of the Merger (defined below). Vyrix was previously a carve-out of the sexual dysfunction
therapeutics business, including the late-stage men&rsquo;s health product candidates, Zertane and Zertane-ED, from Ampio, which
carve out was announced in December 2013. Luoxis Diagnostics, Inc., or Luoxis, was incorporated under the laws of the State of
Delaware on January 24, 2013 and was majority owned by Ampio immediately prior to the completion of the Merger. Luoxis was focused
on initially developing and advancing the RedoxSYS System. The MiOXSYS System was developed following the completed development
of the RedoxSYS System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 20, 2015, Rosewind formed Rosewind Merger Sub V, Inc.
and Rosewind Merger Sub L, Inc., each a wholly-owned subsidiary formed for the purpose of the Merger, and on April 16, 2015, Rosewind
Merger Sub V, Inc. merged with and into Vyrix and Rosewind Merger Sub L, Inc. merged with and into Luoxis, and Vyrix and Luoxis
became subsidiaries of Rosewind. Immediately thereafter, Vyrix and Luoxis merged with and into Rosewind with Rosewind as the surviving
corporation (herein referred to as the Merger). Concurrent with the closing of the Merger, Rosewind abandoned its pre-merger business
plans to develop a sailing school, and we now solely pursue the specialty healthcare market, focusing on urological related conditions,
including the business of Vyrix and Luoxis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 8, 2015, we (i) reincorporated as a
domestic Delaware corporation under Delaware General Corporate Law and changed our name from Rosewind Corporation to Aytu
BioScience, Inc., and (ii) effected a reverse stock split in which each common stock holder received one share of common
stock for each every 12.174 shares outstanding (herein referred to as the Reverse Stock Split). All share and per share
amounts in this prospectus have been adjusted to reflect the effect of the Reverse Stock Split. At our annual meeting of
shareholders held on May 24, 2016, our shareholders approved (1) an amendment to our Certificate of Incorporation to reduce
the number of authorized shares of common stock from 300.0 million to 100.0 million, which amendment was effective on June 1,
2016, and (2) an amendment to our Certificate of Incorporation to effect a reverse stock split at a ratio of any whole number
between 1-for-4 and 1-for-12, as determined by our Board of Directors, at any time before November 24, 2016, if and as
determined by our Board of Directors. Our Board approved a 1-for-12 reverse stock split, which was effective on June 30, 2016.
Fractional shares were rounded up resulting in outstanding shares of common stock. The effects of the reverse stock split have
not been applied to the financial or stock information in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_002"></A>THE OFFERING</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus relates to the resale by the selling stockholders
identified in this prospectus of up to 7,604,168 shares of our common stock, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&sect;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,666,698 shares of common stock issued in May 2016 upon the conversion of convertible notes; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Wingdings; font-size: 10pt">&sect;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,666,698 shares of common stock issuable upon the exercise of warrants issued in May 2016 upon the conversion of convertible notes; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Wingdings; font-size: 10pt">&sect;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">270,772 shares of common stock issuable upon the exercise of warrants issued to the placement agent for our 2015 private placement of convertible notes</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse; margin-left: 0.6in">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock offered by the selling stockholders</FONT></TD>
    <TD STYLE="width: 2%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 30%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,604,168 shares</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock outstanding before the offering <SUP>(1)</SUP></FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44,863,179 shares</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 1pt; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock to be outstanding after the offering <SUP>(2)</SUP></FONT></TD>
    <TD STYLE="padding-right: 1pt; padding-left: 1pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 1pt; padding-left: 2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;48,800,649 shares</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 1pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock OTCQX Symbol</FONT></TD>
    <TD STYLE="padding-right: 1pt; padding-left: 1pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 2pt; padding-left: 1pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AYTU</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.6in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(1)</SUP></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the number of shares outstanding as of May 31, 2016. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumes the exercise of all of the warrants for which the underlying shares are being offered by this prospectus.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Use of Proceeds </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The 3,666,698 shares currently outstanding that are being offered
for resale by the selling stockholders will be sold for the accounts of the selling stockholders named in this prospectus. As a
result, all proceeds from the sales of the 3,666,698 shares of common stock currently outstanding and offered for resale hereby
will go to the selling stockholders and we will not receive any proceeds from the resale of those shares of common stock by the
selling stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may receive up to a total of $1,941,658 in gross proceeds
if all of the warrants are exercised hereunder for cash. However, as we are unable to predict the timing or amount of potential
exercises of the warrants, we have not allocated any proceeds of such exercises to any particular purpose. Accordingly, all such
proceeds are allocated to working capital. It is possible that the warrants may expire and may never be exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">After the exercise of any of the warrants, we would not receive
any proceeds from the resale of those shares by the selling stockholders because those shares will be sold for the accounts of
the selling stockholders named in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will incur all costs associated with this registration statement
and prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dividend Policy </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have never paid dividends on our capital stock and do not
anticipate paying any dividends for the foreseeable future. See &ldquo;Dividend Policy.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_003"></A>RISK FACTORS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid"><I>Investing in our securities includes
a high degree of risk. Prior to making a decision about investing in our securities, you should consider carefully the specific
factors discussed below, together with all of the other information contained in this prospectus. If any of the following risks
actually occurs, our business, financial condition, results of operations and future prospects would likely be materially and adversely
affected. This could cause the market price of our common stock to decline and could cause you to lose all or part of your investment.</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Risks Related to Our Financial Condition
and Capital Requirements&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have limited operating history, have incurred losses,
and can give no assurance of profitability.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a commercial-stage healthcare company with a limited
operating history. Prior to implementing our commercial strategy in the fourth calendar quarter of 2015, we did not have a focus
on profitability. As a result, we have not generated material revenue to date and are not profitable, and have incurred losses
in each year since our inception. Our net loss for the years ended June 30, 2015 and 2014 was $7.7 million and $5.6 million, respectively.
Our net loss for the nine months ended March 31, 2016 was $12.9 million. We have not demonstrated the ability to be a profit-generating
enterprise to date, and without significant financing, there is substantial doubt about our ability to continue as a going concern.
We expect to incur substantial losses for the foreseeable future. Our ability to generate significant revenue is uncertain, and
we may never achieve profitability. We have a very limited operating history on which investors can evaluate our potential for
future success. Potential investors should evaluate us in light of the expenses, delays, uncertainties, and complications typically
encountered by early-stage healthcare businesses, many of which will be beyond our control. These risks include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">U.S. regulatory approval of our products and product
candidates;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">foreign regulatory approval of our products and product
candidates;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">lack of sufficient capital;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">uncertain market acceptance of our products and product
candidates;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">unanticipated problems, delays, and expense relating
to product development and implementation;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">lack of sufficient intellectual property;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">competition; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">technological changes.</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a result of our limited operating history, and the increasingly
competitive nature of the markets in which we compete, our historical financial data, which, prior to April 16, 2015, consists
of allocations of expenses from Ampio, is of limited value in anticipating future operating expenses. Our planned expense levels
will be based in part on our expectations concerning future operations, which is difficult to forecast accurately based on our
limited operating history and the recentness of the acquisition of our products ProstaScint, Primsol and Natesto. We may be unable
to adjust spending in a timely manner to compensate for any unexpected budgetary shortfall.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have not received any material revenues from the commercialization
of our current products to date and might not receive significant revenues from the commercialization of our current products or
our product candidates in the near term. Even though ProstaScint and Primsol are each an approved drug that we are marketing, we
only acquired ProstaScint in May 2015 and Primsol in October 2015 and have limited experience on which to base the revenue we could
expect to receive from their sales. We acquired Natesto in April 2016 and do not expect to launch it until July 2016 and have no
experience on which to base expected revenue from Natesto. To obtain revenues from our products and product candidates, we must
succeed, either alone or with others, in a range of challenging activities, including expanding markets for our existing products
and completing clinical trials of our product candidates, obtaining positive results from those clinical trials, achieving marketing
approval for those product candidates, manufacturing, marketing and selling our existing products and those products for which
we, or our collaborators, may obtain marketing approval, satisfying any post-marketing requirements and obtaining reimbursement
for our products from private insurance or government payors. We, and our collaborators, if any, may never succeed in these activities
and, even if we do, or one of our collaborators does, we may never generate revenues that are sufficient enough for us to achieve
profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid"><B><I>We may need to raise additional
funding, which may not be available on acceptable terms, or at all. Failure to obtain necessary capital when needed may force us
to delay, limit or terminate our product expansion and development efforts or other operations.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are expending resources to expand the market for ProstaScint
and Primsol, and to launch Natasto, none of which might be successful and all of which might take longer and be more expensive
than we anticipate. We also are currently advancing our product candidates through clinical development. Developing product candidates
is expensive, lengthy and risky, and we expect to incur research and development expenses in connection with our ongoing clinical
development activities with the MiOXSYS System. As of March 31, 2016, our cash and cash equivalents were $8.7 million available
to fund our operations offset by $2.3 million in accounts payable and the Primsol payable. In May 2016, we conducted a public offering
of our common stock and warrants from which we received net proceeds of approximately $6.7 million. Our operating plan may change
as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public
or private equity or debt financings, government or other third-party funding, marketing and distribution arrangements and other
collaborations, strategic alliances and licensing arrangements or a combination of these approaches. In any event, we will require
additional capital to continue the expansion of marketing efforts for ProstaScint, Primsol and Natesto and to obtain regulatory
approval for, and to commercialize, our product candidates. Raising funds in the current economic environment, as well our lack
of operating history, may present additional challenges. Even if we believe we have sufficient funds for our current or future
operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any additional fundraising efforts may divert our management
from their day-to-day activities, which may adversely affect our ability to expand any existing product or develop and commercialize
our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms
acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders
and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market
price of our shares to decline. The sale of additional equity or convertible securities would dilute all of our stockholders. The
incurrence of indebtedness would result in increased fixed payment obligations and we may be required to agree to certain restrictive
covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license
intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business.
We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than
otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise
agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we are unable to obtain funding on a timely basis, we may
be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization
of any product candidate or be unable to expand the market for ProstaScint, Primsol or Natesto or expand our operations generally
or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition
and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we do not obtain the capital necessary to fund our
operations, we will be unable to successfully expand the commercialization of ProstaScint, Primsol and Natesto and to develop,
obtain regulatory approval of, and commercialize, our product candidates.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The expansion of marketing and commercialization activities
for our existing products and the development of pharmaceutical products, medical diagnostics and medical devices is capital-intensive.
We anticipate we may require additional financing to continue to fund our operations. Our future capital requirements will depend
on, and could increase significantly as a result of, many factors including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">the costs, progress and timing of our efforts to expand
the marketing of ProstaScint and Primsol and to launch Natesto;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">progress in, and the costs of, our pre-clinical studies
and clinical trials and other research and development programs;</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">the costs of securing manufacturing arrangements for
commercial production;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">the scope, prioritization and number of our research
and development programs;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">the achievement of milestones or occurrence of other
developments that trigger payments under any collaboration agreements we obtain;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">the costs of establishing, expanding or contracting
for sales and marketing capabilities for any existing products and if we obtain regulatory clearances to market our product candidates;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">the extent to which we are obligated to reimburse,
or entitled to reimbursement of, clinical trial costs under future collaboration agreements, if any; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">the costs involved in filing, prosecuting, enforcing
and defending patent claims and other intellectual property rights.</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If funds are not available, we may be required to delay, reduce
the scope of, or eliminate one or more of our commercialization efforts or our technologies, research or development programs..</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We no longer can rely on funding from Ampio to support
our operations.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a part of the Merger, Ampio forgave debt incurred by Luoxis
and Vyrix in exchange for shares of our common stock and also committed an additional $10.0 million for additional shares of our
common stock, which was due in April 2016 and which Ampio paid in full in December 2015. We have no agreement with Ampio for future
funding. Consequently, we will need to support our business with revenue from our operations or from financing from third party
sources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our investment in Acerus Pharmaceuticals Corporation could
decline in value.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 28, 2016, we purchased approximately $2.0 million worth
of shares of common stock of Acerus Pharmaceutics Corporation as a condition to our licensing of Natesto. The per share purchase
price was Cdn.$0.207. Acerus common stock is traded on the Toronto Stock Exchange under the symbol &ldquo;ASP.&rdquo; On June 14,
2016, the closing price per share was Cdn.$0.11. Pursuant to Canadian securities laws, we cannot sell that stock until August
29, 2016. During the time that we own those shares, there can be no assurance that the value of that stock will not decline and
we could lose our entire investment in that stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We will incur increased costs associated with, and our
management will need to devote substantial time and effort to, compliance with public company reporting and other requirements.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a public company, we incur significant legal, accounting
and other expenses that Vyrix and Luoxis did not incur as private companies. In addition, the rules and regulations of the SEC
and any national securities exchange to which we may be subject in the future impose numerous requirements on public companies,
including requirements relating to our corporate governance practices, with which we will need to comply. Further, we will continue
to be required to, among other things, file annual, quarterly and current reports with respect to our business and operating results.
Based on currently available information and assumptions, we estimate that we will incur approximately $500,000 in expenses on
an annual basis as a direct result of the requirements of being a publicly traded company. Our management and other personnel will
need to devote substantial time to gaining expertise regarding operations as a public company and compliance with applicable laws
and regulations, and our efforts and initiatives to comply with those requirements could be expensive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid"><B><I>If we fail to establish and maintain
proper internal controls, our ability to produce accurate financial statements or comply with applicable regulations could be impaired.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our management is responsible for establishing and maintaining
adequate internal control over financial reporting. Pursuant to Section 404 of the Sarbanes-Oxley Act, our management will be required
to deliver a report that assesses the effectiveness of our internal control over financial reporting for the year ending June 30,
2016. Due to the short period of time between the Merger and June 30, 2015, we did not conduct an assessment of our internal control
over financial reporting (in accordance with the SEC&rsquo;s guidance under Section 215.02 of the SEC&rsquo;s Compliance and Disclosure
Interpretations on Regulation S-K).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we conclude that our internal control over financial reporting
is not effective, we cannot be certain as to the timing of completion of our evaluation, testing and remediation actions or their
effect on our operations because there is presently no precedent available by which to measure compliance adequacy. As a consequence,
we may not be able to complete any necessary remediation process in time to meet our deadline for compliance with Section 404 of
the Sarbanes-Oxley Act. Also, there can be no assurance that we will not identify one or more material weaknesses in our internal
controls in connection with evaluating our compliance with Section 404 of the Sarbanes-Oxley Act. The presence of material weaknesses
could result in financial statement errors which, in turn, could require us to restate our operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we are unable to conclude that we have effective internal
control over financial reporting or if our independent auditors are unwilling or unable to provide us, when required, with an attestation
report on the effectiveness of internal control over financial reporting as required by Section 404 of the Sarbanes-Oxley Act,
investors may lose confidence in our operating results, our stock price could decline and we may be subject to litigation or regulatory
enforcement actions. In addition, if we are unable to meet the requirements of Section 404 of the Sarbanes-Oxley Act, we may not
be able to obtain listing on a securities exchange such as the NYSE MKT or NASDAQ.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Risks Related to Product Development,
Regulatory Approval and Commercialization&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>ProstaScint may prove to be difficult to effectively commercialize
following our acquisition of the product from Jazz Pharmaceuticals.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Various commercial, regulatory, and manufacturing factors may
impact our ability to maintain or grow revenues following our acquisition of ProstaScint in May 2015. Specifically, we may encounter
difficulty by virtue of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">our inability to secure continuing prescribing of
ProstaScint by current or previous users of the product;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">our inability to effectively transfer and scale manufacturing
as needed to maintain an adequate commercial supply;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">our inability to gain regulatory clearance required
as the new distributor of the product in the U.S. and elsewhere where we seek to commercialize ProstaScint;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">our inability to adequately resource a manufacturing
site transfer, which, we expect, will be required in order to guarantee ongoing commercial supply;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">reimbursement and medical policy changes that may
adversely affect the pricing, profitability or commercial appeal of ProstaScint; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">our inability to effectively identify and align with
commercial partners outside the United States, or the inability of those selected partners to gain the required regulatory, reimbursement,
and other approvals needed to enable commercial success of ProstaScint.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Natesto may prove to be difficult to effectively commercialize
following our exclusive licensing of the product from Acerus Pharmaceuticals.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Various commercial, regulatory, and manufacturing factors may
impact our ability to grow revenues from our acquisition of the exclusive U.S. rights to Natesto in April 2016, which we plan to
launch in July 2016. Specifically, we may encounter difficulty by virtue of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">our inability to secure prescribing of Natesto by
current or previous prescribers of testosterone replacement therapies; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">reimbursement and medical policy changes that may
adversely affect the pricing, profitability or commercial appeal of Natesto</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid"><B><I>Primsol may prove to be difficult
to effectively commercialize following our acquisition of the product from FSC Laboratories.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Various commercial, regulatory, and manufacturing factors may
impact our ability to maintain or grow revenues following our acquisition of Primsol in October 2015. Specifically, we may encounter
difficulty by virtue of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">our inability to secure continuing prescribing of
Primsol by current or previous users of the product;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">our inability to scale manufacturing as needed to
maintain an adequate commercial supply;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">our inability to gain regulatory clearance required
as the new distributor of the product in the U.S. and elsewhere where we seek to commercialize Primsol;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">reimbursement and medical policy changes that may
adversely affect the pricing, profitability or commercial appeal of Primsol; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">our inability to effectively identify and align with
commercial partners outside the United States, or the inability of those selected partners to gain the required regulatory, reimbursement,
and other approvals needed to enable commercial success of Primsol.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have limited experience selling our current products
as they have been acquired from another company or are newly approved for sale. As a result, we may be unable to successfully commercialize
our products and product candidates.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Despite our management&rsquo;s extensive experience in launching
and managing commercial-stage healthcare companies, we have limited marketing, sales and distribution experience with our current
products. Our ability to achieve profitability depends on attracting and retaining customers for our current products, and building
brand loyalty for ProstaScint, Primsol and Natesto. To successfully perform sales, marketing, distribution and customer support
functions, we will face a number of risks, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">our ability to attract and retain skilled support
team, marketing staff and sales force necessary to increase the market for our approved products and to maintain market acceptance
for our product candidates;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the ability of our sales and marketing team to identify
and penetrate the potential customer base; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the difficulty of establishing brand recognition and
loyalty for our products.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, we may seek to enlist one or more third parties
to assist with sales, distribution and customer support globally or in certain regions of the world. If we do seek to enter into
these arrangements, we may not be successful in attracting desirable sales and distribution partners, or we may not be able to
enter into these arrangements on favorable terms, or at all. If our sales and marketing efforts, or those of any third-party sales
and distribution partners, are not successful, our currently approved products may not achieve increased market acceptance and
our product candidates may not gain market acceptance, which would materially impact our business and operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We cannot be certain that we will be able to obtain regulatory
approval for, or successfully commercialize, any of our product candidates.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may not be able to develop our current or any future product
candidates. Our product candidates will require substantial additional clinical development, testing, and regulatory approval before
we are permitted to commence commercialization. The clinical trials of our product candidates are, and the manufacturing and marketing
of our product candidates will be, subject to extensive and rigorous review and regulation by numerous government authorities in
the United States and in other countries where we intend to test and, if approved, market any product candidate. Before obtaining
regulatory approvals for the commercial sale of any product candidate, we must demonstrate through pre-clinical testing and clinical
trials that the product candidate is safe and effective for use in each target indication. This process can take many years and
may include post-marketing studies and surveillance, which will require the expenditure of substantial resources. Of the large
number of drugs in development in the U.S., only a small percentage successfully completes the FDA regulatory approval process
and is commercialized. Accordingly, even if we are able to obtain the requisite financing to continue to fund our development and
clinical programs, we cannot assure you that any of our product candidates will be successfully developed or commercialized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are not permitted to market a product in the U.S. until we
receive approval of a New Drug Application, or an NDA, for that product from the FDA, or in any foreign countries until we receive
the requisite approval from such countries. Obtaining approval of an NDA is a complex, lengthy, expensive and uncertain process,
and the FDA may delay, limit or deny approval of any product candidate for many reasons, including, among others:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">we may not be able to demonstrate that a product candidate
is safe and effective to the satisfaction of the FDA;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the results of our clinical trials may not meet the
level of statistical or clinical significance required by the FDA for marketing approval;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the FDA may disagree with the number, design, size,
conduct or implementation of our clinical trials;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the FDA may require that we conduct additional clinical
trials;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the FDA may not approve the formulation, labeling
or specifications of any product candidate;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the clinical research organizations, or CROs, that
we retain to conduct our clinical trials may take actions outside of our control that materially adversely impact our clinical
trials;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the FDA may find the data from pre-clinical studies
and clinical trials insufficient to demonstrate that a product candidate&rsquo;s clinical and other benefits outweigh its safety
risks, such as the risk of drug abuse by patients or the public in general;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the FDA may disagree with our interpretation of data
from our pre-clinical studies and clinical trials;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the FDA may not accept data generated at our clinical
trial sites;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">if an NDA, if and when submitted, is reviewed by an
advisory committee, the FDA may have difficulties scheduling an advisory committee meeting in a timely manner or the advisory
committee may recommend against approval of our application or may recommend that the FDA require, as a condition of approval,
additional pre-clinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the FDA may require development of a Risk Evaluation
and Mitigation Strategy, or REMS, as a condition of approval or post-approval;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the FDA may not approve the manufacturing processes
or facilities of third-party manufacturers with which we contract; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the FDA may change its approval policies or adopt
new regulations.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These same risks apply to applicable foreign regulatory agencies
from which we may seek approval for any of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any of these factors, many of which are beyond our control,
could jeopardize our ability to obtain regulatory approval for and successfully market any product candidate. Moreover, because
a substantial portion of our business is or may be dependent upon our product candidates, any such setback in our pursuit of initial
or additional regulatory approval would have a material adverse effect on our business and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid"><B><I>If we fail to successfully acquire
new products, we may lose market position.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acquiring new products is an important factor in our planned
sales growth, including products that already have been developed and found market acceptance. If we fail to identify existing
or emerging consumer markets and trends and to acquire new products, we will not develop a strong revenue source to help pay for
our development activities as well as possible acquisitions. This failure would delay implementation of our business plan, which
could have a negative adverse effect on our business and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we do not secure collaborations with strategic partners
to test, commercialize and manufacture product candidates, we may not be able to successfully develop products and generate meaningful
revenues.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may enter into collaborations with third parties to conduct
clinical testing, as well as to commercialize and manufacture our products and product candidates. If we are able to identify and
reach an agreement with one or more collaborators, our ability to generate revenues from these arrangements will depend on our
collaborators&rsquo; abilities to successfully perform the functions assigned to them in these arrangements. Collaboration agreements
typically call for milestone payments that depend on successful demonstration of efficacy and safety, obtaining regulatory approvals,
and clinical trial results. Collaboration revenues are not guaranteed, even when efficacy and safety are demonstrated. The current
economic environment may result in potential collaborators electing to reduce their external spending, which may prevent us from
developing our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Even if we succeed in securing collaborators, the collaborators
may fail to develop or effectively commercialize our products or product candidates. Collaborations involving our product candidates
pose a number of risks, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">collaborators may not have sufficient resources or
may decide not to devote the necessary resources due to internal constraints such as budget limitations, lack of human resources,
or a change in strategic focus;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">collaborators may believe our intellectual property
is not valid or is unenforceable or the product candidate infringes on the intellectual property rights of others;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">collaborators may dispute their responsibility to
conduct development and commercialization activities pursuant to the applicable collaboration, including the payment of related
costs or the division of any revenues;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">collaborators may decide to pursue a competitive product
developed outside of the collaboration arrangement;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">collaborators may not be able to obtain, or believe
they cannot obtain, the necessary regulatory approvals;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">collaborators may delay the development or commercialization
of our product candidates in favor of developing or commercializing their own or another party&rsquo;s product candidate; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">collaborators may decide to terminate or not to renew
the collaboration for these or other reasons.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a result, collaboration agreements may not lead to development
or commercialization of our product candidates in the most efficient manner or at all. For example, our former collaborator that
licensed Zertane conducted clinical trials which we believe demonstrated efficacy in treating PE, but the collaborator undertook
a merger that we believe altered its strategic focus and thereafter terminated the collaboration agreement. The Merger also created
a potential conflict with a principal customer of the acquired company, which sells a product to treat premature ejaculation in
certain European markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Collaboration agreements are generally terminable without cause
on short notice. Once a collaboration agreement is signed, it may not lead to commercialization of a product candidate. We also
face competition in seeking out collaborators. If we are unable to secure collaborations that achieve the collaborator&rsquo;s
objectives and meet our expectations, we may be unable to advance our products or product candidates and may not generate meaningful
revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We or our strategic partners may choose not to continue
an existing product or choose not to develop a product candidate at any time during development, which would reduce or eliminate
our potential return on investment for that product.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At any time and for any reason, we or our strategic partners
may decide to discontinue the development or commercialization of a product or product candidate. If we terminate a program in
which we have invested significant resources, we will reduce the return, or not receive any return, on our investment and we will
have missed the opportunity to have allocated those resources to potentially more productive uses. If one of our strategic partners
terminates a program, we will not receive any future milestone payments or royalties relating to that program under our agreement
with that party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid"><B><I>Our pre-commercial product candidates
are expected to undergo clinical trials that are time-consuming and expensive, the outcomes of which are unpredictable, and for
which there is a high risk of failure. If clinical trials of our product candidates fail to satisfactorily demonstrate safety and
efficacy to the FDA and other regulators, we or our collaborators may incur additional costs or experience delays in completing,
or ultimately be unable to complete, the development and commercialization of these product candidates.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pre-clinical testing and clinical trials are long, expensive
and unpredictable processes that can be subject to extensive delays. We cannot guarantee that any clinical studies will be conducted
as planned or completed on schedule, if at all. It may take several years to complete the pre-clinical testing and clinical development
necessary to commercialize a drug or biologic, and delays or failure can occur at any stage. Interim results of clinical trials
do not necessarily predict final results, and success in pre-clinical testing and early clinical trials does not ensure that later
clinical trials will be successful. A number of companies in the pharmaceutical and biotechnology industries have suffered significant
setbacks in advanced clinical trials even after promising results in earlier trials and we cannot be certain that we will not face
similar setbacks. The design of a clinical trial can determine whether its results will support approval of a product and flaws
in the design of a clinical trial may not become apparent until the clinical trial is well advanced. An unfavorable outcome in
one or more trials would be a major set-back for that product candidate and for us. Due to our limited financial resources, an
unfavorable outcome in one or more trials may require us to delay, reduce the scope of, or eliminate one or more product development
programs, which could have a material adverse effect on our business, prospects and financial condition and on the value of our
common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with clinical testing and trials, we face a number
of risks, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">a product candidate is ineffective, inferior to existing
approved medicines, unacceptably toxic, or has unacceptable side effects;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">patients may die or suffer other adverse effects for
reasons that may or may not be related to the product candidate being tested;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the results may not confirm the positive results of
earlier testing or trials; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the results may not meet the level of statistical
significance required by the FDA or other regulatory agencies to establish the safety and efficacy of the product candidate.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we do not successfully complete pre-clinical and clinical
development, we will be unable to market and sell products derived from our product candidates and generate revenues. Even if we
do successfully complete clinical trials, those results are not necessarily predictive of results of additional trials that may
be needed before an NDA may be submitted to the FDA. Although there are a large number of drugs and biologics in development in
the United States and other countries, only a small percentage result in the submission of an NDA to the FDA, even fewer are approved
for commercialization, and only a small number achieve widespread physician and consumer acceptance following regulatory approval.
If our clinical trials are substantially delayed or fail to prove the safety and effectiveness of our product candidates in development,
we may not receive regulatory approval of any of these product candidates and our business, prospects and financial condition will
be materially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Delays, suspensions and terminations in our clinical trials
could result in increased costs to us and delay or prevent our ability to generate revenues.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Human clinical trials are very expensive, time-consuming, and
difficult to design, implement and complete. We currently expect clinical trials of our therapeutic product candidates could take
up to 24 months to complete, but the completion of trials for these candidates may be delayed for a variety of reasons, including
delays in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">demonstrating sufficient safety and efficacy to obtain
regulatory approval to commence a clinical trial;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">reaching agreement on acceptable terms with prospective
CROs and clinical trial sites;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">validating test methods to support quality testing
of the drug substance and drug product;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">obtaining sufficient quantities of the drug substance
or device ports;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">manufacturing sufficient quantities of a product candidate;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">obtaining approval of an IND from the FDA;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">obtaining institutional review board approval to conduct
a clinical trial at a prospective clinical trial site;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">determining dosing and clinical design and making
related adjustments; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">patient enrollment, which is a function of many factors,
including the size of the patient population, the nature of the protocol, the proximity of patients to clinical trial sites, the
availability of effective treatments for the relevant disease and the eligibility criteria for the clinical trial.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The commencement and completion of clinical trials for our product
candidates may be delayed, suspended or terminated due to a number of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">lack of effectiveness of product candidates during
clinical trials;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">adverse events, safety issues or side effects relating
to the product candidates or their formulation or design;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">inability to raise additional capital in sufficient
amounts to continue clinical trials or development programs, which are very expensive;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the need to sequence clinical trials as opposed to
conducting them concomitantly in order to conserve resources;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">our inability to enter into collaborations relating
to the development and commercialization of our product candidates;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">failure by us or our collaborators to conduct clinical
trials in accordance with regulatory requirements;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">our inability or the inability of our collaborators
to manufacture or obtain from third parties materials sufficient for use in pre-clinical studies and clinical trials;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">governmental or regulatory delays and changes in regulatory
requirements, policy and guidelines, including mandated changes in the scope or design of clinical trials or requests for supplemental
information with respect to clinical trial results;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">failure of our collaborators to advance our product
candidates through clinical development;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">delays in patient enrollment, variability in the number
and types of patients available for clinical trials, and lower-than anticipated retention rates for patients in clinical trials;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">difficulty in patient monitoring and data collection
due to failure of patients to maintain contact after treatment;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">a regional disturbance where we or our collaborative
partners are enrolling patients in our clinical trials, such as a pandemic, terrorist activities or war, or a natural disaster;
and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">varying interpretations of our data, and regulatory
commitments and requirements by the FDA and similar foreign regulatory agencies.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid">Many of these factors may also ultimately
lead to denial of an NDA for a product candidate. If we experience delay, suspensions or terminations in a clinical trial, the
commercial prospects for the related product candidate will be harmed, and our ability to generate product revenues will be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, we may encounter delays or product candidate rejections
based on new governmental regulations, future legislative or administrative actions, or changes in FDA policy or interpretation
during the period of product development. If we obtain required regulatory approvals, such approvals may later be withdrawn. Delays
or failures in obtaining regulatory approvals may result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">varying interpretations of data and commitments by
the FDA and similar foreign regulatory agencies; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">diminishment of any competitive advantages that such
product candidates may have or attain.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Furthermore, if we fail to comply with applicable FDA and other
regulatory requirements at any stage during this regulatory process, we may encounter or be subject to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">diminishment of any competitive advantages that such
product candidates may have or attain;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">delays or termination in clinical trials or commercialization;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">refusal by the FDA or similar foreign regulatory agencies
to review pending applications or supplements to approved applications;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">product recalls or seizures;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">suspension of manufacturing;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">withdrawals of previously approved marketing applications;
and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">fines, civil penalties, and criminal prosecutions.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The medical device regulatory clearance or approval process
is expensive, time consuming and uncertain, and the failure to obtain and maintain required clearances or approvals could prevent
us from broadly commercializing the MiOXSYS System for clinical use.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The MiOXSYS System is subject to 510(k) clearance by the FDA
prior to its marketing for commercial use in the United States, and to regulatory approvals beyond CE Marking required by certain
foreign governmental entities prior to its marketing outside the United States. In addition, any changes or modifications to a
device that has received regulatory clearance or approval that could significantly affect its safety or effectiveness, or would
constitute a major change in its intended use, may require the submission of a new application for 510(k) clearance, pre-market
approval, or foreign regulatory approvals. The 510(k) clearance and pre-market approval processes, as well as the process of obtaining
foreign approvals, can be expensive, time consuming and uncertain. It generally takes from four to twelve months from submission
to obtain 510(k) clearance, and from one to three years from submission to obtain pre-market approval; however, it may take longer,
and 510(k) clearance or pre-market approval may never be obtained. We have limited experience in filing FDA applications for 510(k)
clearance and pre-market approval. In addition, we are required to continue to comply with applicable FDA and other regulatory
requirements even after obtaining clearance or approval. There can be no assurance that we will obtain or maintain any required
clearance or approval on a timely basis, or at all. Any failure to obtain or any material delay in obtaining FDA clearance or any
failure to maintain compliance with FDA regulatory requirements could harm our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid"><B><I>The approval process for pharmaceutical
and medical device products outside the United States varies among countries and may limit our ability to develop, manufacture
and sell our products internationally. Failure to obtain marketing approval in international jurisdictions would prevent our product
candidates from being marketed abroad.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In order to market and sell our products in the European Union
and many other jurisdictions, we, and our collaborators, must obtain separate marketing approvals and comply with numerous and
varying regulatory requirements. The approval procedure varies among countries and may involve additional testing. We may conduct
clinical trials for, and seek regulatory approval to market, our product candidates in countries other than the United States.
Depending on the results of clinical trials and the process for obtaining regulatory approvals in other countries, we may decide
to first seek regulatory approvals of a product candidate in countries other than the United States, or we may simultaneously seek
regulatory approvals in the United States and other countries. If we or our collaborators seek marketing approval for a product
candidate outside the United States, we will be subject to the regulatory requirements of health authorities in each country in
which we seek approval. With respect to marketing authorizations in Europe, we will be required to submit a European Marketing
Authorization Application, or MAA, to the European Medicines Agency, or EMA, which conducts a validation and scientific approval
process in evaluating a product for safety and efficacy. The approval procedure varies among regions and countries and may involve
additional testing, and the time required to obtain approval may differ from that required to obtain FDA approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Obtaining regulatory approvals from health authorities in countries
outside the United States is likely to subject us to all of the risks associated with obtaining FDA approval described above. In
addition, marketing approval by the FDA does not ensure approval by the health authorities of any other country, and approval by
foreign health authorities does not ensure marketing approval by the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We or our collaborators intend to seek FDA approval for
some of our product candidates using an expedited process established by the FDA. If we, or our collaborators, are unable to secure
clearances to use expedited development pathways from the FDA for certain of our drug product candidates, we, or they, may be required
to conduct additional pre-clinical studies or clinical trials beyond those that we, or they, contemplate, which could increase
the expense of obtaining, and delay the receipt of, necessary marketing approvals and of any product revenues.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Assuming successful completion of clinical trials, we expect
to submit NDAs to the FDA at various times in the future under Section 505(b)(2) of the Food, Drug and Cosmetic Act, as amended,
or the FDCA. NDAs submitted under this section are eligible to receive FDA approval by relying in part on the FDA&rsquo;s findings
of safety and efficacy for a previously approved drug. The FDA&rsquo;s 1999 guidance on Section 505(b)(2) applications states that
new indications for a previously approved drug, a new combination product, a modified active ingredient, or changes in dosage form,
strength, formulation, and route of administration of a previously approved product are encompassed within the Section 505(b)(2)
NDA process. Relying on Section 505(b)(2) is advantageous because we or our collaborators may not be required (i) to perform the
full range of safety and efficacy trials that is otherwise required to secure approval of a new drug, and (ii) obtain a &ldquo;right
of reference&rdquo; from the applicant that obtained approval of the previously approved drug. However, a Section 505(b)(2) application
must support the proposed change of the previously approved drug by including necessary and adequate information, as determined
by the FDA, and the FDA may still require us to perform a portion or the full range of safety and efficacy trials. There can be
no assurance that we would be successful under any Section 505(b)(2) application. We specifically intended to do this for Zertane
and any future collaborator could as well.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Even if we, or our collaborators, obtain marketing approvals
for our product candidates, the terms of approvals and ongoing regulation of our products may limit how we or they market our products,
which could materially impair our ability to generate revenue.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Even if we receive regulatory approval for a product candidate,
this approval may carry conditions that limit the market for the product or put the product at a competitive disadvantage relative
to alternative therapies. For instance, a regulatory approval may limit the indicated uses for which we can market a product or
the patient population that may utilize the product, or may be required to carry a warning in its labeling and on its packaging.
Products with boxed warnings are subject to more restrictive advertising regulations than products without such warnings. These
restrictions could make it more difficult to market any product candidate effectively. Accordingly, assuming we, or our collaborators,
receive marketing approval for one or more of our product candidates, we, and our collaborators expect to continue to expend time,
money and effort in all areas of regulatory compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid"><B><I>Any of our products and product
candidates for which we, or our collaborators, obtain marketing approval in the future could be subject to post-marketing restrictions
or withdrawal from the market and we, and our collaborators, may be subject to substantial penalties if we, or they, fail to comply
with regulatory requirements or if we, or they, experience unanticipated problems with our products following approval.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any of our approved products and product candidates for which
we, or our collaborators, obtain marketing approval, as well as the manufacturing processes, post-approval studies and measures,
labeling, advertising and promotional activities for such products, among other things, are or will be subject to continual requirements
of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing
information and reports, registration and listing requirements, requirements relating to manufacturing, quality control, quality
assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians
and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on
the indicated uses for which the product may be marketed or to the conditions of approval, including the FDA requirement to implement
a REMS to ensure that the benefits of a drug or biological product outweigh its risks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The FDA may also impose requirements for costly post-marketing
studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA and other agencies, including
the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they
are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved
labeling. The FDA imposes stringent restrictions on manufacturers&rsquo; communications regarding off-label use and if we, or our
collaborators, do not market any of our product candidates for which we, or they, receive marketing approval for only their approved
indications, we, or they, may be subject to warnings or enforcement action for off-label marketing. Violation of the FDCA and other
statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations
or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we do not achieve our projected development and commercialization
goals in the timeframes we announce and expect, the commercialization of our product candidates may be delayed, and our business
will be harmed.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We sometimes estimate for planning purposes the timing of the
accomplishment of various scientific, clinical, regulatory and other product development objectives. These milestones may include
our expectations regarding the commencement or completion of scientific studies and clinical trials, the submission of regulatory
filings, or commercialization objectives. From time to time, we may publicly announce the expected timing of some of these milestones,
such as the initiation or completion of an ongoing clinical trial, the initiation of other clinical programs, receipt of marketing
approval, or a commercial launch of a product. The achievement of many of these milestones may be outside of our control. All of
such milestones are based on a variety of assumptions which may cause the timing of achievement of the milestones to vary considerably
from our estimates, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">our available capital resources or capital constraints
we experience;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the rate of progress, costs and results of our clinical
trials and research and development activities, including the extent of scheduling conflicts with participating clinicians and
collaborators, and our ability to identify and enroll patients who meet clinical trial eligibility criteria;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">our receipt of approvals from the FDA and other regulatory
agencies and the timing thereof;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">other actions, decisions or rules issued by regulators;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">our ability to access sufficient, reliable and affordable
supplies of compounds used in the manufacture of our product candidates;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the efforts of our collaborators with respect to the
commercialization of our products; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the securing of, costs related to, and timing issues
associated with, product manufacturing as well as sales and marketing activities.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we fail to achieve announced milestones in the timeframes
we announce and expect, the commercialization of our product candidates may be delayed and our business, prospects and results
of operations may be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid"><B><I>We rely on third parties to conduct
our clinical trials and perform data collection and analysis, which may result in costs and delays that prevent us from successfully
commercializing product candidates.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We rely, and will rely in the future, on medical institutions,
clinical investigators, contract research organizations, contract laboratories, and collaborators to perform data collection and
analysis and others to carry out our clinical trials. Our development activities or clinical trials conducted in reliance on third
parties may be delayed, suspended, or terminated if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the third parties do not successfully carry out their
contractual duties or fail to meet regulatory obligations or expected deadlines;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">we replace a third party; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the quality or accuracy of the data obtained by third
parties is compromised due to their failure to adhere to clinical protocols, regulatory requirements, or for other reasons.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Third party performance failures may increase our development
costs, delay our ability to obtain regulatory approval, and delay or prevent the commercialization of our product candidates. While
we believe that there are numerous alternative sources to provide these services, in the event that we seek such alternative sources,
we may not be able to enter into replacement arrangements without incurring delays or additional costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, for Zertane, we are using, and relying on, single
suppliers and single manufacturers for drug supply for our planned Phase 3 clinical trials and our commercial supply. Although
there are potential alternative suppliers and manufacturers for Zertane if need be, we have not qualified these vendors to date.
If we or a collaborator were required to change vendors, it could result in a failure to meet regulatory requirements or projected
timelines and necessary quality standards for successful manufacturing of the various required lots of material for our development
and commercialization efforts, any of which could have an adverse effect on any business, prospects and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Even if collaborators with which we contract in the future
successfully complete clinical trials of our product candidates, those product candidates may not be commercialized successfully
for other reasons.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Even if we contract with collaborators that successfully complete
clinical trials for one or more of our product candidates, those candidates may not be commercialized for other reasons, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">failure to receive regulatory clearances required
to market them as drugs;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">being subject to proprietary rights held by others;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">being difficult or expensive to manufacture on a commercial
scale;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">having adverse side effects that make their use less
desirable; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">failing to compete effectively with products or treatments
commercialized by competitors.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Any third-party manufacturers we engage are subject to
various governmental regulations, and we may incur significant expenses to comply with, and experience delays in, our product commercialization
as a result of these regulations.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The manufacturing processes and facilities of third-party manufacturers
we have engaged are for our current approved products are, and any future third-party manufacturer will be, required to comply
with the federal Quality System Regulation, or QSR, which covers procedures and documentation of the design, testing, production,
control, quality assurance, labeling, packaging, sterilization, storage and shipping of devices. The FDA enforces the QSR through
periodic unannounced inspections of manufacturing facilities. Any inspection by the FDA could lead to additional compliance requests
that could cause delays in our product commercialization. Failure to comply with applicable FDA requirements, or later discovery
of previously unknown problems with the manufacturing processes and facilities of third-party manufacturers we engage, including
the failure to take satisfactory corrective actions in response to an adverse QSR inspection, can result in, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">administrative or judicially imposed sanctions;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">injunctions or the imposition of civil penalties;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">recall or seizure of the product in question;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">total or partial suspension of production or distribution;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the FDA&rsquo;s refusal to grant pending future clearance
or pre-market approval;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">withdrawal or suspension of marketing clearances or
approvals;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">clinical holds;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">warning letters;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">refusal to permit the export of the product in question;
and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">criminal prosecution.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any of these actions, in combination or alone, could prevent
us from marketing, distributing or selling our products, and would likely harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, a product defect or regulatory violation could
lead to a government-mandated or voluntary recall by us. We believe the FDA would request that we initiate a voluntary recall if
a product was defective or presented a risk of injury or gross deception. Regulatory agencies in other countries have similar authority
to recall drugs or devices because of material deficiencies or defects in design or manufacture that could endanger health. Any
recall would divert our management attention and financial resources, expose us to product liability or other claims, and harm
our reputation with customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We face substantial competition from companies with considerably
more resources and experience than we have, which may result in others discovering, developing, receiving approval for, or commercializing
products before or more successfully than us.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We compete with companies that design, manufacture and market
already-existing and new urology products. We anticipate that we will face increased competition in the future as new companies
enter the market with new technologies and/or our competitors improve their current products. One or more of our competitors may
offer technology superior to ours and render our technology obsolete or uneconomical. Most of our current competitors, as well
as many of our potential competitors, have greater name recognition, more substantial intellectual property portfolios, longer
operating histories, significantly greater resources to invest in new technologies, more substantial experience in product marketing
and new product development, greater regulatory expertise, more extensive manufacturing capabilities and the distribution channels
to deliver products to customers. If we are not able to compete successfully, we may not generate sufficient revenue to become
profitable. Our ability to compete successfully will depend largely on our ability to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">expand the market for our approved products, especially
ProstaScint, Primsol and Natesto;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">successfully commercialize our product candidates
alone or with commercial partners;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">discover and develop product candidates that are superior
to other products in the market;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">obtain required regulatory approvals;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">attract and retain qualified personnel; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">obtain patent and/or other proprietary protection
for our product candidates.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid">Established pharmaceutical companies
devote significant financial resources to discovering, developing or licensing novel compounds that could make our products and
product candidates obsolete. Our competitors may obtain patent protection, receive FDA approval, and commercialize medicines before
us. Other companies are or may become engaged in the discovery of compounds that may compete with the product candidates we are
developing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the MiOXSYS System and ProstaScint, we compete with companies
that design, manufacture and market already existing and new in-vitro diagnostics and diagnostic imaging systems and radio-imaging
agents for cancer detection. Additionally, with respect to Primsol, we compete with numerous companies who produce antimicrobial
treatments for various pathogens inclusive of products containing trimethoprim as contained in Primsol.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Natesto competes in a large, growing market. The U.S. prescription
testosterone market is comprised primarily of topically applied treatments in the form of gels, solutions, and patches. Testopel&reg;
and Aveed&reg;, injectable products typically implanted directly under the skin by a physician, are also FDA-approved. AndroGel
is the market-leading TRT and is marketed by AbbVie.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There are any number of antibiotics available on the market
that could compete with Primsol. Even though Primsol is the only FDA-approved liquid formulation of trimethoprim, an antibiotic
that is well established in current guidelines for treating UTIs, we may not be able to effectively compete with these existing
antibiotics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">While no oral medication has been approved by the FDA for PE,
Priligy (dapoxetine) has been approved in some countries. Many commonly prescribed oral medications may delay orgasm and be prescribed
alone or in combination with other treatments. These medications include antidepressants, treatments for erectile dysfunction and
tramadol for the treatment of pain. We also are aware of topical products which are over-the-counter, or OTC, monograph products
for premature ejaculation which include brands such as Promescent (Absorption Pharmaceuticals), a topical spray approved by the
FDA in 2013, EjectDelay (Innovus Pharma) and PreBoost (Aspen Park Pharmaceuticals), all of which would compete with Zertane.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We anticipate that we will face increased competition in the
future as new companies enter the market with new technologies and our competitors improve their current products. One or more
of our competitors may offer technology superior to ours and render our technology obsolete or uneconomical. Most of our current
competitors, as well as many of our potential competitors, have greater name recognition, more substantial intellectual property
portfolios, longer operating histories, significantly greater resources to invest in new technologies, more substantial experience
in new product development, greater regulatory expertise, more extensive manufacturing capabilities and the distribution channels
to deliver products to customers. If we are not able to compete successfully, we may not generate sufficient revenue to become
profitable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any new product we develop or commercialize that competes with
a currently-approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and/or safety in order
to address price competition and be commercially successful. If we are not able to compete effectively against our current and
future competitors, our business will not grow and our financial condition and operations will suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Government restrictions on pricing and reimbursement,
as well as other healthcare payor cost-containment initiatives, may negatively impact our ability to generate revenues.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The continuing efforts of the government, insurance companies,
managed care organizations and other payors of health care costs to contain or reduce costs of health care may adversely affect
one or more of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">our or our collaborators&rsquo; ability to set a price
we believe is fair for our approved products;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">our ability to generate revenue from our approved
products and achieve profitability; and</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the availability of capital.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid">The 2010 enactments of the Patient
Protection and Affordable Care Act, or PPACA, and the Health Care and Education Reconciliation Act, or the Health Care Reconciliation
Act, are expected to significantly impact the provision of, and payment for, health care in the United States. Various provisions
of these laws have only recently taken effect or have yet to take effect, and are designed to expand Medicaid eligibility, subsidize
insurance premiums, provide incentives for businesses to provide health care benefits, prohibit denials of coverage due to pre-existing
conditions, establish health insurance exchanges, and provide additional support for medical research. Amendments to the PPACA
and/or the Health Care Reconciliation Act, as well as new legislative proposals to reform healthcare and government insurance programs,
along with the trend toward managed healthcare in the United States, could influence the purchase of medicines and medical devices
and reduce demand and prices for our products and product candidates, if approved. This could harm our or our collaborators&rsquo;
ability to market any approved products and generate revenues. As we expect to receive significant revenues from reimbursement
of our ProstaScint, Natesto and Primsol products by commercial third-party payors and government payors, cost containment measures
that health care payors and providers are instituting and the effect of further health care reform could significantly reduce potential
revenues from the sale of any of our products and product candidates approved in the future, and could cause an increase in our
compliance, manufacturing, or other operating expenses. In addition, in certain foreign markets, the pricing of prescription drugs
and devices is subject to government control and reimbursement may in some cases be unavailable. We believe that pricing pressures
at the federal and state level, as well as internationally, will continue and may increase, which may make it difficult for us
to sell any approved product at a price acceptable to us or any of our future collaborators.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, in some foreign countries, the proposed pricing
for a drug or medical device must be approved before it may be lawfully marketed. The requirements governing pricing vary widely
from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal
products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products
for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct
or indirect controls on the profitability of the company placing the medicinal product on the market. A member state may require
that physicians prescribe the generic version of a drug instead of our approved branded product. There can be no assurance that
any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement
and pricing arrangements for any of our products or product candidates. Historically, pharmaceutical products launched in the European
Union do not follow price structures of the United States and generally tend to have significantly lower prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our financial results will depend on the acceptance among
hospitals, third-party payors and the medical community of our products and product candidates.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our future success depends on the acceptance by our target customers,
third-party payors and the medical community that our products and product candidates are reliable, safe and cost-effective. Many
factors may affect the market acceptance and commercial success of our products and product candidates, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">our ability to convince our potential customers of
the advantages and economic value our products and product candidates over existing technologies and products;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the relative convenience and ease of our products
and product candidates over existing technologies and products;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the introduction of new technologies and competing
products that may make our products and product candidates less attractive for our target customers;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">our success in training medical personnel on the proper
use of our products and product candidates;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the willingness of third-party payors to reimburse
our target customers that adopt our products and product candidates;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the acceptance in the medical community of our products
and product candidates;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the extent and success of our marketing and sales
efforts; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">general economic conditions.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid"><B><I>If third-party payors do not
reimburse our customers for the products we sell or if reimbursement levels are set too low for us to sell one or more of our products
at a profit, our ability to sell those products and our results of operations will be harmed.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">While ProstaScint, Natesto and Primsol are already FDA-approved
and, in the case of ProstaScint and Primsol, generating revenues in the U.S., the products may not receive, or continue to receive,
physician, hospital, or laboratory acceptance, or they may not maintain adequate reimbursement from third party payors. Additionally,
even if one of our product candidates is approved and reaches the market, the product may not achieve physician, hospital, or laboratory
acceptance, or it may not obtain adequate reimbursement from third party payors. We expect to sell our Primsol products and possibly
other product candidates to target customers substantially all of whom receive reimbursement for the health care services they
provide to their patients from third-party payors, such as Medicare, Medicaid, other domestic and foreign government programs,
private insurance plans and managed care programs. Reimbursement decisions by particular third-party payors depend upon a number
of factors, including each third-party payor&rsquo;s determination that use of a product is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">a covered benefit under its health plan;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">appropriate and medically necessary for the specific
indication;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">cost effective; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">neither experimental nor investigational.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Third-party payors may deny reimbursement for covered
products if they determine that a medical product was not used in accordance with cost-effective diagnosis methods, as
determined by the third-party payor, or was used for an unapproved indication. Third-party payors also may refuse to
reimburse for procedures and devices deemed to be experimental. Obtaining coverage and reimbursement approval for a product
from each government or third-party payor is a time consuming and costly process that could require us to provide supporting
scientific, clinical and cost-effectiveness data for the use of our potential product to each government or third-party
payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. In
addition, eligibility for coverage does not imply that any product will be covered and reimbursed in all cases or reimbursed
at a rate that allows our potential customers to make a profit or even cover their costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Third-party payors are increasingly attempting to contain health
care costs by limiting both coverage and the level of reimbursement for medical products and services. Levels of reimbursement
may decrease in the future, and future legislation, regulation or reimbursement policies of third-party payors may adversely affect
the demand for and reimbursement available for any product or product candidate, which in turn, could negatively impact pricing.
If our customers are not adequately reimbursed for our products, they may reduce or discontinue purchases of our products, which
would result in a significant shortfall in achieving revenue expectations and negatively impact our business, prospects and financial
condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Manufacturing risks and inefficiencies may adversely affect
our ability to produce our products.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As part of the acquisition of ProstaScint from Jazz Pharmaceuticals,
we terminated the relationship with the third-party manufacturer of ProstaScint. We have initiated the process of transferring
the manufacturing to Biovest International, which we believe is a qualified manufacturer and with whom we have entered into a Master
Services Agreement. In the event that this manufacturing transfer does not occur by the time our current inventory expires, we
may not be able to supply sufficient quantities and on a timely basis, while maintaining product quality, acceptable manufacturing
costs and complying with regulatory requirements, such as quality system regulations. In addition, we expect to engage third parties
to manufacture components of the MiOXSYS and RedoxSYS systems. We have an agreement for supplies of Natesto with Acerus, from whom
we license Natesto, and have entered into a supply agreement for Primsol with the same manufacturer used by FSC Laboratories, from
whom we purchased Primsol. For any future product, we expect to use third-party manufacturers because we do not have our own manufacturing
capabilities. In determining the required quantities of any product and the manufacturing schedule, we must make significant judgments
and estimates based on inventory levels, current market trends and other related factors. Because of the inherent nature of estimates
and our limited experience in marketing our current products, there could be significant differences between our estimates and
the actual amounts of product we require. If we do not effectively maintain our supply agreements for Natesto and Primsol, we will
face difficulty finding replacement suppliers, which could harm sales of those products. If we do not effectively transition sites
with our manufacturing and development partners to enable to production scale of ProstaScint, or if we do not secure collaborations
with manufacturing and development partners to enable production to scale of the MiOXSYS system, we may not be successful in selling
ProstaScint or in commercializing the MiOXSYS system in the event we receive regulatory approval of the MiOXSYS System. If we fail
in similar endeavors for future products, we may not be successful in establishing or continuing the commercialization of our products
and product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid">Reliance on third-party manufacturers
entails risks to which we would not be subject if we manufactured these components ourselves, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">reliance on third parties for regulatory compliance
and quality assurance;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">possible breaches of manufacturing agreements by the
third parties because of factors beyond our control;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">possible regulatory violations or manufacturing problems
experienced by our suppliers; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">possible termination or non-renewal of agreements
by third parties, based on their own business priorities, at times that are costly or inconvenient for us.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Further, if we are unable to secure the needed financing to
fund our internal operations, we may not have adequate resources required to effectively and rapidly transition our site of ProstaScint
manufacturing. We may not be able to meet the demand for the RedoxSYS System if one or more of any third-party manufacturers is
unable to supply us with the necessary components that meet our specifications. It may be difficult to find alternate suppliers
for any of our products or product candidates in a timely manner and on terms acceptable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Any third-party manufacturers we engage are subject to
various governmental regulations, and we may incur significant expenses to comply with, and experience delays in, our product commercialization
as a result of these regulations.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The manufacturing processes and facilities of third-party manufacturers
we engage are required to comply with the federal Quality System Regulation, or QSR, which covers procedures and documentation
of the design, testing, production, control, quality assurance, labeling, packaging, sterilization, storage and shipping of devices.
The FDA enforces the QSR through periodic unannounced inspections of manufacturing facilities. Any inspection by the FDA could
lead to additional compliance requests that could cause delays in our product commercialization. Failure to comply with applicable
FDA requirements, or later discovery of previously unknown problems with the manufacturing processes and facilities of third-party
manufacturers we engage, including the failure to take satisfactory corrective actions in response to an adverse QSR inspection,
can result in, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">administrative or judicially imposed sanctions;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">injunctions or the imposition of civil penalties;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">recall or seizure of the product in question;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">total or partial suspension of production or distribution;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the FDA&rsquo;s refusal to grant pending future clearance
or pre-market approval;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">withdrawal or suspension of marketing clearances or
approvals;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">clinical holds;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">warning letters;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">refusal to permit the export of the product in question;
and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">criminal prosecution.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid">Any of these actions, in combination
or alone, could prevent us from marketing, distributing or selling our products, and would likely harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, a product defect or regulatory violation could
lead to a government-mandated or voluntary recall by us. We believe the FDA would request that we initiate a voluntary recall if
a product was defective or presented a risk of injury or gross deception. Regulatory agencies in other countries have similar authority
to recall drugs or devices because of material deficiencies or defects in design or manufacture that could endanger health. Any
recall would divert our management attention and financial resources, expose us to product liability or other claims, and harm
our reputation with customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our future growth depends, in part, on our ability to
penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our future profitability will depend, in part, on our ability
to commercialize our products and product candidates in foreign markets for which we intend to primarily rely on collaboration
with third parties. If we commercialize our products or product candidates in foreign markets, we would be subject to additional
risks and uncertainties, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">our inability to directly control commercial activities
because we are relying on third parties;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the burden of complying with complex and changing
foreign regulatory, tax, accounting and legal requirements;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">different medical practices and customs in foreign
countries affecting acceptance in the marketplace;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">import or export licensing requirements;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">longer accounts receivable collection times;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">longer lead times for shipping;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">language barriers for technical training;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">reduced protection of intellectual property rights
in some foreign countries, and related prevalence of generic alternatives to our products;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">foreign currency exchange rate fluctuations;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">our customers&rsquo; ability to obtain reimbursement
for our products in foreign markets; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the interpretation of contractual provisions governed
by foreign laws in the event of a contract dispute.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Foreign sales of our products or product candidates could also
be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions and changes
in tariffs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We are subject to various regulations pertaining to the
marketing of our approved products.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are subject to various federal and state laws pertaining
to healthcare fraud and abuse, including prohibitions on the offer of payment or acceptance of kickbacks or other remuneration
for the purchase of our products, including inducements to potential patients to request our products and services. Additionally,
any product promotion educational activities, support of continuing medical education programs, and other interactions with health-care
professionals must be conducted in a manner consistent with the FDA regulations and the Anti-Kickback Statute. The Anti-Kickback
Statute prohibits persons or entities from knowingly and willfully soliciting, receiving, offering or providing remuneration, directly
or indirectly, to induce either the referral of an individual, or the furnishing, recommending, or arranging for a good or service,
for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs. Violations of the
Anti-Kickback Statute can also carry potential federal False Claims Act liability. Additionally, many states have adopted laws
similar to the Anti-Kickback Statute. Some of these state prohibitions apply to referral of patients for healthcare items or services
reimbursed by any third-party payer, not only the Medicare and Medicaid programs, and do not contain identical safe harbors. These
and any new regulations or requirements may be difficult and expensive for us to comply with, may adversely impact the marketing
of our existing products or delay introduction of our product candidates, which may have a material adverse effect on our business,
operating results and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid"><B><I>Our products and product candidates
may cause undesirable side effects that could delay or prevent their regulatory approval, limit the commercial profile of an approved
label, or result in significant negative consequences following marketing approval, if any.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Undesirable side effects caused by our product candidates could
cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or
the delay or denial of regulatory approval by the FDA or other regulatory authorities. For example, adverse events associated with
tramadol use in general and observed in the PE clinical trials included: gastrointestinal, or GI disorders (nausea) and central
nervous system disorders (sleepiness, dizziness, headache) and decreased blood pressure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Further, if a product candidate receives marketing approval
and we or others identify undesirable side effects caused by the product after the approval, or if drug abuse is determined to
be a significant problem with an approved product, a number of potentially significant negative consequences could result, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">regulatory authorities may withdraw or limit their
approval of the product;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">regulatory authorities may require the addition of
labeling statements, such as a &ldquo;boxed&rdquo; warning or a contraindication;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">we may be required to change the way the product is
distributed or administered, conduct additional clinical trials or change the labeling of the product;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">we may decide to remove the product from the marketplace;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">we could be sued and held liable for injury caused
to individuals exposed to or taking the product; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">our reputation may suffer.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any of these events could prevent us from achieving or maintaining
market acceptance of the affected product candidate and could substantially increase the costs of commercializing an affected product
or product candidates and significantly impact our ability to successfully commercialize or maintain sales of our product or product
candidates and generate revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Favorable results in the prior clinical trials of Zertane
outside of the United States may not be predictive of the results in any future Phase 3 clinical trials of Zertane in the United
States or the designs of our Phase 3 clinical trials may be inadequate for FDA approval.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A number of companies in the pharmaceutical and biotechnology
industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in earlier-stage
development. The prior clinical trials of Zertane showed favorable safety and efficacy data; however, we will have different enrollment
criteria in our planned Phase 3 clinical trials. In the Phase 2 clinical trials, we were able to enroll patients utilizing a broader
definition of PE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ejaculation latency, most commonly quantified using intravaginal
ejaculation latency time, or IELT, is a dominant component of PE assessment in clinical trials. IELT is defined as the time between
vaginal intromission and intravaginal ejaculation. Although a standard cut-off for ejaculatory latency does not exist, it has been
suggested that an IELT of two minutes or less may serve as an adequately sensitive criterion for defining PE and some studies have
used IELT values from one to two minutes for defining PE. In a pre-IND meeting with FDA, we agreed to use an IELT of less than
or equal to 1 minute as one of the enrollment criteria for our planned Phase 3 clinical trials. The previous European Phase 3 trials
allowed for an IELT of less than two minutes however a significant proportion of enrollees had an IELT of one minute or less. In
our then-planned Phase 3 clinical trials, we would be utilizing the definition of lifelong PE adopted by the International Society
for Sexual Medicine, or the ISSM: &ldquo;premature ejaculation is a male sexual dysfunction characterized by ejaculation which
always or nearly always occurs prior to or within a minute of vaginal penetration; and inability to delay ejaculation on all or
nearly all vaginal penetrations; and negative personal consequences, such as distress, bother, frustration and/or the avoidance
of sexual intimacy.&rdquo; As a result, we could encounter difficulty enrolling a sufficient number of patients in a timely fashion
and we may not observe a similarly favorable safety and efficacy profile as our prior clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid">In addition, Ampio obtained guidance
from the FDA on our planned Phase 3 trials at a pre-IND meeting held in June 2012, including information to help us define the
target patient population, select co-primary endpoints and design an acceptable patient-reported outcome measure. As a result of
direction provided at the meeting, along with the existing data from six clinical trials of Zertane conducted outside the U.S.
to date, we believe Zertane is positioned to advance into Phase 3 clinical trials in the United States. However, we can provide
no assurance that the FDA will not change its guidance about the Phase 3 clinical trials and require us or a collaborator to significantly
modify the design of, or endpoints for, our planned clinical trials. Any change in the guidance we have received could delay and/or
render more expensive a Phase 3 trial for Zertane.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We were not involved in any of the prior clinical studies for
Zertane and are relying on the data collected from those prior clinical trials by various third parties, including a previous partner
of Ampio Pharmaceuticals. Dr. David Bar-Or (now the Chief Scientific Officer of Ampio Pharmaceuticals) discovered the utility of
tramadol hydrochloride for the treatment of PE in June 1999, and this discovery and accompanying intellectual property were at
that time the property of DMI BioSciences, Inc., or DMI BioSciences. DMI BioSciences conducted various clinical trials, prior to
licensing the worldwide rights to tramadol hydrochloride for PE to Biovail Laboratories International, or Biovail. Biovail also
conducted several clinical trials and began two Phase 3 clinical trials, which trials were completed by Ampio upon its acquisition
of DMI Biosciences, to whom the rights had reverted. This lack of prior involvement may have a negative impact on our understanding
of these prior clinical trials and the design of the Phase 3 trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Zertane and Natesto contain, and future our other product
candidates may contain controlled substances, the manufacture, use, sale, importation, exportation, prescribing and distribution
of which are subject to regulation by the DEA.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Natesto, which is approved by the FDA, is regulated by the DEA
as a Schedule III controlled substance. Before any commercialization of Zertane, and potentially our other product candidates,
the DEA will need to determine the controlled substance schedule, taking into account the recommendation of the FDA. This may be
a lengthy process that could delay our marketing of a product candidate and could potentially diminish any regulatory exclusivity
periods for which we may be eligible. Natesto is and Zertane, if approved, will, and our other product candidates may, if approved,
be regulated as &ldquo;controlled substances&rdquo; as defined in the Controlled Substances Act of 1970, or CSA, and the implementing
regulations of the DEA, which establish registration, security, recordkeeping, reporting, storage, distribution, importation, exportation,
inventory, quota and other requirements administered by the DEA. These requirements are applicable to us, to our third-party manufacturers
and to distributors, prescribers and dispensers of our product candidates. The DEA regulates the handling of controlled substances
through a closed chain of distribution. This control extends to the equipment and raw materials used in their manufacture and packaging,
in order to prevent loss and diversion into illicit channels of commerce. A number of states and foreign countries also independently
regulate these drugs as controlled substances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The DEA regulates controlled substances as Schedule I, II, III,
IV or V substances. Schedule I substances by definition have no established medicinal use, and may not be marketed or sold in the
United States. A pharmaceutical product may be listed as Schedule II, III, IV or V, with Schedule II substances considered to present
the highest risk of abuse and Schedule V substances the lowest relative risk of abuse among such substances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Natesto is regulated by the DEA as a Schedule III controlled
substance. We expect that Zertane will, and our other product candidates may, be listed by the DEA as Schedule IV controlled substances
under the CSA. Consequently, the manufacturing, shipping, storing, selling and using of the products will be subject to a high
degree of regulation. Also, distribution, prescribing and dispensing of these drugs are highly regulated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Annual registration is required for any facility that
manufactures, distributes, dispenses, imports or exports any controlled substance. The registration is specific to the
particular location, activity and controlled substance schedule. Because of their restrictive nature, these laws and
regulations could limit commercialization of our product candidates containing controlled substances. Failure to comply with
these laws and regulations could also result in withdrawal of our DEA registrations, disruption in manufacturing and
distribution activities, consent decrees, criminal and civil penalties and state actions, among other consequences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid"><B><I>If testosterone replacement therapies
are found, or are perceived, to create health risks, our ability to sell Natesto could be materially adversely affected and our
business could be harmed.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Recent publications have suggested potential health risks associated
with testosterone replacement therapy, such as increased cardiovascular disease risk, including increased risk of heart attack
or stroke, fluid retention, sleep apnea, breast tenderness or enlargement, increased red blood cells, development of clinical prostate
disease, including prostate cancer, and the suppression of sperm production. Prompted by these events, the FDA held a T-class Advisory
Committee meeting on September 17, 2014 to discuss this topic further. The FDA has also asked health care professionals and patients
to report side effects involving prescription testosterone products to the agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At the T-class Advisory Committee meeting held on September
17, 2014, the Advisory Committee discussed (i) the identification of the appropriate patient population for whom testosterone replacement
therapy should be indicated and (ii) the potential risk of major adverse cardiovascular events, defined as non-fatal stroke, non-fatal
myocardial infarction and cardiovascular death associated with testosterone replacement therapy. At the meeting, the Advisory Committee
voted that the FDA should require sponsors of testosterone products to conduct a post marketing study (e.g. observational study
or controlled clinical trial) to further assess the potential cardiovascular risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">It is possible that the FDA&rsquo;s evaluation of this topic
and further studies on the effects of testosterone replacement therapies could demonstrate the risk of major adverse cardiovascular
events or other health risks or could impose requirements that impact the marketing and sale of Natesto, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">mandate that certain warnings or precautions be included
in our product labeling;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">require that our product carry a &ldquo;black box
warning&rdquo;; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">limit use of Natesto to certain populations, such
as men without specified conditions.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Demonstrated testosterone replacement therapy safety risks,
as well as negative publicity about the risks of hormone replacement therapy, including testosterone replacement, could hurt sales
of and impair our ability to successfully relaunch Natesto, which could have a materially adverse impact on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>FDA action regarding testosterone replacement therapies
could add to the cost of producing and marketing Natesto.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The FDA is requiring post-marketing safety studies for all testosterone
replacement therapies approved in the U.S. to assess long-term cardiovascular events related to testosterone use. Depending on
the total cost and structure of the FDA&rsquo;s proposed safety studies there may be a substantial cost associated with conducting
these studies. Pursuant to our license agreement with Acerus Pharmaceuticals is, Acerus is obligated to reimburse us for the entire
cost of any studies required for Natesto by the FDA. However, in the event that Acerus is not able to reimburse us for the cost
of any required safety studies, we may be forced to incur this cost, which could have a material adverse impact on our business
and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Generic tramadol hydrochloride is available in the United
States and abroad for treatment of pain.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Although the generic drug is not available in the same dosage
or formulation as Zertane for treatment of PE, it is possible that physicians could prescribe the generic version of the drug &ldquo;off
label&rdquo; for the treatment of PE instead of Zertane, which would adversely affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our approved products may not be accepted by physicians,
patients, or the medical community in general.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Even if the medical community accepts a product as safe and
efficacious for its indicated use, physicians may choose to restrict the use of the product if we or any collaborator is unable
to demonstrate that, based on experience, clinical data, side-effect profiles and other factors, our product is preferable to any
existing medicines or treatments. We cannot predict the degree of market acceptance of any of our approved products, which will
depend on a number of factors, including, but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">the efficacy and safety of the product;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the approved labeling for the product and any required
warnings;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the advantages and disadvantages of the product compared
to alternative treatments;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">our and any collaborator&rsquo;s ability to educate
the medical community about the safety and effectiveness of the product;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the reimbursement policies of government and third-party
payors pertaining to the product; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">the market price of our product relative to competing
treatments.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the case of Zertane, tramadol hydrochloride is a well-established
centrally acting synthetic analgesic that has been used for more than 30 years as a treatment for moderate to severe pain. As an
opioid, tramadol hydrochloride has been associated with certain adverse effects including dizziness, nausea, constipation, vertigo,
headache, vomiting and drowsiness. As a result, physicians may be reluctant to prescribe Zertane to treat premature ejaculation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may use hazardous chemicals and biological materials
in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our research and development processes may involve the controlled
use of hazardous materials, including chemicals and biological materials. We cannot eliminate the risk of accidental contamination
or discharge and any resultant injury from these materials. We may be sued for any injury or contamination that results from our
use or the use by third parties of these materials, and our liability may exceed any insurance coverage and our total assets. Federal,
state and local laws and regulations govern the use, manufacture, storage, handling and disposal of these hazardous materials and
specified waste products, as well as the discharge of pollutants into the environment and human health and safety matters. Compliance
with environmental laws and regulations may be expensive and may impair our research and development efforts. If we fail to comply
with these requirements, we could incur substantial costs, including civil or criminal fines and penalties, clean-up costs or capital
expenditures for control equipment or operational changes necessary to achieve and maintain compliance. In addition, we cannot
predict the impact on our business of new or amended environmental laws or regulations or any changes in the way existing and future
laws and regulations are interpreted and enforced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Intellectual Property Risks Related to
Our Business&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our ability to compete may decline if we do not adequately
protect our proprietary rights.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our commercial success depends on obtaining and maintaining
proprietary rights to our products and product candidates as well as successfully defending these rights against third-party challenges.
We will only be able to protect our products and product candidates from unauthorized use by third parties to the extent that valid
and enforceable patents, or effectively protected trade secrets, cover them. Our ability to obtain patent protection for our products
and product candidates is uncertain due to a number of factors, including that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">we may not have been the first to make the inventions
covered by pending patent applications or issued patents;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">we may not have been the first to file patent applications
for our products and product candidates;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">others may independently develop identical, similar
or alternative products, compositions or devices and uses thereof;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">our disclosures in patent applications may not be
sufficient to meet the statutory requirements for patentability;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">any or all of our pending patent applications may
not result in issued patents;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">we may not seek or obtain patent protection in countries
that may eventually provide us a significant business opportunity;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt; text-align: left">&bull;</TD><TD STYLE="text-align: left">any patents issued to us may not provide a basis for commercially
viable products, may not provide any competitive advantages, or may be successfully challenged by third parties;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">our compositions, devices and methods may not be patentable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">others may design around our patent claims to produce competitive products which fall outside of the scope of our patents;
or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">others may identify prior art or other bases which could invalidate our patents.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid">Even if we have or obtain patents covering
our products and product candidates, we may still be barred from making, using and selling them because of the patent rights of
others. Others may have filed, and in the future may file, patent applications covering products that are similar or identical
to ours. There are many issued U.S. and foreign patents relating to chemical compounds, therapeutic products, diagnostic devices,
and some of these relate to our products and product candidates. These could materially affect our ability to sell our products
and develop our product candidates. Because patent applications can take many years to issue, there may be currently pending applications
unknown to us that may later result in issued patents that our products and product candidates may infringe. These patent applications
may have priority over patent applications filed by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Obtaining and maintaining a patent portfolio entails significant
expense and resources. Part of the expense includes periodic maintenance fees, renewal fees, annuity fees, various other governmental
fees on patents and/or applications due in several stages over the lifetime of patents and/or applications, as well as the cost
associated with complying with numerous procedural provisions during the patent application process. We may or may not choose to
pursue or maintain protection for particular inventions. In addition, there are situations in which failure to make certain payments
or noncompliance with certain requirements in the patent process can result in abandonment or lapse of a patent or patent application,
resulting in partial or complete loss of patent rights in the relevant jurisdiction. If we choose to forgo patent protection or
allow a patent application or patent to lapse purposefully or inadvertently, our competitive position could suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Legal actions to enforce our patent rights can be expensive
and may involve the diversion of significant management time. In addition, these legal actions could be unsuccessful and could
also result in the invalidation of our patents or a finding that they are unenforceable. We may or may not choose to pursue litigation
or other actions against those that have infringed on our patents, or used them without authorization, due to the associated expense
and time commitment of monitoring these activities. If we fail to protect or to enforce our intellectual property rights successfully,
our competitive position could suffer, which could harm our business, prospects, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Pharmaceutical and medical device patents and patent applications
involve highly complex legal and factual questions, which, if determined adversely to us, could negatively impact our patent position.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The patent positions of pharmaceutical and medical device
companies can be highly uncertain and involve complex legal and factual questions. The interpretation and breadth of claims
allowed in some patents covering pharmaceutical compositions may be uncertain and difficult to determine, and are often
affected materially by the facts and circumstances that pertain to the patented compositions and the related patent claims.
The standards of the United States Patent and Trademark Office, or USPTO, are sometimes uncertain and could change in the
future. Consequently, the issuance and scope of patents cannot be predicted with certainty. Patents, if issued, may be
challenged, invalidated or circumvented. U.S. patents and patent applications may also be subject to interference
proceedings, and U.S. patents may be subject to re-examination proceedings, post-grant review and/or inter partes review in
the USPTO. Foreign patents may be subject to opposition or comparable proceedings in the corresponding foreign patent office,
which could result in either loss of the patent or denial of the patent application or loss or reduction in the scope of one
or more of the claims of the patent or patent application. In addition, such interference, re-examination, post-grant review,
inter partes review and opposition proceedings may be costly. Accordingly, rights under any issued patents may not provide us
with sufficient protection against competitive products or processes. In addition, changes in or different interpretations of
patent laws in the United States and foreign countries may permit others to use our discoveries or to develop and
commercialize our technology and products and product candidates without providing any compensation to us, or may limit the
number of patents or claims we can obtain. The laws of some countries do not protect intellectual property rights to the same
extent as U.S. laws and those countries may lack adequate rules and procedures for defending our intellectual property
rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid">&nbsp;</P>




<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we fail to obtain and maintain patent protection and trade
secret protection of our products and product candidates, we could lose our competitive advantage and competition we face would
increase, reducing any potential revenues and adversely affecting our ability to attain or maintain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Developments in patent law could have a negative impact
on our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">From time to time, the United States Supreme Court, other federal
courts, the United States Congress or the USPTO may change the standards of patentability and any such changes could have a negative
impact on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, the Leahy-Smith America Invents Act, or the America
Invents Act, which was signed into law in 2011, includes a number of significant changes to U.S. patent law. These changes include
a transition from a &ldquo;first-to-invent&rdquo; system to a &ldquo;first-to-file&rdquo; system, changes the way issued patents
are challenged, and changes the way patent applications are disputed during the examination process. These changes may favor larger
and more established companies that have greater resources to devote to patent application filing and prosecution. The USPTO has
developed regulations and procedures to govern the full implementation of the America Invents Act, and many of the substantive
changes to patent law associated with the America Invents Act, and, in particular, the first-to-file provisions, became effective
on March 16, 2013. Substantive changes to patent law associated with the America Invents Act may affect our ability to obtain patents,
and if obtained, to enforce or defend them. Accordingly, it is not clear what, if any, impact the America Invents Act will ultimately
have on the cost of prosecuting our patent applications, our ability to obtain patents based on our discoveries and our ability
to enforce or defend any patents that may issue from our patent applications, all of which could have a material adverse effect
on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we are unable to protect the confidentiality of our
trade secrets, our business and competitive position would be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to patent protection, because we operate in the
highly technical field of discovery and development of therapies and medical devices, we rely in part on trade secret protection
in order to protect our proprietary technology and processes. However, trade secrets are difficult to protect. We expect to enter
into confidentiality and intellectual property assignment agreements with our employees, consultants, outside scientific and commercial
collaborators, sponsored researchers, and other advisors. These agreements generally require that the other party keep confidential
and not disclose to third parties all confidential information developed by the party or made known to the party by us during the
course of the party&rsquo;s relationship with us. These agreements also generally provide that inventions conceived by the party
in the course of rendering services to us will be our exclusive property. However, these agreements may not be honored and may
not effectively assign intellectual property rights to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to contractual measures, we try to protect the confidential
nature of our proprietary information using physical and technological security measures. Such measures may not, for example, in
the case of misappropriation of a trade secret by an employee or third party with authorized access, provide adequate protection
for our proprietary information. Our security measures may not prevent an employee or consultant from misappropriating our trade
secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to
protect our interests fully. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult,
expensive, and time-consuming, and the outcome is unpredictable. In addition, courts outside the United States may be less willing
to protect trade secrets. Trade secrets may be independently developed by others in a manner that could prevent legal recourse
by us. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated,
or if any such information was independently developed by a competitor, our competitive position could be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may not be able to enforce our intellectual property
rights throughout the world.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The laws of some foreign countries do not protect intellectual
property rights to the same extent as the laws of the United States. Many companies have encountered significant problems in protecting
and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly
developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating
to pharmaceuticals and medical devices. This could make it difficult for us to stop the infringement of some of our patents, if
obtained, or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory
licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability
of patents against third parties, including government agencies or government contractors. In these countries, patents may provide
limited or no benefit. Patent protection must ultimately be sought on a country-by-country basis, which is an expensive and time-consuming
process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and we will not
have the benefit of patent protection in such countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Proceedings to enforce our patent rights in foreign jurisdictions
could result in substantial costs and divert our efforts and attention from other aspects of our business. Accordingly, our efforts
to protect our intellectual property rights in such countries may be inadequate. In addition, changes in the law and legal decisions
by courts in the United States and foreign countries may affect our ability to obtain adequate protection for our technology and
the enforcement of intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Third parties may assert ownership or commercial rights
to inventions we develop.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Third parties may in the future make claims challenging the
inventorship or ownership of our intellectual property. We have or expect to have written agreements with collaborators that provide
for the ownership of intellectual property arising from our collaborations. These agreements provide that we must negotiate certain
commercial rights with collaborators with respect to joint inventions or inventions made by our collaborators that arise from the
results of the collaboration. In some instances, there may not be adequate written provisions to address clearly the resolution
of intellectual property rights that may arise from a collaboration. If we cannot successfully negotiate sufficient ownership and
commercial rights to the inventions that result from our use of a third-party collaborator&rsquo;s materials where required, or
if disputes otherwise arise with respect to the intellectual property developed with the use of a collaborator&rsquo;s samples,
we may be limited in our ability to capitalize on the market potential of these inventions. In addition, we may face claims by
third parties that our agreements with employees, contractors, or consultants obligating them to assign intellectual property to
us are ineffective, or in conflict with prior or competing contractual obligations of assignment, which could result in ownership
disputes regarding intellectual property we have developed or will develop and interfere with our ability to capture the commercial
value of such inventions. Litigation may be necessary to resolve an ownership dispute, and if we are not successful, we may be
precluded from using certain intellectual property, or may lose our exclusive rights in that intellectual property. Either outcome
could have an adverse impact on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Third parties may assert that our employees or consultants
have wrongfully used or disclosed confidential information or misappropriated trade secrets.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We might employ individuals who were previously employed at
universities or other biopharmaceutical or medical device companies, including our competitors or potential competitors. Although
we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work
for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise
used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other
third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition
to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending
against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>A dispute concerning the infringement or misappropriation
of our proprietary rights or the proprietary rights of others could be time consuming and costly, and an unfavorable outcome could
harm our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There is significant litigation in the pharmaceutical and medical
device industries regarding patent and other intellectual property rights. While we are not currently subject to any pending intellectual
property litigation, and are not aware of any such threatened litigation, we may be exposed to future litigation by third parties
based on claims that our products or product candidates infringe the intellectual property rights of others. If our development
and commercialization activities are found to infringe any such patents, we may have to pay significant damages or seek licenses
to such patents. A patentee could prevent us from using the patented drugs, compositions or devices. We may need to resort to litigation
to enforce a patent issued to us, to protect our trade secrets, or to determine the scope and validity of third-party proprietary
rights. From time to time, we may hire scientific personnel or consultants formerly employed by other companies involved in one
or more areas similar to the activities conducted by us. Either we or these individuals may be subject to allegations of trade
secret misappropriation or other similar claims as a result of prior affiliations. If we become involved in litigation, it could
consume a substantial portion of our managerial and financial resources, regardless of whether we win or lose. We may not be able
to afford the costs of litigation. Any adverse ruling or perception of an adverse ruling in defending ourselves against these claims
could have a material adverse impact on our cash position and stock price. Any legal action against us or our collaborators could
lead to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">payment of damages, potentially treble damages, if we are found to have willfully infringed a party&rsquo;s patent rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">injunctive or other equitable relief that may effectively block our ability to further develop, commercialize, and sell products;
or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">we or our collaborators having to enter into license arrangements that may not be available on commercially acceptable terms,
if at all, all of which could have a material adverse impact on our cash position and business, prospects and financial condition.
As a result, we could be prevented from commercializing our products and product candidates.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border: white 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; border: white 1pt solid; margin-bottom: 0pt; text-align: center"><B>Risks Related
to Our Organization, Structure and Operation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We intend to acquire, through asset purchases or in-licensing,
businesses or products, or form strategic alliances, in the future, and we may not realize the intended benefits of such acquisitions
or alliances.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We intend to acquire, through asset purchases or in-licensing,
additional businesses or products, form strategic alliances and/or create joint ventures with third parties that we believe will
complement or augment our existing business. If we acquire businesses or assets with promising markets or technologies, we may
not be able to realize the benefit of acquiring such businesses or assets if we are unable to successfully integrate them with
our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing
any new products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits
or enhancing our business. We cannot assure you that, following any such acquisition or alliance, we will achieve the expected
synergies to justify the transaction. These risks apply to our acquisition of ProstaScint in May 2015, Primsol in October 2015
and Natesto in April 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Ampio could influence us, including influencing the election
of our directors, and its interests may conflict with or differ from your interests as stockholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of May 31, 2016, Ampio owned 2.7% of our outstanding common
stock. However, from April 2015 to January 2016, Ampio owned approximately 81.5%, which had declined to 5.5% in February 2016.
In addition, three of our four directors all have current or prior connections to Ampio. Michael Macaluso, is the Chief Executive
Officer and a director of Ampio, and Josh Disbrow, our Chief Executive Officer, was Chief Executive Officer of Luoxis and Chief
Operating Officer of Ampio. Jarrett Disbrow, our Chief Operating Officer, was Chief Executive Officer of Vyrix. Gregory Gould,
our Chief Financial Officer, is also the Chief Financial Officer of Ampio. Further, we have entered into a services agreement with
Ampio pursuant to which Ampio provides us with corporate overhead services. As a result of its past and current relationship with
us, Ampio may be able to influence our management and affairs as well as matters submitted to our stockholders for approval, including
the election of directors and approval of any merger, consolidation, or sale of all or substantially all of our assets or other
major corporate transactions. This potential influence may have the effect of delaying or preventing a change in control of our
company and might affect the market price of our common stock. This potential influence may delay, deter or prevent acts that would
be favored by our other stockholders, as the interests of Ampio may not always coincide with our interests or the interests of
our other stockholders. For example, Ampio may seek to cause us to take courses of action that, in its judgment, could enhance
its investment in us, but which might involve risks to our other stockholders or adversely affect us or our other stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may be unable to achieve some or all of the benefits
that we expect to achieve from our separation from Ampio.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a stand-alone, independent public company, we believe that
our business will benefit from, among other things, allowing our management to design and implement corporate policies and strategies
that are based primarily on the characteristics of our business, allowing us to focus our financial resources wholly on our own
operations and implement and maintain a capital structure designed to meet our own specific needs. However, as a result of our
separation of our business from Ampio in April 2015, as a result of the Merger, there is a risk that we may be more susceptible
to market fluctuations and other adverse events than we would have been if we were still a part of Ampio. We may not be able to
achieve some or all of the benefits that we expect to achieve as a stand-alone healthcare company or such benefits may be delayed
or may not occur at all. For example, there can be no assurance that analysts and investors will place a greater value on our company
as a stand-alone healthcare company than on our business as a part of Ampio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our historical financial information as a business conducted
by Ampio may not be representative of our results as an independent public company.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The historical financial information included herein does not
necessarily reflect what our financial position, operating results or cash flows would have been had we been an independent entity
during the historical periods presented. The historical costs and expenses reflected in our financial statements include amounts
for certain corporate functions historically provided by Ampio, including costs of finance and other administrative services, and
income taxes. These expense allocations were developed on the basis of what we and Ampio considered to be reasonable prices for
the utilization of services provided or the benefits received by us. The historical financial information in our audited financial
statements may not be indicative of what our results of operations, financial position, changes in equity and cash flows would
have been had we been a separate stand-alone entity during the periods presented or will be in the future. We have not made adjustments
to reflect many significant changes that will occur in our cost structure, funding and operations as a result of our separation
from Ampio, including changes in our employee base, changes in our tax structure, potential increased costs associated with reduced
economies of scale and increased costs associated with being a publicly traded, stand-alone company, such as compliance costs,
nor have we made offsetting adjustments to reflect the benefits of this offering, as these factors are presently difficult to quantify.
These same risks will apply to the financial information of any business we acquire when it is included in our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may have received better terms from unaffiliated third
parties than the terms we received in our agreements with Ampio.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The agreements related to our separation from Ampio, including
the assignment and assumption agreement, services agreement and the other agreements, were negotiated in the context of our separation
from Ampio while we were still part of Ampio and, accordingly, may not reflect terms that would have resulted from arm&rsquo;s-length
negotiations among unaffiliated third parties. The terms of the agreements we negotiated in the context of our separation related
to, among other things, allocation of assets, liabilities, rights, indemnifications and other obligations among Ampio and us. We
may have received better terms from third parties because third parties may have competed with each other to win our business.
One of our directors is also a member of the Ampio board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our ability to operate our business effectively may suffer
if we or Ampio terminate our services agreement, or if we are unable to establish on a cost-effective basis our own administrative
and other support functions in order to operate as a stand-alone company after the expiration or termination of our services agreement
with Ampio.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prior to the Merger, we relied on administrative and other resources
of Ampio to operate our business. We have entered into a services agreement to retain the ability for specified periods to use
certain Ampio resources. We may elect to continue this agreement for an indefinite period of time. Any decision by us to terminate
this agreement would be approved by disinterested members of our management and board of directors under our procedures regarding
related party transactions. After the termination of this agreement, we will need to create our own administrative and other support
systems or contract with third parties to replace Ampio&rsquo;s services. These services may not be provided at the same level,
and we may not be able to obtain the same benefits that we received prior to the separation. These services may not be sufficient
to meet our needs, and if our agreement with Ampio is terminated, we may not be able to replace these services at all or obtain
these services at prices and on terms as favorable as we currently have with Ampio. Any failure or significant downtime in our
own administrative systems or in Ampio&rsquo;s administrative systems during the transitional period could result in unexpected
costs, impact our results or prevent us from paying our suppliers or employees and performing other administrative services on
a timely basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Adverse developments at Ampio could negatively impact
our company.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We acquired the businesses of Luoxis (the MiOXSYS and RedoxSYS
systems) and Vyrix (Zertane) from Ampio in the Merger. In addition, Joshua Disbrow and Jarrett Disbrow held executive positions
at Ampio and/or its subsidiaries prior to the Merger. Michael Macaluso, one of our directors, is the Chief Executive Officer and
a director of Ampio. Gregory Gould, our Chief Financial Officer, is currently the Chief Financial Officer at Ampio. Further, prior
to January 2016, Ampio owned approximately 81.5% of our outstanding common stock. As a result, negative developments, including
negative publicity, at Ampio could be imputed to our company and have an adverse impact on our business and prospects, including
our ability to raise capital or enter into collaborations, and on the price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Any disputes that arise between us and Ampio with respect
to our past and ongoing relationships could harm our business operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Disputes may arise between Ampio and us in a number of areas
relating to our past and ongoing relationships, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">intellectual property, technology and business matters, including failure to make required technology transfers and failure
to comply with non-compete provisions applicable to Ampio and us;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">labor, tax, employee benefit, indemnification and other matters arising from our separation from Ampio;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">distribution and supply obligations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt; text-align: left"></TD><TD STYLE="width: 20pt">&bull;</TD><TD>employee retention and recruiting;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt; text-align: left"></TD><TD STYLE="width: 20pt">&bull;</TD><TD>business combinations involving us;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt; text-align: left"></TD><TD STYLE="width: 20pt">&bull;</TD><TD>sales or distributions by Ampio of all or any portion of its ownership interest in us;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt">&bull;</TD><TD>the nature, quality and pricing of transitional services Ampio has agreed to provide us; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">business opportunities that may be attractive to both Ampio and us.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid">We may not be able to resolve any potential
conflicts, and even if we do, the resolution may be less favorable than if we were dealing with an unaffiliated party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The agreements we have entered into with Ampio may be amended
upon agreement between the parties. Given our past and present relationship with Ampio, Ampio may be able to influence us to agree
to amendments to these agreements that may be less favorable to us than the original terms of the agreements or that we might obtain
from others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We only have one independent director, which could result
in a Board of Directors that does not thoroughly represent the interests of minority shareholders and could prevent our common
stock from being listed on a securities exchange.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Currently, we have only one independent director, Carl Dockery,
who only recently joined our board of directors in April 2016. To have our stock listed on a securities exchange we will be required
to have a majority of independent directors, which we may never have. In the absence of a majority of independent directors, we
would be prevented from listing our stock on an exchange. In addition, the Board, which includes our Chief Executive Officer and
Chief Operating Officer, who are also brothers, could establish policies and enter into transactions over the objections of the
sole independent director. This could present the potential for a conflict of interest between us and our shareholders generally
and the controlling officers, shareholders or directors. The absence of more independent directors who could provide a more neutral
point of view could jeopardize your interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Some of our management may have conflicts of interest
because of their ownership of Ampio common stock, options to acquire Ampio common stock and positions with Ampio.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Two of our four directors and two of our four executive officers
own Ampio common stock and/or options to purchase Ampio common stock. In addition, one of our directors is also the Chief Executive
Officer and a director of Ampio and our Chief Financial Officer is also the Chief Financial Officer of Ampio. Ownership of Ampio
common stock and options to purchase Ampio common stock by our directors and officers and the presence of a director of Ampio on
our board of directors could create, or appear to create, conflicts of interest with respect to matters involving both us and Ampio.
For example, corporate opportunities may arise that are applicable or complementary to both of our businesses and that each business
would be free to pursue, such as the potential acquisition of a particular business or technology. However, we do not believe that
Ampio intends to acquire businesses that are focused on urological disorders. We have not established at this time any procedural
mechanisms to address actual or perceived conflicts of interest of these individuals and expect that our board of directors, in
the exercise of its fiduciary duties, will determine how to address any actual or perceived conflicts of interest on a case-by-case
basis. If any corporate opportunity arises and if our directors or officers do not pursue it on our behalf, we may not become aware
of, and may potentially lose, a significant business opportunity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We will need to develop and expand our company, and we
may encounter difficulties in managing this development and expansion, which could disrupt our operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of May 31, 2016, we had 21 full-time employees, and in connection
with being a public company, we expect to increase our number of employees and the scope of our operations. To manage our anticipated
development and expansion, we must continue to implement and improve our managerial, operational and financial systems, expand
our facilities and continue to recruit and train additional qualified personnel. Also, our management may need to divert a disproportionate
amount of its attention away from its day-to-day activities and devote a substantial amount of time to managing these development
activities. Due to our limited resources, we may not be able to effectively manage the expansion of our operations or recruit and
train additional qualified personnel. This may result in weaknesses in our infrastructure, give rise to operational mistakes, loss
of business opportunities, loss of employees and reduced productivity among remaining employees. The physical expansion of our
operations may lead to significant costs and may divert financial resources from other projects, such as the planned expanded commercialization
of our approved products and the development of our product candidates. If our management is unable to effectively manage our expected
development and expansion, our expenses may increase more than expected, our ability to generate or increase our revenue could
be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to expand
the market for our approved products and develop our product candidates, if approved, and compete effectively will depend, in part,
on our ability to effectively manage the future development and expansion of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We depend on key personnel and attracting qualified management
personnel and our business could be harmed if we lose personnel and cannot attract new personnel.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our success depends to a significant degree upon the technical
and management skills of our officers and key personnel. The loss of the services of any of these individuals would likely have
a material adverse effect on us. Our success also will depend upon our ability to attract and retain additional qualified management,
marketing, technical, and sales executives and personnel. We do not maintain key person life insurance for any of our officers
or key personnel. The loss of any of our key executives, or the failure to attract, integrate, motivate, and retain additional
key personnel could have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We compete for such personnel against numerous companies, including
larger, more established companies with significantly greater financial resources than we possess. There can be no assurance that
we will be successful in attracting or retaining such personnel, and the failure to do so could have a material adverse effect
on our business, prospects, financial condition, and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Product liability and other lawsuits could divert our
resources, result in substantial liabilities and reduce the commercial potential of our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The risk that we may be sued on product liability claims is
inherent in the development and commercialization of pharmaceutical and medical device products. Side effects of, or manufacturing
defects in, products that we develop and commercialized could result in the deterioration of a patient&rsquo;s condition, injury
or even death. Once a product is approved for sale and commercialized, the likelihood of product liability lawsuits increases.
Claims may be brought by individuals seeking relief for themselves or by individuals or groups seeking to represent a class. These
lawsuits may divert our management from pursuing our business strategy and may be costly to defend. In addition, if we are held
liable in any of these lawsuits, we may incur substantial liabilities and may be forced to limit or forgo further commercialization
of the affected products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may be subject to legal or administrative proceedings and
litigation other than product liability lawsuits which may be costly to defend and could materially harm our business, financial
condition and operations.<BR>
<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Although we maintain general liability, clinical trial liability
and product liability insurance, this insurance may not fully cover potential liabilities. In addition, inability to obtain or
maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product or other legal or
administrative liability claims could prevent or inhibit the commercial production and sale of any of our products and product
candidates that receive regulatory approval, which could adversely affect our business. Product liability claims could also harm
our reputation, which may adversely affect our collaborators&rsquo; ability to commercialize our products successfully.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>In order to satisfy our obligations as a public company,
we may need to hire additional qualified accounting and financial personnel with appropriate public company experience in the event
that we no longer utilize the finance and administrative functions of Ampio.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a public company, we must establish and maintain effective
disclosure and financial controls. We may need to hire additional accounting and financial personnel with appropriate public company
experience and technical accounting knowledge, and it may be difficult to recruit and maintain such personnel. Even if we are able
to hire appropriate personnel, our existing operating expenses and operations will be impacted by the direct costs of their employment
and the indirect consequences related to the diversion of management resources from product development efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our internal computer systems, or those of our third-party
contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development
programs.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Despite the implementation of security measures, our internal
computer systems and those of our third-party contractors and consultants are vulnerable to damage from computer viruses, unauthorized
access, natural disasters, terrorism, war and telecommunication and electrical failures. While we do not believe that we have experienced
any such system failure, accident, or security breach to date, if such an event were to occur and cause interruptions in our operations,
it could result in a loss of clinical trial data for our product candidates which could result in delays in our regulatory approval
efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach
results in a loss of or damage to our data or applications or other data or applications relating to our technology or product
candidates, or inappropriate disclosure of confidential or proprietary information, we could incur liabilities and the further
development of our product candidates could be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We will need to upgrade our enterprise resource planning
systems.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As we grow our business, we will need to upgrade our enterprise
resource planning, or ERP, system. Our ERP system is critical to our ability to accurately maintain books and records, keep track
of product inventory, marketing and sales, and prepare our financial statements. The implementation of a new ERP system will require
the investment of significant financial and human resources. In addition, we may not be able to successfully complete the full
implementation of the ERP system without experiencing difficulties. Any disruptions, delays or deficiencies in the design and implementation
of the new ERP system could adversely affect our ability to monitor our business and prepare our financial statements on an accurate
and timely basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our ability to use our net operating loss carryforwards
and certain other tax attributes may be limited.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of March 31, 2016, we had federal net operating loss carryforwards
of approximately $24.3 million. The available net operating losses, if not utilized to offset taxable income in future periods,
will begin to expire in 2031 and will completely expire in 2035. Under the Internal Revenue Code of 1986, as amended (the &ldquo;Code&rdquo;)
and the regulations promulgated thereunder, including, without limitation, the consolidated income tax return regulations, various
corporate changes could limit our ability to use our net operating loss carryforwards and other tax attributes (such as research
tax credits) to offset our income. Because Ampio&rsquo;s equity ownership interest in our company fell to below 80% in January
2016, we will be deconsolidated from Ampio&rsquo;s consolidated federal income tax group. As a result, certain of our net operating
loss carryforwards may not be available to us and we may not be able to use them to offset our U.S. federal taxable income. As
a consequence of the deconsolidation, it is possible that certain other tax attributes and benefits resulting from U.S. federal
income tax consolidation may no longer be available to us. Our company and Ampio do not have a tax sharing agreement that could
mitigate the loss of net operating losses and other tax attributes resulting from the deconsolidation or our incurrence of liability
for the taxes of other members of the consolidated group by reason of the joint and several liability of group members. In addition
to the deconsolidation risk, an &ldquo;ownership change&rdquo; (generally a 50% change (by value) in equity ownership over a three-year
period) under Section 382 of the Code could limit our ability to offset, post-change, our U.S. federal taxable income. Section
382 of the Code imposes an annual limitation on the amount of post-ownership change taxable income a corporation may offset with
pre-ownership change net operating loss carryforwards and certain recognized built-in losses. Either the deconsolidation or the
ownership change scenario could result in increased future tax liability to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Risks Related to Securities Markets and
Investment in our Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>There is not now, and there may never be, an active and
orderly trading market for our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">An active trading market for our shares may never develop or
be sustained. As a result, investors in our common stock must bear the economic risk of holding those shares for an indefinite
period of time. Although our common stock is quoted on the OTCQX, an over-the-counter quotation system, trading of our common stock
is extremely limited and sporadic and at very low volumes. We do not now, and may not in the future, meet the initial listing standards
of any national securities exchange, and we presently anticipate that our common stock will continue to be quoted on the OTCQX
or another over-the-counter quotation system for the foreseeable future. In those venues, our stockholders may find it difficult
to obtain accurate quotations as to the market value of their shares of our common stock, and may find few buyers to purchase their
stock and few market makers to support its price. As a result of these and other factors, you may be unable to resell your shares
of our common stock at or above the price for which you purchased them, or at all. Further, an inactive market may also impair
our ability to raise capital by selling additional equity in the future, and may impair our ability to enter into strategic partnerships
or acquire companies or products by using shares of our common stock as consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we fail to comply with the continued trading standards
of the OTCQX U.S. Premier tier, it may result in our common stock moving tiers in the OTC Markets.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is currently quoted for trading on
the OTCQX U.S. Premier tier, and the continued quotation of our common stock on the OTCQX U.S. Premier tier is subject to
our compliance with a number of standards. These standards include the requirement of our common stock to have a minimum
bid price of $1.00 per share as of the close of business for at least one of every thirty consecutive calendar days. On
February 10, 2016, the OTC Markets Group, Inc. notified us that we were not in compliance with the above listing standards
relating to the trading price of our common stock, and that if in the following 180 calendar days, our common stock did not
close at or above $1.00 for ten consecutive trading days, our common stock would be moved from the OTCQX U.S. Premier tier to
the OTCQX U.S. tier, which may negatively affect the trading and price of our common stock. There can be no assurance that we
will meet this quotation standard of the OTCQX U.S. Premier tier within the 180 day time period allotted. We undertook the
1-for-12 reverse stock split on June 30, 2016 to increase our stock price, but such action might not increase our stock price
above $1.00 or, if it does, any such increase might not last for any significant time, including the ten consecutive days
required by the OTCQX.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our share price is volatile and may be influenced by numerous
factors, some of which are beyond our control.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The trading price of our common stock is likely to be highly
volatile, and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. In addition
to the factors discussed in this &ldquo;Risk Factors&rdquo; section and elsewhere in this prospectus, these factors include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">the products or product candidates we acquire for commercialization;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">the product candidates we seek to pursue, and our ability to obtain rights to develop, commercialize and market those product
candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt; text-align: left"></TD><TD STYLE="width: 20pt">&bull;</TD><TD>our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt; text-align: left"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">actual or anticipated adverse results or delays in our clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt; text-align: left"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">our failure to expand the market for our currently approved products or commercialize our product candidates, if approved;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt; text-align: left"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">unanticipated serious safety concerns related to the use of any of our product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt; text-align: left"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">adverse regulatory decisions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt; text-align: left"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">additions or departures of key scientific or management personnel;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt; text-align: left"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">changes in laws or regulations applicable to our product candidates, including without limitation clinical trial requirements
for approvals;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt; text-align: left"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">disputes or other developments relating to patents and other proprietary rights and our ability to obtain patent protection
for our product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt; text-align: left"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">our dependence on third parties, including CROs and scientific and medical advisors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt; text-align: left"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">failure to meet or exceed any financial guidance or expectations regarding development milestones that we may provide to the
public;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">actual or anticipated variations in quarterly operating results;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt; text-align: left"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">failure to meet or exceed the estimates and projections of the investment community;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt; text-align: left"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">overall performance of the equity markets and other factors that may be unrelated to our operating performance or the operating
performance of our competitors, including changes in market valuations of similar companies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt; text-align: left"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">conditions or trends in the healthcare, biotechnology and pharmaceutical industries;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt; text-align: left"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">introduction of new products offered by us or our competitors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt; text-align: left"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt; text-align: left"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">our ability to maintain an adequate rate of growth and manage such growth;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt; text-align: left"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">issuances of debt or equity securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt; text-align: left"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">sales of our common stock by us or our stockholders in the future, or the perception that such sales could occur;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt; text-align: left"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">trading volume of our common stock;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt; text-align: left"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">ineffectiveness of our internal control over financial reporting or disclosure controls and procedures;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt; text-align: left"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">general political and economic conditions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt; text-align: left"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">effects of natural or man-made catastrophic events; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt; text-align: left"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">other events or factors, many of which are beyond our control.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid">In addition, the stock market in general,
and the stocks of small-cap healthcare, biotechnology and pharmaceutical companies in particular, have experienced extreme price
and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad
market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance.
The realization of any of the above risks or any of a broad range of other risks, including those described in these &ldquo;Risk
Factors,&rdquo; could have a dramatic and material adverse impact on the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>FINRA sales practice requirements may limit a stockholder&rsquo;s
ability to buy and sell our stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Financial Industry Regulatory Authority, or FINRA, has adopted
rules requiring that, in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that
the investment is suitable for that customer. Prior to recommending speculative or low-priced securities to their non-institutional
customers, broker-dealers must make reasonable efforts to obtain information about the customer&rsquo;s financial status, tax status,
investment objectives and other information. Under interpretations of these rules, FINRA has indicated its belief that there is
a high probability that speculative or low-priced securities will not be suitable for at least some customers. Because these FINRA
requirements are applicable to our common stock, they may make it more difficult for broker-dealers to recommend that at least
some of their customers buy our common stock, which may limit the ability of our stockholders to buy and sell our common stock
and could have an adverse effect on the market for and price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If securities or industry analysts do not publish research
or publish inaccurate or unfavorable research about our business, our stock price and any trading volume could decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any trading market for our common stock that may develop will
depend in part on the research and reports that securities or industry analysts publish about us or our business. Securities and
industry analysts do not currently, and may never, publish research on us or our business. If no securities or industry analysts
commence coverage of our company, the trading price for our stock could be negatively affected. If securities or industry analysts
initiate coverage, and one or more of those analysts downgrade our stock or publish inaccurate or unfavorable research about our
business, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish
reports on us regularly, demand for our stock could decrease, which might cause our stock price and any trading volume to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may be exposed to additional risks as a result of &ldquo;going
public&rdquo; by means of a reverse merger transaction.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may be exposed to additional risks because the business of
Vyrix and Luoxis has become a public company through a &ldquo;reverse merger&rdquo; transaction. There has been increased focus
by government agencies on transactions such as the Merger in recent years, and we may be subject to increased scrutiny by the SEC
and other government agencies and holders of our securities as a result of the completion of that transaction. Additionally, our
&ldquo;going public&rdquo; by means of a reverse merger transaction may make it more difficult for us to obtain coverage from securities
analysts of major brokerage firms following the Merger because there may be little incentive to those brokerage firms to recommend
the purchase of our common stock. As a result, our business or stock price could suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Because we became public by means of a &ldquo;reverse
merger,&rdquo; it may be more difficult to list on a national exchange such as the NASDAQ, New York Stock Exchange or NYSE MKT.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">It may be more difficult to list on a major exchange because
we have conducted a reverse merger. In 2011, the SEC approved new rules of the three major U.S. listing markets that toughen the
standards that companies going public through a reverse merger must meet to become listed on those exchanges. Under the rules,
NASDAQ, the New York Stock Exchange (or NYSE) and NYSE MKT impose more stringent listing requirements for companies that become
public through a reverse merger. Specifically, the rules prohibit a reverse merger company from applying to list on either the
NASDAQ, NYSE or NYSE MKT until:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">the company has completed a one-year &ldquo;seasoning period&rdquo; by trading in the U.S. over the counter market or on another
regulated U.S. or foreign exchange following the reverse merger, and filed all required reports with the SEC, including audited
financial statements; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt; text-align: left"></TD><TD STYLE="width: 20pt">&bull;</TD><TD>the company maintains the requisite minimum share price for a sustained period, and for at least 30 of the 60 trading days,
immediately prior to its listing application and the exchange&rsquo;s decision to list.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid">It is possible for a reverse merger
company to be exempt from these special requirements, but only if a listing is in connection with a substantial, firm commitment
underwritten public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have a substantial number of shares of authorized but
unissued capital stock, and if we issue additional shares of our capital stock in the future, our existing stockholders will be
diluted.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Certificate of Incorporation authorize the issuance of up
to 100,000,000 shares of our common stock and up to 50,000,000 shares of preferred stock with the rights, preferences and privileges
that our Board of Directors may determine from time to time. As of May 31, 2016, we had 44,863,179 shares of our common stock issued
and outstanding, which represents approximately 45% of our total authorized shares of common stock. In addition to capital raising
activities, which we expect to continue to pursue in order to raise the funding we will need in order to continue our operations,
other possible business and financial uses for our authorized capital stock include, without limitation, future stock splits, acquiring
other companies, businesses or products in exchange for shares of our capital stock, issuing shares of our capital stock to partners
or other collaborators in connection with strategic alliances, attracting and retaining employees by the issuance of additional
securities under our equity compensation plans, or other transactions and corporate purposes that our Board of Directors deems
are in the best interest of our company. Additionally, shares of our capital stock could be used for anti-takeover purposes or
to delay or prevent changes in control or our management. Any future issuances of shares of our capital stock may not be made on
favorable terms or at all, they may not enhance stockholder value, they may have rights, preferences and privileges that are superior
to those of our common stock, and they may have an adverse effect on our business or the trading price of our common stock. The
issuance of any additional shares of our common stock will reduce the book value per share and may contribute to a reduction in
the market price of the outstanding shares of our common stock. Additionally, any such issuance will reduce the proportionate ownership
and voting power of all of our current stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Sales of a substantial number of shares of our common
stock in the public market, or the perception that such sales could occur, could cause our stock price to fall.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If our existing stockholders sell, or indicate an intention
to sell, substantial amounts of our common stock in the public market after the legal restrictions on resale discussed in this
prospectus lapse or after those shares become registered for resale pursuant to an effective registration statement, the trading
price of our common stock could decline. We have registered for resale under the Securities Act an aggregate of 2,463,080 shares
of our common stock held by former Luoxis and Vyrix shareholders and those shares are freely tradable without restriction, except
for shares held by our affiliates, and any sales of those shares or any perception in the market that such sales may occur could
cause the trading price of our common stock to decline. We also have registered for resale 7,879,096 shares issued in February
2016 upon the conversion of 2015 convertible notes and 267,052 shares of common stock issuable upon the exercise of warrants at
an exercise price of $0.65 per share issued in February 2016 to the placement agents for the 2015 convertible notes. In addition,
of the shares offered hereby, an aggregate of 3,937,470 are issuable upon the exercise of warrants. The perception of these possible
issuances and sales could negatively impact the price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, shares of common stock that are reserved for future
issuance under our 2015 Stock Plan and any future equity incentive plans will become eligible for sale in the public market to
the extent permitted by the provisions of various vesting schedules, Rule 144 and Rule 701 under the Securities Act, and any future
registration of such shares under the Securities Act. If these additional shares of common stock are sold, or if it is perceived
that they will be sold, in the public market, the trading price of our common stock could decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Future sales and issuances of our common stock or rights
to purchase common stock, including pursuant to our equity incentive plan or otherwise, could result in dilution of the percentage
ownership of our stockholders and could cause our stock price to fall.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect that significant additional capital will be needed
in the future to continue our planned operations. To raise capital, we may sell common stock, convertible securities or other equity
securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible
securities or other equity securities in more than one transaction, investors in a prior transaction may be materially diluted
by subsequent sales. Additionally, any such sales may result in material dilution to our existing stockholders, and new investors
could gain rights, preferences and privileges senior to those of holders of our common stock. Further, any future sales of our
common stock by us or resales of our common stock by our existing stockholders could cause the market price of our common stock
to decline. Any future grants of options, warrants or other securities exercisable or convertible into our common stock, or the
exercise or conversion of such shares, and any sales of such shares in the market, could have an adverse effect on the market price
of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Some provisions of our charter documents and applicable
Delaware law may discourage an acquisition of us by others, even if the acquisition may be beneficial to some of our stockholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Provisions in our Certificate of Incorporation and Amended and
Restated Bylaws, as well as certain provisions of Delaware law, could make it more difficult for a third-party to acquire us, even
if doing so may benefit some of our stockholders. These provisions include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">the authorization of 50,000,000 shares of &ldquo;blank check&rdquo; preferred stock, the rights, preferences and privileges
of which may be established and shares of which may be issued by our Board of Directors at its discretion from time to time and
without stockholder approval;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">limiting the removal of directors by the stockholders;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">allowing for the creation of a staggered board of directors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">eliminating the ability of stockholders to call a special meeting of stockholders; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20pt">
</TD>
    <TD STYLE="width: 20pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid">&bull;</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid; text-align: left">establishing advance notice requirements
        for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These provisions may frustrate or prevent any attempts by our
stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our
board of directors, which is responsible for appointing the members of our management. In addition, we are subject to Section 203
of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in any of a broad range
of business combinations with an interested stockholder for a period of three years following the date on which the stockholder
became an interested stockholder, unless such transactions are approved by the board of directors. This provision could have the
effect of discouraging, delaying or preventing someone from acquiring us or merging with us, whether or not it is desired by or
beneficial to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any provision of our Certificate of Incorporation or Bylaws
or of Delaware law that is applicable to us that has the effect of delaying or deterring a change in control could limit the opportunity
for our stockholders to receive a premium for their shares of our common stock in the event that a potentially beneficial acquisition
is discouraged, and could also affect the price that some investors are willing to pay for our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The elimination of personal liability against our directors
and officers under Delaware law and the existence of indemnification rights held by our directors, officers and employees may result
in substantial expenses.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Certificate of Incorporation and our Bylaws eliminate the
personal liability of our directors and officers to us and our stockholders for damages for breach of fiduciary duty as a director
or officer to the extent permissible under Delaware law. Further, our Certificate of Incorporation and our Bylaws and individual
indemnification agreements we intend to enter with each of our directors and executive officers provide that we are obligated to
indemnify each of our directors or officers to the fullest extent authorized by the Delaware law and, subject to certain conditions,
advance the expenses incurred by any director or officer in defending any action, suit or proceeding prior to its final disposition.
Those indemnification obligations could expose us to substantial expenditures to cover the cost of settlement or damage awards
against our directors or officers, which we may be unable to afford. Further, those provisions and resulting costs may discourage
us or our stockholders from bringing a lawsuit against any of our current or former directors or officers for breaches of their
fiduciary duties, even if such actions might otherwise benefit our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We do not intend to pay cash dividends on our capital
stock in the foreseeable future.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have never declared or paid any dividends on our common stock and do not anticipate
paying any dividends in the foreseeable future. Any future payment of cash dividends in the future would depend on our financial
condition, contractual restrictions, solvency tests imposed by applicable corporate laws, results of operations, anticipated cash
requirements and other factors and will be at the discretion of the our Board of Directors. Our stockholders should not expect
that we will ever pay cash or other dividends on our outstanding capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_004"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus, including the sections entitled &ldquo;Risk
Factors,&rdquo; &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and &ldquo;Business,&rdquo;
contains forward-looking statements that are based on our management&rsquo;s belief and assumptions and on information currently
available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable,
these statements relate to future events or our future financial performance, and involve known and unknown risks, uncertainties
and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different
from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.
Forward-looking statements in this prospectus include, but are not limited to, statements about:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">the commercial success and market acceptance of any of our products
and product candidates that are approved for marketing in the United States or other countries;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">the accuracy of our estimates of the size and characteristics of the
markets that may be addressed by our products and product candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt; text-align: left"></TD><TD STYLE="width: 20pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to manufacture sufficient amounts of our product candidates
for clinical trials and our products for commercialization activities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">our need for, and ability to raise, additional capital;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the number, designs, results and timing of our clinical trials;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the regulatory review process and any regulatory approvals that may
be issued or denied by the U.S. Food and Drug Administration or other regulatory agencies;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our need to secure collaborators to license, manufacture, market and
sell any products for which we receive regulatory approval in the future;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to protect our intellectual property and operate our business
without infringing upon the intellectual property rights of others;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the medical benefits, effectiveness and safety of our products and
product candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt; text-align: left"></TD><TD STYLE="width: 20pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the safety and efficacy of medicines or treatments introduced by competitors
that are targeted to indications which our products and product candidates have been developed to treat;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our current or prospective collaborators&rsquo; compliance or non-compliance
with their obligations under our agreements with them; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">other factors discussed elsewhere in this prospectus.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In some cases, you can identify forward-looking statements by
terminology such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expects,&rdquo; &ldquo;intends,&rdquo;
&ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential,&rdquo;
&ldquo;continue&rdquo; or the negative of these terms or other comparable terminology. These statements are only predictions. You
should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other
factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual
results to differ materially from current expectations include, among other things, those listed under &ldquo;Risk Factors&rdquo;
and elsewhere in this prospectus. Actual events or results may vary significantly from those implied or projected by the forward-looking
statements. No forward-looking statement is a guarantee of future performance. You should read this prospectus and the documents
that we reference in this prospectus and have filed with the Securities and Exchange Commission as exhibits to this prospectus
completely and with the understanding that our actual future results may be materially different from any future results expressed
or implied by these forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The forward-looking statements in this prospectus represent
our views as of the date of this prospectus. We anticipate that subsequent events and developments will cause our views to change.
However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention
of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements
as representing our views as of any date subsequent to the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_005"></A>USE OF PROCEEDS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The 3,666,698 shares currently outstanding that are being
offered for resale by the selling stockholders will be sold for the accounts of the selling stockholders named in this prospectus.
As a result, all proceeds from the sales of the 3,666,698 shares of common stock currently outstanding and offered for resale
hereby will go to the selling stockholders and we will not receive any proceeds from the resale of those shares of common stock
by the selling stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may receive up to a total of $1,941,658 in gross proceeds
if all of the warrants are exercised hereunder for cash. However, as we are unable to predict the timing or amount of potential
exercises of the warrants, we have not allocated any proceeds of such exercises to any particular purpose. Accordingly, all such
proceeds are allocated to working capital. It is possible that the warrants may expire and may never be exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">After the exercise of any of the warrants, we would not receive
any proceeds from the resale of those shares by the selling stockholders because those shares will be sold for the accounts of
the selling stockholders named in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will incur all costs associated with this registration statement
and prospectus.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_006"></A>MARKET FOR COMMON STOCK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is quoted on the OTCQX under the symbol &ldquo;AYTU.&rdquo;
Prior to December 14, 2015, our common stock was quoted on the OTCQB Market. The following table sets forth the range of bid and
asked closing quotations for our common stock on the OTCQX or OTCQB, for the periods shown. The quotations represent inter-dealer
prices without retail markup, markdown or commission, and may not necessarily represent actual transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended June 30, 2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">High</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Low</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">First Quarter</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3.04</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2.43</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.26</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.43</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.09</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.17</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fourth Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10.35</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.45</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended June 30, 2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">High</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Low</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">First Quarter</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2.45</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2.01</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.31</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.31</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.04</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.95</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fourth Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">11.81</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.43</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year
    Ending June 30, 2016</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">High</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Low</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">First Quarter</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.75</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.63</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Second Quarter</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.75</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.14</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Third Quarter</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.50</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.56</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fourth Quarter (through June 28, 2016)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.63</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.30</FONT></TD><TD STYLE="text-align: left"></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 28, 2016, the closing price as reported on the OTCQX
of our common stock was $0.39. As of June 28, 2016, there were 473 holders of record of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Equity Compensation Plan Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In June 2015, our shareholders approved the adoption of a stock
and option award plan (the &ldquo;2015 Plan&rdquo;), under which 10,000,000 shares were reserved for future issuance under restricted
stock awards, options, and other equity awards. The 2015 Plan permits grants of equity awards to employees, directors and consultants.
The following table displays equity compensation plan information as of June 30, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Plan Category</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Securities to<BR> be Issued upon Exercise<BR> of Outstanding<BR> Options (a)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted-Average<BR> Exercise Price of<BR> Outstanding Options (b)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Securities Remaining<BR> Available for Issuance under<BR> Equity Compensation Plans<BR> (Excluding Securities Reflected<BR> in Column (a))(c)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left">Equity compensation plans approved by security holders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">10,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Equity compensation plans not approved by security holders</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Total</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">10,000,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with our private placement of approximately $5.2
million of convertible notes in July and August 2015, we are obligated to issue to the placement agents warrants for an amount
of shares equal to 8% of the number of shares of our common stock issued upon conversion of the notes and any accrued interest.
The placement agents&rsquo; warrant has a term of five years from the date of issuance of the related notes in July and August
2015, will have an exercise price equal to 100% of the price per share at which equity securities are sold in our next equity financing,
and provides for cashless exercise. Those warrants were not approved by our stockholders. In connection with the conversion of
a portion of the notes in February 2016, which was triggered by an equity financing in January 2016, we issued warrants to the
placement agents to purchase an aggregate of 267,052 shares of our common stock at an exercise price of $0.65 per share. In connection
with the conversion of the remaining portion of the notes in May 2016, which was triggered by our public offering that month, we
issued warrants to the placement agents to purchase an aggregate of 270,772 shares of our common stock at an exercise price of
$0.40 per share. In connection with our May 2016 public offering, we issued warrants to purchase an aggregate of 1,312,500 shares
of common stock to the underwriters of the public offering. Since June 30, 2015, we also have issued options to purchase common
stock. As a result of these warrant and option issuances, as of May 31, 2016, we had outstanding (i) under our 2015 Plan options
to purchase an aggregate of 3,867,500 shares of common stock with a weighted average exercise price of $1.50 per share, and had
an aggregate of 6,132,500 shares available for the grant of other equity awards under the 2015 Plan, and (ii) warrants to purchase
an aggregate of 1,850,324 shares of common stock with a weighted average exercise price of $0.51 per share, which warrants are
considered equity compensation not approved by our stockholders.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_007"></A>DIVIDEND POLICY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have not paid any cash dividends on our common stock and
our Board of Directors presently intends to continue a policy of retaining earnings, if any, for use in our operations. The declaration
and payment of dividends in the future, of which there can be no assurance, will be determined by the Board of Directors in light
of conditions then existing, including earnings, financial condition, capital requirements and other factors. Delaware law prohibits
us from declaring dividends where, if after giving effect to the distribution of the dividend:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">we would not be able to pay our debts as they become due in the usual
course of business; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">our total assets would be less than the sum of our total liabilities
plus the amount that would be needed to satisfy the rights of stockholders who have preferential rights superior to those receiving
the distribution.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except as set forth above, there are no restrictions that currently
materially limit our ability to pay dividends or which we reasonably believe are likely to limit materially the future payment
of dividends on common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Board of Directors has the right to authorize the issuance
of preferred stock, without further stockholder approval, the holders of which may have preferences over the holders of our common
stock as to payment of dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_008"></A>MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AND RESULTS OF OPERATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a commercial-stage specialty healthcare company concentrating
on developing and commercializing products with an initial focus on urological diseases and conditions. We are currently focused
on addressing significant medical needs in the areas of urological cancers, hypogonadism, urinary tract infections, male infertility,
and sexual dysfunction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Through a multi-step reverse triangular merger, on April 16,
2015, Vyrix Pharmaceuticals, Inc. (&lsquo;&lsquo;Vyrix&rsquo;&rsquo;) and Luoxis Diagnostics, Inc. (&lsquo;&lsquo;Luoxis&rsquo;&rsquo;)
merged with and into our Company (herein referred to as the Merger) and we abandoned our pre-merger business plans to solely pursue
the specialty healthcare market, including the business of Vyrix and Luoxis. In the Merger, we acquired the RedoxSYS, MiOXSYS and
Zertane products. On June 8, 2015, we reincorporated as a domestic Delaware corporation under Delaware General Corporate Law and
changed our name from Rosewind Corporation to Aytu BioScience, Inc., and effected a reverse stock split in which each common stock
holder received one share of common stock for each every 12.174 shares outstanding (herein referred to as the Reverse Stock Split).
All share and per share amounts in this report have been adjusted to reflect the effect of the Reverse Stock Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In May 2015, we entered into an asset purchase agreement with
Jazz Pharmaceuticals, Inc., pursuant to which we purchased assets related to Jazz Pharmaceuticals&rsquo; product known as ProstaScint
(capromab pendetide), including certain intellectual property and contracts, and the product approvals, inventory and work in progress
(together, the &lsquo;&lsquo;ProstaScint Business&rsquo;&rsquo;), and assumed certain of Jazz Pharmaceuticals&rsquo; liabilities,
including those related to product approvals and the sale and marketing of ProstaScint. The purchase price consists of the upfront
payment of $1.0 million. We also agreed to pay an additional $500,000 payable within five days after transfer for the ProstaScint-related
product inventory and $227,000 payable on September 30, 2015 (which represents a portion of certain FDA fees). We also will pay
8% on its net sales made after October 31, 2017, payable up to a maximum aggregate payment of an additional $2.5 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In October 2015, we entered into an asset purchase agreement
with FSC Laboratories, Inc., or FSC. Pursuant to the agreement, we purchased assets related to FSC&rsquo;s product known as Primsol
(trimethoprim solution), including certain intellectual property and contracts, inventory, work in progress and all marketing and
sales assets and materials related solely to Primsol (together, the &lsquo;&lsquo;Primsol Business&rsquo;&rsquo;), and assumed
certain of FSC&rsquo;s liabilities, including those related to the sale and marketing of Primsol arising after the closing. We
paid $500,000 at closing for the Primsol Business and we paid an additional $142,000, of which $102,000 went to inventory and $40,000
towards the Primsol Business, for the transfer of the Primsol-related product inventory. We also paid $500,000 on April 1, 2016
and agreed to pay an additional (a) $500,000 no later than June 30, 2016, and (b) $250,000 no later than September 30, 2016 (together,
the &lsquo;&lsquo;Installment Payments&rsquo;&rsquo;), for a total purchase price of $1,892,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In October 2015, we and Biovest International, Inc., or Biovest,
(whose contract manufacturing business is now known as Cell Culture Company, or C3) entered into a Master Services Agreement, pursuant
to which Biovest is to provide manufacturing services to us for our product ProstaScint. The agreement provides that we may engage
Biovest from time to time to provide services in accordance with mutually agreed upon project addendums and purchase orders for
ProstaScint. We expect to use the agreement from time to time for manufacturing services, including without limitation, the manufacturing,
processing, quality control testing, release or storage of ProstaScint. The agreement provides customary terms and conditions,
including those for performance of services by Biovest in compliance with project addendums, industry standards, regulatory standards
and all applicable laws. Biovest will be responsible for obtaining and maintaining all governmental approvals, at our expense,
during the term of the agreement. The agreement has a term of four years, provided that either party may terminate the agreement
or any project addendum under the agreement on 30 days written notice of a material breach under the agreement. In addition, we
may terminate the agreement or any project addendum under the agreement upon 180 days written notice for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In April 2016, we entered into a license and supply agreement
to acquire the exclusive U.S. rights to Natesto nasal gel from Acerus Pharmaceuticals Corporation, or Acerus, which rights we will
acquire effective upon the expiration of the current licensee&rsquo;s rights, expected to occur on June 30, 2016. We paid Acerus
an upfront fee of $2.0 million upon execution of the agreement. On September 5, 2016 we will pay an additional $2.0 million. On
January 1, 2017, we will pay an additional $4.0 million. We also purchased on April 28, 2016, an aggregate of 12,245,411 shares
of Acerus common stock for Cdn.$2,534,800 (approximately US$2.0 million), with a purchase price per share equal to Cdn.$0.207 or
approximately US$0.16 per share. We cannot dispose of these shares until August 29, 2016. We also agreed to make various payments
up to an aggregate of $37.5 million based on net sales of Natesto. During the term of the agreement, we will purchase all of our
Natesto product needs from Acerus at a designated price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In May 2016, we sold in an underwritten public offering of 18,750,000
shares of our common stock, par value $0.0001 per share, and warrants to purchase up to an aggregate 18,750,000 shares of common
stock at a combined public offering price of $0.40 per share and related warrant. Each warrant is exercisable for five years from
issuance and have an exercise price equal to $0.50. In addition, we granted the underwriters a 45-day option to purchase up to
an additional 2,812,500 shares of common stock and/or 2,812,500 additional warrants. The underwriters elected a partial exercise
their over-allotment option to purchase 2,049,250 warrants. The net proceeds from the sale of the shares was approximately $6.7
million, after deducting underwriting discounts and commissions and estimated offering expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date, we have financed operations through a combination of
private and public debt and equity financings including net proceeds from the private placements of stock and convertible notes.
Although it is difficult to predict our liquidity requirements, based upon our current operating plan, we believe we will have
sufficient cash to meet our projected operating requirements for at least the next 12 months. See &ldquo;Liquidity and Capital
Resources.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have only begun to generate revenues from the commercialization
of our product candidates in the last few quarters. We have recognized approximately $1.6 million in revenue from ProstaScint,
Primsol and RedoxSYS sales during the nine month period ended March 31, 2016. We have incurred accumulated net losses since our
inception, and at we had an accumulated deficit of $31.3 million. Our net loss was $12.9 million for the nine months ended March
31, 2016 and we had used $8.0 million in cash from operations during the same period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Significant Accounting Policies and Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Basis of Presentation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These historical financial statements prior to April 16, 2015
include the financial statements of Vyrix from its inception in November 2013, combined with the carve-out financial statements
related to the Vyrix Acquired Assets from March 23, 2011, the date Ampio originally acquired the Vyrix assets (the &ldquo;Vyrix
Acquired Assets&rdquo;) through its merger with DMI BioSciences, Inc. (&ldquo;BioSciences&rdquo;) and the financial statements
of Luoxis from its inception in January 2013, combined with the carve-out financial statements related to Luoxis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The carve-out financial statements present the statements of
financial position of Vyrix and Luoxis and the Vyrix Acquired Assets and the statement of operations and cash flows for purposes
of presenting complete comparative stand-alone financial statements in accordance with Regulation S-X, Article 3, <I>General Instructions
to Financial Statements, and Staff Accounting Bulletin Topic 1-B1, Costs Reflected in Historical Financial Statements</I>. Historically,
financial statements have not been prepared for Vyrix and Luoxis, as they were not held in a separate legal entity. Although Vyrix
and Luoxis have not been segregated as a separate legal entity, related revenues, direct costs and expenses, assets and liabilities
have historically been segregated on Ampio&rsquo;s books. In addition, we allocated corporate overhead costs based on a review
of specific labor and other overhead expenses and a reasonable estimate of activities related to Vyrix and Luoxis. Allocated labor
and other overhead totaled $264,000 in 2015 and $253,000 in 2014. We also prepared a calculation of income tax expense and deferred
income tax assets and liabilities on a &ldquo;separate return&rdquo; basis (see Note 4 &ndash; Income Taxes). These financial statements
do not include a carve-out for cash as the operations have historically been funded by Ampio. The historical carve-out financial
statements may not be indicative of the future results of Vyrix and Luoxis as a stand-alone entities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;We&rdquo;, &ldquo;us&rdquo; and &ldquo;our&rdquo; as
referred to herein include Vyrix and Luoxis, collectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Cash and Cash Equivalents</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We consider all highly liquid instruments purchased with an
original maturity of three months or less to be cash equivalents. Cash equivalents consist primarily of money market fund investments.
Our investment policy is to preserve principal and maintain liquidity. We periodically monitor our positions with, and the credit
quality of, the financial institutions with which we invest. Periodically, throughout the year, we have maintained balances in
excess of federally insured limits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Accrued Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accrued compensation consists of a 2016 employee bonus accrual.
As of the filing date of this report, a majority of the bonus had not been paid. The Board of Directors will evaluate the payment
of the bonus the first part of fiscal 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0pt; text-align: justify"><B><I>Revenue
Recognition/Deferred Revenue</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><I>Product &amp; Service Sales</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recognize revenue from product and service sales when there
is persuasive evidence that an arrangement exists, delivery has occurred or service has been rendered, the price is fixed or determinable
and collectability is reasonably assured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><I>License Agreements and Royalties</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payments received upon signing of license agreements are for
the right to use the license and are deferred and amortized over the lesser of the license term or patent life of the licensed
drug. Milestone payments relate to obtaining regulatory approval in the territories, cumulative sales targets, and other projected
milestones and are recognized at the time the milestone requirements are achieved. Royalties will be recognized as revenue when
earned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Estimated Sales Returns and Allowances</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We record estimated reductions in revenue for potential returns
of products by customers. As a result, management must make estimates of potential future product returns and other allowances
related to current period product revenue. In making such estimates, management analyzes historical returns, current economic trends
and changes in customer demand and acceptance of our products. If management were to make different judgments or utilize different
estimates, material differences in the amount of our reported revenue could result.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Fixed Assets</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fixed assets are recorded at cost and after being placed in
service, are depreciated using the straight-line method over estimated useful lives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>In-Process Research and Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In-process research and development, or IPRD, relates to the
Zertane product and clinical trial data acquired in connection with the 2011 business combination of BioSciences. The $7.5 million
recorded was based on an independent, third party appraisal of the fair value of the assets acquired. IPRD is considered an indefinite-lived
intangible asset and its fair value will be assessed annually and written down if impaired. Once the Zertane product obtains regulatory
approval and commercial production begins, IPRD will be reclassified to an intangible that will be amortized over its estimated
useful life. If Aytu decided to abandon the Zertane product, the IPRD would be expensed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Patents</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Costs of establishing patents, consisting of legal and filing
fees paid to third parties, are expensed as incurred. The fair value of the Zertane patents, determined by an independent, third
party appraisal to be $500,000, acquired in connection with the 2011 acquisition of BioSciences is being amortized over the remaining
U.S. patent life since our acquisition of approximately 11 years. The fair value of the Luoxis patents was $380,000 when they were
acquired in connection with the 2013 formation of Luoxis and is being amortized over the remaining U.S. patent life since our acquisition
of approximately 15 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Business Combinations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company accounts for its business acquisitions under the
acquisition method of accounting as indicated in the Financial Accounting Standards Board&rsquo;s, or FASB, Accounting Standards
Codification, or ASC, 805, &ldquo;Business Combinations&rdquo;, which requires the acquiring entity in a business combination to
recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree; and establishes
the acquisition date as the fair value measurement point. Accordingly, we recognize assets acquired and liabilities assumed in
business combinations, including contingent assets and liabilities and non-controlling interest in the acquiree, based on the fair
value estimates as of the date of acquisition. In accordance with ASC 805, we recognize and measure goodwill as of the acquisition
date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Goodwill</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The ProstaScint and Primsol purchase price allocations were
based upon an analysis of the fair value of the assets and liabilities acquired. The final purchase price may be adjusted up to
one year from the date of the acquisition. Identifying the fair value of the tangible and intangible assets and liabilities acquired
required the use of estimates by management, and were based upon currently available data, as noted below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We allocated the excess of purchase price over the identifiable
intangible and net tangible assets to goodwill. Such goodwill is not deductible for tax purposes and represents the value placed
on entering new markets and expanding market share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We test our goodwill for impairment annually, or whenever events
or changes in circumstances indicate an impairment may have occurred, by comparing the carrying value to its implied fair value.
Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market conditions,
adverse changes in applicable laws or regulations and a variety of other circumstances. If we determine that an impairment has
occurred, we are required to record a write-down of the carrying value and charge the impairment as an operating expense in the
period the determination is made. In evaluating the recoverability of the carrying value of goodwill, we must make assumptions
regarding estimated future cash flows and other factors to determine the fair value of the acquired assets. Changes in strategy
or market conditions could significantly impact those judgments in the future and require an adjustment to the recorded balances.
The goodwill was recorded as part of the acquisition of ProstaScint that occurred in May 2015 and the acquisition of Primsol that
occurred in October 2015. There was no impairment of goodwill at March 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Use of Estimates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The preparation of financial statements in accordance with Generally
Accepted Accounting Principles in the United States of America, or GAAP, requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities as of the date of
the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant items subject
to such estimates and assumptions include the fair value of warrant derivative liability, hybrid debt instruments, valuation allowances,
stock-based compensation, useful lives of fixed assets, estimates of contingent consideration in business combinations and assumptions
in evaluating impairment of indefinite lived assets. Actual results could differ from these estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Derivatives</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We account for financial instruments (convertible debt with
embedded derivative features &ndash; conversion options and conversion provisions) and related warrants by recording the fair value
of each instrument in its entirety and recording the fair value of the warrant derivative liability. The warrants related to the
convertible promissory notes were calculated using a Monte Carlo based valuation model. We recorded a derivative expense at the
inception of the instrument reflecting the difference between the fair value at issuance compared to the fair value as of March
31, 2016. Changes in the fair value in subsequent periods will be recorded as unrealized gain or loss on fair value of debt instruments
for the financial instruments and to derivative income or expense for the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Income Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are included in the consolidated tax returns of Ampio. Our
taxes are computed and reported on a &ldquo;separate return&rdquo; basis for these financial statements. Deferred taxes are provided
on an asset and liability method whereby deferred tax assets are recognized for deductible temporary differences and operating
loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences
are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced
by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred
tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates
on the date of enactment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The amount of income taxes and related income tax positions
taken would be subject to audits by federal and state tax authorities if we filed these taxes on a separate basis. We have adopted
accounting guidance for uncertain tax positions which provides that in order to recognize an uncertain tax benefit, the taxpayer
must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount
that is more than 50% likely to be realized upon settlement with the taxing authority. We believe that we have no material uncertain
tax positions. Our policy is to record a liability for the difference between the benefits that are both recognized and measured
pursuant to the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) Accounting Standards Codification(&ldquo;ASC&rdquo;)
740-10, Accounting for Uncertainty in Income Taxes&mdash;an interpretation of FASB Statement No. 109 (&ldquo;ASC 740-10&rdquo;)
and tax position taken or expected to be taken on the tax return. Then, to the extent that the assessment of such tax positions
changes, the change in estimate is recorded in the period in which the determination is made. We report tax-related interest and
penalties as a component of income tax expense. During the periods reported, our management has concluded that no significant tax
position requires recognition under ASC 740-10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Stock-Based Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We account for share based payments by recognizing compensation
expense based upon the estimated fair value of the awards on the date of grant. We determine the estimated grant fair value using
the Black-Scholes option pricing model and recognize compensation costs ratably over the vesting period using the graded method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Research and Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development costs are expensed as incurred with
expense recorded in the respective periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Fair Value of Financial Instruments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The carrying amounts of financial instruments, including cash
and cash equivalents, accounts receivable, accounts payable and accrued liabilities and convertible notes are carried at cost which
approximates fair value due to the short maturity of these instruments. The fair value of warrants issued in connection with the
Aytu convertible notes was valued using a Monte Carlo option pricing model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Impairment of Long-Lived Assets</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We routinely perform an annual evaluation of the recoverability
of the carrying value of our long-lived assets to determine if facts and circumstances indicate that the carrying value of assets
or intangible assets may be impaired and if any adjustment is warranted. Based on its evaluation as of June 30, 2015 and 2014,
respectively, no impairment existed for long-lived assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Adoption of Newly Issued Accounting Pronouncements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In September 2015, the Financial Accounting Standards Board
(&ldquo;FASB&rdquo;) issued Accounting Standards Update (&ldquo;ASU&rdquo;) 2015-16, &ldquo;Business Combinations (Topic 805):
Simplifying the Accounting for Measurement-Period Adjustments,&rdquo; which requires that an acquirer recognize adjustments to
estimated amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are
determined. The amendments require that the acquirer record, in the same period&rsquo;s financial statements, the effect on earnings
of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the estimated amounts,
calculated as if the accounting had been completed at the acquisition date. The amendments also require an entity to present separately
on the face of the income statement or disclose in the notes the portion of the amount recorded in current-period earnings by line
item that would have been recorded in previous reporting periods if the adjustment to the estimated amounts had been recognized
as of the acquisition date. The amendment is effective for financial statements issued for fiscal years beginning after December
15, 2015 and early adoption is permitted. During the quarter ended September 30, 2015, the Company early adopted this standard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In April 2015, the FASB issued ASU 2015-03, &ldquo;Interest-Imputation
of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs&rdquo; to simplify the presentation of debt
issuance costs. The amendments in the update require that debt issuance costs related to a recognized debt liability be presented
in the balance sheet as a direct reduction of the carrying amount of the debt. Recognition and measurement of debt issuance costs
were not affected by this amendment. In August 2015, FASB issued ASU 2015-15, &ldquo;Presentation and Subsequent Measurement of
Debt Issuance Costs Associated with Line-of-Credit Arrangements &mdash; Amendments to SEC Paragraphs Pursuant to Staff Announcement
at June 18, 2015 EITF Meeting&rdquo; which clarified that the SEC would not object to an entity deferring and presenting debt issuance
costs as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit arrangement.
The amendments are effective for financial statements issued for fiscal years beginning after December 15, 2015. During the quarter
ended September 30, 2015, the Company early adopted this standard and recorded debt issuance costs as a debt discount. There was
no impact related to this adoption as the Company did not have any debt issuance costs prior to adoption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In November 2015, the FASB issued ASU No. 2015-17 regarding
ASC Topic 470 &quot;Income Taxes: Balance Sheet Classification of Deferred Taxes.&quot; The amendments in ASU 2015-17 eliminate
the requirement to bifurcate deferred taxes between current and non-current on the balance sheet and requires that deferred tax
liabilities and assets be classified as noncurrent on the balance sheet. The amendments for ASU-2015-17 can be applied retrospectively
or prospectively and early adoption is permitted. Aytu early adopted ASU 2015-17 and there was no material impact on its financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Recently Issued Accounting Pronouncements, Not Adopted
as of March 31, 2016</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In March 2016, the FASB issued Accounting Standards Update No.
2016-09, &ldquo;Compensation &ndash;Stock Compensation (Topic 718): Improvements to Employee Share Based Payment Accounting&rdquo;.
The standard includes multiple provisions intended to simplify various aspects of the accounting for share based payments. The
amendments are expected to significantly impact net income, EPS, and the statement of cash flows. Implementation and administration
may present challenges to companies with significant share based payment activities. The amendments are effective for public entities
for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted
in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. The Company
is currently evaluating the impact of this standard on its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2016, the FASB issued Accounting Standards Update
2016-02, &ldquo;Leases (Topic 842)&rdquo;. The new standard establishes a right-of-use (ROU) model that requires a lessee to record
a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified
as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new
standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years.
A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into
after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients
available. The Company is currently evaluating the impact of its pending adoption of this standard on its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January 2016, the FASB issued ASU 2016-01, &ldquo;Financial
Instruments &ndash; Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities,&rdquo;
which requires that all equity investments be measured at fair value with changes in the fair value recognized through net income
(other than those accounted for under the equity method of accounting or those that result in consolidation of the investee). The
amendments in this update also require an entity to present separately in other comprehensive income the portion of the total change
in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to
measure the liability at fair value in accordance with the fair value option for financial instruments. In addition, the amendments
in this update eliminate the requirement to disclose the fair value of financial instruments measured at amortized cost for entities
that are not public business entities and the requirement to disclose the method(s) and significant assumptions used to estimate
the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet for public
business entities. The amendment is effective for financial statements issued for fiscal years beginning after December 15, 2017.
Early adoption is not permitted. The Company is currently evaluating the impact of this standard on its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In July 2015, the FASB issued ASU 2015-11, &ldquo;Simplifying
the Measurement of Inventory.&rdquo; ASU 2015-11 clarifies that inventory should be held at the lower of cost or net realizable
value. Net realizable value is defined as the estimated selling price, less the estimated costs to complete, dispose and transport
such inventory. ASU 2015-11 will be effective for fiscal years and interim periods beginning after December 15, 2016. ASU 2015-11
is required to be applied prospectively and early adoption is permitted. The adoption of ASU 2015-11 is not expected to have a
material impact on the Company&rsquo;s financial position or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In August 2014, the FASB issued ASU 2014-15, &ldquo;Presentation
of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&rsquo;s Ability to Continue
as a Going Concern&rdquo; (&ldquo;ASU 2014-15&rdquo;). ASU 2014-15 is intended to define management&rsquo;s responsibility to evaluate
whether there is substantial doubt about an organization&rsquo;s ability to continue as a going concern and to provide related
footnote disclosures. The amendments in this ASU are effective for reporting periods ending after December 15, 2016, with early
adoption permitted. The Company is evaluating the impact the adoption of ASU 2014-15 will have on its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In May 2014, the FASB issued ASU 2014-09 regarding ASC Topic
606, &ldquo;Revenue from Contracts with Customers&rdquo;. The standard provides principles for recognizing revenue for the transfer
of promised goods or services to customers with the consideration to which the entity expects to be entitled in exchange for those
goods or services. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers: Deferral of the Effective
Date, which deferred the effective date of the new revenue standard for periods beginning after December 15, 2017, with early adoption
permitted. In March 2016, the FASB issued ASU 2016-08, which addresses principal versus agent considerations. The Company is currently
evaluating the effect that the updated standard will have on its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of Operations &ndash; Year Ended June 30, 2015 Compared
to Year Ended June 30, 2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Results of operations for the year ended June 30, 2015 (&ldquo;2015&rdquo;)
and the year ended June 30, 2014 (&ldquo;2014&rdquo;) reflected losses of approximately $7,723,000 and $5,579,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Revenue</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have not generated significant revenue in our operating history,
although we do expect to begin generating material revenues in the next fiscal year. We recognized revenue during 2015 and 2014
of $262,000 and $59,000, respectively. In 2012, we received a payment of $500,000 under our license agreement for Zertane with
a Korean pharmaceutical company. This payment was deferred and is being recognized over 10 years. In 2014, we received a payment
of $250,000 under our license agreement for Zertane with a Canadian-based supplier. This payment was deferred and is being recognized
over seven years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The $176,000 product and service revenue recognized in 2015
represents sales of our ProstaScint product and the RedoxSYS System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Research and Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development costs consist of clinical trials and
sponsored research, labor, stock-based compensation, sponsored research &ndash; related party and consultants and other. These
costs relate solely to research and development without an allocation of general and administrative expenses and are summarized
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years Ended June 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Clinical trials and sponsored research</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">2,244,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">3,411,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Labor</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">411,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">195,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">517,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">244,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Sponsored research - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">204,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">126,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Consultants and other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">47,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">83,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,423,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,059,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Comparison of Years Ended June 30, 2015 and 2014</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses decreased $636,000, or 15.7%,
in 2015 over 2014. This was due primarily to decreased costs in clinical trial and sponsored research related to the Zertane trials.
Research and development expenses could increase in 2016 as compared to the 2015 level depending on how we proceed with the Zertane
trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>General and Administrative</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">General and administrative expenses consist of personnel costs
for employees in executive, business development and operational functions and director fees; stock-based compensation; patents
and intellectual property; professional fees including legal, auditing and accounting; occupancy, travel and other including rent,
governmental and regulatory compliance, insurance, investor/public relations and professional subscriptions. These costs are summarized
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years Ended June 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%">Labor</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">979,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">557,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">256,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Patent costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">488,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">582,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,189,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">238,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Occupancy, travel and other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,227,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">714,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,383,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,347,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Comparison of Years Ended June 30, 2015 and 2014</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">General and administrative costs increased $2,036,000, or 86.7%,
in 2015 over 2014. The increase in professional fees, labor costs and stock-based compensation primarily relates to increased costs
related to the Merger and associated SEC filings and legal expenses, professional staffing, bonuses earned and stock options granted
as well as the continuing vesting of stock option awards granted in previous years. Occupancy, travel and other increased due to
the additional travel to commercialize the RedoxSYS System. We expect general and administrative expenses to increase in 2016 due
to the expected overall growth of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Net Cash Used in Operating Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During 2015, our operating activities used $6.6 million in cash.
The use of cash was approximately $1,089,000 lower than the net loss due primarily to non-cash charges for stock-based compensation,
depreciation and amortization, amortization of prepaid research and development related party, an increase in accounts payable
and an increase in contingent consideration related to the ProstaScint asset purchase. Cash used in operating activities also included
a $24,000 deferred tax benefit and $561,000 decrease in payable to Ampio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During 2014, our operating activities used $5.5 million in cash.
The use of cash was approximately $77,000 lower than the net loss due primarily to non-cash charges for stock-based compensation,
depreciation and amortization and an increase in related party payable. Cash used in operating activities also included an $814,000
deferred tax benefit, a $497,000 increase in prepaid expenses and a $465,000 increase in research and development - related party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Net Cash Used in Investing Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During 2015, cash of $1.0 million was used to acquire ProstaScint
as well as deposits for office space.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During 2014, cash of $9,000 was used to purchase fixed assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Net Cash from Financing Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net cash provided by financing activities in 2015 was $12.4
million which reflects a $7.4 million loan from Ampio which was later converted to stock, $5.0 million stock subscription payment
from Ampio, $27,000 paid out to Luoxis option holders pursuant to the Merger and $20,000 paid out for liabilities pursuant to the
Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net cash provided by financing activities in 2014 was $5.2 million
which reflects a $4.6 million loan from Ampio and $637,000 in contributions from Ampio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of Operations &ndash; March 31, 2016 Compared to
March 31, 2015</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Results of operations for the three months ended March 31, 2016
and the three months ended March 31, 2015 reflected losses of approximately $7.3 million and $1.8 million for each period, respectively.
These losses include in part non-cash charges related to the amortization of the beneficial conversion feature, stock-based compensation,
depreciation, amortization and accretion, amortization of debt issuance costs, amortization of prepaid research and development
&ndash; related party and derivative expense collectively in the amount of $4.5 million for the three months ended March 31, 2016
and $327,000 for the three months ended March 31, 2015. The non-cash charges increased in the three months ended March 31, 2016
primarily due to the increase in amortization of the beneficial conversion feature, amortization of intangible assets and derivative
expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Results of operations for the nine months ended March 31, 2016
and the nine months ended March 31, 2015 reflected losses of approximately $12.9 million and $5.6 million for each period, respectively.
These losses include in part non-cash charges related to the amortization of the beneficial conversion feature, stock-based compensation,
depreciation, amortization and accretion, amortization of debt issuance costs, amortization of prepaid research and development
&ndash; related party and derivative expense offset by deferred taxes collectively in the amount of $5.2 million for the nine months
ended March 31, 2016 and $891,000 for the nine months ended March 31, 2015. The non-cash charges increased in the nine months ended
2016 primarily due to the increase in amortization of the beneficial conversion feature, the amortization of intangible assets,
derivative expense, depreciation, amortization and accretion offset by a decrease in stock-based compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Revenue</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.25in; text-indent: 0pt; text-align: justify"><I>Product
and service revenue</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recognized $647,000 and $2,000 for the three months ended
March 31, 2016 and 2015, respectively, related to the sale of our products ProstaScint and Primsol, as well as the RedoxSYS and
MiOXSYS System due to our acquisitions and expanded marketing of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recognized $1,561,000 and $15,000 for the nine months ended
March 31, 2016 and 2015, respectively, related to the sale of our products ProstaScint and Primsol, as well as the RedoxSYS and
MiOXSYS System due to our acquisitions and expanded marketing of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As is customary in the pharmaceutical industry, our gross product
sales are subject to a variety of deductions in arriving at reported net product sales. Provisions for these deductions are recorded
concurrently with the recognition of gross product sales revenue and include discounts, chargebacks, distributor fees, processing
fees, as well as allowances for returns and Medicaid rebates. Provision balances relating to estimated amounts payable to direct
customers are netted against accounts receivable and balances relating to indirect customers are included in accounts payable and
accrued liabilities. The provisions recorded to reduce gross product sales and net product sales are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended March 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left">Gross product and service revenue</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">929,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,093,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">15,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Provisions to reduce gross product sales to net product and service sales</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(282,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(532,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net product and service revenue</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">647,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,561,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">15,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Percentage of provisions to gross sales</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-30.4</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-25.4</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.0</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><I>License revenue</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The $21,000 license revenue recognized in each of the three
months periods ended March 31, 2016 and 2015, and the $64,000 license revenue recognized in each of the nine month periods ended
March 2016 and 2015, respectively, represents the amortization of the upfront payments received on our license agreements. The
initial payment of $500,000 from the license agreement for Zertane with a Korean pharmaceutical company was deferred and is being
recognized over ten years. The initial payment of $250,000 from the license agreement for Zertane with a Canadian-based supplier
was deferred and is being recognized over seven years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.25in; text-indent: 0pt; text-align: justify"><I>Cost
of Sales</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">The cost of sales of $341,000 and $622,000
recognized for the three and nine months ended March 31, 2016, respectively, are related to the ProstaScint and Primsol products
and the RedoxSYS System. We did not recognize any cost of sales for the three and nine months ended March 31, 2015, which predated
the acquisition of our ProstaScint and Primsol products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.25in; text-indent: 0pt; text-align: justify"><I>Research
and Development</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development costs are summarized as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended March 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left">Clinical trials and sponsored research</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">976,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">455,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,882,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,756,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Labor</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">123,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">117,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">333,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">115,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">63,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">323,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Sponsored research - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">144,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">156,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Consultants and other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">30,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">39,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,192,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">742,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,452,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,574,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development costs consist of drug and device
development and clinical trials, labor, as well as stock-based compensation. Costs of research and development increased $450,000,
or 60.6%, for the three months ended March 31, 2016 compared to the three months ended March 31, 2015. Costs of research and development
increased $878,000, or 34.1%, for the nine months ended March 31, 2016 compared to the nine months ended March 31, 2015. The increase
in both periods is primarily due to an increase in clinical trials and sponsored research primarily related to attempting to reproduce
our manufacturing process with a new manufacturer for our ProstaScint product. During the remainder of fiscal year of 2016, we
anticipate our clinical trials and sponsored research to be more than the previous fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.25in; text-indent: 0pt; text-align: justify"><I>Selling,
General and Administrative</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Selling, general and administrative costs are summarized as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended March 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%">Labor</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">958,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">204,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,270,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">530,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">258,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">157,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">484,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">427,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Patent costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">63,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">128,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">229,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">330,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">121,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">334,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">694,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">772,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Occupancy, travel and other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">845,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">247,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,994,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">875,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,245,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,070,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,671,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,934,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Selling, general and administrative costs increased $1,175,000,
or 109.8% for the three months ended March 31, 2016 compared to the three months ended March 31, 2015. Selling, general and administrative
costs increased $2,737,000, or 93.3% for the nine months ended March 31, 2016 compared to the nine months ended March 31, 2015.
The increase in both periods is primarily due to labor as a result of increased staffing due to our commercialization efforts for
our ProstaScint and Primsol products as well as an increase in occupancy, travel and other. We anticipate our selling, general
and administrative costs for the remainder of our fiscal year 2016 to continue to grow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.2pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.2pt"><I>&#9;Amortization of Finite-Lived Intangible
Assets</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amortization of finite-lived intangible assets increased $101,000
for the three months ended March 31, 2016 and $232,000 for the nine months ended March 31, 2016. This expense increased in both
the three month and nine month periods ended March 31, 2016 due to the acquisition of the ProstaScint and Primsol businesses and
the corresponding amortization of their finite-lived intangible assets. As we continue to license and purchase additional assets
as part of our business strategy we would expect this non-cash expense to continue to grow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Net Cash Used in Operating Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the nine month period ended March 31, 2016, our operating
activities used $8.0 million in cash which was less than our net loss of $12.9 million primarily as a result of the increases to
non-cash amortization of the beneficial conversion feature, stock-based compensation, depreciation, amortization and accretion
and the increase in accrued compensation offset by increases in inventory and prepaid expenses and other.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the corresponding 2015 period, our operating activities
used $4.8 million in cash which was less than the net loss of $5.6 million primarily as a result of non-cash stock-based compensation
and a decrease prepaid expenses and other offset by a decrease in related party payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Net Cash Used in Investing Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the nine month period ended March 31, 2016 we used cash
in investing activities of $742,000 to purchase fixed assets of $204,000 and $540,000 was used to acquire the Primsol business.
We also received a returned security deposit of $2,000 during the period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the nine month period ended March 31, 2015, we used cash
of $2,000 for a security deposit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Net Cash from Financing Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net cash provided by financing activities in the nine month
period ended March 31, 2016 of $10.0 million was primarily related to the issuance of convertible promissory notes which reflects
gross proceeds of $5.2 million offset by the cash portion of the debt issuance costs of $298,000 related to the convertible notes,
as well as the $5.0 million stock subscription payment from Ampio and $200,000 for a sale of stock subscriptions offset by the
issuance costs of $30,000 related to the debt conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the corresponding 2015 period, the only proceeds in financing
activities was a $3.7 million contribution from Ampio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Liquidity and Capital Resources</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a relatively young company and we have not yet generated
significant revenue as our primary activities are focused on acquiring, developing and commercializing our primary product candidates,
and raising capital. As of March 31, 2016, we had cash and cash equivalents totaling $8.7 million available to fund our operations
offset by $2.3 million in accounts payable and the Primsol payable. In April 2016, we spent $4.0 million for the Natesto licensing
agreement and have a remaining commitment of $6.0 million during fiscal year 2017. In May 2016, we completed a registered public
offering of common stock and warrants for $6.7 million in proceeds net of expenses. Based upon our resources at March 31, 2016,
and after giving affect to the offering proceeds, we believe we have adequate capital to continue operations into the second half
of fiscal 2017. We also intend to seek additional capital within the next 12 months to help acquire new products as well as to
support general operations. We will evaluate the capital markets from time to time to determine when to raise additional capital
in the form of equity, convertible debt or other financing instruments, depending on market conditions relative to our need for
funds at such time. We will seek to raise additional capital at such time as we conclude that such capital is available on terms
that we consider to be in the best interests of our Company and our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have prepared a budget for the remainder of fiscal year 2016
and fiscal 2017 which reflects cash requirements from operations of approximately $2.0 million per quarter. Depending on the availability
of capital we could expend additional funds for purchase of assets and commercialization of products. Accordingly, it will be necessary
to raise additional capital and/or enter into licensing or collaboration agreements. At this time, we expect to satisfy our future
cash needs through private or public sales of our securities or debt financings. We cannot be certain that financing will be available
to us on acceptable terms, or at all. Over the last three years, including recently, volatility in the financial markets has adversely
affected the market capitalizations of many bioscience companies and generally made equity and debt financing more difficult to
obtain. This volatility, coupled with other factors, may limit our access to additional financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we cannot raise adequate additional capital in the future
when we require it, we will be required to delay, reduce the scope of, or eliminate one or more of our commercialization efforts
or our research or development programs. We also may be required to relinquish greater or all rights to product candidates at less
favorable terms than we would otherwise choose. This may lead to impairment or other charges, which could materially affect our
balance sheet and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Off Balance Sheet Arrangements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We do not have off-balance sheet arrangements, financings,
or other relationships with unconsolidated entities or other persons, also known as &ldquo;variable interest entities&rdquo;.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_009"></A>BUSINESS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Business Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a specialty healthcare company concentrating on developing
and commercializing products with an initial focus on urological conditions. We are focused primarily on the urological disorders
market and specifically urological cancers, hypogonadism, urinary tract infections, male infertility, and sexual dysfunction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are currently focused on commercializing our ProstaScint&reg;
product, which has been re-launched in the U.S. through a focused commercial infrastructure and we are working on developing corporate
relationships outside the U.S. to launch ProstaScint in major healthcare markets around the world. We are also preparing to launch
Natesto in the U.S. for the treatment of hypogonadism, or low testosterone, and we plan to expand our commercial infrastructure
to support this launch and grow ProstaScint revenues. We acquired ProstaScint in May 2015 from Jazz Pharmaceuticals. ProstaScint,
which is approved by the FDA, is a marketed biologic imaging agent specifically indicated for the diagnostic staging of prostate
cancer patients. In April 2016, we acquired the exclusive U.S. rights to Natesto<SUP>TM</SUP> (testosterone) nasal gel from Acerus.
Natesto is an FDA-approved testosterone replacement therapy, or TRT, and is the only nasally-administered formulation of testosterone
available in the United States. We are also commercializing our Primsol&reg; product, which we plan to launch through a focused
commercial infrastructure in the U.S. while developing corporate relationships outside the U.S. to launch Primsol in major healthcare
markets around the world. We acquired Primsol in October 2015 from FSC Laboratories. Primsol, which also is approved by the FDA,
is a marketed anti-infective specifically indicated for the treatment of uncomplicated urinary tract infections. In April 2016,
we entered into a co-promotion agreement for Primsol with Allegis Pharmaceuticals, LLC, or Allegis, a commercial-stage pharmaceutical
company focused on the pediatric market in the U.S. Under the co-promotion agreement, Allegis will have the exclusive right to
commercialize Primsol for the pediatric market in the United States, while we will retain the exclusive right to commercialize
Primsol for the non-pediatric market. Given Aytu&rsquo;s strategic focus on urology, and our intent to promote Primsol for urinary
tract infections, we believe that establishing this co-promote with Allegis makes sense to enable prescription growth in the pediatric
market, where a significant portion of Primsol&rsquo;s historical sales have been derived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, we have developed the MiOXSYS<SUP>TM</SUP> System
as a diagnostic device for the detection of infertility in semen analysis. The MiOXSYS System is CE Marked and approved for sale
in Europe and other markets around the world, so we are initiating efforts to build a global distribution network comprised of
companies focused on infertility and urological diseases. Along with the development of the MiOXSYS System, we have launched the
RedoxSYS&reg; oxidation-reduction potential system, or the RedoxSYS&reg; System, into the global research market and are developing
numerous clinical applications beyond infertility. Further, Zertane is now subject to an accepted Investigational New Drug application
by the FDA, and a Phase 3 clinical development program has been designed and accepted by the FDA. Depending on our success in raising
additional funds, we may decide to focus our capital resources on other strategies and not pursue clinical testing of Zertane in
the U.S. If we decide not to pursue clinical testing of Zertane, we will seek strategic options to maximize the value of Zertane,
inclusive of divestiture, out-licensing, and strategic commercial collaborations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect to create value by implementing a focused, four-pronged
strategy. Our primary focus is on growing our current, revenue-generating products, launching the recently acquired Natesto in
the U.S., and building a complementary portfolio of aligned urology assets. In less than one year since our inception we have acquired
or in-licensed three FDA-approved, marketed assets, launched a specialty urology sales force, initiated ex-U.S. partnering discussions
for our commercial products ProstaScint and Primsol and pipeline asset Zertane, advanced our lead diagnostic asset MiOXSYS to CE
Marking, engaged in asset purchase and licensing discussions for products aligned to our strategy, and have begun preparing to
launch Natesto in the U.S. through our own sales force.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe the strategy of focusing on commercializing assets
prescribed by urologists makes sense for several reasons. First, urology is a large yet concentrated specialty practice area that
can be efficiently targeted. There are approximately 10,000 active urologists in the U.S., and we believe that this audience can
be efficiently reached with a relatively small, focused sales force. Additionally, 90% of urologists practice in metropolitan areas
where concentrated sales targeting can be achieved and &ldquo;windshield&rdquo; or sales representative driving time between targets
can be minimized. Importantly, 81% of urologists practice in group practices, and over 60% are in practices of four or more physicians.
Further, and important in building a balanced yet focused product portfolio, sub-specialization within large urology clinics is
common whereby there is frequently individual clinical focus on specific areas within urology including prostate cancer and conditions,
infertility, sexual dysfunction, urinary incontinence, etc. This enables a company to offer multiple products to the various sub-specialties
within these focused, concentrated customer targets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Further, urologists treat a wide range of therapeutic areas
and are thus appropriate targets across a broad range of clinical assets (ProstaScint &ndash; prostate cancer; Natesto &ndash;
hypogonadism; Primsol &ndash; urinary tract infections; MiOXSYS &ndash; male infertility; Zertane (if approved) &ndash; premature
ejaculation). Importantly, in urology, direct physician office purchasing of drugs, devices, and diagnostics is common. Along with
this, a significant proportion of urology groups are privately-owned and often own and operate their own outpatient surgery centers
and in-office laboratories. Further, large urology group practices have substantial payer influence and can have the ability to
negotiate as large groups to achieve better reimbursement and coverage for favored treatments and procedures. Perhaps as important
as these other factors, urologists are exposed to relatively limited promotional focus by &ldquo;Big Pharma&rdquo; and we believe
can therefore be accessed and impacted more readily by an emerging company such as Aytu over time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Aytu BioScience&rsquo;s Four Strategic Value Drivers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="tpg63.jpg" ALT=""><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The primary elements of our strategy are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left"><I>Launching ProstaScint, Primsol, and MiOXSYS outside the United States via a developing distribution network launching Natesto
and expanding commercialization of ProstaScint and Primsol, our revenue-generating, FDA-approved products in the United States
via a direct commercial infrastructure.</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Ex-U.S</I>. As neither ProstaScint nor Primsol have been
previously approved and marketed outside the U.S., we believe we can realize commercial opportunities through efficient corporate
partnerships in key markets around the world. Also, with MiOXSYS now CE Marked we can develop a distribution network to launch
this first-in-class in vitro diagnostic device.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>United States</I>. We have launched a commercial infrastructure
in the U.S. in order to support increased sales and distribution of ProstaScint and Primsol in the U.S. We have a highly experienced
sales force that is distinctly focused on impacting the prescribing of urologists, and through this efficient sales channel we
are able to increase prescribing of our unique urology assets. Now, with our recent acquisition of the U.S. rights to Natesto we
plan to expand our commercial footprint in order to effectively support a planned product launch of Natesto in July 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ProstaScint has several unique selling features that we believe
will enable significant sales growth and regular use by healthcare providers diagnosing and treating prostate cancer. ProstaScint
is the only imaging agent that specifically targets prostate cancer cells and demonstrates high sensitivity, specificity, and accuracy.
In multiple clinical studies researchers have shown that when SPECT/CT scans were used in patients pre-treated with ProstaScint,
ProstaScint imaging was highly sensitive in detecting prostate cancer and significantly predictive of 10-year biochemical disease
free survival in prostate cancer patients (86.6% vs. 65.5%; p=0.0014). Additionally, the American Cancer Society specifically recognizes
ProstaScint by name in current prostate cancer diagnosis guidelines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prostate cancer is the most common cancer among men in the United
States, with an estimated 241,000 annual cases (as of 2012). Further, more than 2.2 million men are alive with some history of
prostate cancer, and over 30,000 U.S. men die each year from the disease. The effect of prostate cancer on healthcare economics
is substantial, which makes the need for accurate disease staging critical for treatment and management strategies. The U.S. market
for the diagnosis and screening of prostate cancer is expected to total $17.4 billion in 2017, a CAGR of 7.5% since 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Natesto is a novel, recently FDA-approved testosterone replacement
therapy, or TRT, indicated for the treatment of hypogonadism in men. Natesto is the only nasal formulation of testosterone and
is delivered via a proprietary nasal gel to enable simple, discreet use of testosterone into the nostrils. By virtue of applying
Natesto to the nasal muscosa, and not to the man&rsquo;s skin, there is no risk of transference to others. As such Natesto is the
only TRT that does not have a black box warning associated with this potential for transference. Additionally, Natesto is a convenient
form of testosterone that does not require application to large areas of the man&rsquo;s body (arms, shoulders, upper torso, under
arms) as required with market-leading products AndroGel and Axiron. A convenient form of TRT, applied two-to-three times in the
nostrils, may be an appropriate option for men over 45 with hypogonadism who have active lifestyles, travel frequently, and value
having a discreet way to treat their hypogonadism.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Low testosterone is a condition affecting approximately 13 million
U.S. men, with U.S. revenues estimated at $2.4 billion in 2013. The market is expected to grow to $5.0 billion by 2017, and we
believe multiple factors are in place to position Natesto favorably in gaining market share in this large, growing market. By gaining
less than a 5% share of the current U.S. market (assuming similar pricing and reimbursement), a novel TRT product could achieve
annual revenues in excess of $120.0 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Primsol is an antimicrobial agent that is indicated to treat
uncomplicated urinary tract infections (UTIs). Primsol is the only oral solution containing trimethoprim and offers a novel solution
for UTI patients who are either allergic to sulfamethoxazole (which is commonly combined with trimethoprim) or have difficulty
swallowing pills. Because many prostate cancer patients have temporary urinary catheters placed, they are frequently diagnosed
with recurrent urinary tract infections. Primsol offers a solution to those patients and enables us to sell multiple products to
a similar base of U.S. prescribing clinicians.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left"><I>Developing a pipeline of novel urological therapeutics through assertive acquisition, licensing, or co-promotion, inclusive
of both marketed and late-stage development assets.</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In order to diversify our product portfolio and create more
value, we intend to seek to acquire complementary products or product candidates to develop and/or commercialize including marketed
assets. Initially, the focus will be on acquiring products or product candidates for urological conditions but we will opportunistically
consider other products or product candidates based on their ability to create value and complement our focus. We plan to pursue
product acquisitions, inclusive of therapeutics, diagnostics, and devices, which we will evaluate for their strategic fit and potential
for near-term and/or accretive value to us. In less than nine months from the Company&rsquo;s inception we are generating revenue
from the acquisition of both ProstaScint and Primsol, and are planning to launch Natesto. We expect to continue to identify and
acquire additional, complementary urology assets in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left"><I>Completing U.S. studies in male infertility with the MiOXSYS System to enable 510k de novo clearance by FDA</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">With MiOXSYS now CE marked and available for sale in many markets
outside the U.S., we are positioned to initiate our clinical studies in the U.S. to enable 510k de novo clearance. We expect to
received guidance from FDA on clinical study design and patient criteria and implement the required clinical program as soon as
possible. If approved, MiOXSYS would be the first and only semen analysis diagnostic test for the detection of oxidative stress
in infertility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Male infertility is prevalent and underserved, and oxidative
stress is widely implicated in its pathophysiology. As such, we have bolstered our research focus in this area with the MiOXSYS
System to complement our focus on urologic conditions. The global male infertility market is expected to grow to over $300 million
by 2020 with a CAGR of nearly 5% from 2014 to 2020. Oxidative stress is broadly implicated in the pathophysiology of idiopathic
male infertility, yet very few diagnostic tools exist to effectively measure oxidative stress levels in men. However, antioxidants
are widely available and recommended to infertile men. With the introduction of the MiOXSYS System, we believe for the first time
there will be an easy and effective diagnostic tool to assess degree of oxidative stress and monitor patients&rsquo; responses
to antioxidant therapy and improve diagnosis of male infertility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Through our extensive network of researchers developed at one
of our predecessor companies Luoxis, the RedoxSYS System has demonstrated the potential to have broad clinical applications inclusive
of male infertility in semen analysis studies. Studies have been completed at a major U.S. university and major hospital outside
the U.S. in the evaluation of male infertility. As such, we developed the MiOXSYS System as a line extension to RedoxSYS to specifically
assess oxidative stress in semen as a tool to assess male infertility. In January 2016, the MiOXSYS System received CE Marking
and is now available for sale in multiple ex-U.S. markets including Europe, the Middle East, and parts of Asia. In March 2016,
the MiOXSYS System obtained Health Canada Class II Medical Device approval. With Health Canada approval in place, the Company will
begin initial marketing of the product in Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left"><I>Maximizing the value of Zertane, our product candidate for the on-demand treatment of premature ejaculation through pursuit
of global or regional licensing partners or asset sale.</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our therapeutic product candidate is Zertane, a Phase 3-ready
oral product for the treatment of PE. The premature ejaculation market in the U.S. and Europe is expected to reach over $1.3 billion
in annual sales in 2017, representing an increase of 10.3% over 2010. According to published analyses, PE is a highly prevalent
male sexual dysfunction affecting 20% to 30% of men worldwide. Based on internal market research and published reports, we believe
that PE is up to 1.5-times more prevalent than erectile dysfunction, or ED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Zertane is in advanced clinical studies, and we have already
completed pivotal study-enabling studies in Europe that demonstrate favorable efficacy and safety in more than 600 patients with
PE. In addition, Zertane obtained an active IND with the FDA. We also expect to seek collaboration agreements to commercialize
Zertane outside the U.S. We already have such agreements in place to commercialize Zertane in South Korea and Brazil, Canada, the
Republic of South Africa, certain countries in Sub-Saharan Africa, Colombia and Latin America which will &mdash; if approved &mdash;
provide royalty and milestone-based revenue for us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our FDA &ndash; Approved Urology Products</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Three of our products have received FDA approval for marketing
in the U.S.: ProstaScint, Primsol and Natesto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ProstaScint for the Detection of Prostate Cancer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 20, 2015, we acquired ProstaScint&reg; from Jazz Pharmaceuticals.
ProstaScint Kit, or capromab pendetide, is a radio-labeled monoclonal antibody, which is a biologic product that targets a specific
antigen. ProstaScint targets prostate specific membrane antigen, or PSMA, a protein uniquely expressed by prostate tissue. A radioactive
substance called Indium (In 111) is attached to the proprietary, mouse-derived antibody. The radiolabeled antibody is infused into
the patient and is taken up by prostate cancer cells which can be detected and visualized with a special nuclear medicine scan
(single-photon emission tomography, or SPECT). ProstaScint has been shown to be clinically effective in determining the course
of treatment for a patient who has had a prostatectomy and/or has suspected metastasis (spread of the cancer cells beyond the prostate).
Further, ProstaScint has demonstrated efficacy in patients classified as high risk or with recurrent prostate cancer. ProstaScint
has been approved by the FDA and Health Canada, and significant clinical data exist demonstrating the significant predictive value
in prostate cancer staging.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Prostate Cancer Market</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">According to the American Cancer Society prostate cancer is
the most common cancer among men in the United States, with an estimated 241,000 annual cases (as of 2012). Further, more than
2.2 million men are alive with some history of prostate cancer, and over 30,000 U.S. men die each year from the disease. The effect
of prostate cancer on healthcare economics is substantial, which makes the need for accurate disease staging critical for treatment
and management strategies. The U.S. market for the diagnosis and screening of prostate cancer is expected to total $17.4 billion
in 2017, a CAGR of 7.5% since 2012. Importantly, ProstaScint is the only FDA-approved radiopharmaceutical (for use in radioimmunoscintigraphy)
specifically indicated for prostate cancer screening and is specifically highlighted in the American Cancer Society practice guidelines
for prostate cancer screening and staging.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prostate cancer is classified into four stages based on severity:
Stages 1 through 4. Stage 3 is considered &ldquo;high risk&rdquo; and Stage 4 is when cancer has become metastatic. Radioimmunoscintigraphy
has been established as a diagnostic to stage cancer malignancy and one of the most widespread clinical uses has been for the detection
of prostate cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>ProstaScint Clinical Data</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Multiple clinical studies have been conducted in the United
States and published in peer-reviewed publications that consistently demonstrate substantial clinical efficacy of ProstaScint in
staging prostate cancer patients and specifically identify whether the cancer is confined to the prostate or has metastasized to
other parts of the body. Through more accurate clinical staging and identification of metastatic prostate cancer, clinicians are
able to better direct therapeutic interventions and improve outcomes. A brief summary of key clinical findings for ProstaScint
from select studies are summarized below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Principal</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investigator(s)/</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Primary Authors</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Publication</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0; padding-bottom: 1pt; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patient&nbsp;Population</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Conclusion/Results</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ellis RJ et al.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Int. J. Radiation Oncology Biol. Phy. (2010)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients presenting for primary radiotherapy having a clinical diagnosis of localized primary prostate cancer; Patients evaluated for tumor stage using conventional staging and SPECT/CT (N=239)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SPECT/CT imaging with ProstaScint pre-treatment was significantly predictive of 10-year biochemical disease-free survival (86.6% vs. 65.5%; p=0.0014)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Haseman MK et al.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Urology (2007)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Men with prostate cancer who underwent imaging with ProstaScint pretreatment; Patients were divided according to the presence or absence of central abdominal uptake (CAU) (N=341)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SPECT/CT imaging with ProstaScint pretreatment effectively predicted death rates among patients with central abdominal uptake (CAU), and demonstrated that prostate cancer-specific death rates were 10 times higher in patients identified with ProstaScint as having central abdominal uptake (p=0.005).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ellis RJ et al.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brachytherapy (2005)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Men with prostate cancer of all risk categories who underwent imaging with ProstaScint pretreatment; patients were divided into low, intermediate, and high risk and underwent brachytherapy (N=239)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SPECT/CT imaging with ProstaScint pretreatment effectively predicted biochemical disease recurrence regardless of the patient&rsquo;s risk category; 7-year outcomes data from brachytherapy patients with treatment based on the ProstaScint scan showed a significant difference in biochemical disease-free survival.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Radiation oncology experts have published numerous papers expressing
the potential for expanded use of ProstaScint in prostate cancer imaging due to advances in imaging technologies since the product&rsquo;s
initial approval. Since the early 2000s, significantly greater image resolution has been enabled due to the advent of dual head
cameras (and improved imaging in general) along with the use of co-registered images where radiologists now combine the images
of SPECT and computerized tomography, or CT, or magnetic resonance imaging, or MRI. Because of these factors, we believe there
is significant commercial opportunity for ProstaScint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>ProstaScint Product Information</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ProstaScint is provided as a two-vial kit which contains all
of the non-radioactive ingredients necessary to produce a single unit dose for administration by intravenous injection. The ProstaScint
vial contains 0.5 mg of capromab pendetide in 1 mL of sodium phosphate buffered saline solution adjusted to pH 6; a sterile, pyrogen-free,
clear, colorless solution that may contain some translucent particles. The vial of sodium acetate buffer contains 82 mg of sodium
acetate in 2 mL of water for injection adjusted to pH 5 &ndash; 7 with glacial acetic acid; it is a sterile, pyrogen-free, clear,
and colorless solution. Neither solution contains a preservative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each kit also includes one sterile 0.22 &mu;m Millex&reg; GV
filter, prescribing information, and two identification labels. The hospital is responsible for addition of Indium In 111. ProstaScint
may also be helpful in conjunction with other scans (CT or MRI) for higher risk patients, by detecting lymph nodes in the abdomen
that are involved with prostate cancer cells, but may still appear falsely normal on CT or MRI scans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The procedure to administer ProstaScint is as follows: the patient
is given an intravenous, or IV, infusion of the monoclonal antibody, and 30 minutes later, a scan is performed. A second scan is
done between 96 and 120 hours (4 &ndash; 5 days) after the infusion. The first scan (on the day of the infusion) takes approximately
1 hour, while the second scan takes approximately 2.5 hours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>ProstaScint Uses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ProstaScint is indicated as a diagnostic imaging agent in newly-diagnosed
patients with biopsy-proven prostate cancer, thought to be clinically-localized after standard diagnostic evaluation (e.g. chest
x-ray, bone scan, CT scan, or MRI), who are at high-risk for pelvic lymph node metastases. It is not indicated in patients who
are not at high risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ProstaScint is also indicated as a diagnostic imaging agent
in post-prostatectomy patients with a rising PSA and a negative or equivocal standard metastatic evaluation in whom there is a
high clinical suspicion of occult metastatic disease. The imaging performance of Indium In 111 ProstaScint following radiation
therapy has not been studied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information provided by Indium In 111 ProstaScint imaging
should be considered in conjunction with other diagnostic information. Scans that are positive for metastatic disease should be
confirmed histologically in patients who are otherwise candidates for surgery or radiation therapy unless medically contraindicated.
Scans that are negative for metastatic disease should not be used in lieu of histological confirmation. ProstaScint is not indicated
as a screening tool for carcinoma of the prostate nor for re-administration for the purpose of assessment of response to treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ProstaScint was initially marketed by Cytogen Corporation, which
was acquired by EUSA Pharma. Jazz Pharmaceuticals acquired EUSA in June 2012 but significantly reduced promotion of ProstaScint
due to a lack of strategic focus. Despite limited commercialization efforts, peak annual unit sales of ProstaScint of 8,216 kits
were achieved. At current pricing, this unit sales volume would equate to approximately $14.6 million in annual revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Natesto for Testosterone Replacement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 22, 2016, we entered into and closed a license and
supply agreement to acquire the exclusive U.S. rights to Natesto<SUP>TM</SUP> (testosterone) nasal gel from Acerus Pharmaceuticals
Corporation, or Acerus, which rights we will acquire effective upon the expiration of the current licensee's rights, expected to
occur on June 30, 2016. Natesto is a patented, FDA-approved testosterone replacement therapy, or TRT, and is the only nasally-administered
formulation of testosterone available in the United States. Natesto is a discreet, easy-to-administer nasal gel that may be appropriate
for men with active lifestyles as Natesto is small, portable, TSA-compliant, and easy to use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Importantly, Natesto is not applied directly to the patient&rsquo;s
skin as other topically applied TRTs are. Rather, it is delivered directly into the nasal mucosa via a patented nasal applicator.
Thus, Natesto does not carry a black box warning related to testosterone transference to a man&rsquo;s female partner or children
&mdash; as other topically (primarily gels) administered TRTs do by virtue of their delivery directly onto the skin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tpg67.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Image of Natesto (testosterone) nasal gel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The unique delivery of Natesto also enables simple, discreet
use by a single three times daily application into the nose and may improve compliance over topical forms that are applied to large
sections of the arms, shoulders, and other large areas of the man&rsquo;s upper torso. It also offers a more discreet method of
TRT administration compared to films/patches (Androderm &amp; Testoderm, which is applied to the scrotum) and doesn&rsquo;t involve
the pain, potential for site injection infections, and the administration inconvenience of the injectable TRTs such as Testopel
and Aveed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A concern associated with the use of the currently marketed
testosterone gels is the unintentional transfer of testosterone to women (or children) by skin contact with the man&rsquo;s application
site. In the event of a female partner receiving inadvertent testosterone exposure due to intimate contact with her male partner,
she may develop hyperandrogenism, a condition characterized by excess levels of androgens. This condition may result in women developing
acne, scalp hair loss, excessive facial or body hair, breast atrophy, and other symptoms. Natesto, as it is nasally administered,
does not present this potential complication of &lsquo;transference&rsquo; and thus does not have a black box warning as is associated
with the topically applied testosterone supplements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Natesto is an androgen indicated for replacement therapy in
adult males for conditions associated with a deficiency or absence of endogenous testosterone including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion,
orchitis, vanishing testis syndrome, orchiectomy, Klinefelter&rsquo;s syndrome, chemotherapy, or toxic damage from alcohol or heavy
metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH] and
luteinizing hormone [LH]) above the normal range.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: left">Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency
or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low serum testosterone concentrations but have
gonadotropins in the normal or low range.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The U.S. Testosterone Replacement Therapy Market</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe we have an opportunity to increase revenue with Natesto
in the U.S. following our planned launch later this calendar year. Natesto competes in a large, growing market. The U.S. TRT market
is large, with annual revenues in the U.S. in 2013 of $2.4 billion. Revenues are expected to increase to $5 billion by 2017. If
the TRT market grows as expected, with as little as 5% market penetration, a novel, patent-protected TRT product could achieve
sales of $250 million. Even at the current market size of over $2 billion, a product with 5% market penetration could achieve sales
in excess of $100 million annually, assuming comparatively similar product pricing and reimbursement levels as seen with other
TRTs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The U.S. prescription testosterone market is comprised primarily
of topically applied treatments in the form of gels, solutions, and patches. Testopel&reg; and Aveed&reg;, injectable products
typically implanted directly under the skin by a physician, are also FDA-approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The actively marketed, FDA-approved TRTs include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.25in">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 14%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Brand Name</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 26%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form of Delivery</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 24%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 14%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year Approved</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 18%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Black Box Warning</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Androderm&reg;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Film/Patch</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actavis</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1995</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AndroGel&reg;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gel</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AbbVie</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aveed&reg;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Injection</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Endo Pharmaceuticals</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Axiron&reg;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solution</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eli Lilly &amp; Company</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2010</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fortesta&reg;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gel</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Endo Pharmaceuticals</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2010</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Striant&reg;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extended Release Tablet</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Endo Pharmaceuticals</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2003</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Testim&reg;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gel</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Endo Pharmaceuticals</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2002</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Testoderm&reg;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Film/Patch</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Johnson &amp; Johnson</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1993</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Testopel&reg;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Injection</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Endo Pharmaceuticals</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1972</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vogelxo&reg;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gel</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upsher-Smith</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">AndroGel&reg;, marketed by AbbVie, is the leading TRT and had 2012
revenues of $1.15 billion. AndroGel commanded over half of the total TRT market across its 1.0% and 1.62% formulations of the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Importantly, however, AndroGel is beginning to face generic threats
with the expiration of key patents for its 1.0% formulation, and Teva Pharmaceuticals has a competitive generic product in waiting.
AbbVie has attempted to block Teva&rsquo;s launch through the filing of a citizen&rsquo;s petition. Products with significant shares
of the TRT market and promotional spending include Axiron, Testim, Fortesta, Androderm, and Testopel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>About Hypogonadism</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Male hypogonadism is a condition in which the body does not produce
enough testosterone &mdash; the hormone that plays a key role in masculine growth and development during puberty &mdash; or has
an impaired ability to produce sperm or both. Men can be born with male hypogonadism, or it can develop later in life from injury
or infection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Hypogonadism is formally defined as deficient or absent male
gonadal function that results in insufficient testosterone secretion. Hypogonadism may be caused primarily by testicular
failure, or secondarily by hypothalamic-pituitary axis dysfunction, resulting in the production or release of insufficient
testosterone to maintain testosterone-dependent functions and systems. It can also result from a combination of testicular
failure and hypothalamic-pituitary axis dysfunction. Hypogonadism affects an estimated approximately 13 million men in the
United States, and although it may occur in men at any age, low testosterone levels are especially common in older males.
More than 60% of men over age 65 have free testosterone levels below the normal values of men aged 30 to 35. Studies suggest
that hypogonadism in adult men is often underdiagnosed and under treated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Low testosterone, as male hypogonadism is also known, is associated
with a number of signs and symptoms, most notably loss of libido and erectile dysfunction (ED). Other signs of low testosterone
include depressive symptoms, a decrease in cognitive abilities, irritability and lethargy or loss of energy. Deficient endogenous
testosterone also has negative effects on bone mass and is a significant risk factor for osteoporosis in men. Progressive decrease
in muscle mass and muscle strength and testicular dysfunction, often resulting in impaired sperm production, are also associated
with low testosterone levels.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">A younger patient may have pure hypogonadism as a primary event,
whereas an older man may have an age-related decline in testosterone production that is a part of his ED profile. However, because
both ED and loss of libido are hallmarks of hypogonadism, for a patient who presents with ED it is recommended that he have a basic
hormone profile to determine if he has low testosterone. Treatments to normalize testosterone can not only improve libido, energy
level and the potential to have normal erections, but can also improve the response to sildenafil, if that is deemed appropriate
treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Natesto Clinical Studies Demonstrating Safety and Efficacy&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Natesto has been shown to be safe and effective in men with
hypogonadism. It was approved by the FDA in May 2014. In its pivotal clinical trial, Natesto was evaluated for efficacy in a
90-day, open-label, multicenter study of 306 hypogonadal men. Eligible patients were 18 years of age and older (mean age 54
years) and had morning serum total testosterone concentrations less than 300 ng/dL. Patients were Caucasian (89%),
African-American (6%), Asian (5%), or of other ethnicities (less than 1%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Patients were instructed to self-administer Natesto (11 mg of
testosterone) intranasally either two or three times daily. The primary endpoint was the percentage of patients with an
average serum total testosterone concentration (C<SUB>avg</SUB>) within the normal range (300 to 1050 ng/dL) on Day 90.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The secondary endpoint was the percentage of patients with a
maximum total testosterone concentration (C<SUB>max</SUB>) above three predetermined limits: greater than 1500 ng/dL, between
1800 and 2500 ng/dL, and greater than 2500 ng/dL. A total of 78 hypogonadal men received Natesto (11 mg of testosterone)
three times daily (33 mg of testosterone daily). Of these, a total of 73 hypogonadal men were included in the statistical
evaluation of efficacy (total testosterone pharmacokinetics) on Day 90 based on the intent-to-treat (ITT) population with
last observation carried forward (LOCF). Ninety percent of these 73 patients had a C<SUB>avg</SUB> within the normal range
(300 to 1050 ng/dL) on Day 90. The percentages of patients with C<SUB>avg</SUB> below the normal range (less than 300 ng/dL)
and above the normal range (greater than 1050 ng/dL) on Day 90 were 10% and 0%, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The table below (Table 3 from the Natesto Prescribing Information)
summarizes the mean (SD) serum total testosterone concentrations on Day 90 in 69 patients who had a full pharmacokinetic sampling
profile and were treated with Natesto (11 mg of testosterone) three times daily for 90 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="tpg70a.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In the same clinical trial studying the safety and efficacy of Natesto,
which was conducted at 39 U.S. outpatient sites, it was shown that 70% of the per protocol patients in the twice-daily &lsquo;titration
arm&rsquo; (n=141) achieved normal testosterone levels. Ninety-one percent of the per protocol patients in the thrice-daily group
(n=77) achieved normal testosterone levels, demonstrating that the majority of men in both treatment groups achieved normalization
of testosterone levels while taking Natesto. The efficacy of both B.I.D. (twice daily) and T.I.D. (three times daily) dosing of
Natesto is demonstrated in the graphs below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="tpg70b.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Natesto Product Features and Patient Benefits</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We believe Natesto has a unique opportunity to gain market share
in the more than $2 billion U.S. market given the product&rsquo;s novel features and patient benefits including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">Ease of administration; Appropriate for men with busy,
active lives;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">Established efficacy in pivotal FDA trials with a unique,
low dose of testosterone; Effective in improving serum testosterone levels while using a proven, lower dose of testosterone;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">Discreet product presentation and ease of transport (TSA
compliant); Important for men who travel frequently and desire a simple, portable solution that travels easily with them;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">No risk of secondary exposure to testosterone due to dermal
transference, an important consideration when thinking about a hypogonadal man&rsquo;s partner&rsquo;s or child&rsquo;s safety;
and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">Safety, with a lower incidence of rising PSA levels than
the market leading product AndroGel; Natesto demonstrates a 5.5% rate of rising PSA levels in clinical trials, while AndroGel
demonstrated a rising PSA rate of over 11% in clinical trials. This is an important consideration as physicians concerned with
understanding and tracking prostate cancer risk frequently monitor PSA levels in men over 50 years of age.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Natesto has proven efficacy and a product profile well suited for
men suffering from hypogonadism who have active, busy lifestyles who want a simple, discreet TRT option. We believe Natesto can
play an important role in the treatment of hypogonadism, a condition affecting approximately 13 million U.S. men.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Natesto Market Opportunity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Two recent developments have presented a unique opportunity for
Natesto that we believe will enable us to effectively compete and be well positioned in the more than $2 billion TRT market. As
previously indicated, AndroGel&rsquo;s patent expired in 2015 and, unless a citizen&rsquo;s petition filed by AbbVie to delay a
Teva Pharmaceuticals generic is successful long-term, we expect a generic entrant to begin eroding AbbVie&rsquo;s market share.
As a result, we expect there to be diminished promotional support in the form of fewer physician details and lower overall promotional
spending by AbbVie. In conjunction with the market leader&rsquo;s diminished intellectual property position and potential diminished
promotional spending, the TRT market has received increased scrutiny from the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On January 31, 2014 and subsequently on March 3, 2015, the FDA issued
Safety Announcements relating to the possible increased risk of non-fatal heart attacks and strokes in patients taking testosterone.
While the FDA has not concluded that the FDA-approved testosterone treatment increases the risk of stroke, heart attack, or death,
this recent safety consideration has caused patient advocates and consumer groups to ask for increased scrutiny on the direct to
consumer advertising associated with the leading testosterone replacement products, most notably AndroGel and Axiron. As a result,
we expect decreased advertising spending in the TRT category to enable newer, less established products like Natesto to more effectively
infiltrate the market through on-label, physician-directed promotion with a direct selling effort. While the potential safety concerns
may cause a decrease in physician prescribing, we expect that physicians will continue to prescribe TRTs for patients for whom
TRT treatment is appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Leading urology groups including the American Urological Association,
or AUA, have strongly commented in favor of continued prescribing of TRTs for appropriate patients, and the safety data precipitating
the FDA&rsquo;s comments have been called into question. Importantly, the FDA has not called for discontinuation of TRTs. Rather,
patients were encouraged to speak with their health care professional and not stop taking TRTs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In the FDA&rsquo;s initial statement about the potential cardiovascular
risks associated with TRT treatment, the agency commented:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: left">&ldquo;Patients should not stop taking
their prescribed testosterone products without first discussing their questions or concerns with their health care professionals.
.... The prescribing information in the drug labels of FDA-approved testosterone products should be followed.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Importantly, following the FDA&rsquo;s statement, the AUA issued
a strong response reiterating the clinical importance of low testosterone and maintaining their support for the appropriate use
of testosterone replacement therapy:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: left">&ldquo;Men with hypogonadism may
also experience reduced muscle mass and strength and increased body fat. Hypogonadism may also contribute to reduced bone mineral
density and anemia. Testosterone therapy is appropriate treatment for patients with clinically significant hypogonadism, including
those with idiopathic clinical hypogonadism that may or may not be age-related, after full discussion of potential adverse effects.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Additional publications publicly refuted the validity of the data
that precipitated the FDA&rsquo;s safety concern in a subsequent statement following the 2014 annual meeting of the AUA:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: left">&ldquo;During the last several months
there has been a firestorm of negative media attention regarding testosterone deficiency and its treatment, precipitated by a study
reporting an increased rate of nonfatal myocardial infarction (MI) associated with testosterone prescriptions. This public judgment
of T therapy demands a response. As researchers and clinicians with extensive experience with T deficiency and its treatment, we
disagree that the recent study published in PLoS One presents any credible evidence that T prescriptions increase health risks,
and we find baseless the general assertion that testosterone is prescribed to men &ldquo;who are simply reluctant to accept the
fact that they are getting older.&rdquo; We object to comments questioning whether T deficiency is real, regardless of whether
it is called hypogonadism or &ldquo;low T&rdquo; as used in advertisements.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">AbbVie&rsquo;s sales of AndroGel dropped 5% in the first half of
2014, following the FDA&rsquo;s initial Safety Announcement and the subsequent reaction of the AUA and others. In the face of significant
new competitive entrants (Aveed, Vogelxo) at that time and the FDA&rsquo;s expressed safety concerns, this represents a relatively
insignificant sales decline. We believe this decline speaks to a real, present need in hypogonadism and a substantial opportunity
for newly marketed products like Natesto. Natesto has proven safety, a recent FDA approval that speaks to the product&rsquo;s efficacy,
and unique product features and patient benefits we believe will set Natesto apart from the topically administered competitive
products in the more than $2&nbsp;billion U.S. TRT market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Primsol for the Treatment of Urinary Tract Infections&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In October 2015 we acquired Primsol (trimethoprim hydrochloride
oral solution) from FSC Laboratories, Inc. Primsol is the only FDA-approved trimethoprim-only oral solution for urinary tract infections
and is standard therapy for such infections. Primsol is a sulfa-free, pleasant tasting, dye-free liquid that is appropriate for
patients that are sulfa allergic and individuals that have difficulty swallowing pills. Primsol has demonstrated efficacy in eradicating
key pathogens implicated in urinary tract infections including <I>E. coli</I> and has demonstrated similar efficacy to trimethoprim-sulfamethoxazole
combination agents. Primsol addresses a significant issue as many patients experience an allergic reaction to sulfamethoxazole.
As the only oral solution containing only trimethoprim, Primsol offers distinct advantages over sulfa-containing antibacterial
agents. Primsol was approved by the FDA in 2000 and was originally marketed by Ascent Pediatrics. FSC Laboratories acquired Primsol
from Taro Pharmaceutical.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On April 4, 2016, we entered into a co-promotion agreement for Primsol
oral solution with Allegis Pharmaceuticals. Under the agreement, the third party will exclusively promote Primsol to pediatricians
across the U.S. We retain all other rights in the U.S. and around the world and will continue to market the product in urologic
indications. This co-promotion enables us to focus exclusively on the urology channel while monetizing Primsol by virtue of a relationship
with a company focused on selling to a non-core non-urology audience than can drive prescription growth of Primsol.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>About Primsol&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Primsol is a solution of the synthetic antibacterial trimethoprim
in water prepared with the aid of hydrochloric acid. Each 5 mL for oral administration contains trimethoprim hydrochloride equivalent
to 50 mg trimethoprim and the inactive ingredients bubble gum flavor, fructose, glycerin, methylparaben, monoammonium glycyrrhizinate,
povidone, propylparaben, propylene glycol, saccharin sodium, sodium benzoate, sorbitol, water and hydrochloric acid and/or sodium
hydroxide to adjust pH to a range of 3.0 &ndash; 5.0. Primsol is indicated for the treatment of initial episodes of uncomplicated
urinary tract infections in adults due to susceptible strains of the following organisms: <I>Escherichia coli, Proteus mirabilis,
Klebsiella pneumoniae, Enterobacter</I> species and coagulase-negative Staphylococcus species, including <I>S. saprophyticus</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">For the treatment of uncomplicated urinary tract infections the
usual oral adult dosage of Primsol is 100 mg (10 mL) every 12 hours or 200 mg (20 mL) every 24 hours, each for 10 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Urinary tract infections, or UTIs are among the most common diagnoses
in the U.S., where the prevalence is estimated at 8.1 million physician office visits. Additionally, one fourth of women will have
recurrent UTIs requiring the repeated use of oral antibiotics. Current UTI treatment recommendations include the use of trimethoprim-containing
products given the compound&rsquo;s longstanding, established efficacy profile in effectively eradicating the key pathogens implicated
in UTIs. Primsol has demonstrated efficacy in the eradication of the key pathogens implicated in urinary tract infections as demonstrated
by a series of quantitative methods and clinical studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Quantitative methods are used to determine antimicrobial minimum
inhibitory concentrations, or MICs, to eradicate pathogens implicated in urinary tract infections. These MICs provide estimates
of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized
procedures are based on a dilution method (broth or agar) or equivalent with standardized inoculum concentrations and standardized
concentrations of trimethoprim powder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The MIC values should be interpreted according to the following
criteria:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">For testing aerobic microorganisms isolated from urinary tract infections:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>MIC (mcg/mL) Interpretation&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 50%; font-size: 10pt; margin-left: 1in">
<TR>
    <TD STYLE="vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; padding-left: 10pt; text-indent: -10pt; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&le; 8</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; padding-top: 3pt; padding-bottom: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; width: 78%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Susceptible (S)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ge; 16</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resistant (R)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">A report of &ldquo;Susceptible&rdquo; indicates that the pathogen
is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of
&ldquo;Intermediate&rdquo; indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible
to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in
body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category
also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation.
A report of &ldquo;Resistant&rdquo; indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in
the blood reaches the concentrations usually achievable; and other therapy should be selected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Standardized susceptibility test procedures require the use of laboratory
control microorganisms to control the technical aspects of the laboratory procedures. Standard trimethoprim powder as contained
in Primsol provides the following MIC values against E. coli demonstrating significant susceptibility of this primary causal organism
in urinary tract infections:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 50%; font-size: 10pt; margin-left: 1in">
<TR>
    <TD STYLE="vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; padding-left: 10pt; text-indent: -10pt; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Microorganism MIC</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; padding-top: 3pt; padding-bottom: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; width: 52%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(mcg/mL)</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Escherichia coli</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.5 &ndash; 2</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Trimethoprim has been shown to be active against the following microbial
strains as indicated below and demonstrated through in vitro and clinical studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Aerobic gram-positive microorganisms</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify"><I>Staphylococcus species</I> (coagulase-negative strains,
including <I>S. saprophyticus</I>)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify"><I>Streptococcus pneumoniae</I> (penicillin-susceptible
strains)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Aerobic gram-negative microorganisms</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify"><I>Enterobacter
                                         species</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify"><I>Escherichia coli</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify"><I>Haemophilus influenza</I> (excluding beta-lactamase
negative, ampicillin resistant strains)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify"><I>Klebsiella pneumonia</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify"><I>Proteus mirabilis</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Primsol has demonstrated efficacy in the treatment of uncomplicated
urinary tract infections without the potential side effects and allergic reactions sometimes attributed to sulfa-containing trimethoprim
formulations. Importantly, and despite the fact that FSC Laboratories did not historically promote Primsol to urologists, 26% of
Primsol prescriptions over the six-year period of September 2009 through August 2015 were written by urologists. This, we believe,
underscores the unmet market opportunity for Primsol in presenting this treatment option more assertively to urologists. As our
sales team will already be accessing urologists through their promotion of ProstaScint, Primsol can be positioned as a first-line
treatment option for urologists treating uncomplicated UTIs. With two FDA-approved products directed at urologists, we are able
to efficiently drive awareness and increase through a focused field effort. ProstaScint and Primsol are commercially complementary
and enable us to utilize our field sales force&rsquo;s synergies to affect prescription growth on both products while directing
promotional efforts to our urology customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Primsol was previously marketed by FSC Laboratories. Due to FSC&rsquo;s
strategic refocusing and new product acquisitions to which sales efforts were diverted, Primsol had only limited commercial emphasis
in the three to four years preceding our acquisition of the product. Despite FSC&rsquo;s limited commercial focus, annual unit
sales of 7,842 units were achieved. At current pricing, this would result in annual revenues of approximately $5.3 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>MiOXSYS In Vitro Diagnostic System for Male Infertility&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Male infertility is a significant medical condition that urologists
and infertility specialists treat frequently in the office setting or specialized fertility centers around the world. Of all sexually
active couples, 8% to 12% are infertile and male infertility is the sole cause or contributing factor up to 50% of the time. The
global male infertility market is large and growing. The market for male infertility diagnosis and treatments is expected to grow
to more than $300 million globally by 2020, with a CAGR of nearly 5% from 2014 to 2020. Despite the prevalence of male infertility,
difficulties remain in effectively diagnosis root causes. Oxidative stress assessment is considered a standard practice in complex
andrology laboratories around the world, but due to various factors oxidative stress testing is not routinely employed in clinicians&rsquo;
offices or standard laboratory settings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Seminal oxidative stress has been well established throughout the
peer-reviewed literature to play a substantial role in unexplained male infertility, and researchers and clinicians actively consider
oxidative stress when conducting laboratory infertility assessment. While oxidative stress is well established as a leading contributing
factor to male infertility, a significant proportion of male infertility remains unexplained in part because of the lack of standardized
tests available to clinicians and researchers to assess oxidative stress in semen and plasma. This lack of standardization has
resulted in poor implementation of semen and plasma analysis around the world. Further, current testing platforms are cost-prohibitive
for small office settings or local medical laboratories and require extensive training and on-site expertise. Additionally, antioxidant
supplementation is frequently recommended to patients by clinicians without an effective method of measuring treatment success.
As such, we believe introducing the MiOXSYS System to assess oxidative stress levels in semen and seminal fluid represents a significant
commercial opportunity and novel way for clinicians to assess male factor infertility and assess therapeutic responses of patients
in a simple, reliable, and cost-effective way.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The MiOXSYS System was CE Marked in January 2016, and we expect
to initiate early commercialization efforts outside the U.S. by the end of fiscal 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">An attractive aspect of the reproductive health market relates to
reimbursement as infertility treatments and the associated diagnostic tests are generally paid directly by patients. The current
infertility treatments could cost in excess of $10,000 per treatment cycle, so the addition of a moderately priced oxidative stress
test would consume nominal relative costs while providing specific, actionable information needed to improve the oxidative status
of infertile patients. The current infertility treatments include antioxidant supplements and lifestyle modifications that lower
oxidative stress (e.g., smoking cessation, exercise, dietary changes, etc.), so the measurements reported by the MiOXSYS System
could effectively guide treatment in the infertile patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The global male infertility market is expect to grow to more than
$300 million by 2020. With a substantial base of conditions for which the MiOXSYS System may present utility, we believe there
is significant revenue potential from this first-in-class system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As part of our strategy to develop future clinical applications
of the RedoxSYS System (the MiOXSYS System&rsquo;s predecessor product for plasma and whole blood detection), we have conducted
initial studies in male reproductive health. Male infertility is a significant medical condition in which oxidative stress is well
known to play a substantial role. As such, we believe developing a clinical application to assess oxidative stress levels with
the uniquely designed and programmed MiOXSYS System for semen analysis represents a significant commercial opportunity. Oxidative
stress is well established as a leading contributing factor to male infertility. Further, a significant proportion of male infertility
remains unexplained in part because of the lack of standardized tests available to clinicians and researchers to assess oxidative
stress in semen and seminal plasma. This lack of standardization has resulted in poor implementation of semen and plasma analysis
around the world. Further, currently available tests are cumbersome, time consuming to perform, and costly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We conducted initial proof-of-concept clinical studies in male infertility
with a leading research center in the United States, which demonstrated that oxidation-reduction potential effectively measures
oxidative stress levels in semen and seminal plasma &mdash; and that these levels strongly correlate with established markers of
infertility. Semen analysis studies are routinely conducted to assess causes of infertility, so we expect clinicians and oxidative
stress researchers to readily integrate the MiOXSYS System into routine use upon the completion of more extensive studies and regulatory
clearance for this use. Additional studies are now in the late planning stages that will evaluate the MiOXSYS System&rsquo;s performance
in the detection of oxidative stress levels and correlations with key semen parameters in both healthy and infertile males. The
MiOXSYS System must receive 510(k) de novo clearance from the FDA before we can market it for clinical use in the United States.
Of the $300 million male infertility market projected for 2020, the North American, Middle Eastern, and Asia Pacific markets dominate
due to prevalence, awareness of treatment, and availability of treatment resources. Thus, it is important that we have already
established distribution relationships and direct access to major oxidative stress researchers in many of these important markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Following our initial proof of concept studies with a leading center
in the United States with the MiOXSYS system, we conducted our CE Mark-enabling study with over 300 infertile patients. The two
key studies conducted with these leading centers are presented below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>United States-Based Proof-of-Concept Clinical Study&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Fifty-one (51) male patients were seen in a national clinic for
suspected infertility. In addition to standard semen analyses (WHO 5<SUP>th</SUP> Edition, 2010), samples were measured for oxidative
stress using the MiOXSYS System. Raw sORP values were normed to sperm concentration (mv/10<SUP>6</SUP> sperm/mL) and compared across
six semen parameters that are associated with fertility: ejaculate volume, concentration, total sperm number, total motility, progressive
motility, and normal morphology. Higher sORP values are associated with a higher state of oxidative stress.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Patients with abnormally low ejaculate volume had similar sORP values
as those with a normal volume. Those with an abnormally low sperm concentration or overall total number, have significantly higher
sORP values than those in the normal range. Abnormally few motile sperm or few sperm with a progressive motility were also associated
with significantly higher sORP values than those in the normal range. Lastly, semen samples that had fewer normal sperm had slightly,
but not significantly, higher sORP values. Thus, most abnormal semen parameters appear to be associated with higher measures of
oxidative stress.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">When samples that achieve all six parameters of associated with
fertile semen are compared to samples that fail one or more of the parameters, the samples that meet the parameters have significantly
lower sORP values than those that fail one or more. A cutoff value of 1.635 mv/10<SUP>6</SUP> sperm/mL separated those that met
fertility standards from those that did not. In the current study, 85.7% of samples that met standards fell below this cutoff value,
whereas 71.8% of those that failed one or more parameters had sORP values above this cutoff. The probability that a semen sample
with a measured sORP value higher than the cutoff is abnormal in at least one of the semen parameters, is 96.5%. Lastly, the more
parameters that a semen sample falls within the abnormal range, the higher the sORP values, thus those that are abnormal on five
or six parameters have higher sORP values than those that are abnormal on one or two.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Data derived from patients of the national clinic confirms the results
obtained in an international fertility clinic. Overall, semen that falls into the abnormal range for concentration, total number,
motility, and morphology have higher levels of oxidative stress as indicated by higher sORP values. These values are uniquely obtained
using the MiOXSYS System for semen analysis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In April 2016, we observed encouraging data from two prospective
studies of MiOXSYS System that demonstrated its clinical utility as a tool for measuring ORP to assess the degree of oxidative
stress levels in human semen.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The first study measured sORP in the semen samples of infertile
men that correlated well with the sperm concentration, motility, and morphology. The second study further suggests that sORP is
an easy to determine one-step indicator of increased oxidative stress in semen samples of infertile men especially with leukocytospermia.
The results are currently being validated in a larger cohort of infertile men.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>International Pivotal Clinical Study&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Three-hundred sixty-six (366) male partners from couples
seeking fertility advisement in an international clinic were recruited. In addition to standard semen analyses (WHO
5<SUP>th</SUP> Edition, 2010), samples were measured for oxidative stress using the MiOXSYS System. Raw sORP values were
normed to sperm concentration (mv/10<SUP>6</SUP> sperm/mL) and compared across six semen parameters that are associated with
fertility: ejaculate volume, concentration, total sperm number, total motility, progressive motility, and normal morphology.
Higher sORP values are associated with a higher state of oxidative stress. Patients with abnormally low ejaculate volume had
similar sORP values as those with a normal volume. Those with an abnormally low sperm concentration or overall total number,
have significantly higher sORP values than those in the normal range. Abnormally few motile sperm or few sperm with a
progressive motility were also associated with significantly higher sORP values than those in the normal range. Lastly, semen
samples that had fewer normal sperm had significantly higher sORP values than those that fell into the range of normal
morphology. Thus, most abnormal semen parameters appear to be associated with higher measures of oxidative stress.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">When samples that achieve all six parameters associated with fertile
semen are compared to samples that fail one or more of the parameters, the samples that meet the parameters have significantly
lower sORP values than those that fail one or more. A cutoff value of 1.635 mv/10<SUP>6</SUP> sperm/mL separated those that met
fertility standards from those that did not. In the current study, 91.43% of samples that met fertility standards fell below this
cutoff value whereas 59.5% of those that failed one or more had sORP values above this cutoff. The probability that a semen sample
with a measured sORP value higher than the cutoff is abnormal in at least one of the semen parameters, is 98.6%. Lastly, the more
parameters that a semen samples falls within the abnormal range, the higher the sORP values, thus those that are abnormal on five
or six parameters have higher sORP values than those that are abnormal on one or two.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Data derived from patients at this international clinic confirms
the results obtained in United States fertility clinic. Overall, semen that falls into the abnormal range for concentration, total
number, motility, and morphology have higher levels of oxidative stress as indicated by higher sORP values. These values are obtained
uniquely using the MiOXSYS System for semen analysis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Proof of concept clinical studies have been conducted at the Cleveland
Clinic&rsquo;s Department of Urology, and two posters were presented at the 2015 American Society for Reproductive Medicine in
November 2015. These abstracts are presented below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Establishing the Oxidation-Reduction Potential in Semen and Seminal
Plasma&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">A. Agarwal,<SUP>1</SUP> S. S. Du Plessis,<SUP>1,2</SUP> R. Sharma,1
L. Samanta,<SUP>1,3</SUP> A. Harlev,<SUP>1,4</SUP> G. Ahmad,<SUP>1,5</SUP> S. Gupta,<SUP>1</SUP> E. S. Sabanegh<SUP>6</SUP>; 1.
Center For Reproductive Medicine, Cleveland Clinic, Cleveland, OH, 2. Medical Physiology, Stellenbosch University, Tygerberg, South
Africa, 3. Redox Biology Laboratory, School of Life Sciences, Ravenshaw University, Orissa, India, 4. Soroka Medical Center, Ben-Gurion
University, Beer Sheva, Israel, 5. Physiology and Cell Biology, University of Health Sciences, Lahore, Pakistan, 6. Department
of Urology, Cleveland Clinic, Cleveland, OH</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Abstract:&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Objective:</B> Oxidation-reduction potential (ORP) is a novel
measure of oxidative stress or redox imbalance in biological samples. Static ORP (sORP) provides an integrated measure of the balance
between total oxidants and reductants in a biological system, whereas capacity ORP (cORP) equates to the amount of antioxidant
reserves. sORP has been shown to correlate well with illness and injury severity that accompanies the state of oxidative stress;
cORP correlates with the ability to respond to illness or injury. Our objectives were to evaluate whether 1) ORP can be measured
in semen and seminal plasma samples and 2) ORP levels correlate with sperm motility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Design:</B> Prospective study measuring ORP in both semen and
seminal plasma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Materials and Methods:</B> Semen samples (n=18) from normal control
subjects were divided into two fractions and the seminal plasma was isolated from one fraction (300 x g, 7min). Sperm count and
motility were assessed manually. sORP (mV/106 sperm) and cORP (&mu;C/106 sperm) were measured in both fractions (RedoxSYS&reg;,
Aytu BioScience). Values are reported as Mean &plusmn; SEM. Spearman correlation and Receiver Operating Characteristic curves (ROC)
were used for statistical analysis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Results:</B> sORP and cORP levels in semen correlated significantly
with the levels in seminal plasma. A significant negative correlation existed between sperm motility and sORP in both semen (r=-0.609;
p=0.004) and seminal plasma (r=-0.690; p=0.002). Furthermore, a sORP cutoff of 4.73mV/106 sperm in semen (sensitivity = 100%, specificity
= 89.5%, AUC=0.947) and 4.65mV/106 sperm in seminal plasma (sensitivity = 100%, specificity = 93.8%, AUC = 0.969) was highly predictive
of abnormal sperm motility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Conclusions:</B> RedoxSYS&reg; accurately measured sORP and cORP
in both semen and seminal plasma samples. Based on high sensitivity as assessed by ROC analysis, sORP levels can be used to screen
infertile men with oxidative stress. These results are being validated in a larger cohort of infertile men.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Effect of Time on Oxidation-Reduction Potential in Semen and
Seminal Plasma&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">R. Sharma,<SUP>1</SUP> S. S. Du Plessis,<SUP>1,2</SUP> A. Agarwal,<SUP>1</SUP>
A. Harlev,<SUP>1,3</SUP> L. Samanta,<SUP>1,4</SUP> G. Ahmad,<SUP>1,5</SUP> S. Gupta,<SUP>1</SUP> E. S. Sabanegh<SUP>6</SUP>; 1.
Center For Reproductive Medicine, Cleveland Clinic, Cleveland, OH, 2. Medical Physiology, Stellenbosch University, Tygerberg, South
Africa, 3. Soroka Medical Center, Ben-Gurion University, Beer Sheva, Israel, 4. Redox Biology Laboratory, School of Life Science,
Ravenshaw University, Orissa, India, 5. Physiology and Cell Biology, University of Health Sciences, Lahore, Pakistan, 6. Department
of Urology, Cleveland Clinic, Cleveland, OH</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Abstract:&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Objective:</B> Oxidation-reduction potential (ORP) is a novel
measure of oxidative stress or redox imbalance in biological fluids. Reactive oxygen species (ROS) are highly reactive and have
a very short half-life. ROS levels in the seminal ejaculate should be measured within an hour after collection to prevent a reduction
in ROS levels over time. The traditional methods of measuring seminal ROS are time sensitive and time consuming, making it difficult
to use them for diagnostic purposes. It would be highly advantageous to employ a method that is independent of semen age and provides
results in real time. The objective was to assess the effect of time on static ORP (sORP), which provides a snapshot of current
redox balance, and capacity ORP (cORP) which is indicative of the amount of antioxidant reserves available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Design:</B> Prospective study measuring ORP in semen and seminal
plasma samples at time 0 and 120 minutes. Materials and Methods: The sORP and cORP of both semen (n=18) and seminal plasma (n=15)
samples from normal control subjects were measured after liquefaction (time 0) and after 120 minutes of incubation at room temperature
(RedoxSYS&reg;, Aytu BioScience). Values are mean &plusmn; SEM. Spearman correlation was used for statistical analysis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Results:</B> A significant correlation was seen between sORP
at time 0 and 120 minutes in semen and seminal plasma. Similar correlations were found for cORP values at both time intervals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Conclusions:</B> ORP values are not affected by the age of semen
or seminal plasma for up to 120 minutes, making it easier to employ this new technology for diagnostic use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>RedoxSYS System for Research Use&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We completed the development of the RedoxSYS System (MiOXSYS&rsquo;
predecessor product) during the two years preceding the Merger. In 2014, we received ISO 13485 certification, demonstrating our
compliance with global quality standards in medical device manufacturing. This enabled the launch of the RedoxSYS System into the
research market around the world. We also received a CE marking in Europe and Health Canada clearance to begin the market development
of the RedoxSYS System as a clinical diagnostic in Europe, Canada, and elsewhere around the world where CE marking is recognized.
We launched sales efforts into the research market in late 2014 and since that time have placed the RedoxSYS System at a number
of prominent research centers in the United States, Europe, and Israel. We expect to leverage these research relationships and
build numerous applications in areas where researchers are studying oxidative stress. Currently, there are no available research
platforms that measure oxidation-reduction potential in biologic fluids (i.e., blood, plasma, serum, semen, seminal fluid, cerebrospinal
fluid, tissue, and cells). While oxidative stress is commonly studied in research settings around the world (both academia and
industry), the current assessment methods are incomplete, time consuming, and often impractical for assessing oxidative stress
completely. To position the RedoxSYS System effectively in the research market, we have placed key personnel in the United States,
Europe, and Asia to develop direct research business relationships as well as distribution networks. Through these proof of concept
studies and clinical exploratory studies, we identified the application of oxidation-reduction potential in male infertility assessment.
As such, MiOXSYS was developed specifically for assessing semen and seminal plasma ORP levels. While we expect additional clinical
applications to be developed through these applications, our near-term focus is on completing the development of MiOXSYS for use
in semen analysis for male infertility assessment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Background on the MiOXSYS System&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">MiOXSYS is a novel, portable device that measures oxidation-reduction
potential, or ORP, a global measure of oxidative stress. MiOXSYS is the first and only system that measures ORP in biologic specimens
to provide a complete measure of redox balance, which is broadly implicated across a wide range of both acute and chronic conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Potential Role of ORP in Diagnosing Male Infertility&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Oxidation-reduction potential is defined in the published literature
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: left">&ldquo;ORP in a biological system
is an integrated measure of the balance between total oxidants and reductants. In plasma, many constituents contribute to the ORP.
Reactive oxygen species (ROS), such as the superoxide ion, hydroxyl radical, hydrogen peroxide, nitric oxide, peroxynitrite, transition
metal ions, and hypochlorous acid, contribute to the oxidative potential. Plasma reductants include thiols, vitamin C, tocopherol,
&beta;-carotene, lycopene, uric acid, bilirubin, and flavinoids. Enzymes such as superoxide dismutase, or SOD, catalase, and glutathione
peroxidase, are involved in the conversion of ROS into less reactive species. ORP monitoring of plasma represents a single measurement
that integrates the overall quantitative balance among the oxidants and reductants of the system.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Given that ORP represents a single, global measure of oxidative
stress in a biological system, we believe the potential for ORP to serve as a standardized marker in semen analysis and other aspects
of infertility assessment is significant. A major limitation of oxidative stress assays relates to the fact that there is poor
standardization in testing. As many factors contribute to oxidative stress (e.g., free radical proliferation, antioxidant depletion,
DNA damage, etc.), it is important to have an integrated measure that combines all known and unknown oxidants and reductants in
the respective system into one measurement. We believe ORP is an integrated measure of oxidative stress that can be easily and
quickly measured with the MiOXSYS System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In the context of infertility, having an integrated value representing
all relevant biologic constituents contributing to oxidative stress will enable simple, robust analysis in a two to three minute
test. There are various techniques in use to assess semen in cases of male infertility. The most commonly implemented techniques
involve DNA fragmentation, oxidative stress analysis, microscopic examination, sperm penetration assays, sperm agglutination, computer
assisted semen analysis, and others. The currently available oxidative stress analysis tools are widely considered expensive and
cumbersome to use in routine clinical practice. In both developed countries as well as in the developing world, expensive analysis
tools and recurring reagent expenses make routine testing nearly impossible to implement with regularity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>The MiOXSYS System Overview&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The MiOXSYS System is comprised of two distinct, patented components
that enable a system capable of measuring the ORP and antioxidant capacity of a biological fluid: an analyzer and sensor strips.
In mechanical terms, ORP is defined as the potential between a working electrode, and a reference electrode at equilibrium. The
RedoxSYS System has been specifically studied in human whole blood, serum, semen, seminal plasma, blood plasma, and other biological
fluids.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The MiOXSYS System measures two distinct elements to determine a
patient&rsquo;s oxidation reduction potential:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">Static ORP &mdash; the standard potential between a working
electrode and a reference electrode with no driving current (or extremely small current). This is proportional to the balance
of redox agents and is what is classically defined as ORP. Low ORP values mean that the biological sample is in the normal range
of oxidative stress. Higher than normal ORP values means that the biological sample is in a higher oxidation state.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Capacity &mdash; the measure
of antioxidant reserve available in the body&rsquo;s system. High capacity values mean that the biological sample has levels of
antioxidant reserves. Lower than normal capacity values means that the biological sample has below normal antioxidant reserves.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>The MiOXSYS Analyzer&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The MiOXSYS analyzer is a portable, lightweight desktop platform
that may be used in a clinical or research laboratory or near a patient care area. The analyzer is a small device that accepts
an inserted sensor that has collected a small specimen as obtained by traditional specimen collection procedures. The analyzer
is battery powered and equipped with a custom 5 lead strip connector. The reader consists of a Galvanostat analog circuit with
greater than 1012 MHz input impedance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The analyzer contains a 10 MHz external crystal (internal 4X PLL
for 40 MHz operation), and a programming/serial header is externally accessible. The device has internal power/heart-beat indicator
LED, primary storage of 128Mbit (16Mbyte) SPI Flash (3.3V) (Bulk data storage), and secondary storage of 2Mbit (256Kbyte) SPI FRAM
(3.3V) (Hi-Speed Storage).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The MiOXSYS analyzer contains a user-friendly interface that is
flexibly designed to accommodate multiple endpoints depending upon the specific clinical condition being considered. The interface
is LCD, 16x2, with a white backlight, variable delay auto-off time-out. Two status LED indicators are visible through front panel
mounted lenses. Further, the reader contains three DPDT push-button switches (Left, Center, Right), power on button(s) for battery
mode operation, switch usage switch, audible alerts, strip detection, and test completion signals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Further, the MiOXSYS analyzer enables data transfer, has USB serial
communication, and is configured for data download to a connected PC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The MiOXSYS analyzer&rsquo;s power management consists of an external
5VDC power jack with input capacitance and filtering, a boost converter supplied by external 5VDC power or internal Li-Ion battery,
and provides main 5VDC digital board supply. The reader functions with or without the battery connected. The battery lasts in excess
of 24 hours with continuous operation to enable prolonged use outside of a laboratory setting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Image of the MiOXSYS Analyzer&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="tpg79.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>The MiOXSYS Sensor Strips&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The MiOXSYS sensor strips, via standard biological specimen collection
techniques, receive 20 &ndash; 40 microliters of a specimen from which the ORP clinical analysis is performed. The ORP sensor strips
are small, disposable, and biocompatible and consist of a ceramic substrate and a five-lead configuration. Significant intellectual
property surrounds the design, construct, and electrochemical algorithms associated with the sensors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Image of the MiOXSYS Sensor Strips&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="tpg80.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Regulatory Pathway&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We achieved ISO 13485: 2003 in early 2014 following the successful
development of a compliant medical device quality system. Following the issuance of our ISO certification, we were awarded a CE
marking for the RedoxSYS System, which has enabled initial market development in Europe and markets that accept a CE marking. In
January 2016, we achieved CE Marking for MiOXSYS following technical validation and clinical study completion in male infertility.
In March 2016, we obtained Health Canada Class II Medical approvals for MiOXSYS. In the United States, we intend to pursue 510k
de novo clearance with the FDA for the MiOXSYS System. We have recent, ongoing correspondence with the FDA and have confirmed that
MiOXSYS is appropriate for the 510k de novo pathway, and we are pursuing regulatory clearance through this pathway.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>United States Commercial Strategy&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Commercial Strategy&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If the clinical studies to measure oxidative stress in male infertility
are successful, we expect to pursue that intended use for the MiOXSYS System via the FDA 510k de novo pathway. If cleared for the
infertility intended use, we intend to seek to commercialize MiOXSYS System as a new tool for the assessment of oxidative stress
in infertility in men. We envision pursuing a direct sales effort to high priority urology/andrology laboratories, infertility
clinics and reference centers across the United States. We have identified the primary, influential centers in the United States
and believe our commercial deployment will be efficient through a focused sales and marketing effort. We intend to seek to sell
the MiOXSYS System into individual centers and laboratories but will focus our revenue model on the repeat ordering of the disposable,
single use MiOXSYS sensor strips. We expect to realize a favorable gross margin on the basis of estimated low cost of goods sold
on both components of the system. We envision an average selling price for the disposable sensors of approximately $25 &ndash;
$40. We envision selling the MiOXSYS analyzers for $2,500 &ndash; $5,500 but will also pursue an instrument rental agreement model
with minimum disposable sensor purchase requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We also intend to leverage our urology commercialization efforts
with other products with a focus on urology centers, infertility clinics, and reproductive health laboratories around the United
States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We believe a focused sales force at the onset of commercialization
will enable effective representation of our products and penetration of the reproductive health market. Our sales efforts into
the research markets will be enabled initially through a full-time business development professional who will focus on collaborative
research and research sales to major oxidative stress centers in the United States. We expect to pursue identical pricing in the
research market and the clinical diagnostics markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>ROW Commercial Strategy&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We intend to undertake a similar strategy outside the United States
for the RedoxSYS and MiOXSYS systems while complementing our efforts in infertility and research with adjunct applications in critical
care conditions. To efficiently execute across our strategy, we intend to utilize a network of established distributors in the
target markets in Europe and Asia. We have already engaged with distributors in multiple countries, while many other potential
distributors are in advanced stages of discussions with us. We anticipate slightly reduced pricing outside the U.S. for the disposable
sensors given the anticipated lower pricing observed ex-US for diagnostic and research products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our Business Development Strategy &mdash; Identifying &amp; Acquiring
Complementary Urology Assets&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">A key growth and value driver for the Company is the ongoing identification
and acquisition of novel urology products for commercialization. We seek to identify unique products with urologic indications
that may be non-strategic, undervalued or under-resourced by the company that currently markets the product. We believe that we
can continue to acquire strategically aligned products at an appropriate valuation and grow those products via our focused sales
and marketing efforts. We will also consider acquiring novel, late-stage development products that represent unique commercial
opportunities and can be efficiently developed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We are actively identifying unique product assets to acquire based
on specific attributes including but not limited to: therapeutic area/indication; growth potential; intellectual property position
(patents, regulatory, manufacturing or development technicalities, etc.), valuation, strategic fit, commercial orientation and
other factors. Indications of interest include products to treat conditions such as urinary incontinence, sexual dysfunction, hypogonadism,
prostate and other urological cancers, urinary tract infections, and other urological conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Zertane, Our Phase 3-Ready Candidate for the Treatment of Premature
Ejaculation&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Zertane, is a specifically formulated orally disintegrating tablet,
or ODT, of tramadol hydrochloride patented for the on-demand treatment of premature ejaculation, or PE. Zertane is being developed
utilizing a regulatory pathway pursuant to Section 505(b)(2) of the FDCA, as the active ingredient is already well characterized
for the treatment of pain, and we are relying on the FDA&rsquo;s finding of safety of tramadol hydrochloride to support its use
in a new indication, PE, at a lower dose. If we receive marketing approval for Zertane, we believe it will be the first commercial
product approved by the FDA for PE. The FDA accepted the IND for Zertane in late 2015. The IND would allow for initiation of Phase
3 clinical studies by virtue of the positive clinical data generated to date and the well-established safety profile of tramadol
hydrochloride.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By virtue of significant development work performed by a previous
partner of Ampio, Zertane has already been evaluated outside the United States in two Phase 1 clinical trials, two Phase 2 clinical
trials and two Phase 3 clinical trials. The two Phase 1 safety trials were conducted to characterize the concentration of tramadol
hydrochloride in plasma after oral administration of a single Zertane ODT (89 mg) in healthy volunteers. Two randomized, placebo-controlled,
blinded Phase 2 clinical trials were conducted in a total of 102 patients. These trials evaluated doses of tramadol hydrochloride
between 25 and 120 mg in male subjects with PE. Two placebo-controlled, randomized and double-blind Phase 3 clinical trials were
conducted in Europe to investigate tramadol hydrochloride 62 mg and 89 mg ODT for the treatment of PE when taken as needed between
two and eight hours before a sexual event. This development work has demonstrated a favorable safety and efficacy profile of Zertane
in men with PE. Furthermore, the safety and pharmacology of the drug substance in Zertane, tramadol hydrochloride, is well characterized,
which should eliminate the need for us to conduct additional pre-clinical studies and safety trials. Based on guidance received
at a recent consultation meeting with the FDA, we believe Zertane is well positioned to initiate a Phase 3 clinical program in
the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The premature ejaculation market in the U.S. and Europe is expected
to reach over $1.3 billion in annual sales in 2017, representing an increase of 10.3% since 2010. According to published analyses,
premature ejaculation, or PE, is a highly prevalent male sexual dysfunction affecting 20 &ndash; 30% of men worldwide. Based on
internal market research and published reports, we believe that PE is up to 1.5-times more prevalent than erectile dysfunction,
or ED. Currently, there are no FDA-approved prescription products in the United States to treat PE, and to our knowledge, only
two other prescription products have been approved elsewhere in the world. Treatment options for PE have traditionally included
antidepressant drugs prescribed &ldquo;off label,&rdquo; topical numbing medications, and cognitive behavior therapy or counseling,
all of which have had limited effectiveness in treating the disorder. PE therefore represents an area of significant unmet medical
need. In addition, approximately 23% of the more than 12,000 men with PE surveyed in a 2007 study published in European Urology
also suffered from ED. Accordingly, we believe that a combination product candidate to treat both PE and ED represents another
significant worldwide market opportunity for us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Zertane is a specifically formulated orally disintegrating tablet,
or ODT, of tramadol hydrochloride patented for the on-demand treatment of PE. Zertane is being developed utilizing a regulatory
pathway pursuant to Section 505(b)(2) of the FDCA, as the active ingredient is already well characterized for the treatment of
pain, and we are relying on the FDA&rsquo;s finding of safety of tramadol hydrochloride to support its use in a new indication,
PE, at a lower dose. If the FDA approves Zertane, we believe it will be the first commercial prescription product approved by the
FDA for PE and would be attractive to a commercial partner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We already have partnerships in place to market Zertane in South
Korea and Brazil, which could provide near-term revenue for us if, working with our partners, we are able to successfully obtain
regulatory approval in those countries. In addition, we recently entered into an agreement with Endo Ventures Limited, which recently
acquired Paladin Labs Inc., or Paladin, a leading Canadian specialty pharmaceutical company, to provide exclusive rights to market,
sell and distribute Zertane in Canada, the Republic of South Africa, certain countries in Sub-Saharan Africa, Colombia and Latin
America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">According to published analyses, PE is a highly prevalent male sexual
dysfunction affecting 20 &ndash; 30% of men worldwide. Based on internal market research and published reports, we believe that
PE is up to 1.5-times more prevalent than erectile dysfunction. Presently, there are no approved prescription pharmaceuticals in
the United States to treat PE and only two pharmaceuticals known to be approved elsewhere in the world. Current &ldquo;off label&rdquo;
or unapproved therapies used to treat PE carry with them unwanted side effects and inconsistent or limited effectiveness. Topical
over-the-counter, or OTC, options are not preferred due to route of administration and may also have an impact on partner satisfaction.
Oral therapeutics, specifically selective serotonin reuptake inhibitors, or SSRIs, carry potentially significant side effects most
notably of which is diminished libido. PDE-5 inhibitors have been prescribed &ldquo;off label&rdquo; for PE but have not demonstrated
efficacy. Outside of oral or topical therapeutics, non-medical options include behavioral therapy and relationship counseling,
both of which can be time consuming and stressful and frequently ineffective for men and their partners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Zertane contains 89 mg tramadol hydrochloride in an orally dissolving
tablet, or ODT. Tramadol hydrochloride is a well-established, centrally acting synthetic analgesic and has been used for more than
30 years as a treatment for moderate to severe pain. The drug and its active metabolite (M1, <I>O</I>-desmethyltramadol) act as
an opiate agonist, apparently by selective activity at the &mu;-receptor. Although the mechanism by which tramadol hydrochloride
delays ejaculation has not been identified, numerous laboratory studies have shown that tramadol hydrochloride also acts as an
<I>N</I>-methyl-D-aspartate receptor antagonist, 5-hydroxytryptamine type 2C receptor antagonist, 5 nicotinic acetylcholine receptor
antagonist, M1 and M3 muscarinic acetylcholine receptor antagonist, and a serotonin and norepinephrine modulator. It is possible
that one or a combination of these effects leads to a delay in ejaculation. The relative contribution of tramadol hydrochloride
versus its M1 metabolite to delay ejaculation is unknown. However, the metabolite is six times more potent than the parent drug
in producing analgesia in animal models and 200 times more potent in &mu;-receptor binding. As a pain medication, tramadol hydrochloride
has been associated with certain adverse effects including dizziness, nausea, constipation, vertigo, headache, vomiting and drowsiness.
However, we intend that our labeling for Zertane, if regulatory approval is obtained, will suggest &ldquo;as required&rdquo; dosing
before sexual intercourse and not to exceed one tablet per day. Based on previous clinical studies, we believe that limiting the
dosing to no more than once per day will minimize any side effects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Clinical Data&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Six European clinical trials have been completed with Zertane: two
Phase 1 trials in healthy volunteers and two Phase 2 and two Phase 3 trials in men with lifelong PE. The two Phase 1 safety trials
were conducted to characterize the concentration of tramadol hydrochloride in plasma after oral administration of a single Zertane
ODT (89 mg) in healthy volunteers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Two randomized, placebo-controlled, blinded Phase 2 clinical trials
were conducted in a total of 102 patients. The first of these showed that a single 25-mg dose of conventionally formulated immediate
release tramadol hydrochloride (i.e., immediate-release gelatin capsules) was safe, well-tolerated and prolonged time to ejaculation
in some, but not all, patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The second trial evaluated three higher doses of tramadol hydrochloride:
65 mg, 85 mg and 120 mg. In this trial, a clear dose response was seen for both efficacy and safety, leading DMI Biosciences to
conclude that the optimal tramadol hydrochloride dose to treat PE was likely to be in the range 60 &ndash; 90 mg.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Two placebo-controlled, randomized and double-blind Phase 3 clinical
trials were conducted in Europe to investigate tramadol hydrochloride 62 mg and 89 mg ODT for the treatment of PE when taken as
needed between two and eight hours before a sexual event. A total of 677 patients were randomized in the trials and received either
the 62 or 89 mg ODT or a matching placebo ODT. Our claim that Zertane was efficacious in the Phase 3 trials is based on at least
one of the two doses resulting in statistically significant improvements in both IELT and PEP measures (i.e., co-primary endpoints)
from baseline to the end of the trial. Using IELT in combination with a self-report questionnaire (e.g., PEP or POPE) has gained
acceptance as meaningful measures of pharmacoactivity and efficacy in the scientific and regulatory communities. The results of
the Phase 3 trials suggest that tramadol hydrochloride 89 mg ODT is consistently more effective as a treatment for PE than tramadol
hydrochloride 62 mg ODT. In accordance with the definitions from the clinical trial protocols, only the tramadol hydrochloride
89 mg ODT dose satisfied the claim for effective treatment of PE in both Phase 3 trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the six prior clinical trials of
Zertane.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 10%; padding-top: 3pt; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Trial
    Name</B></FONT><FONT STYLE="font-size: 8pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(Dates/Sponsor)</B></FONT></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 5%; padding-top: 3pt; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Phase</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 10%; padding-top: 3pt; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Demographic</B></FONT><FONT STYLE="font-size: 8pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(Age)</B></FONT></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 8%; padding-top: 3pt; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Enrollment</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 10%; padding-top: 3pt; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Design</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 11%; padding-top: 3pt; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Duration</B></FONT><FONT STYLE="font-size: 8pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>of Double-</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>blind</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Treatment</B></FONT></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 11%; padding-top: 3pt; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Zertane</B></FONT><FONT STYLE="font-size: 8pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Dose (mg)</B></FONT></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 28%; padding-top: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Noteworthy
    Findings</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">BVF-324-101
    (June 26, 2009 to July 5, 2009/ Biovail*)</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">1</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Healthy
    males</FONT><FONT STYLE="font-size: 8pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">and females</FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">(18 &ndash; 55 yr)</FONT></FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">20</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Comparative</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">N/A</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">89</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Overall
    systemic exposure of tramadol hydrochloride and 2 metabolites were similar following 89 mg ODT and the reference 89 mg tramadol
    hydrochloride solution.</FONT><FONT STYLE="font-size: 8pt"><BR>
    <BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">13 subjects experienced a total of 37 adverse events (AEs) during
    the study. Most common AEs were GI disorders (nausea) and central nervous system disorders (sleepiness, dizziness, and headache).</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">BVF-324-102
    (July 14, 2009 to July 30, 2009/Biovail*)</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">1</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Healthy
    males</FONT><FONT STYLE="font-size: 8pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">(19 &ndash; 55 yr)</FONT></FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">424</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Alcohol</FONT><FONT STYLE="font-size: 8pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">interaction study</FONT></FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">N/A</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">89</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">There
    was no significant difference in the peak and total systemic exposures of tramadol hydrochloride compared to when tramadol
    hydrochloride 89 mg ODT was taken with water, or with either strength of alcohol.</FONT><FONT STYLE="font-size: 8pt"><BR>
    <BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">Tramadol hydrochloride was well tolerated with alcohol. 7 subjects
    experienced 11 AEs, most frequently decreased blood pressure and dizziness.</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">KNL
    40237 (March 13, 2003 to July 7, 2003/DMI**)</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Men
    with PE</FONT><FONT STYLE="font-size: 8pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">(18 &ndash; 70 yr)</FONT></FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">37</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Double-blind,</FONT><FONT STYLE="font-size: 8pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">randomized</FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">placebo-controlled</FONT></FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">3
    weeks</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">25</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Treatment
    with tramadol hydrochloride 25 mg had no statistically different effect than placebo in subjects with a baseline IELT of 2
    minutes or less (n=30; <I>P</I>=0.4560) or in a subpopulation of subjects with a baseline IELT of 1 minute or less (n=19;
    <I>P</I>=0.1796).</FONT><FONT STYLE="font-size: 8pt"><BR>
    <BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">46 AEs emerged during treatment (28 with tramadol hydrochloride and
    18 with placebo). There were no deaths, serious or other significant AEs. All AEs were of mild intensity. Most common AEs
    were GI disorders (nausea) and central nervous system disorders (headache).</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">KNL
    40491 (September 28, 2004 to October 18, 2005/DMI**)</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Men
    with PE</FONT><FONT STYLE="font-size: 8pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">(18 &ndash; 70 yr)</FONT></FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">68</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Double-blind,</FONT><FONT STYLE="font-size: 8pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">randomized</FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">placebo-controlled</FONT></FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">12
    weeks</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">65,
85, 120</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Tramadol
    hydrochloride significantly increased the median IELT compared to both Baseline and placebo. Statistically significant increases
    in IELT compared to Baseline were observed to be 3.0-fold (<I>P</I>=0.0013), 4.2-fold (<I>P</I>&lt;0.0001), and 5.1-fold (<I>P</I>&lt;0.0001)
    for the 65-, 85-, and 120-mg dose levels, respectively.</FONT><FONT STYLE="font-size: 8pt"><BR>
    <BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">Doses of 65 and 85 mg were generally well tolerated. 120 mg was less
    well tolerated with adverse events known to be associated with tramadol hydrochloride (headache, dizziness, somnolence, insomnia)
    and related to sexual function (penile hypoaesthesia, anorgasmia, and ED).</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">BVF-324-301
    (August 17, 2009 to September 9, 2010/Biovail*)</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">3</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Men
    with PE</FONT><FONT STYLE="font-size: 8pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">(18 &ndash; 65 yr)</FONT></FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">221</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Double-blind,</FONT><FONT STYLE="font-size: 8pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">randomized</FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">placebo-controlled</FONT></FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">12
    weeks</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">62,
    89</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">There
    was a statistically significant change in IELT from Baseline to the end of the study for tramadol hydrochloride ODT 89 mg
    compared to placebo (p = 0.002). The significant difference was apparent at the first visit during the double-blind treatment
    period and each visit thereafter (p &le; 0.05 for all Visits). Tramadol hydrochloride 62 mg and 89 mg ODT demonstrated statistically
    significant improvements in PEP measures compared with placebo.</FONT><FONT STYLE="font-size: 8pt"><BR>
    <BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">During the double-blind treatment or open-label extension periods,
    21 subjects experienced at least 1 treatment-emergent AE. There were no deaths or serious AEs during the study.</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">BVF-324-302
    (September 30, 2009 to August 23, 2010/Biovail*)</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">3</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Men
    with PE</FONT><FONT STYLE="font-size: 8pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">(18 &ndash; 65 yr)</FONT></FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">456</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Double-blind,</FONT><FONT STYLE="font-size: 8pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">randomized</FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">placebo-controlled</FONT></FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">12
    weeks</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">62,
    89</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">There
    was a statistically significant change in IELT from Baseline to the end of the study for tramadol hydrochloride ODT 62 and
    89 mg compared to placebo (p = 0.01 and p = 0.02). Tramadol hydrochloride 62 mg and 89 mg ODT demonstrated statistically significant
    improvements in both IELT and PEP measures compared with placebo.</FONT><FONT STYLE="font-size: 8pt"><BR>
    <BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">A total of 28 out of 399 subjects (7.5%) experienced at least 1 treatment-emergent
    AE during the double-blind or open-label treatment period. No subject died or experienced a severe AE.</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Total</B></FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>896</B></FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify"><I>Biovail Laboratories International, SRL</I></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><I>**</I></TD><TD STYLE="text-align: justify"><I>DMI BioSciences, Inc.</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Phase 3-Ready Clinical Program in United States &mdash; Ready
for a Strategic Partner to Engage&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">With the approval of the IND the regulatory pathway has been agreed
upon with the FDA. As in the Phase 3 trials conducted in Europe, co-primary endpoints will be used for determination of efficacy.
Both improvement in IELT, which will be captured by the partner in a blinded diary, and PE-related frustration or bother, which
will be assessed after each sexual intercourse attempt as well as at the final study visit by a single question in the POPE, will
be evaluated as co-primary endpoints to determine efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Importantly, clinical trial supplies are already manufactured and
packaged and would simply require appropriate clinical labeling of the product candidate. Additionally, our manufacturing process
has already been validated at the site of commercial manufacture, and clinical study sites in the U.S. have been identified and
validated. Depending on our success in raising additional funds, we may decide to focus our capital resources on other strategies
and not pursue clinical testing of Zertane in the U.S. If we decide not to pursue clinical testing of Zertane, we will seek strategic
options to maximize the value of Zertane, inclusive of divestiture, out-licensing, and strategic commercial collaborations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Ex-U.S. Partnering Has Begun&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We have already demonstrated that there is partnering interest for
Zertane around the world as evidenced by the partnerships we have in place with notable regional pharmaceutical companies. We plan
to leverage these partnerships to gain approval and eventual marketing authorization for Zertane in several key markets around
the world. We already have partnerships in place with Daewoong Pharmaceuticals Co., Ltd. in South Korea and FBM Industria Farmaceutica
Ltda. in Brazil, thereby providing potential royalty and milestone-based revenue if, working with our partners, we are successfully
able to obtain regulatory approval in those countries. In addition, our recent agreement with Paladin (an operating unit of Endo
Pharmaceuticals plc) provides Paladin with exclusive rights to market, sell and distribute Zertane in Canada, the Republic of South
Africa, certain countries in Sub-Saharan Africa, Colombia and Latin America. Before marketing any products in Brazil and South
Korea, approval must be received from the Brazilian Health Surveillance Agency (Anvisa) and the Ministry of Food and Drug Safety
(MFDS, previously the Korean Food and Drug Administration), respectively. We intend to leverage the expertise of our local collaborators
in these jurisdictions to navigate the regulatory requirements and help determine an efficient and effective pathway to bringing
Zertane to market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Government Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Approval Process for Pharmaceutical Products&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>FDA Approval Process for Pharmaceutical Products&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In the United States, pharmaceutical products are subject to extensive
regulation by the FDA. The Federal Food, Drug, and Cosmetic Act, or the FDC Act, and other federal and state statutes and regulations,
govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion
and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.
Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions,
such as FDA refusal to approve pending NDAs, warning letters, product recalls, product seizures, total or partial suspension of
production or distribution, injunctions, fines, civil penalties, and criminal prosecution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Pharmaceutical product development in the United States typically
involves the performance of satisfactory nonclinical, also referred to as pre-clinical, laboratory and animal studies under the
FDA&rsquo;s Good Laboratory Practice, or GLP, regulation, the development and demonstration of manufacturing processes, which conform
to FDA mandated current good manufacturing requirements, or cGMP, including a quality system regulating manufacturing, the submission
and acceptance of an IND application, which must become effective before human clinical trials may begin in the United States,
obtaining the approval of Institutional Review Boards, or IRBs, at each site where we plan to conduct a clinical trial to protect
the welfare and rights of human subjects in clinical trials, adequate and well-controlled clinical trials to establish the safety
and effectiveness of the drug for each indication for which FDA approval is sought, and the submission to the FDA for review and
approval of an NDA. Satisfaction of FDA requirements typically takes many years and the actual time required may vary substantially
based upon the type, complexity, and novelty of the product or disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Pre-clinical tests generally include laboratory evaluation of a
product candidate, its chemistry, formulation, stability and toxicity, as well as certain animal studies to assess its potential
safety and efficacy. Results of these pre-clinical tests, together with chemistry, manufacturing controls and analytical data and
the clinical trial protocol, which details the objectives of the trial, the parameters to be used in monitoring safety, and the
effectiveness criteria to be evaluated, along with other requirements must be submitted to the FDA as part of an IND, which must
become effective before human clinical trials can begin. The entire clinical trial and its protocol must be in compliance with
what are referred to as good clinical practice, or GCP, requirements. The term, GCP, is used to refer to various FDA laws and regulations,
as well as international scientific standards intended to protect the rights, health and safety of patients, define the roles of
clinical trial sponsors and assure the integrity of clinical trial data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">An IND automatically becomes effective 30 days after receipt by
the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the intended conduct of the trials and
imposes what is referred to as a clinical hold. Pre-clinical studies generally take several years to complete, and there is no
guarantee that an IND based on those studies will become effective, allowing clinical testing to begin. In addition to FDA review
of an IND, each medical site that desires to participate in a proposed clinical trial must have the protocol reviewed and approved
by an independent IRB or Ethics Committee, or EC. The IRB considers, among other things, ethical factors, and the selection and
safety of human subjects. Clinical trials must be conducted in accordance with the FDA&rsquo;s GCP requirements. The FDA and/or
IRB may order the temporary, or permanent, discontinuation of a clinical trial or that a specific clinical trial site be halted
at any time, or impose other sanctions for failure to comply with requirements under the appropriate entity jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Clinical trials to support NDAs for marketing approval are typically
conducted in three sequential phases, but the phases may overlap. In Phase 1 clinical trials, a product candidate is typically
introduced either into healthy human subjects or patients with the medical condition for which the new drug is intended to be used.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The main purpose of the trial is to assess a product candidate&rsquo;s
safety and the ability of the human body to tolerate the product candidate. Phase 1 clinical trials generally include less than
50 subjects or patients. During Phase 2 trials, a product candidate is studied in an exploratory trial or trials in a limited number
of patients with the disease or medical condition for which it is intended to be used in order to: (i) further identify any possible
adverse side effects and safety risks, (ii) assess the preliminary or potential efficacy of the product candidate for specific
target diseases or medical conditions, and (iii) assess dosage tolerance and determine the optimal dose for Phase 3 trials. Phase
3 trials are generally undertaken to demonstrate clinical efficacy and to further test for safety in an expanded patient population
with the goal of evaluating the overall risk-benefit relationship of the product candidate. Phase 3 trials are generally designed
to reach a specific goal or endpoint, the achievement of which is intended to demonstrate the candidate product&rsquo;s clinical
efficacy and adequate information for labeling of the approved drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">There are three main types of NDAs, which are covered by Section
505 of the FDC Act: (1) an application that contains full reports of investigations of safety and efficacy (Section 505(b)(1));
(2) an application that contains full reports of investigations of safety and effectiveness but where at least some of the information
required for approval comes from studies not conducted by or for the applicant and for which the application has not obtained a
right of reference (Section 505(b)(2)); and (3) an application that contains information to show that the proposed product is identical
in active ingredient, dosage form, strength, route of administration, labeling, quality, performance characteristics, and intended
use, among other things, to a previously approved product (Section 505(j)). Section 505(b)(2) expressly permits the FDA to rely,
for approval of an NDA, on data not developed by the applicant. In the pre-IND briefing meeting with Ampio and in June 2012, the
FDA agreed that our NDA may be submitted under Section 505(b)(2). As such, we intend to rely on studies published in the scientific
literature and reference FDA-approved NDAs for tramadol-containing products (NDAs 21-693, 20-281 and 21-692) to support the safety
and efficacy demonstrated in our clinical program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">After completion of the required clinical testing, an NDA is prepared
and submitted to the FDA. FDA approval of the NDA is required before marketing of the product may begin in the U.S. The NDA must
include the results of all pre-clinical, clinical, and other testing and a compilation of data relating to the product&rsquo;s
pharmacology, chemistry, manufacture, and controls. The cost of preparing and submitting an NDA is substantial. Under federal law,
the submission of most NDAs is additionally subject to a substantial application user fee, currently exceeding $2.3 million and
the manufacturer and/or sponsor under an approved NDA are also subject to annual product and establishment user fees, currently
approximately $0.1 million per product and $0.6 million per establishment. These fees are typically increased annually.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The FDA has 60 days from its receipt of an NDA to determine whether
the application will be accepted for filing based on the FDA&rsquo;s threshold determination that it is sufficiently complete to
permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to
certain performance goals in the review of NDAs. Most such applications for standard review drug products are reviewed within ten
months; most applications for priority review drugs are reviewed in six months. Priority review can be applied to drugs that the
FDA determines offer major advances in treatment, or provide a treatment where no adequate therapy exists. The review process for
both standard and priority review may be extended by the FDA for three additional months to consider certain late-submitted information,
or information intended to clarify information already provided in the submission. The FDA may also refer applications for novel
drug products, or drug products which present difficult questions of safety or efficacy, to an advisory committee &mdash; typically
a panel that includes clinicians and other experts &mdash; for review, evaluation, and a recommendation as to whether the application
should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations.
Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally,
the FDA will inspect the facility or the facilities at which the drug is manufactured. The FDA will not approve the product unless
compliance with cGMP is satisfactory and the NDA contains data that provide substantial evidence that the drug is safe and effective
in the indication studied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">After the FDA evaluates the NDA and the manufacturing facilities,
it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies
in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application.
If and when those deficiencies have been addressed to the FDA&rsquo;s satisfaction in a resubmission of the NDA, the FDA will issue
an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information
included. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.
As a condition of NDA approval, the FDA may require a risk evaluation and mitigation strategy, or REMS, to help ensure that the
benefits of the drug outweigh the potential risks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">REMS can include medication guides, communication plans for healthcare
professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification
for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries.
The requirement for a REMS can materially affect the potential market and profitability of the drug. Moreover, product approval
may require substantial post-approval testing and surveillance to monitor the drug&rsquo;s safety or efficacy. Once granted, product
approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial
marketing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>The Hatch-Waxman Act&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In seeking approval for a drug through an NDA, applicants are required
to list with the FDA each patent whose claims cover the applicant&rsquo;s product. Upon approval of a drug, each of the patents
listed in the application for the drug is then published in the FDA&rsquo;s Approved Drug Products with Therapeutic Equivalence
Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential competitors
in support of approval of an abbreviated new drug application, or ANDA. An ANDA provides for marketing of a drug product that has
the same active ingredients in the same strengths and dosage form as the listed drug and has been shown through bioequivalence
testing to be therapeutically equivalent to the listed drug. Other than the requirement for bioequivalence testing, ANDA applicants
are not required to conduct, or submit results of, pre-clinical or clinical tests to prove the safety or effectiveness of their
drug product. Drugs approved in this way are commonly referred to as &ldquo;generic equivalents&rdquo; to the listed drug, and
can often be substituted by pharmacists under prescriptions written for the original listed drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The ANDA applicant is required to certify to the FDA concerning
any patents listed for the approved product in the FDA&rsquo;s Orange Book that: 1) the required patent information has not been
filed; 2) the listed patent has expired; 3) the listed patent has not expired, but will expire on a particular date and approval
is sought after patent expiration; or 4) the listed patent is invalid or will not be infringed by the new product. A certification
that the new product will not infringe the already approved product&rsquo;s listed patents, or that such patents are invalid, is
called a Paragraph IV certification. If the applicant does not challenge the listed patents, the ANDA application will not be approved
until all the listed patents claiming the referenced product have expired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If the ANDA applicant has provided a Paragraph IV certification
to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has
been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to
the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph
IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months, expiration of the patent,
settlement of the lawsuit, or a decision in the infringement case that is favorable to the ANDA applicant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The ANDA application also will not be approved until any non-patent
exclusivity listed in the Orange Book for the referenced product has expired. Federal law provides a period of five years following
approval of a drug containing no previously approved active ingredients during which ANDAs for generic versions of those drugs
cannot be submitted, unless the submission contains a Paragraph IV challenge to a listed patent &mdash; in which case the submission
may be made four years following the original product approval. Federal law provides for a period of three years of exclusivity
during which FDA cannot grant effective approval of an ANDA based on the approval of a listed drug that contains previously approved
active ingredients but is approved in a new dosage form, route of administration or combination, or for a new use; the approval
of which was required to be supported by new clinical trials conducted by, or for, the applicant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Post-Approval Regulation&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Even if a product candidate receives regulatory approval, the approval
is typically limited to specific clinical indications. Further, even after regulatory approval is obtained, subsequent discovery
of previously unknown problems with a product may result in restrictions on its use or even complete withdrawal of the product
from the market. Any FDA-approved products manufactured or distributed by us are subject to continuing regulation by the FDA, including
record-keeping requirements and reporting of adverse events or experiences. Further, drug manufacturers and their subcontractors
are required to register their establishments with the FDA and state agencies, and are subject to periodic inspections by the FDA
and state agencies for compliance with cGMP, which impose rigorous procedural and documentation requirements upon us and our contract
manufacturers. We cannot be certain that we or our present or future contract manufacturers or suppliers will be able to comply
with cGMP regulations and other FDA regulatory requirements. Failure to comply with these requirements may result in, among other
things, total or partial suspension of production activities, failure of the FDA to grant approval for marketing, and withdrawal,
suspension, or revocation of marketing approvals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If the FDA approves one or more of our product candidates, we and
the contract manufacturers we use for manufacture of clinical supplies and commercial supplies must provide certain updated safety
and efficacy information. Product changes, as well as certain changes in the manufacturing process or facilities where the manufacturing
occurs or other post-approval changes may necessitate additional FDA review and approval. The labeling, advertising, promotion,
marketing and distribution of a drug or biologic product or medical devices, also must be in compliance with FDA and Federal Trade
Commission, or FTC, requirements which include, among others, standards and regulations for direct-to-consumer advertising, off-label
promotion, industry sponsored scientific and educational activities, and promotional activities involving the Internet. The FDA
and FTC have very broad enforcement authority, and failure to abide by these regulations can result in penalties, including the
issuance of a warning letter directing us to correct deviations from regulatory standards and enforcement actions that can include
seizures, fines, injunctions and criminal prosecution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Approval Process for Medical Devices&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In the United States, the FDCA, FDA regulations and other federal
and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical
testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion,
sales and distribution, export and import, and post-market surveillance. The FDA regulates the design, manufacturing, servicing,
sale and distribution of medical devices, including molecular diagnostic test kits and instrumentation systems. Failure to comply
with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal
to approve pending applications, warning letters, product recalls, product seizures, total or partial suspension of production
or distribution, injunctions, fines, civil penalties and criminal prosecution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Unless an exemption applies, each medical device we wish to distribute
commercially in the United States will require marketing authorization from the FDA prior to distribution. The two primary types
of FDA marketing authorization applicable to a device are premarket notification, also called 510(k) clearance, and premarket approval,
also called PMA approval. The type of marketing authorization is generally linked to the classification of the device. The FDA
classifies medical devices into one of three classes (Class I, II or III) based on the degree of risk the FDA determines to be
associated with a device and the level of regulatory control deemed necessary to ensure the device&rsquo;s safety and effectiveness.
Devices requiring fewer controls because they are deemed to pose lower risk are placed in Class I or II. Class I devices are deemed
to pose the least risk and are subject only to general controls applicable to all devices, such as requirements for device labeling,
premarket notification and adherence to the FDA&rsquo;s current Good Manufacturing Practices, or cGMP, known as the Quality System
Regulations, or QSR. Class II devices are intermediate risk devices that are subject to general controls and may also be subject
to special controls such as performance standards, product-specific guidance documents, special labeling requirements, patient
registries or post-market surveillance. Class III devices are those for which insufficient information exists to assure safety
and effectiveness solely through general or special controls and include life sustaining, life-supporting or implantable devices,
devices of substantial importance in preventing impairment of human health, or which present a potential, unreasonable risk of
illness or injury.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Most Class I devices and some Class II devices are exempted by regulation
from the 510(k) clearance requirement and can be marketed without prior authorization from the FDA. Some Class I devices that have
not been so exempted and Class II devices are eligible for marketing through the 510(k) clearance pathway. By contrast, devices
placed in Class III generally require PMA approval or 510(k) de novo clearance prior to commercial marketing. The PMA approval
process is more stringent, time-consuming and expensive than the 510(k) clearance process, however, the 510(k) clearance process
has also become increasingly stringent and expensive. The FDA has provided initial guidance to us that the RedoxSYS System is appropriate
for the 510(k) clearance process, likely through the de novo pathway.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">510(k) Clearance. To obtain 510(k) clearance for a medical device,
an applicant must submit a premarket notification to the FDA demonstrating that the device is &ldquo;substantially equivalent&rdquo;
to a device legally marketed in the United States that is not subject to PMA approval, commonly known as the &ldquo;predicate device.&rdquo;
A device is substantially equivalent if, with respect to the predicate device, it has the same intended use and has either (i)
the same technological characteristics or (ii) different technological characteristics and the information submitted demonstrates
that the device is as safe and effective as a legally marketed device and does not raise different questions of safety or effectiveness.
A showing of substantial equivalence sometimes, but not always, requires clinical data. Generally, the 510(k) clearance process
can exceed 90 days and may extend to a year or more.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">After a device has received 510(k) clearance for a specific intended
use, any change or modification that significantly affects its safety or effectiveness, such as a significant change in the design,
materials, method of manufacture or intended use, may require a new 510(k) clearance or PMA approval and payment of an FDA user
fee. The determination as to whether or not a modification could significantly affect the device&rsquo;s safety or effectiveness
is initially left to the manufacturer using available FDA guidance; however, the FDA may review this determination to evaluate
the regulatory status of the modified product at any time and may require the manufacturer to cease marketing and recall the modified
device until 510(k) clearance or PMA approval is obtained. The manufacturer may also be subject to significant regulatory fines
or penalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Before we can submit a medical device for 510(k) clearance, we may
have to perform a series of generally short studies over a period of months, including method comparison, reproducibility, interference
and stability studies to ensure that users can perform the test successfully. Some of these studies may take place in clinical
environments, but are not usually considered clinical trials. For PMA submissions, we would generally be required to conduct a
longer clinical trial over a period of years that supports the clinical utility of the device and how the device will be used.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Although clinical investigations of most devices are subject to
the investigational device exemption, or IDE, requirements, clinical investigations of diagnostic tests, including our products
and products under development, are generally exempt from the IDE requirements. Thus, clinical investigations by intended users
for intended uses of our products generally do not require the FDA&rsquo;s prior approval but may require approval of an Institutional
Review Board, or IRB, and written informed consent by the patient, provided the clinical evaluation testing is non-invasive, does
not require an invasive sampling procedure that presents a significant risk, does not intentionally introduce energy into the subject
and is not used as a diagnostic procedure without confirmation by another medically established test or procedure. In addition,
our products must be labeled per FDA regulations &ldquo;for research use only-RUO&rdquo; or &ldquo;for investigational use only-IUO,&rdquo;
and distribution controls must be established to assure that our products distributed for research, method comparisons or clinical
evaluation studies are used only for those purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Regulation after FDA Clearance or Approval&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Any devices we manufacture or distribute pursuant to clearance or
approval by the FDA are subject to pervasive and continuing regulation by the FDA and certain state agencies. We are required to
adhere to applicable regulations setting forth detailed cGMP requirements, as set forth in the QSR, which include, among other
things, testing, control and documentation requirements. Noncompliance with these standards can result in, among other things,
fines, injunctions, civil penalties, recalls or seizures of products, total or partial suspension of production, refusal of the
government to grant 510(k) clearance or PMA approval of devices, withdrawal of marketing approvals and criminal prosecutions, fines
and imprisonment. Our contract manufacturers&rsquo; facilities operate under the FDA&rsquo;s cGMP requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Foreign Regulatory Approval&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Outside of the United States, our ability to market our product
candidates will be contingent also upon our receiving marketing authorizations from the appropriate foreign regulatory authorities,
whether or not FDA approval has been obtained. The foreign regulatory approval process in most industrialized countries generally
encompasses risks similar to those we will encounter in the FDA approval process. The requirements governing conduct of clinical
trials and marketing authorizations, and the time required to obtain requisite approvals, may vary widely from country to country
and differ from those required for FDA approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In the European Union, we are required under the European Medical
Device Directive (Council Directive 93/42/EEC) to affix the CE mark to certain of our products in order to sell the products in
member countries of the European Union. The CE mark is an international symbol that represents adherence to certain essential principles
of safety and effectiveness mandated in the European Medical Device Directive, which are referred to as the &ldquo;essential requirements&rdquo;.
Once affixed, the CE mark enables a product to be sold within the European Economic Area, or EEA, which is composed of the 28 member
states of the EU plus Norway, Iceland and Liechtenstein as well as other countries that accept the CE mark.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">To demonstrate compliance with the essential requirements, we must
undergo a conformity assessment procedure which varies according to the type of medical device and its classification. Except for
low risk medical devices (Class I with no measuring function and which are not sterile) where the manufacturer can issue an EC
Declaration of Conformity based on a self-assessment of the conformity of its products with the essential requirements of the Medical
Devices Directive, a conformity assessment procedure requires the intervention of an organization accredited by a member state
of the EEA to conduct conformity assessments, or a notified body. Depending on the relevant conformity assessment procedure, the
notified body would typically audit and examine the technical file and the quality system for the manufacture, design and final
inspection of our devices. The notified body issues a CE certificate of Conformity following successful completion of a conformity
assessment procedure conducted in relation to the medical device and its manufacturer and their conformity with the essential requirements.
This certificate entitles the manufacturer to affix the CE mark to its medical devices after having prepared and signed a related
EC Declaration of Conformity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If we modify our devices we may need to apply for permission to
affix the CE mark to the modified product. Additionally, we may need to apply for a CE mark for any new products that we may develop
in the future. Certain products regulated as medical devices according to EC-Directives are subject to vigilance requirements for
reporting of adverse events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We will be subject to additional regulations in other countries
in which we market, sell and import our products, including Canada. We or our distributors must receive all necessary approvals
or clearance prior to marketing and/or importing our products in those markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The International Standards Organization, or ISO, promulgates internationally
recognized standards, including those for the requirements of quality systems. To support ISO certifications, surveillance audits
are conducted by a notified body yearly and recertification audits every three years that assess continued compliance with the
relevant ISO standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Other Regulatory Matters&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Manufacturing, sales, promotion and other activities following product
approval are also subject to regulation by numerous regulatory authorities in addition to the FDA, including, in the United States,
the Centers for Medicare &amp; Medicaid Services, other divisions of the Department of Health and Human Services, the Drug Enforcement
Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety &amp; Health Administration,
the Environmental Protection Agency and state and local governments. In the United States, sales, marketing and scientific/educational
programs must also comply with state and federal fraud and abuse laws. Pricing and rebate programs must comply with the Medicaid
rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the Health Care Reform
Law, as amended by the Health Care and Education Affordability Reconciliation Act, or ACA. If products are made available to authorized
users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. The handling
of any controlled substances must comply with the U.S. Controlled Substances Act and Controlled Substances Import and Export Act.
Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing,
sales, promotion and other activities are also potentially subject to federal and state consumer protection and unfair competition
laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The distribution of pharmaceutical products is subject to additional
requirements and regulations, including extensive recordkeeping, licensing, storage and security requirements intended to prevent
the unauthorized sale of pharmaceutical products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The failure to comply with regulatory requirements subjects firms
to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can
result in criminal prosecution, fines, imprisonment or other penalties, injunctions, recall or seizure of products, total or partial
suspension of production, denial or withdrawal of product approvals, or refusal to allow a firm to enter into supply contracts,
including government contracts. In addition, even if a firm complies with FDA and other requirements, new information regarding
the safety or effectiveness of a product could lead the FDA to modify or withdraw product approval. Prohibitions or restrictions
on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Changes in regulations, statutes or the interpretation of existing
regulations could impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements; (ii)
additions or modifications to product labeling; (iii) the recall or discontinuation of our products; or (iv) additional record-keeping
requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>United States Patent Term Restoration and Marketing Exclusivity&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Depending upon the timing, duration and other specific aspects of
the FDA approval of our drug candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug
Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman
Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development
and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total
of 14 years from the product&rsquo;s approval date. The patent term restoration period is generally one-half the time between the
effective date of an IND and the submission date of an NDA plus the time between the submission date of an NDA and the approval
of that application. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension
must be submitted prior to the expiration of the patent. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews
and approves the application for any patent term extension or restoration. In the future, if any of our NDA&rsquo;s are approved,
we intend to apply for restoration of patent term for one of our currently owned or licensed patents to add patent life beyond
the current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of
the relevant NDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Market exclusivity provisions under the FDCA can also delay the
submission or the approval of certain marketing applications. The FDCA provides a five-year period of non-patent marketing exclusivity
within the United States to the first applicant to obtain approval of an NDA for a new chemical entity, or NCE. A drug is a new
chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule
or ion responsible for the action of the drug substance. Recently, the FDA stated that it may change its interpretation of 5-year
NCE exclusivity determinations to apply to each drug substance in a fixed-combination drug product, not for the drug product as
a whole. If this change is implemented, for example, a fixed-combination drug product that contains a drug substance with a single,
new active moiety would be eligible for 5 year NCE exclusivity, even if the fixed-combination also contains a drug substance with
a previously approved active moiety. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application,
or ANDA, or a Section 505(b)(2) NDA submitted by another company for another drug based on the same active moiety, regardless of
whether the drug is intended for the same indication as the original innovator drug or for another indication, where the applicant
does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted
after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the
FDA by the innovator NDA holder. The FDCA also provides three years of marketing exclusivity for an NDA, or supplement to an existing
NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed
by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing
drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical
investigations and does not prohibit the FDA from approving ANDAs for drugs containing the active agent for the original indication
or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an
applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the pre-clinical studies
and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. Orphan drug exclusivity, as
described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances. Pediatric exclusivity
is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing
exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent
term, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &ldquo;Written Request&rdquo;
for such a trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Reimbursement&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We do not anticipate that the sales of two of our product candidates
(Zertane and the MiOXSYS System), once approved for sale, will be heavily dependent upon reimbursement by third-party payors. Traditionally,
sales of pharmaceutical products that are not &ldquo;life style&rdquo; indications depend, in part, on the extent to which products
will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations.
These third-party payors are increasingly reducing reimbursements for medical products and services. ProstaScint is dependent upon
reimbursement for continued use in the U.S. market, and ProstaScint does have a reimbursement code as assigned by the American
Medical Association. ProstaScint is currently reimbursed by Medicare, Medicaid, and various private health plans. However, reimbursement
is not universally available throughout the United States for ProstaScint. Primsol is also dependent upon reimbursement for continued
use in the U.S. market, and Primsol is covered under a Rebate Agreement between us and Centers for Medicare and Medicaid Services.
This, in turn, enables states to offer public payer coverage of Primsol through their separate Medicaid and public assistance programs.
Primsol is also covered by many private payers who offer coverage benefits to patients for branded, prescription antibiotic treatments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Lack of third-party reimbursement for our product candidate or a
decision by a third-party payor to not cover our product candidates could reduce physician usage of the product candidate and have
a material adverse effect on our sales, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, in some foreign countries, the proposed pricing for
a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to
country. For example, the European Union provides options for its member states to restrict the range of medicinal products for
which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use.
A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls
on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that
has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements
for any of our products. Historically, products launched in the European Union do not follow price structures of the United States
and generally tend to be significantly lower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>DEA Regulation&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Natesto, already approved by the FDA, is a &ldquo;controlled substance&rdquo;
as defined in the Controlled Substances Act of 1970, or CSA, because it contains testosterone. As a result, the U.S. Drug Enforcement
Agencies, or DEA, regulate Natesto and have listed it as a Schedule III substance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Zertane, because it contains tramadol, will be regulated as a &ldquo;controlled
substance&rdquo; as defined in the CSA and the DEA. The DEA regulates controlled substances as Schedule I, II, III, IV or V substances.
Schedule I substances by definition have no established medicinal use, and may not be marketed or sold in the United States. A
pharmaceutical product may be listed as Schedule II, III, IV or V. The DEA implements regulations, which establish registration,
security, recordkeeping, reporting, storage, distribution, importation, exportation, inventory, quota and other requirements administered
by the DEA for controlled substances. These requirements are directly applicable to us and also applicable to our manufacturers
and to distributors, prescribers and dispensers of Natesto and, if approved Zertane. The DEA regulates the handling of controlled
substances through a closed chain of distribution. This control extends to the equipment and raw materials used in their manufacture
and packaging in order to prevent loss and diversion into illicit channels of commerce.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We expect that Zertane will be listed by the DEA as Schedule IV
controlled substances under the CSA. Consequently, any importation of API for Zertane, as well as the manufacture, shipping, storage,
sales and use of Zertane, will be subject to a high degree of regulation. Also, distribution and dispensing of these drugs are
highly regulated. We do not expect this designation will affect our ability to align with a strategic partner to commercialize
Zertane.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Annual registration is required for any facility that manufactures,
distributes, dispenses, imports or exports any controlled substance. The registration is specific to the particular location, activity
and controlled substance schedule. For example, separate registrations are needed for import and manufacturing, and each registration
will specify which schedules of controlled substances are authorized. Similarly, separate registrations are also required for separate
facilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The DEA typically inspects a facility to review its security measures
prior to issuing a registration and on a periodic basis. Reports must also be made for thefts or losses of any controlled substance,
and to obtain authorization to destroy any controlled substance. In addition, special permits and notification requirements apply
to imports and exports of narcotic drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The DEA establishes annually an aggregate quota for how much of
a controlled substance may be produced in total in the United States based on the DEA&rsquo;s estimate of the quantity needed to
meet legitimate scientific and medicinal needs. The DEA may adjust aggregate production quotas and individual production and procurement
quotas from time to time during the year, although the DEA has substantial discretion in whether or not to make such adjustments.
Our or our manufacturers&rsquo; quotas of an active ingredient may not be sufficient to meet commercial demand or complete clinical
trials. Any delay, limitation or refusal by the DEA in establishing our or our manufacturers&rsquo; quota for controlled substances
could delay or stop our clinical trials or product launches, which could have a material adverse effect on our business, financial
position and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">To enforce these requirements, the DEA conducts periodic inspections
of registered establishments that handle controlled substances. Failure to maintain compliance with applicable requirements, particularly
as manifested in loss or diversion, can result in administrative, civil or criminal enforcement action that could have a material
adverse effect on our business, results of operations and financial condition. The DEA may seek civil penalties, refuse to renew
necessary registrations, or initiate administrative proceedings to revoke those registrations. In some circumstances, violations
could result in criminal proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Individual states also independently regulate controlled substances.
We and our manufacturers will be subject to state regulation on distribution of these products, including, for example, state requirements
for licensures or registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Intellectual Property&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We have an extensive range of intellectual property across our primary
assets, Zertane, MiOXSYS, and RedoxSYS. We have patent protection in the United States and several other large markets worldwide.
Specifically, we have numerous patents issued and pending for the RedoxSYS/MiOXSYS systems and their use in the U.S., Europe, Canada,
Israel, and in Japan. Further, we have patent protection in the United States and several other large markets worldwide for the
use of tramadol hydrochloride to treat PE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We have restructured our patent portfolio related to Zertane to
focus on our patent family for the use of tramadol to treat premature ejaculation. Issued patents in this family in the United
States, Australia, Canada, China, Hong Kong, Japan, Korea and South Africa will be maintained and issued patents in all European
countries, Mexico, New Zealand, Philippines and Singapore will be allowed to lapse through non-payment of annuities. The standard
20-year expiration for patents in this family is in 2022. The other two families related to Zertane for a combination of tramadol
and a phosphodiesterase inhibitor to treat comorbid premature ejaculation and erectile dysfunction and to treat sexual dysfunction
side effects associated with administration of tramadol will be allowed to lapse worldwide through non-payment of annuities for
issued patents and non-response to outstanding actions for pending applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We have restructured our patent portfolio related to RedoxSYS/MiOXSYS
to focus on the United States and core foreign jurisdictions which include Europe, Japan, Canada and Israel. In other foreign jurisdictions,
patents and pending applications will be allowed to lapse through non-payment of annuities for issued patents and non-response
to outstanding actions for pending applications. The portfolio to be supported in the United States and core foreign jurisdictions
consists of 10 issued patents and 18 pending applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The portfolio primarily consists of four families filed in the United
States and in core foreign jurisdictions. The first family includes four issued patents and five pending applications with claims
directed to the measurement of the ORP of a patient sample to evaluate various conditions. The standard 20-year expiration for
patents in this family is in 2028. The second family includes two pending United States applications, and three pending applications
in core foreign jurisdictions with claims directed to the measurement of the ORP capacity of a patient sample to evaluate various
conditions. The standard 20-year expiration for patents in this family is in 2033. The third family includes six issued patents
and three pending applications with claims directed to devices and methods for the measurement of ORP and ORP capacity. The standard
20-year expiration for patents in this family is in 2032. The fourth family includes one pending United States application and
four pending applications in core foreign jurisdictions with claims directed to multiple layer gel test strip measurement devices
and methods of making for use in measuring ORP and ORP capacity. The standard 20-year expiration for patents in this family is
in 2033.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">ProstaScint is protected by significant trade secrets and manufacturing
know-how related to the production of the product and linkage of the base monoclonal antibody and imaging component. The antibody
in the ProstaScint product is produced by a proprietary cell line.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Primsol is protected by a formulation patent and its regulatory
designation. By virtue of the fact that Primsol was approved as an NDA and the extremely large backlog of Abbreviated New Drug
Applications at FDA (two to three year review time currently), we don&rsquo;t expect generic competition for Primsol in the next
three to four years. There are currently no generic competitors filed with the FDA under Paragraph IV, which is required of potential
generic competitors seeking to genericize an on-patent NDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Aytu has an exclusive license from Acerus Pharmaceuticals SRL for
the United States to intellectual property related to a nasal gel drug product containing testosterone to treat hypogonadism in
males, including the FDA approved product Natesto&reg;, as well as an authorized generic version and OTC versions thereof. The
license includes sublicense rights to intellectual property owned by Mattern Pharmaceuticals and exclusively licensed to Acerus
by Mattern Pharmaceuticals. The sublicensed intellectual property includes four Orange Book listed patents directed at nasal gel
formulations containing testosterone or methods of testosterone replacement therapy by nasal administration of the same. It further
includes a pending unpublished application, and two patents that are not listed in the Orange Book directed at a method of making
a testosterone formulation and a method for reducing physical or chemical interactions between a nasal testosterone formulation
and a plastic container.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Acerus license also grants rights to intellectual property owned
by Acerus which includes twelve nonprovisional patent applications, some of which may be abandoned. These patent applications include
at least three pending applications directed to testosterone titration methods, intranasal testosterone bio-adhesive gel formulations,
and controlled release testosterone formulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We also maintain trade secrets and proprietary know-how that we
seek to protect through confidentiality and nondisclosure agreements. These agreements may not provide meaningful protection or
adequate remedies in the event of unauthorized use or disclosure of confidential and proprietary information. If we do not adequately
protect our trade secrets and proprietary know-how, our competitive position and business prospects could be materially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We expect to seek United States and foreign patent protection for
drug and diagnostic products we discover, as well as therapeutic and diagnostic products and processes. We expect also to seek
patent protection or rely upon trade secret rights to protect certain other technologies which may be used to discover and characterize
drugs and diagnostic products and processes, and which may be used to develop novel therapeutic and diagnostic products and processes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The patent positions of companies such as ours involve complex legal
and factual questions and, therefore, their enforceability cannot be predicted with any certainty. Our issued and licensed patents,
and those that may be issued to us in the future, may be challenged, invalidated or circumvented, and the rights granted under
the patents or licenses may not provide us with meaningful protection or competitive advantages. Our competitors may independently
develop similar technologies or duplicate any technology developed by us, which could offset any advantages we might otherwise
realize from our intellectual property. Furthermore, even if our product candidates receive regulatory approval, the time required
for development, testing, and regulatory review could mean that protection afforded us by our patents may only remain in effect
for a short period after commercialization. The expiration of patents or license rights we hold could adversely affect our ability
to successfully commercialize our pharmaceutical drugs or diagnostics, thus harming our operating results and financial position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We will be able to protect our proprietary intellectual property
rights from unauthorized use by third parties primarily to the extent that such rights are covered by valid and enforceable patents
or are effectively maintained as trade secrets. If we must litigate to protect our intellectual property from infringement, we
may incur substantial costs and our officers may be forced to devote significant time to litigation-related matters. The laws of
certain foreign countries do not protect intellectual property rights to the same extent as do the laws of the United States. Our
pending patent applications, or those we may file or license from third parties in the future, may not result in patents being
issued. Until a patent is issued, the claims covered by an application for patent may be narrowed or removed entirely, thus depriving
us of adequate protection. As a result, we may face unanticipated competition, or conclude that without patent rights the risk
of bringing product candidates to market exceeds the returns we are likely to obtain. We are generally aware of the scientific
research being conducted in the areas in which we focus our research and development efforts, but patent applications filed by
others are maintained in secrecy for at least 18 months and, in some cases in the United States, until the patent is issued. The
publication of discoveries in scientific literature often occurs substantially later than the date on which the underlying discoveries
were made. As a result, it is possible that patent applications for products similar to our drug or diagnostic products and product
candidates may have already been filed by others without our knowledge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The biotechnology and pharmaceutical industries are characterized
by extensive litigation regarding patents and other intellectual property rights, and it is possible that our development of products
and product candidates could be challenged by other pharmaceutical or biotechnology companies. If we become involved in litigation
concerning the enforceability, scope and validity of the proprietary rights of others, we may incur significant litigation or licensing
expenses, be prevented from further developing or commercializing a product or product candidate, be required to seek licenses
that may not be available from third parties on commercially acceptable terms, if at all, or subject us to compensatory or punitive
damage awards. Any of these consequences could materially harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Competition&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The healthcare industry is highly competitive and subject to significant
and rapid technological change as researchers learn more about diseases and develop new technologies and treatments. Significant
competitive factors in our industry include product efficacy and safety; quality and breadth of an organization&rsquo;s technology;
skill of an organization&rsquo;s employees and its ability to recruit and retain key employees; timing and scope of regulatory
approvals; government reimbursement rates for, and the average selling price of, products; the availability of raw materials and
qualified manufacturing capacity; manufacturing costs; intellectual property and patent rights and their protection; and sales
and marketing capabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our competitors may also succeed in obtaining FDA or other regulatory
approvals for their product candidates more rapidly than we are able to do, which could place us at a significant competitive disadvantage
or deny us marketing exclusivity rights. Market acceptance of our product candidates will depend on a number of factors, including:
(i) potential advantages over existing or alternative therapies or tests, (ii) the actual or perceived safety of similar classes
of products, (iii) the effectiveness of sales, marketing, and distribution capabilities, and (iv) the scope of any approval provided
by the FDA or foreign regulatory authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We cannot assure you that any of our products that we successfully
develop will be clinically superior or scientifically preferable to products developed or introduced by our competitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our currently approved products compete in highly competitive fields
whereby there are numerous options available to clinicians including generics. These generic treatment options are frequently less
expensive and more widely available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>ProstaScint&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Currently, there are several FDA approved imaging techniques for
cancer in general, however there is only one specifically targeting prostate cancer &mdash; ProstaScint. The other imaging methods
are F18-fluorodeoxyglucose (F18-FDG), C11-Acetate, and C11-Choline. The primary advantage of these methods is that they all use
PET imaging, a technique with better resolution than SPECT. The use of PET is also a disadvantage, however, since it uses radiolabels
with short half-lives necessitating the need for a local or on-site cyclotron to generate the labels. The half-life of fluorine-18
(F18) and of carbon-11 (C11) are approximately 110 and 20 minutes, respectively. The radiolabel used by ProstaScint is Indium-11,
with a half-life of about 2 &ndash; 3 days. This longer time period allows the radiolabel to be made remotely and shipped to the
imaging facility; however it does use SPECT as the imaging modality.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As indicated, ProstaScint is the only radio-imaging marker that
is specific for prostate cancer. ProstaScint is based on radiolabeling the antibody against prostate specific membrane antigen,
or PSMA, a protein express by prostate cells. This specificity for prostate cells is what allows ProstaScint to detect the metastases
of prostate cancer regardless of location. The mechanism of labeling for F18-FDG, C11-Acetate, and C11-Choline is the intracellular
accumulation of these markers in cancer cells, due to the fact that cancer cells typically have a higher cellular metabolism than
non-cancerous cells. Thus, these markers can accumulate in any type of cancer cell with a high metabolism, unfortunately prostate
cancer cells tend to have a lower cellular metabolism resulting in higher false positives attributed to hyperplasia and prostatitis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In a meta-analysis of 21 studies evaluating accuracy, sensitivity,
specificity, positive/negative predictive values, ProstaScint using combined SPECT/CT imaging was comparable to PET/CT imaging
based on F18-FDG and C11-Choline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Natesto</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Natesto competes in a large, growing market. The U.S. TRT market
is large, with annual revenues in the U.S. in 2013 of $2.4 billion. Revenues are expected to increase to $5 billion by 2017. If
the TRT market grows as expected, with as little as 5% market penetration, a novel, patent-protected TRT product could achieve
sales of $250 million. Even at the current market size of approximately $2 billion, a product with 5% market penetration could
achieve sales of approximately $100 million annually, assuming comparatively similar product pricing and reimbursement levels as
seen with other TRTs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The U.S. prescription testosterone market is comprised primarily
of topically applied treatments in the form of gels, solutions, and patches. Testopel&reg; and Aveed&reg;, injectable products
typically implanted directly under the skin by a physician, are also FDA-approved. AndroGel is the market-leading TRT and is marketed
by AbbVie.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Primsol&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">There are any number of antibiotics available on the market that
could compete with Primsol. However, Primsol is the only FDA-approved liquid formulation of trimethoprim, an antibiotic that is
well established in current guidelines for treating UTIs. Further, Primsol is the only trimethoprim oral solution on the U.S. market
that does not contain sulfamethoxazole, or sulfa. Therefore, Primsol is appropriate for UTI patients that have difficulty swallowing
tablets, such as the elderly, and particularly for patients that experience adverse reactions to sulfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>MiOXSYS/RedoxSYS&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">With respect to MiOXSYS competitive offerings, there are other oxidative
stress diagnostic tests available throughout the world, although none are approved in the United States for clinical use. Diagnostic
systems that are marketed for clinical use outside the United States include the FRAS 4 system (H&amp;D srl), FREE Carpe Diem (Diacron
International), and the FORM and FORMPlus systems (Callegari srl). These systems are used in both research and clinical settings
but do not generate significant sales in the clinical setting. If approved in the United States for clinical use, these systems
could present competition to the MiOXSYS System. However, their testing parameters differ significantly from MiOXSYS and would
need to demonstrate clinical superiority to MiOXSYS in order to substantially detract from MiOXSYS prescribing and sales. Additionally,
to our knowledge these systems have not demonstrated clinical feasibility in human semen or seminal plasma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Zertane&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">PE has traditionally been treated by behavioral or psychosexual
therapy, antidepressant drugs, such as SSRIs, or topical desensitizing agents, all of which have significant drawbacks. Behavioral
and psychosexual therapy as a treatment for PE requires an understanding partner and can be frustrating, embarrassing, time consuming
and expensive, among other things. Antidepressant drugs are sometimes prescribed &ldquo;off-label&rdquo; and have numerous shortcomings,
including side effects such as nausea, headaches, drop of libido, ED, need for chronic dosing, ramp up periods, variable responses
and unwanted drug-drug interactions. Topical agents, including lidocaine-based products affect spontaneity, can numb a partner
and be messy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Dapoxetine (brand name Priligy), owned by Allergan, is currently
the only approved oral prescription drug to treat PE, with approval in several European countries. Priligy is not approved in the
United States. In addition, we are aware of a topical product in late-stage development for PE by Plethora Solutions referred to
as PSD502 and studies of Botox for the treatment of PE are being conducted in the United States. These products &mdash; if approved
in the United States &mdash; would represent competition and alternative choices for physicians and potential patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, generic tramadol hydrochloride is available in the
United States and abroad for treatment of pain. Although the generic drug is not available in the same dosage as Zertane for treatment
of PE, it is possible that physicians could prescribe the generic version of the drug &ldquo;off label&rdquo; for the treatment
of PE instead of Zertane, if Zertane is approved for commercialization. Patients could use generic tramadol hydrochloride dosages
that are either higher or lower than what will be approved for Zertane or they could attempt to split dosages to arrive at the
dosages approved for Zertane. While any such &ldquo;off label&rdquo; use of generic tramadol hydrochloride for treatment of PE
may constitute infringement of our patent portfolio, liability in that circumstance would be at the level of the physician or the
patient making enforcement difficult or impractical.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Research and Development&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our strategy is to minimize our research and development activities.
When we do conduct research and development, we intend to utilize consultants with domain experience for research, development
and regulatory guidance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our MiOXSYS System has been developed in conjunction with numerous
medical device and diagnostic development consultants. Further, we have relationships with regulatory consultants who are actively
assisting in the development of our regulatory strategy with the FDA. To complement our internal clinical research efforts with
the MiOXSYS System, we have engaged with numerous universities around the world to identify and develop research and clinical applications
for the MiOXSYS System. Through these engagements we have access to data and analyses that enable us to develop new uses for the
MiOXSYS and RedoxSYS systems. Additionally, we have formal research agreements in place with two prominent U.S.-based universities
and one prominent European university for which we are paying a research fee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Manufacturing&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our business strategy is to use cGMP compliant contract manufacturers
for the manufacture of clinical supplies as well as for commercial supplies if required by our commercialization plans, and to
transfer manufacturing responsibility to our collaboration partners when possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>ProstaScint&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We have acquired a two-year supply of ProstaScint through our asset
purchase agreement with Jazz Pharmaceuticals. Further, we intend to intend to transfer the manufacturing of ProstaScint to a new
contract manufacturer, and have initiated discussions with the contract manufacturer and expect to sign an agreement whereby we
will transfer the production to a similar facility operated by the new contract manufacturer. Accordingly, we also expect to put
a supply agreement in place for an extended duration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On October 8, 2015, we and Biovest International, Inc., or Biovest,
entered into a Master Services Agreement, pursuant to which Biovest is to provide manufacturing services to us for ProstaScint.
The agreement provides that we may engage Biovest from time to time to provide services in accordance with mutually agreed upon
project addendums and purchase orders for ProstaScint. We expect to use the agreement from time to time for manufacturing services,
including without limitation, the manufacturing, processing, quality control testing, release or storage of ProstaScint. The agreement
provides customary terms and conditions, including those for performance of services by Biovest in compliance with project addendums,
industry standards, regulatory standards and all applicable laws. Biovest will be responsible for obtaining and maintaining all
governmental approvals, at our expense, during the term of the agreement. The agreement has a term of four years, provided that
either party may terminate the agreement or any project addendum under the agreement on 30 days written notice of a material breach
under the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, we may terminate the agreement or any project addendum
under the agreement upon 180 days written notice for any reason. In conjunction with entering into the agreement, we submitted
a work order to Biovest to provide us with active pharmaceutical ingredient for ProstaScint over a four-year period at a total
cost of $5.0 million, of which we paid $1.0 million upon submission of the work order and $500,000 in each of January and April
2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Natesto</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On April 22, 2016, we entered into a license and supply agreement
with Acerus pursuant to which we will pay Acerus a supply price per unit of the greater of (i) a fixed percentage of Acerus&rsquo;
cost of goods sold for Natesto, not to exceed a fixed ceiling price and (ii) a low double digit percentage of the net selling price
for the first year of the agreement, that increases in each of the second and third years and remains constant after that.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Primsol&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We have entered into a supply agreement for Primsol with the same
manufacturer used by FSC Laboratories, from whom we purchased Primsol. Pursuant to the agreement, we can order supply as needed
at a fixed price for the first two years of the agreement; thereafter we will negotiate the price but do not expect the supply
price to increase by more than 25%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>MiOXSYS/RedoxSYS&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We have completed the technical development of the RedoxSYS System
by engaging contract development and manufacturing companies in the United States. We secured supply and quality agreements with
manufacturers for both the RedoxSYS and MiOXSYS instruments as well as the RedoxSYS and MiOXSYS sensor strips. Both manufacturers
hold long-standing ISO 13485:2003 certifications and are established medical device manufacturers. Both manufacturers have high
volume manufacturing capacity such that production volumes can be easily scaled. Both manufacturers have been audited by our quality
engineers and are fully compliant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Zertane&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We are party to a 10-year supply agreement with an established manufacturer
of tramadol hydrochloride for Zertane. Importantly, product supply has been produced for our planned clinical trials for Zertane.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Employees&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As of May 31, 2016, we had 21 full-time employees and utilized the
services of a number of consultants on a temporary basis. Overall, we have not experienced any work stoppage and do not anticipate
any work stoppage in the foreseeable future. None of our employees is subject to a collective bargaining agreement. Management
believes that relations with our employees are good.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Properties&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On August 19, 2015, Aytu entered into a 37 month non-cancellable
operating lease for new office space effective September 1, 2015. The new lease has initial base rent of $8,500 per month beginning
in October 2015, with the total base rent over the term of the lease of approximately $318,000 which includes rent abatements.
We have also opened a 1,333 square foot office in Raleigh, North Carolina for which the lease runs until July 31, 2018. We believe
our current office space is sufficient to meet our current needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We recognize rental expense of the facility on a straight-line basis
over the term of the lease. Differences between the straight-line net expenses on rent payments are classified as liabilities between
current deferred rent and long-term deferred rent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Legal Proceedings&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We are currently not party to any material legal or administrative
proceedings and are not aware of any material pending or threatened legal or administrative proceedings in which we will become
involved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_010"></A>MANAGEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table sets forth the names and ages of all of our
directors and executive officers. Our Board of Directors is currently comprised of four members, who are elected annually to serve
for one year or until their successor is duly elected and qualified, or until their earlier resignation or removal. Executive officers
serve at the discretion of the Board of Directors and are appointed by the Board of Directors. Each of the directors and executive
officers listed below joined us upon the closing of the Merger on April 16, 2015, except for Jonathan McGrael who joined us in
late September 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 29%; border-bottom: black 1pt solid; padding-right: 1pt; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 4%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 65%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 1pt; padding-left: 2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joshua R. Disbrow</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and Director</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 1pt; padding-left: 2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jarrett T. Disbrow</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Operating Officer and Director</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 1pt; padding-left: 2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gregory A. Gould</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer, Secretary, and Treasurer</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 1pt; padding-left: 2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jonathan H. McGrael</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice President of Commercial Operations</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 1pt; padding-left: 2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Macaluso</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 1pt; padding-left: 2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carl C. Dockery</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following is a biographical summary of the experience of our
executive officers and directors during the past five years, and an indication of directorships held by the director in other companies
subject to the reporting requirements under the federal securities law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Michael Macaluso &ndash; Director</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Michael Macaluso has been a member of our Board of Directors since
April 16, 2015. Mr. Macaluso is also the Chairman and Chief Executive Officer of Ampio. Mr. Macaluso has been a member of Ampio
Pharmaceuticals&rsquo; Board of Directors since March 2010 and Ampio&rsquo;s Chief Executive Officer since January 2012. Mr. Macaluso
served in the roles of president and Chief Executive Officer of Isolagen, Inc. (AMEX: ILE) from June 2001 until September 2004.
Mr. Macaluso also served on the board of directors of Isolagen from June 2001 until April 2005. From October 1998 until June 2001,
Mr. Macaluso was the owner of Page International Communications, a manufacturing business. Mr. Macaluso was a founder and principal
of International Printing and Publishing, a position Mr. Macaluso held from 1989 until 1997, when he sold that business to a private
equity firm. Mr. Macaluso&rsquo;s experience in executive management and marketing within the pharmaceutical industry, monetizing
company opportunities, and corporate finance led to the conclusion that he should serve as a director of our company in light of
our business and structure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Carl C. Dockery &ndash; Director</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Carl Dockery joined our Board in April 2016. Mr. Dockery is a financial
executive with 30 years of experience as an executive in the insurance and reinsurance industry and more recently in 2006 as the
founder and president of a registered investment advisory firm, Alpha Advisors, LLC. Mr. Dockery&rsquo;s career as an insurance
executive began in 1988 as an officer and director of two related and closely held insurance companies, including serving as secretary
of Crossroads Insurance Co. Ltd. of Bermuda and as vice president of Gulf Insurance Co. Ltd. of Grand Cayman. Familiar with the
London reinsurance market, in the 1990s, Mr. Dockery worked at Lloyd&rsquo;s and the London Underwriting Centre brokering various
types of reinsurance placements. Mr. Dockery serves as a director of CytoDyn Inc. (OTCQB: &ldquo;CYDY&rdquo;), a biotechnology
company. Mr. Dockery graduated from Southeastern University with a Bachelor of Arts in Humanities. Mr. Dockery&rsquo;s financial
expertise and experience, as well as his experience as a director of a publicly traded biopharmaceutical company, led to the conclusion
that he should serve as a director of our company in light of our business and structure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Joshua R. Disbrow &ndash; Chief Executive Officer and Director</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Joshua R. Disbrow has been employed by us since April 16, 2015.
Prior to the closing of the Merger, Mr. Disbrow was the Chief Executive Officer of Luoxis since January 2013. Mr. Disbrow was also
the Chief Operating Officer of Ampio since December 2012. Prior to joining Ampio, he served as the Vice President of Commercial
Operations at Arbor Pharmaceuticals, a specialty pharmaceutical company, from May 2007 through October 2012. He joined Arbor as
that company&rsquo;s second full-time employee. Mr. Disbrow led the company&rsquo;s commercial efforts from inception to the company&rsquo;s
acquisition in 2010 and growth to over $127 million in net sales in 2011. By the time Mr. Disbrow departed Arbor in late 2012,
he had led the growth of the commercial organization to comprise over 150 people in sales, marketing sales training, managed care,
national accounts, and other commercial functions. Mr. Disbrow has spent over 17 years in the pharmaceutical, diagnostic and medical
device industries and has held positions of increasing responsibility in sales, marketing, sales management, commercial operations
and commercial strategy. Prior to joining Arbor, Mr. Disbrow served as Regional Sales Manager with Cyberonics, Inc., a medical
device company focused on neuromodulation therapies from June 2005 through April 2007. Prior to joining Cyberonics he was the Director
of Marketing at LipoScience, an in vitro diagnostics company. Mr. Disbrow holds an MBA from Wake Forest University and BS in Management
from North Carolina State University. Mr. Disbrow&rsquo;s experience in executive management and marketing within the pharmaceutical
industry, monetizing company opportunities, and corporate finance led to the conclusion that he should serve as a director of our
Company in light of our business and structure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Jarrett T. Disbrow &ndash; Chief Operating Officer and Director</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Jarrett Disbrow has been employed by us since April 16, 2015. Prior
to the closing of the Merger, Mr. Disbrow was the Chief Executive Officer of Vyrix from November 2013. Mr. Disbrow joined Vyrix
from Eurus Pharma LLC, or Eurus Pharma, where he held the position of general manager from 2011 to 2013. Prior to joining Eurus
Pharma, Mr. Disbrow was the founder, president and chief executive officer of Arbor Pharmaceuticals, Inc., or Arbor Pharmaceuticals
from 2006 to 2010. Following Arbor Pharmaceuticals&rsquo; acquisition in 2010, Mr. Disbrow remained with the company as vice president
of commercial development. Prior to founding Arbor Pharmaceuticals in 2006, he was head of marketing for Accentia Biopharmaceuticals,
Inc. from 2002 to 2006. Mr. Disbrow began his career with GlaxoWellcom, Inc. (now GlaxoSmithKline plc) from 1997 to 2001, where
he held positions of increasing responsibility in sales and later marketing. Mr. Disbrow received a BS in business management from
North Carolina State University in Raleigh, NC. Mr. Disbrow&rsquo;s experience in executive management and operations within the
pharmaceutical industry led to the conclusion that he should serve as a director of our company in light of our business and structure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Gregory A. Gould &ndash; Chief Financial Officer, Secretary,
and Treasurer</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Gregory A. Gould has been our Chief Financial Officer since April
16, 2015. Mr. Gould is also the Chief Financial Officer of Ampio where he has been employed since June 2014. Prior to joining Ampio,
he provided financial and operational consulting services to the biotech industry through his consulting company, Gould LLC from
April 2012 until June 2014. Mr. Gould was Chief Financial Officer, Treasurer and Secretary of SeraCare from November 2006 until
the company was sold to Linden Capital Partners in April 2012. During the period from July 2011 until April 2012 Mr. Gould also
served as the Interim President and Chief Executive Officer of SeraCare Life Sciences. Mr. Gould has held several other executive
positions at publicly traded life sciences companies including the Chief Financial Officer role at Atrix Laboratories, Inc., an
emerging specialty pharmaceutical company focused on advanced drug delivery. During Mr. Gould&rsquo;s tenure at Atrix he was instrumental
in the negotiation and sale of the company to QLT, Inc. for over $855 million. He also played a critical role in the management
of several licensing agreements including the global licensing agreement with Sanofi-Synthelabo of the Eligard&reg; products. Mr.
Gould was the Chief Financial Officer at Colorado MedTech, Inc., a publicly traded medical device design and manufacturing company
where he negotiated the transaction to sell the company to KRG Capital Partners. Mr. Gould began his career as an auditor with
Arthur Andersen, LLP. He currently serves on the board of directors of CytoDyn, Inc., a publicly traded drug development company
pursuing anti-viral agents for the treatment of HIV. Mr. Gould graduated from the University of Colorado with a BS in Business
Administration and is a Certified Public Accountant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Jonathan H. McGrael &ndash; Vice President of Commercial Operations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Jonathan McGrael joined us on September 30, 2015 as Vice President
of Sales and in May 2016 became our Vice President of Commercial Operations. Mr. McGrael has spent 17 years in the pharmaceutical
industry and has held positions of increasing responsibility in sales, sales training, marketing, sales management, and leadership
development. Until September 15, 2015, he was Director of Sales at Arbor Pharmaceuticals, which he joined in 2010 as that company&rsquo;s
14<SUP>th</SUP> employee. Under his leadership the sales organization grew from 10 sales representatives to over 400 and achieved
significant, consistent revenue growth throughout his leadership tenure. Mr. McGrael also designed comprehensive leadership development
and training programs for sales leaders, as well as a marketing structure that ensured &ldquo;plug-and-play&rdquo; incorporation
of new products. Mr. McGrael began his career at TAP Pharmaceuticals (now Takeda) where he held positions within the sales and
marketing divisions. He received an MS in Public Health from Missouri State University and a BS in Human Bio-Dynamics also from
Missouri State University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Family Relationships&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Jarrett T. Disbrow, our Chief Operating Officer, is the brother
of Joshua R. Disbrow, our Chief Executive Officer. There are no other family relationships among or between any of our current
or former executive officers and directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Involvement in Certain Legal Proceedings&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">None of our directors or executive officers has been involved in
any legal proceeding in the past 10 years that would require disclosure under Item 401(f) of Regulation S-K promulgated under the
Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Executive Compensation&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In accordance with Item 402 of Regulation S-K promulgated by the
SEC, we are required to disclose certain information regarding the makeup of and compensation for our company&rsquo;s directors,
former directors and named executive officers, in certain cases for each of the last three completed fiscal years. On April 16,
2015, we acquired Luoxis and Vyrix in the Merger. Because our sole director was a director on the boards of directors of Luoxis
and Vyrix, and our named executive officers were, prior to the April 16, 2015, employed by Luoxis and Vyrix, we are providing past
compensation information concerning such director and executive officers with respect to Luoxis and Vyrix.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Compensation of Directors&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In establishing director compensation, our Board is guided by the
following goals:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">compensation should consist of a combination of cash and
equity awards that are designed to fairly pay the directors for work required for a company of our size and scope;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">compensation should align
the directors&rsquo; interests with the long-term interests of stockholders; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">compensation should assist
with attracting and retaining qualified directors.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Jarrett T. Disbrow, who served as a member of Vyrix&rsquo;s board
of directors during 2014, did not receive any compensation, equity awards or non-equity awards for his service as a director, although
Mr. Disbrow did receive compensation in 2014 from and with respect to his employment with Vyrix. James B. Wiegand, who served as
the sole director of Rosewind in 2014, did not receive any compensation, equity awards or non-equity awards for his service as
a director. Mr. Wiegand was appointed President, Chief Executive Officer and Secretary and a director of Rosewind on August 9,
2002. He resigned from all of his positions with us on April 16, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our current compensation package for non-employee directors consists
of 100,000 options per year, which we began in April 2016.&nbsp; No cash compensation is paid at this time.&nbsp; We also reimburse
for expenses incurred in connection with their service as director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table provides information regarding all compensation
paid to non-employee directors of Vyrix and Luoxis during the fiscal year ended June 30, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Name</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Fees Earned<BR> or Paid in<BR> Cash</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock</B></FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option</B></FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Awards<SUP>(1)</SUP> </B>&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">All Other<BR> Compensation</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Macaluso<SUP>(2)</SUP></FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">198,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">198,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary V. Cantrell<SUP>(3)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John A. Donofrio Jr<SUP>(4)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nicholas J. Leb<SUP>(5)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">This column reflects the aggregate grant date fair value
computed in accordance with Financial Accounting Standards Board, or &ldquo;FASB&rdquo;, issued Accounting Standards Update, or
&ldquo;ASC&rdquo;, Topic 718. Pre-Merger awards made to Mr. Macaluso in August 2014 were cancelled in April 2015 and the expenses
were reversed.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">Michael Macaluso was appointed a director of Luoxis in
January 2013 and a director of Vyrix in November 2013. In connection with the Merger, he resigned from the boards of Luoxis and
Vyrix and was appointed a director of Aytu upon the closing of the Merger on April 16, 2015.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(3)</TD><TD STYLE="text-align: justify">Gary V. Cantrell was appointed a director of Vyrix in February
2014. In connection with the Merger, he resigned from this position on April 16, 2015 as we continue to assess the appropriate
corporate governance structure.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(4)</TD><TD STYLE="text-align: justify">John A. Donofrio Jr. was appointed a director of Vyrix
in February 2014. In connection with the Merger, he resigned from this position on April 16, 2015 as we continue to assess the
appropriate corporate governance structure.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(5)</TD><TD STYLE="text-align: justify">Nicholas J. Leb was appointed a director of Vyrix in February
2014. In connection with the Merger, he resigned from this position on April 16, 2015 as we continue to assess the appropriate
corporate governance structure.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Executive Officer Compensation&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">From fiscal year 2012 to the completion of the Merger on April 16,
2015, no compensation was earned by or paid to James B. Wiegand, the former President, Chief Financial Officer and Secretary of
Rosewind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table sets forth all cash compensation earned, as
well as certain other compensation paid or accrued for the years ended June 30, 2015 and 2014 to each of the following named executive
officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Summary Compensation of Named Executive Officers&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 95%; margin-left: 0.25in">
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Name
    and Principal</B></FONT><FONT STYLE="font-size: 8pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Position</B></FONT></FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Year</B></FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Salary</B></FONT><FONT STYLE="font-size: 8pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>($)</B></FONT></FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Bonus</B></FONT><FONT STYLE="font-size: 8pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>($)</B></FONT></FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Stock</B></FONT><FONT STYLE="font-size: 8pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Award</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>($)</B></FONT></FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Option</B></FONT><FONT STYLE="font-size: 8pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Award</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>($)<SUP>(1)</SUP></B></FONT></FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;<B>Non-Equity</B></FONT><FONT STYLE="font-size: 8pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Incentive</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Plan </B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Compensation<BR>
 ($)</B></FONT></FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Change
    in</B></FONT><FONT STYLE="font-size: 8pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Pension</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Value and</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Nonqualified</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Deferred</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Compensation</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Earnings</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>($)</B></FONT></FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>All
    Other</B></FONT><FONT STYLE="font-size: 8pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Compensation</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>($)</B></FONT></FONT></TD>
    <TD NOWRAP STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Total</B></FONT><FONT STYLE="font-size: 8pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>($)</B></FONT></FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: left; width: 19%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Joshua
    R. Disbrow<SUP>(2)</SUP></B></FONT></TD>
    <TD STYLE="text-align: right; width: 1%; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2015</FONT></TD>
    <TD STYLE="text-align: right; width: 1%; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; width: 1%; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">246,000</FONT></TD>
    <TD STYLE="text-align: right; width: 1%; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; width: 1%; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">202,500</FONT></TD>
    <TD STYLE="text-align: right; width: 1%; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; width: 1%; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: right; width: 1%; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; width: 1%; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">198,000</FONT></TD>
    <TD STYLE="text-align: right; width: 1%; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; width: 1%; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: right; width: 1%; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; width: 1%; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: right; width: 1%; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; width: 1%; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">7,045</FONT></TD>
    <TD STYLE="text-align: left; width: 1%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><SUP>(3)</SUP></FONT></TD>
    <TD STYLE="text-align: right; width: 1%; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">653,545</FONT></TD>
    <TD STYLE="text-align: right; width: 1%; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><I>Chief Executive
    Officer</I></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><I>since December 2012</I></FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2014</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">245,000</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">227,500</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">472,500</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Jarrett T.
    Disbrow<SUP>(4)</SUP></B></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2015</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">218,000</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">5,000</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">223,000</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><I>Chief Operating
    Officer,</I></FONT><FONT STYLE="font-size: 8pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Secretary and Treasurer</I></FONT></FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2014</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">140,000</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">5,000</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">223,000</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">368,000</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Gregory A.
    Gould<SUP>(5)</SUP></B></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2015</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">66,000</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">66,000</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><I>Chief Executive
    Officer,</I></FONT><FONT STYLE="font-size: 8pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>since June 2014</I></FONT></FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2014</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Vaughan Cliff,
    M.D.<SUP>(6)</SUP></B></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2015</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><I>Former Chief
    Medical Officer</I></FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2014</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">65,000</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">65,000</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;&nbsp;&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Option awards are reported at fair value at the date of
grant. See Item 15 of Part IV, &ldquo;Notes to the Financial Statements &mdash; Note 7 &mdash; Equity Instruments.&rdquo; Pre-Merger
option awards made in August 2014 to Josh Disbrow and Greg Gould were cancelled in April 2015 and the expenses were reversed.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">Joshua R. Disbrow received a salary increase to $250,000
effective April 16, 2015 when he was appointed Chief Executive Officer of Aytu.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(3)</TD><TD STYLE="text-align: justify">This was a cash payout of in-the-money options issued to
Mr. Disbrow by Luoxis, which options were cashed out in the Merger.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(4)</TD><TD STYLE="text-align: justify">Jarrett T. Disbrow received a salary increase to $250,000
effective April 16, 2015 when he was appointed Chief Operating Officer of Aytu.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(5)</TD><TD STYLE="text-align: justify">Mr. Gould was appointed to Chief Financial Officer, Secretary
and Treasurer effective April 16, 2015. His compensation expense is part of the shared service agreement with Ampio.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(6)</TD><TD STYLE="text-align: justify">Dr. Clift resigned from his position as Chief Medical Officer
of Vyrix on March 31, 2015, prior to the Merger.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our executive officers are reimbursed by us for any out-of-pocket
expenses incurred in connection with activities conducted on our behalf. Executives are reimbursed for business expenses directly
related to Aytu business activities, such as travel, primarily for business development as we grow and expand our product lines.
On average, each executive incurs between $1,000 and $2,000 of out-of-pocket business expenses each month. The executive management
team meets weekly and determines which activities they will work on based upon what we determine will be the most beneficial to
our company and our shareholders. No interest is paid on amounts reimbursed to the executives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Outstanding Equity Awards&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As of June 30, 2015, there were no outstanding equity awards. See
&ldquo;Description of Capital Stock &mdash; Options&rdquo; for a discussion of options granted since June 30, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Grants of Plan-Based Awards&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table sets forth certain information regarding grants
of plan-based awards to the Named Executive Officers as of June 30, 2015:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 92%">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Name</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Grant Date</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">All Other<BR> Option Awards:<BR> Number of<BR> Securities<BR> Underlying<BR> Options<BR> (#)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"><SUP>&nbsp;</SUP></TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Exercise Price of<BR> Option Awards<BR> ($/Share)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant Date</B></FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair Value of</B></FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option Awards</B></FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>($)<SUP>(1)</SUP></B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Named Executive Officers</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left"><SUP>&nbsp;</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 20pt">Joshua R Disbrow</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">8/11/2014</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">150,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><SUP>(2)</SUP></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1.60</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">198,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 20pt">Gregory A. Gould</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8/11/2014</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">50,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><SUP>(2)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">66,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">The amounts reported in this column represent the aggregate
grant date fair value computed in accordance with FASB ASC 718, excluding the effect of any estimated forfeitures and may not
correspond to the actual value that will be realized by the named executive officer.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">These Luoxis options were cancelled in connection with
the Merger. Because the consideration paid to these holders of common stock of Luoxis was less than the exercise price of such
options, no amount was paid to the option holder in connection with the cancellation and keeping with applicable accounting standards,
the unvested portion of the option expense was reversed.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Employment Agreements&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We entered into an employment agreement with Joshua Disbrow in connection
with his employment as our Chief Executive Officer. The agreement is for a term of 24 months beginning on April 16, 2015, subject
to termination by us with or without Cause or as a result of officer&rsquo;s disability, or by the officer with or without Good
Reason (as discussed below). Mr. Disbrow is entitled to receive $250,000 in annual salary, plus a discretionary performance bonus
with a target of 125% of his base salary and 600,000 stock options with 50% vesting upon grant and the remainder vesting on the
following two anniversaries of the grant date. Mr. Disbrow is also eligible to participate in the benefit plans maintained by us
from time to time, subject to the terms and conditions of such plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">We entered into an employment agreement with Jarrett Disbrow, our Chief Operating Officer, in connection
with his employment with us. The agreement is for a term of 24 months beginning on April 16, 2015, subject to termination by us
with or without Cause or as a result of the officer&rsquo;s disability, or by the officer with or without Good Reason (as discussed
below). Mr. Disbrow is entitled to receive $250,000 in annual salary, plus a discretionary performance bonus with a target of
125% of his base salary and 600,000 stock options with 50% vesting upon grant and the remainder vesting on the following two anniversaries
of the grant date. Mr. Disbrow is also eligible to participate in the benefit plans maintained by us from time to time, subject
to the terms and conditions of such plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In September 2015, we entered into an employment agreement with
Jonathan McGrael, our Vice President of Sales, in connection with his employment with us. The agreement is at will, subject to
termination by us with or without Cause or as a result of the officer&rsquo;s disability, or by the officer with or without Good
Reason (as discussed below). Mr. McGrael is entitled to receive $175,000 in annual salary, plus a discretionary performance bonus
with a target of 43% of his base salary and 200,000 stock options. Mr. McGrael will also receive up to $20,000 for relocation reimbursement.
Mr. McGrael is also eligible to participate in the benefit plans maintained by us from time to time, subject to the terms and conditions
of such plans. On May 15, 2016, we amended Mr. McGrael&rsquo;s contract to increase his salary to $190,000 and to name him our
Vice President of Commercial Operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Payments Provided Upon Termination for Good Reason or Without
Cause&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the employment agreements, in the event Mr. Joshua Disbrow&rsquo;s
or Mr. Jarrett Disbrow&rsquo;s employment is terminated without Cause by us or either officer terminates his employment with Good
Reason, we will be obligated to pay him any accrued compensation and a lump sum payment equal to two times his base salary in effect
at the date of termination, as well as continued participation in the health and welfare plans for up to two years. All vested
stock options shall remain exercisable from the date of termination until the expiration date of the applicable award. So long
as a Change in Control is not in effect, then all options which are unvested at the date of termination Without Cause or for Good
Reason shall be accelerated as of the date of termination such that the number of option shares equal to 1/24<SUP>th</SUP> the
number of option shares multiplied by the number of full months of such officer&rsquo;s employment shall be deemed vested and immediately
exercisable by the officer. Any unvested options over and above the foregoing shall be cancelled and of no further force or effect,
and shall not be exercisable by such officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&ldquo;Good Reason&rdquo; with respect to the agreements with Mr.
Joshua Disbrow and Mr. Jarrett Disbrow, means, without the officer&rsquo;s written consent, there is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>a material reduction in the officer&rsquo;s overall responsibilities or authority, or scope of duties (it being understood
that the occurrence of a Change in Control shall not, by itself, necessarily constitute a reduction in the officer&rsquo;s responsibilities
or authority);</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>a material reduction of the level of the officer&rsquo;s compensation (excluding any bonuses) (except where there is a general
reduction applicable to the management team generally, provided, however, that in no case may the base salary be reduced below
certain specified amounts); or</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>a material change in the principal geographic location at which the officer must perform his services.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&ldquo;Good Reason&rdquo; with respect to the agreement with Mr.
McGrael, means, without the officer&rsquo;s written consent, there is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>a material reduction in the officer&rsquo;s overall responsibilities or authority, or scope of duties;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>a material reduction of the level of the officer&rsquo;s compensation (excluding any bonuses) (except where there is a general
reduction applicable to the management team generally, provided, however, that in no case may the base salary be reduced below
certain specified amounts); or</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the Company&rsquo;s material breach of the employment agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&ldquo;Cause&rdquo; with respect to the agreements with Mr. Joshua
Disbrow and Mr. Jarrett Disbrow, means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>conviction of, or entry of a plea of guilty to, or entry of a plea of nolo contendere with respect to, any crime, other than
a traffic violation which is a misdemeanor;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>willful malfeasance or willful misconduct by the officer in connection with his employment;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>gross negligence in performing any of his duties;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>willful and deliberate violation of any of our policies;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>unintended but material breach of any written policy applicable to all employees adopted by us which is not cured to the reasonable
satisfaction of the board;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>unauthorized use or disclosure of any proprietary information or trade secrets of us or any other party as to which the officer
owes an obligation of nondisclosure as a result of the officer&rsquo;s relationship with us;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>willful and deliberate breach of his obligations under the employment agreement; or</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>any other material breach by officer of any of his obligations which is not cured to the reasonable satisfaction of the board.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&ldquo;Cause&rdquo; with respect to the agreement
with Mr. McGrael means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>conviction of, or entry of a plea of guilty to, or entry of a plea of nolo contendere with respect to, a felony or misdemeanor
involving moral turpitude;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>willful malfeasance or willful misconduct by the officer in connection with his employment;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>gross negligence in performing any of his duties;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>material failure to comply with our workplace rules, policies or procedures which is not cured within fifteen days of written
notice;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>material breach of our Proprietary Information and Inventions Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>material breach of the employment agreement which is not cured within fifteen days of written notice;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>unauthorized use or disclosure of any proprietary information or trade secrets of us or any other party as to which the officer
owes an obligation of nondisclosure as a result of the officer&rsquo;s relationship with us; or</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>willful failure or refusal to perform his material duties under the employment agreement or failure to follow any specific
lawful instructions of the Chief Executive Officer or his designee which is not cured within fifteen days of written notice.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The severance benefits described above are contingent on each officer
executing a general release of claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Payments Provided Upon a Change in Control</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the employment agreements, in the event of a Change
in Control of us, all stock options, restricted stock and other stock-based grants granted or may be granted in the future by us
to the officers will immediately vest and become exercisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&ldquo;Change in Control&rdquo; means: the occurrence of any of
the following events:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the acquisition by any individual, entity, or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act)
(the &ldquo;Acquiring Person&rdquo;), other than us, or any of our Subsidiaries, of beneficial ownership (within the meaning of
Rule 13d-3- promulgated under the Exchange Act) of 50% or more of the combined voting power or economic interests of the then outstanding
voting securities of us entitled to vote generally in the election of directors (excluding any issuance of securities by us in
a transaction or series of transactions made principally for bona fide equity financing purposes); or</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the acquisition of us by another entity by means of any transaction or series of related transactions to which we are party
(including, without limitation, any stock acquisition, reorganization, merger or consolidation but excluding any issuance of securities
by us in a transaction or series of transactions made principally for bona fide equity financing purposes) other than a transaction
or series of related transactions in which the holders of the voting securities of us outstanding immediately prior to such transaction
or series of related transactions retain, immediately after such transaction or series of related transactions, as a result of
shares in us held by such holders prior to such transaction or series of related transactions, at least a majority of the total
voting power represented by the outstanding voting securities of us or such other surviving or resulting entity (or if we or such
other surviving or resulting entity is a wholly-owned subsidiary immediately following such acquisition, its parent); or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the sale or other disposition of all or substantially all of the assets of us in one transaction or series of related transactions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Payments Provided Upon Termination for Cause or Without Good
Reason, Death or Disability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the employment agreements, in the event we end the officer&rsquo;s
employment for Cause, if such officer resigns as an employee for reasons other than an event of Good Reason, such officer dies
or disability occurs, then we shall pay to the officer the accrued compensation but shall have no obligation to pay the officer
any amount, whether for salary, benefits, bonuses, or other compensation or expense reimbursements of any kind, accruing after
the end of the employment, and such rights shall, except as otherwise required by law or pursuant to the applicable award agreement
or plan, be forfeited immediately upon the end of the employment. For the sake of clarity, any stock options, restricted stock
or other equity compensation shall, to the extent vested on the date of resignation without Good Reason, the date we end the employment
for Cause, or the date of the officer&rsquo;s death or disability, remain outstanding and exercisable to the extent provided in
the applicable award agreement or plan, by the officer or his personal representative or executor. The table below is as of June
30, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Cause;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Without</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Without Good</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Cause: Good</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Death;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Change in</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Recipient and Benefit</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Reason</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Reason</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Disability</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Control</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Joshua Disbrow</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; padding-left: 9pt">Salary</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">500,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Stock Options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Value of health benefits provided after termination<SUP>(1)</SUP></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">56,510</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.25in">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double">556,510</TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Jarrett Disbrow</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Salary</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Stock Options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Value of health benefits provided after termination<SUP>(1)</SUP></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">56,510</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.25in">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double">556,510</TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">The value of such benefits is determined based on the estimated
cost of providing health benefits to the Named Executive Officer for a period of two years.</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">TRANSACTIONS WITH RELATED PERSONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Related Party Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We describe below all transactions and series of similar transactions,
other than compensation arrangements, during the last three fiscal years, to which we were a party or will be a party, in which:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the amounts involved exceeded or will exceed $120,000; and</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>any of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate family
of the foregoing persons, had or will have a direct or indirect material interest.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in"><B>&nbsp;</B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Merger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On April 16, 2015, pursuant to the Merger Agreement entered into
among Rosewind, Luoxis, Vyrix and two subsidiaries of Rosewind created solely for the purposes of the Merger, and which did not
survive the Merger, the Merger occurred in two stages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In the first stage, each of Vyrix and Luoxis merged with one of
Rosewind&rsquo;s merger subsidiaries. Vyrix and Luoxis survived these mergers. The outstanding shares of stock of Vyrix and the
outstanding shares of stock of Luoxis were converted into the right to receive shares of our common stock. The Vyrix stock and
the Luoxis stock were each converted at an exchange factor. The exchange factor for each of them was determined upon the basis
of a relative value opinion obtained by Ampio, the parent company of Vyrix and Luoxis. The outstanding shares of Rosewind&rsquo;s
merger subsidiary that merged with Vyrix were converted into shares of Vyrix as the surviving corporation. The outstanding shares
of Rosewind&rsquo;s merger subsidiary that merged with Luoxis were converted into shares of Luoxis as the surviving corporation.
After completion of the first stage, Vyrix and Luoxis became subsidiaries of Rosewind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In the second stage, which occurred on the same day as the first
stage, each of Vyrix and Luoxis merged with Rosewind with Rosewind surviving. The first and second stage mergers are referred to
collectively as the &ldquo;Merger.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Concurrently with the Merger:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>The board of directors of Rosewind, whose sole member was James Wiegand, increased the number of directors by one, and appointed
Michael Macaluso to fill the vacancy created by that increase. James Wiegand resigned from the board immediately thereafter. The
board of directors of Rosewind, whose sole member is Michael Macaluso, then appointed Joshua Disbrow as Chief Executive Officer,
Jarrett Disbrow as Chief Operating Officer and Gregory A. Gould as our Chief Financial Officer, Secretary and Treasurer.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>Ampio purchased 4,761,787 shares of our common stock for (i) issuance to Rosewind of a promissory note of Ampio in the principal
amount of $10,000,000, maturing on the first anniversary of the Merger; (ii) cancellation of indebtedness of Luoxis to Ampio in
the amount of $8,000,000; and (iii) cancellation of indebtedness of Vyrix to Ampio in the amount of $4,000,000.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>James Wiegand entered into a consulting agreement with us with a one year duration, providing for compensation of $50,000 to
him.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>Each of James Wiegand and Michael Wiegand executed a release in our favor.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>Each of Ampio, James Wiegand, Michael Wiegand, a trust affiliated with Joshua Disbrow and a trust affiliated with Jarrett Disbrow
entered into a lock-up agreement with us agreeing not to sell its shares of our company for two years (except for the one with
Ampio, more than three years). The lock-up agreements other than the one with Ampio release 25% of the shares subject to it on
or prior to June 30, 2015. All of the lock-up agreements were terminated in December 2015.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>Joshua Disbrow entered into an employment agreement with us.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>Jarrett Disbrow entered into an employment agreement with us.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>The sailing boat owned by Rosewind was transferred to James Wiegand upon the closing of the Merger in exchange for cancellation
of indebtedness owing to James Wiegand in the amount of approximately $30,000 (being the approximate value of the sailing boat).
We paid James Wiegand $20,000 in May 2015 for accrued interest on this indebtedness and other expense that he had incurred prior
to the Merger being completed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Rosewind</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As of August 31, 2014, Rosewind has a secured promissory note to
the sole officer and director for $31,000 for working capital. The loan carries a 6% interest rate, matures on demand and is secured
by the sailing vessel. Accrued interest payable on the loan totaled $18,000 as of August 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">For the year ended August 31, 2014, the sole officer of Rosewind
contributed services valued at $4,000. This amount has been booked to additional paid in capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On March 3, 2015, Rosewind accepted a cash investment from two irrevocable
trusts for estate planning of which Joshua Disbrow and Jarrett Disbrow are beneficiaries. None of such persons have or share investment
control over our shares held by such trusts. None of such persons, nor members of their respective immediate families, are trustees
of such trusts. None of such persons have or share power to revoke such trusts. Accordingly, under Rule 16a-8(b) and related rules,
none of such persons has beneficial ownership over our shares purchased and held by such trusts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Luoxis and Vyrix</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Ampio Loan Agreements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In November 2013, Vyrix entered into a loan agreement with Ampio.
Pursuant to the loan agreement, Ampio agreed to lend Vyrix up to an aggregate amount of $3,000,000 through cash advances of up
to $500,000 each. Unpaid principal amounts under the loan agreement bear simple interest at the &ldquo;Applicable Federal Rate&rdquo;
for long-term obligations prescribed under Section 1274(d) of the Internal Revenue Code of 1986, as amended (or any successor provision
with similar applicability). The initial term of this loan agreement is for one year, subject to automatic extension of successive
one-year terms. Vyrix may repay any outstanding balance at any time without penalty. Ampio has an option of converting any balance
outstanding under the loan agreement into shares of Vyrix common stock at the fair market value per share of Vyrix common stock,
as determined by the Ampio board of directors, as of such conversion date. On April 16, 2015, in connection with the closing of
the Merger, Ampio released Vyrix from its then outstanding obligation of $4,000,000 under the loan agreement as consideration of
its share purchase, and the loan agreement was terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In March 2014, Luoxis entered into a loan agreement with Ampio.
Pursuant to the loan agreement, Ampio agreed to lend Luoxis $3,000,000. Unpaid principal amounts under the loan agreement bear
simple interest at the &ldquo;Applicable Federal Rate&rdquo; for long-term obligations prescribed under Section 1274(d) of the
Internal Revenue Code of 1986, as amended (or any successor provision with similar applicability). The initial term of this loan
agreement is for one year, subject to automatic extension of successive one-year terms. Luoxis may repay any outstanding balance
at any time without penalty. Ampio has an option of converting any balance outstanding under the loan agreement into shares of
Luoxis common stock at the fair market value per share of Luoxis common stock, as determined by the Ampio board of directors, as
of such conversion date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On April 16, 2015, in connection with the closing of the Merger,
Ampio released Luoxis from its then outstanding obligation of $8,000,000 under the loan agreement as consideration of its share
purchase, and the loan agreement was terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On April 16, 2015, Ampio received 4,761,787 shares of common stock
of Aytu for (i) issuance to Aytu of a promissory note from Ampio in the principal amount of $10,000,000, maturing on the first
anniversary of the Merger, (ii) cancellation of indebtedness of Luoxis to Ampio in the amount of $8,000,000; and (iii) cancellation
of indebtedness of Vyrix to Ampio in the amount of $4,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Services Agreements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In January 2013, Luoxis entered into a services agreement with Ampio
whereby Ampio provides corporate overhead services and a shared facility with Luoxis in exchange for $15,000 per month. The amount
can be modified in writing upon the consent of both parties. The agreement may be terminated at any time by either party. In January
2014, Vyrix entered into a services agreement with Ampio whereby Ampio provides corporate overhead services to Vyrix in exchange
for $7,000 per month. The amount can be modified in writing upon the consent of both parties. The agreement may be terminated at
any time by either party. Both agreements were assigned to us upon the closing of the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In July 2015, the prior service agreements were canceled and Aytu
entered into agreements with Ampio whereby Aytu agreed to pay Ampio $30,000 per month for shared overhead which includes costs
related to the shared facility, corporate staff, and other miscellaneous overhead expenses. This agreement will be in effect until
it is terminated in writing by both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Sponsored Research Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In June 2013, Luoxis entered into a sponsored research agreement
with TRLLC, an entity controlled by Ampio&rsquo;s director and Chief Scientific Officer, Dr. Bar-Or. The agreement, which was amended
in September 2013 and provides for Luoxis to pay $6,000 per month to TRLLC in consideration for services related to research and
development of Luoxis&rsquo; RedoxSYS System. In March 2014, Luoxis also agreed to pay a sum of $615,000 which is being amortized
over the contractual term of 60.5 months and is divided between current and long-term on the balance sheet; this amount has been
paid in full. This agreement is set to expire March 2019 and cannot be terminated prior to March 2017.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Review, Approval or Ratification of Transactions with Related
Persons</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Due to the small size of our Company, we do not at this time have
a formal written policy regarding the review of related party transactions, and rely on our Board of Directors to review, approve
or ratify such transactions and identify and prevent conflicts of interest. Our Board of Directors reviews any such transaction
in light of the particular affiliation and interest of any involved director, officer or other employee or stockholder and, if
applicable, any such person&rsquo;s affiliates or immediate family members. Management aims to present transactions to our Board
of Directors for approval before they are entered into or, if that is not possible, for ratification after the transaction has
occurred. If our Board of Directors finds that a conflict of interest exists, then it will determine the appropriate action or
remedial action, if any. Our Board of Directors approves or ratifies a transaction if it determines that the transaction is consistent
with our best interests and the best interest of our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Director Independence</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our common stock is not listed on any exchange. Consequently no
exchange rules regarding director independence are applicable to us. Audit Committee members must satisfy the independence criteria
set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended, for listed companies. In order to be considered
to be independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or
her capacity as a member of the audit committee, the board of directors or any other board committee: (1) accept, directly or indirectly,
any consulting, advisory or other compensatory fee from the listed company or any of its subsidiaries; or (2) be an affiliated
person of the listed company or any of its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Only one of our four directors, Carl Dockery, is independent under
the definition of either the NYSE or Nasdaq. The other three directors are not independent under either definition due to (i) being
an executive officer of our Company, in the case of Josh Disbrow and Jarrett Disbrow, and (ii) the payments we make to Ampio under
the services agreement with Aytu, in the case of Mr. Macaluso.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><A NAME="a_011"></A>SELLING STOCKHOLDERS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table set forth certain information regarding the
selling stockholders and the shares of common stock beneficially owned by them, which information is available to us as of May
31, 2016. The selling stockholders may offer the shares under this prospectus from time to time and may elect to sell some, all
or none of the shares set forth under this prospectus. However, for the purposes of the table below, we have assumed that, after
completion of the offering, none of the shares covered by this prospectus will be held by the selling stockholders. In addition,
a selling stockholder may have sold, transferred or otherwise disposed of all or a portion of that holder&rsquo;s shares of common
stock since the date on which the selling stockholder provided information for this table. We have not made independent inquiries
about such transfers or dispositions. See the section entitled &ldquo;Plan of Distribution&rdquo; beginning on page 106.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Beneficial ownership is determined in accordance with Rule 13d-3(d)
promulgated by the SEC under the Securities Exchange Act of 1934, or the Exchange Act. The percentage of shares beneficially owned
prior to the offering is based on 44,863,179 shares of our common stock outstanding as of May 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Number of</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Shares of</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Common</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Shares of Common Stock</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Stock</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Number of</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Beneficially Owned After</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Beneficially</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">%</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Shares of</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Sale of All Shares of</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Owned Before</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">of</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Common</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Common Stock Pursuant</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; border-bottom: Black 1pt solid">Selling Stockholder</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Any Sale</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Class</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock Offered</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>to this Prospectus <SUP>(1)</SUP></B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Number of</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">% of</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Class</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pacific Capital Management LLC<SUP>(2)</SUP></FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">5,241,494</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">11.0</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">5,241,494</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OEP Opportunities, L.P.<SUP>(2)</SUP></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">1,048,300</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">2.3</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">1,048,300</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dendera Capital Fund LP<SUP>(2)</SUP></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">694,166</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">1.5</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">694,166</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Life Capital/NewBridge Securities Corporation<SUP>(3)(4)</SUP></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">435,028</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">270,772</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">164,256</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chi Squared Capital<SUP>(2)</SUP></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">174,718</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">174,718</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Craig Nemiroff <SUP>(2)</SUP></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">174,718</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">174,718</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt; text-align: right">TOTAL</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right">7,768,424</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right">15.9</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">%</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right">7,604,168</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right">164,256</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>*</B></FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.12in"></TD><TD STYLE="width: 0.25in">*</TD><TD>Represents beneficial ownership of less than one percent of the outstanding shares of our common stock.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.12in"></TD><TD STYLE="width: 0.25in"><SUP>(1)</SUP></TD><TD>Assumes that each selling stockholder will sell all of its shares of common stock subject to sale pursuant to this prospectus.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.12in"></TD><TD STYLE="width: 0.25in"><SUP>(2)</SUP></TD><TD>Half of the total number of shares of common stock consists of shares issuable upon the exercise of warrants that expire on
either July 20 or August 31, 2020, a portion of which shares are being offered by this prospectus.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.12in"></TD><TD STYLE="width: 0.25in"><SUP>(3)</SUP></TD><TD>Consists of shares issuable upon the exercise of warrants that expire on either July 20 or August 31, 2020, all of which shares
are being offered by this prospectus.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.12in"></TD><TD STYLE="width: 0.25in"><SUP>(4)</SUP></TD><TD>Based on available information, we believe that this selling stockholder is an employee of a FINRA-registered broker-dealer.
We believe that the selling stockholder has no agreement or understanding, directly or indirectly, with any person to distribute
the shares of common stock issuable upon exercise of the warrants held by the selling stockholder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Information about any other selling stockholders will be included
in prospectus supplements or post-effective amendments, if required. Information about the selling stockholders may change from
time to time. Any changed information with respect to which we are given notice will be included in prospectus supplements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_012"></A>PLAN OF DISTRIBUTION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We are registering the shares of common stock offered in this prospectus
on behalf of the selling stockholders. The term selling stockholders, which as used herein includes pledgees, donees, transferees
or other successors-in-interest selling shares received from the selling stockholders as a gift, pledge, partnership distribution
or other transfer after the date of this prospectus, may, from time to time, sell, transfer or otherwise dispose of any or all
of their shares of common stock or interests in common stock on any stock exchange, market or trading facility on which the shares
are traded or in private transactions. The selling stockholders will pay any brokerage commissions and similar selling expenses
attributable to the sale of the shares. We will not receive any of the proceeds from the sale of the shares by the selling stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">These dispositions may be at fixed prices, at prevailing market
prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale,
or at negotiated prices. To the extent a selling stockholder gifts, pledges or otherwise transfers the shares offered hereby, such
transferees may offer and sell the shares from time to time under this prospectus, provided that this prospectus has been amended
under Rule 424(b)(3) or other applicable provision of the Securities Act to include the name of such transferee in the list of
selling stockholders under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The selling stockholders may use any one or more of the following
methods when disposing of shares or interests therein:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">on any national securities exchange or quotation service on which
the common stock may be listed or quoted at the time of sale;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">in the over-the-counter market;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">in transactions otherwise than on these exchanges or systems or in
the over-the-counter market;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">ordinary brokerage transactions and transactions in which the broker-dealer
solicits purchasers;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">block trades in which the broker-dealer will attempt to sell the shares
as agent, but may position and resell a portion of the block as principal to facilitate the transaction;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">purchases by a broker-dealer as principal and resale by the broker-dealer
for its account;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">an exchange distribution in accordance with the rules of the applicable
exchange;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">privately negotiated transactions;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">short sales;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">sales pursuant to Rule 144;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">through the writing or settlement of options or other hedging transactions,
whether through an options exchange or otherwise;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">broker-dealers may agree with a selling stockholder to sell a specified
number of such shares at a stipulated price per share;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">a combination of any such methods of sale; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">any other method permitted pursuant to applicable law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The selling stockholders may, from time to time, pledge or grant
a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their
secured obligations, the pledgees or secured parties may offer and sell the shares of common stock, from time to time, under this
prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act amending
the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under
this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In connection with the sale of our common stock or interests therein,
the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in
turn engage in short sales of the common stock in the course of hedging the positions they assume. The selling stockholders may
also sell shares of common stock short and deliver these securities to close out its short positions, or loan or pledge the common
stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions
with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery
to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other
financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The aggregate proceeds to a selling stockholder from the sale of
the shares of common stock offered by it will be the purchase price of the common stock less discounts or commissions, if any.
Each selling stockholder reserves the right to accept and, together with its agents from time to time, to reject, in whole or in
part, any proposed purchase of common stock to be made directly or through agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">To the extent required, the shares of common stock to be sold, the
names of the selling stockholders, the respective purchase prices and public offering prices, the names of any agents, dealer or
underwriter, any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus
supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In order to comply with the securities laws of some states, if applicable,
the common stock may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some
states the common stock may not be sold unless it has been registered or qualified for sale or an exemption from registration or
qualification requirements is available and is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We have advised the selling stockholders that the anti-manipulation
rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities of the selling stockholders
and its affiliates. In addition, we will make copies of this prospectus (as it may be supplemented or amended from time to time)
available to the selling stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The selling stockholders and any broker dealers that act in connection
with the sale of the shares might be deemed to be &ldquo;underwriters&rdquo; as the term is defined in Section 2(11) of the Securities
Act. Consequently, any commissions received by these broker dealers and any profit on the resale of the shares sold by them while
acting as principals might be deemed to be underwriting discounts or commissions under the Securities Act. Because a selling stockholder
may be deemed to be an &ldquo;underwriter&rdquo; as defined in Section 2(11) of the Securities Act, the selling stockholders may
be subject to the prospectus delivery requirements of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The selling stockholders also may resell all or a portion of the
shares in open market transactions in reliance upon Rule 144 under the Securities Act of 1933, provided that such sale meets the
criteria and conform to the requirements of that Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Broker-dealers engaged by the selling stockholders may arrange for
other broker-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the selling stockholders
(or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser) in amounts to be negotiated. The selling
stockholders do not expect these commissions and discounts to exceed what is customary in the types of transactions involved. No
such broker-dealer will receive compensation in excess of that permitted by NASD Rule 2440 and IM-2440. Any profits on the resale
of shares of common stock by a broker-dealer acting as principal might be deemed to be underwriting discounts or commissions under
the Securities Act. Discounts, concessions, commissions and similar selling expenses, if any, attributable to the sale of shares
will be borne by the selling stockholders. The selling stockholders may agree to indemnify any agent, dealer or broker-dealer that
participates in transactions involving sales of the shares if liabilities are imposed on that agent, dealer or broker-dealer under
the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_013"></A>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL
OWNERS AND MANAGEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table sets forth information with respect to the beneficial
ownership of our common stock as of May 31, 2016 for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">each beneficial owner of more than 5% of our outstanding common stock;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">each of our director and named executive officers; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">all of our directors and executive officers as a group.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Beneficial ownership is determined in accordance with the rules
of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power
or investment power with respect to those securities and include common stock that can be acquired within 60 days of May 31, 2016.
The percentage ownership information shown in the table is based upon 44,863,179 shares of common stock outstanding as of May 31,
2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Except as otherwise indicated, all of the shares reflected in the
table are shares of common stock and all persons listed below have sole voting and investment power with respect to the shares
beneficially owned by them, subject to applicable community property laws. The information is not necessarily indicative of beneficial
ownership for any other purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In computing the number of shares of common stock beneficially owned
by a person and the percentage ownership of that person, we deemed outstanding shares of common stock subject to options and warrants
held by that person that are immediately exercisable or exercisable within 60 days of May 31, 2016. We did not deem these shares
outstanding, however, for the purpose of computing the percentage ownership of any other person. Beneficial ownership representing
less than 1% is denoted with an asterisk (*). The information in the table below is based on information known to us or ascertained
by us from public filings made by the stockholders. Except as otherwise indicated in the table below, addresses of the director,
executive officers and named beneficial owners are in care of Aytu BioScience, Inc., 373 Inverness Parkway, Suite 206, Englewood,
Colorado 80112.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Shares</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Beneficially</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Owned</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Number</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Percentage</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-family: Times New Roman, Times, Serif; font-weight: bold; padding-left: 2pt">5% Stockholders:</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">5,047,591</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">11.3</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alpha Venture Capital Partners, L.P.<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 2pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; padding-left: 2pt">Directors and Named Executive Officers:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joshua R. Disbrow <SUP>(2)</SUP></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">403,846</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jarrett T. Disbrow <SUP>(3)</SUP></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">403,846</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gregory A. Gould <SUP>(4)</SUP></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">250,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">Jonathan H. McGrael</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Macaluso <SUP>(5)</SUP></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">582,350</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">1.3</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carl C. Dockery<SUP>(6)</SUP></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">5,147,591</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">11.6</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">All directors and executive officers as a group (six persons)</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">6,787,633</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">14.9</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">Represents beneficial ownership of less than 1%.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><SUP>(1)</SUP></TD><TD>Carl C. Dockery is the President of the general partner of Alpha Venture Capital Partners, L.P. and therefore may be deemed
to beneficially own the shares beneficially owned by Alpha Venture Capital Partners, L.P. The address of Alpha Venture Capital
Partners, L.P. is 2026 Crystal Wood Drive, Lakeland, Florida 33801.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><SUP>(2)</SUP></TD><TD>Does not include 558,567 shares are held by an irrevocable trust for estate planning in which Mr. Disbrow is a beneficiary.
Mr. Disbrow does not have or share investment control over the shares held by the trust, Mr. Disbrow is not the trustee of the
trust (nor is any member of Mr. Disbrow&rsquo;s immediate family) and Mr. Disbrow does not have or share the power to revoke the
trust. As such, under Rule 16a-8(b) and related rules, Mr. Disbrow does not have beneficial ownership over the shares purchased
and held by the trust.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><SUP>&nbsp;</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><SUP>&nbsp;</SUP></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><SUP>(3)</SUP></TD><TD>Does not include 558,567 shares are held by an irrevocable trust for estate planning in which Mr. Disbrow is a beneficiary.
Mr. Disbrow does not have or share investment control over the shares held by the trust, Mr. Disbrow is not the trustee of the
trust (nor is any member of Mr. Disbrow&rsquo;s immediate family) and Mr. Disbrow does not have or share the power to revoke the
trust. As such, under Rule 16a-8(b) and related rules, Mr. Disbrow does not have beneficial ownership over the shares purchased
and held by the trust.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><SUP>(4)</SUP></TD><TD>Consists of options to purchase shares of common stock.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><SUP>(5)</SUP></TD><TD>Includes options to purchase 225,000 shares of common stock.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><SUP>(6)</SUP></TD><TD>Consists of (i) options to purchase 100,000 shares of common stock held by Mr. Dockery, and (ii) 5,047,591 shares held by Alpha
Venture Capital Partners, L.P. Mr. Dockery is the President of the general partner of Alpha Venture Capital Partners, L.P. and
therefore may be deemed to beneficially own the shares beneficially owned by Alpha Venture Capital Partners, L.P.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-indent: -22.5pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B><A NAME="a_014"></A>DESCRIPTION OF CAPITAL
STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We are authorized to issue up to 100.0 million shares of common
stock, $0.0001 par value per share, and 50.0 million shares of preferred stock, $0.0001 par value per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As of May 31, 2016, a total of 44,863,179 shares of our common stock
were issued and outstanding and no shares of our preferred stock were issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We held
our annual meeting of shareholders on May 24, 2016, at which meeting our shareholders approved (1) an amendment to our Certificate
of Incorporation to reduce the number of authorized shares of common stock from 300.0&nbsp;million to 100.0 million, which amendment
was effective on June 1, 2016, and (2) an amendment to our Certificate of Incorporation to effect a reverse stock split at a ratio
of any whole number between 1-for-4 and 1-for-12, as determined by our Board of Directors, at any time before November 24, 2016,
if and as determined by our Board of Directors. Our Board&rsquo;s primary reason for approving the amendment to our Certificate
of Incorporation to reduce our authorized capital stock is to reduce the amount of our annual franchise tax in the State of Delaware,
while still maintaining a sufficient number of authorized shares to permit us to act promptly with respect to future financings,
acquisitions, additional issuances, and for other corporate purposes. The Board believes that the Reverse Stock Split will enhance
our ability to obtain an initial listing on a national securities exchange. The NYSE MKT and The NASDAQ Capital Market each requires,
among other items, an initial bid price of least $4.00 per share and, following initial listing, maintenance of a continued price
of at least $1.00 per share in the case of The NASDAQ Capital Market and an undesignated &ldquo;low selling price&rdquo; in the
case of the NYSE MKT. Reducing the number of outstanding shares of our common stock should, absent other factors, increase the
per share market price of our common stock, although we cannot provide any assurance that the minimum bid price would be achieved
following any reverse stock split or that any listing on an exchange would be obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The holders of common stock are entitled to one vote per share.
Our Certificate of Incorporation does not expressly prohibit cumulative voting. The holders of our common stock are entitled to
receive ratably such dividends, if any, as may be declared by the Board of Directors out of legally available funds. Upon liquidation,
dissolution or winding-up, the holders of our common stock are entitled to share ratably in all assets that are legally available
for distribution. The holders of our common stock have no preemptive, subscription, redemption or conversion rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The rights, preferences and privileges of holders of our common
stock are subject to, and may be adversely affected by, the rights of the holders of any series of preferred stock, which may be
designated solely by action of the Board of Directors and issued in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our Certificate of Incorporation provides our Board of Directors
with the authority to divide the preferred stock into series and to fix and determine the rights and preferences of the shares
of any series of preferred stock established to the full extent permitted by the laws of the State of Delaware and the Certificate
of Incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As of May 31, 2016, we had outstanding warrants to purchase an aggregate
of 26,418,885 shares of our common stock, consisting of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants to purchase 102,613 shares that were originally issued by
Luoxis in 2013 and, in connection with the Merger, were converted into warrants to purchase shares of our common stock at a purchase
price of $4.53 per share. These warrants expire on May 30, 2018;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants to purchase 267,052 shares of our common stock that were
issued in February 2016 to the placement agents in our private placement of convertible notes that we conducted in July and August
2015. These placement agents&rsquo; warrants have a term of five years from the date of issuance of the related notes in July and
August 2015, have an exercise price of $0.65, and provide for cashless exercise;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants to purchase 270,772 shares of our common stock that were
issued in May 2016 to the placement agents in our private placement of convertible notes that we conducted in July and August 2015.
These placement agents&rsquo; warrants have a term of five years from the date of issuance of the related notes in July and August
2015, have an exercise price of $0.40, and provide for cashless exercise;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants to purchase 20,799,250 shares of our common stock that were
issued in the public offering of common stock and warrants we completed on May 6, 2016. These warrants are exercisable for five
years from issuance and have an exercise price equal to $0.50;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants to purchase 3,666,698 shares of our common stock that were
issued upon the closing or our public offering on May 5, 2016. These warrants are exercisable for five years from issuance and
have an exercise price equal to $0.50;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">An option we granted the underwriters of our public offering to purchase
up to an additional 763,250 shares of common stock, which, if exercised, will be exercisable for five years from issuance and have
an exercise price equal to $0.50; this option expires June 20, 2016;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants to purchase 1,312,500 shares of common stock issued to the
underwriters of our public offering. These warrants are exercisable beginning May 2, 2017 until May 2, 2021 and have an exercise
price equal to $0.50.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Prior to the closing of the Merger, each of Vyrix and Luoxis had
an option plan and had made equity grants thereunder. On April 16, 2015, upon the closing of the Merger, an aggregate of $27,476
was paid to holders of in-the-money options and all equity compensation plans of Vyrix and Luoxis were terminated and all the awards
granted thereunder were cancelled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On June 1, 2015, our stockholders approved the 2015 Stock Option
and Incentive Plan, which provides for the award of stock options, stock appreciation rights, restricted stock and other equity
awards for up to an aggregate of 10,000,000 shares of common stock. The shares of common stock underlying any awards that are forfeited,
canceled, reacquired by us prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other
than by exercise) under the 2015 Plan will be added back to the shares of common stock available for issuance under the 2015 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As of May 31, 2016, we had outstanding options to purchase an aggregate
of 3,867,500 shares of our common stock at a weighted average exercise price of $1.50 per share. Of these, an aggregate of 1,677,500
are exercisable. The remainder has vesting requirements with an aggregate of 1,550,000 vesting one third on each of November 11,
2016, 2017 and 2018, an aggregate of 590,000 vesting one quarter on each of November 11, 2016, 2017, 2018 and 2019 and an aggregate
of 50,000 vesting one quarter on each of August 7, 2016, 2017, 2018 and 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The 2015 Plan is administered by our Board or a committee designated
by the Board (as applicable, the Administrator). The Administrator has full power to select, from among the individuals eligible
for awards, the individuals to whom awards will be granted, to make any combination of awards to participants, and to determine
the specific terms and conditions of each award, subject to the provisions of the 2015 Plan. The Administrator may delegate to
our Chief Executive Officer the authority to grant stock options and other awards to employees who are not subject to the reporting
and other provisions of Section 16 of the Exchange Act and not subject to Section 162(m) of the Code, subject to certain limitations
and guidelines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Persons eligible to participate in the 2015 Plan are full or part-time
officers, employees, non-employee directors, directors and other key persons (including consultants and prospective officers) of
our company and its subsidiaries as selected from time to time by the Administrator in its discretion. Approximately 30 individuals
are currently eligible to participate in the 2015 Plan, which includes officers, employees who are not officers, non-employee director,
former employees and other individuals who are primarily consultants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The 2015 Plan provides that upon the effectiveness of a &ldquo;sale
event&rdquo; as defined in the 2015 Plan, except as otherwise provided by the Administrator in the award agreement, all stock options,
stock appreciation rights and other awards will be assumed or continued by the successor entity and adjusted accordingly to take
into account the impact of the transaction. To the extent, however, that the parties to such sale event do not agree that all stock
options, stock appreciation rights or any other awards shall be assumed or continued, then such stock options and stock appreciation
rights shall become fully exercisable and the restrictions and conditions on all such other awards with time-based conditions will
automatically be deemed waived. Awards with conditions and restrictions relating to the attainment of performance goals may become
vested and non-forfeitable in connection with a sale event in the Administrator&rsquo;s discretion. In addition, in the case of
a sale event in which our stockholders will receive cash consideration, we may make or provide for a cash payment to participants
holding options and stock appreciation rights equal to the difference between the per share cash consideration and the exercise
price of the options or stock appreciation rights in exchange for the cancellation thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Quotation on the OTCQX U.S. Premier Market</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our common stock is quoted on the OTCQX U.S. Premier Market under
the symbol &ldquo;AYTU&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Transfer Agent</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The transfer agent of our common stock is VStock Transfer. Their
address is 18 Lafayette Place, Woodmere, NY 11598.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Delaware Anti-Takeover Law and Provisions of Our Certificate
of Incorporation and Bylaws</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Delaware Anti-Takeover Law.</I> We are subject to Section 203
of the Delaware General Corporation Law. Section 203 generally prohibits a public Delaware corporation from engaging in a &ldquo;business
combination&rdquo; with an &ldquo;interested stockholder&rdquo; for a period of three years after the date of the transaction in
which the person became an interested stockholder, unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">prior to the date of the transaction, the board of directors of the
corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested
stockholder;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">upon consummation of the transaction that resulted in the stockholder
becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding
at the time the transaction commenced, excluding specified shares; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">at or subsequent to the date of the transaction, the business combination
is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent,
by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Section 203 defines a &ldquo;business combination&rdquo; to include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">any merger or consolidation involving the corporation and the interested
stockholder;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">any sale, lease, exchange, mortgage, pledge, transfer or other disposition
of 10% or more of the assets of the corporation to or with the interested stockholder;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">subject to exceptions, any transaction that results in the issuance
or transfer by the corporation of any stock of the corporation to the interested stockholder;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">subject to exceptions, any transaction involving the corporation that
has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned
by the interested stockholder; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the receipt by the interested stockholder of the benefit of any loans,
advances, guarantees, pledges or other financial benefits provided by or through the corporation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In general, Section 203 defines an &ldquo;interested stockholder&rdquo;
as any person that is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the owner of 15% or more of the outstanding voting stock of the corporation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>




<P STYLE="font: 10pt Symbol; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">an affiliate or associate of the corporation who was the owner of
15% or more of the outstanding voting stock of the corporation at any time within three years immediately prior to the relevant
date; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the affiliates and associates of the above.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Under specific circumstances, Section 203 makes it more difficult
for an &ldquo;interested stockholder&rdquo; to effect various business combinations with a corporation for a three-year period,
although the stockholders may, by adopting an amendment to the corporation&rsquo;s certificate of incorporation or bylaws, elect
not to be governed by this section, effective 12 months after adoption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our certificate of incorporation and bylaws do not exclude us from
the restrictions of Section 203. We anticipate that the provisions of Section 203 might encourage companies interested in acquiring
us to negotiate in advance with our board of directors since the stockholder approval requirement would be avoided if a majority
of the directors then in office approve either the business combination or the transaction that resulted in the stockholder becoming
an interested stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Certificate of Incorporation and Bylaw. </I>Provisions of our
certificate of incorporation and bylaws may delay or discourage transactions involving an actual or potential change of control
or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares, or
transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely
affect the price of our common stock. Among other things, these provisions include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the authorization of 50,000,000 shares of &ldquo;blank check&rdquo;
preferred stock, the rights, preferences and privileges of which may be established and shares of which may be issued by our Board
of Directors at its discretion from time to time and without stockholder approval;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">limiting the removal of directors by the stockholders;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">allowing for the creation of a staggered board of directors;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">eliminating the ability of stockholders to call a special meeting
of stockholders; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">establishing advance notice requirements for nominations for election
to the board of directors or for proposing matters that can be acted upon at stockholder meetings.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -13.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_015"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The validity of the shares of common stock being offered by this
prospectus will be passed upon for us by Wyrick Robbins Yates &amp; Ponton, LLP, Raleigh, North Carolina.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_016"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The financial statements of Aytu BioScience, Inc. at June 30, 2015
and 2014, and for each of the two years in the period ended June 30, 2015, included in this prospectus have been audited by EKS&amp;H
LLLP, independent registered public accounting firm, as set forth in their report thereon appearing elsewhere herein, and are included
in reliance upon such report given on the authority of such firm as experts in accounting and auditing.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_017"></A>WHERE YOU CAN FIND MORE INFORMATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">This prospectus, which constitutes a part of the registration statement
on Form S-1 that we have filed with the SEC under the Securities Act, does not contain all of the information in the registration
statement and its exhibits. For further information with respect to us and the common stock offered by this prospectus, you should
refer to the registration statement and the exhibits filed as part of that document. Statements contained in this prospectus as
to the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer
you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is
qualified in all respects by this reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We are subject to the reporting requirements of the Securities Exchange
Act of 1934, as amended, and file annual, quarterly and current reports, proxy statements and other information with the SEC. You
can read our SEC filings, including the registration statement, over the Internet at the SEC&rsquo;s website at <I>http://www.sec.gov</I>.
We also maintain a website at <I>http://www.aytubio.com</I>, at which you may access these materials free of charge as soon as
reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained in, or that
can be accessed through, our website is not part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">You may also read and copy any document we file with the SEC at
its public reference facilities at 100 F Street, N.E., Room 1580, Washington, D.C. 20549. You may also obtain copies of these documents
at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Washington, D.C. 20549. Please
call the SEC at 1-800-SEC-0330 for further information on the operation of the public reference facilities. You may also request
a copy of these filings, at no cost, by writing or telephoning us at: 373 Inverness Parkway, Suite 206, Englewood, Colorado 80112,
(720) 437-6500.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>




<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_018"></A>INDEX TO THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Page No.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; font-family: Times New Roman, Times, Serif; text-align: left"><A HREF="#a_019">Report of Independent Registered Public Accounting Firm</A></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; color: #2E74B5">&nbsp;</TD>
    <TD STYLE="width: 12%; font-family: Times New Roman, Times, Serif; text-align: right">F-2</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><A HREF="#a_020">Balance Sheets</A></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">F-3</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_021">Statements of Operations</A></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">F-4</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><A HREF="#a_022">Statement of Stockholders&rsquo; Equity (Deficit)</A></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">F-5</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><A HREF="#a_023">Statements of Cash Flows</A></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">F-6</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><A HREF="#a_024">Notes to Financial Statements</A></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">F-7</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">Quarter Ended March 31, 2016 (unaudited):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt"><A HREF="#a_025">Balance Sheets</A></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">F-22</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 2pt"><A HREF="#a_026">Statements of Operations</A></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">F-23</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt"><A HREF="#a_027">Statement of Stockholders&rsquo; Equity (Deficit)</A></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">F-24</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt"><A HREF="#a_028">Statement of Cash Flows</A></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">F-25</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt"><A HREF="#a_029">Note to Financial Statements</A></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">F-26</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 118; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B><A NAME="a_019"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">To the Board of Directors and Stockholders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Aytu Bioscience, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Englewood, Colorado</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We have audited the accompanying balance sheets of Aytu Bioscience,
Inc. (the &ldquo;Company&rdquo;) as of June 30, 2015 and 2014, and the related statements of operations, stockholders&rsquo; equity,
and cash flows for each of the periods then ended. The Company&rsquo;s management is responsible for these financial statements.
Our responsibility is to express an opinion on these financial statements based on our audits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We conducted our audits in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have,
nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of
internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances,
but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s internal control over financial reporting.
Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management,
as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our
opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In our opinion, the financial statements referred to above present
fairly, in all material respects, the financial position of Aytu Bioscience, Inc. as of June 30, 2015 and 2014, and the results
of its operations and its cash flows for each of the periods then ended, in conformity with accounting principles generally accepted
in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">/s/ EKS&amp;H LLLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">September 28, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Denver, Colorado</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 119; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_020"></A>AYTU BIOSCIENCE, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">June 30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center">Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left; padding-left: 2pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">7,353,061</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,639,650</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 2pt">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">157,058</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 2pt">Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39,442</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 2pt">Prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">370,888</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">521,322</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 2pt">Prepaid research and development - related party (Note 8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">121,983</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">121,983</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 2pt">Deferred tax asset</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">41,427</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,897</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 2pt">Total current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,083,859</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,301,852</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 2pt">Fixed assets, net (Note 2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,706</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57,246</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 2pt">Developed technology, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">780,125</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 2pt">Customer contracts, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">711,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 2pt">Trade names, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">79,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt">Goodwill</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">74,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 2pt">In-process research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 2pt">Patents, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">628,776</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">699,563</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 2pt">Long-term portion of prepaid research and development - related party (Note 8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">335,454</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">457,438</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 2pt">Deposits</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,886</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,142,947</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,714,247</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">18,226,806</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,016,099</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center">Liabilities and Stockholders&rsquo; Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 2pt">Accounts payable and accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,196,817</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">649,503</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 2pt">Accrued liabilities - related party (Note 8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 2pt">Accrued compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">196,503</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 2pt">Deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">85,714</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">85,714</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 2pt">Payable to Ampio</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">561,059</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 2pt">Notes to Ampio</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,600,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 2pt">Interest payable to Ampio</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">46,002</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 2pt">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,479,034</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,092,278</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 2pt">Contingent consideration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">664,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 2pt">Long-term deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">425,893</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">511,607</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 2pt">Noncurrent deferred tax liability</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">41,427</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">42,807</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 2pt">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,610,354</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,646,692</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Commitments and contingencies (Note 5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stockholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 2pt">Preferred Stock, par value $.0001; 50,000,000 shares authorized; none issued</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 2pt">Common Stock, par value $.0001; 300,000,000 shares authorized; shares issued and outstanding 14,259,681 in 2015 and 7,901,426 in 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,426</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">790</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 2pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,996,367</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,026,554</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 2pt">Ampio stock subscription</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,000,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 2pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(18,381,341</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(10,657,937</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 2pt">Total equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">15,616,452</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,369,407</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total liabilities and equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">18,226,806</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,016,099</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">The accompanying notes are an integral part
of these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><A NAME="a_021"></A>AYTU BIOSCIENCE, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Statements of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center">Years Ended June 30,</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Product and service revenue</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">176,068</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">License revenue</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">85,714</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">58,929</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total revenue</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">261,782</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">58,929</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 2pt">Cost of sales</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">88,109</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 2pt">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,219,361</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,933,619</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 2pt">Research and development - related party (Note 8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">203,992</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">125,587</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 2pt">General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,382,640</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,346,557</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 2pt">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,632,320</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,346,834</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 2pt">Interest (expense) income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(114,994</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(45,553</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss, before income tax</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,747,314</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,392,387</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 2pt">Deferred income tax benefit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">23,910</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">813,697</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(7,723,404</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5,578,690</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Weighted average number of Aytu common shares outstanding</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,207,917</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,949,476</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Basic and diluted Aytu net loss per common share</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.84</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.80</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">The accompanying notes are an integral part
of these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_022"></A>AYTU BIOSCIENCE, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Statements of Stockholders&rsquo; Equity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Additional</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Ampio</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Total</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center"></TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Parent&rsquo;s</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">paid-in</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Stock</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Accumulated</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Stockholders&rsquo;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Common Stock</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Equity</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">capital</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Subscription</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Deficit</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Equity</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 23%">Balance - June 30, 2013</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">5,437,158</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">544</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">10,471,515</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">4,418,385</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">(5,079,247</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">9,811,197</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Investment from Ampio in Vyrix</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">637,210</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">637,210</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Issuance of common stock in exchange for Vyrix Acquired Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,464,268</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">246</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,108,725</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,108,479</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">499,690</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">499,690</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(5,578,690</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(5,578,690</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Balance - June 30, 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,901,426</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">790</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,026,554</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,657,937</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,369,407</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Ampio stock subscription payment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,164,448</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">216</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,999,784</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,000,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Issuance of common stock to Ampio in exchange for Aytu debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,597,339</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">260</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,999,740</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Ampio stock subscription payment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Liabilities paid pursuant to the merger</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20,013</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20,013</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Luoxis options paid-out pursuant to the merger</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(27,476</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(27,476</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Reverse merger</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,596,468</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">160</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(160</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,017,938</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,017,938</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(7,723,404</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(7,723,404</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Balance - June 30, 2015</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">14,259,681</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">1,426</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">38,996,367</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">(5,000,000</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">(18,381,341</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">15,616,452</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">The accompanying
notes are an integral part of these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_023"></A>AYTU BIOSCIENCE, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Statements of Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Years Ended June 30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Cash flows from operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">Net loss</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">(7,723,404</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">(5,578,690</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">Stock-based compensation expense</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">1,017,938</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">499,690</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">Depreciation and amortization</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">118,202</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">97,476</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">Amortization of prepaid research and development - related party (Note 8)</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">121,984</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">35,579</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">Deferred taxes</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(23,910</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(813,697</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">Increase in accounts receivable</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(157,058</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">Increase in inventory</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(39,442</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">Decrease (increase) in prepaid expenses, other</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">150,434</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(497,322</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">Increase in prepaid research and development - related party (Note 8)</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(150,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(465,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">(Decrease) increase in interest payable to Ampio</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(46,002</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">46,002</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">Increase in accounts payable</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">547,314</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">421,870</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">Increase in accrued compensation</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">196,503</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">(Decrease) increase in payable to Ampio</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(561,059</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">561,059</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 2pt">(Decrease) increase in deferred revenue</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(85,714</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">191,071</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net cash used in operating activities</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(6,634,214</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(5,501,962</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Cash flows used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 2pt">Deposits</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(4,886</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">Purchase of ProstaScint Business</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(1,000,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 2pt">Purchase of fixed assets</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(9,298</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net cash used in investing activities</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(1,004,886</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(9,298</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Cash flows from financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">Ampio stock subscription payment</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">5,000,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">Proceeds from convertible note from Ampio converted to stock</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">7,400,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">4,600,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">Luoxis option payout pursuant to the merger</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(27,476</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">Liabilities paid out pursuant to the merger</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(20,013</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 2pt">Contribution from Ampio</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">637,210</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">12,352,511</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">5,237,210</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Net change in cash and cash equivalents</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">4,713,411</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(274,050</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Cash and cash equivalents at beginning of period</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">2,639,650</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">2,913,700</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents at end of period</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">7,353,061</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">2,639,650</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Non-cash transactions:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">Ampio stock subscription</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">5,000,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">Ampio unpaid debt converted to stock, received prior to 2015</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">4,600,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">Contingent consideration related to the ProstaScint purchase</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">664,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">Issuance of common stock in exchange for Vyrix acquired assets</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">6,803,356</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">Related party research and development liability included in prepaid research and development - related party</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">150,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part
of these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_024"></A>AYTU BIOSCIENCE, INC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to the Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Note 1 &ndash; Business, Acquisition of Assets and Basis of Presentation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Business/Acquisition of Assets</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Aytu BioScience, Inc. (&ldquo;Aytu&rdquo; or the &ldquo;Company&rdquo;)
was incorporated as Rosewind Corporation on August 9, 2002 in the State of Colorado. Aytu was re-incorporated in the state of Delaware
on June 8, 2015. Aytu is a specialty healthcare company concentrating on developing and commercializing products focused primarily
on the urological disorders market, specifically sexual dysfunction, urological cancer and male infertility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Basis of Presentation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Aytu&rsquo;s current business was formed through a reverse triangular
merger (the &ldquo;Merger&rdquo;) in which Luoxis Diagnostics, Inc. (&ldquo;Luoxis&rdquo;) and Vyrix Pharmaceuticals, Inc. (&ldquo;Vyrix&rdquo;)
merged into Rosewind Corporation in a multi-step merger on April 16, 2015. These historical financial statements prior to April
16, 2015 include the combined financial statements of Vyrix from its inception in November 2013, combined with the carve-out financial
statements related to Vyrix assets acquired in the Merger (the &ldquo;Vyrix Acquired Assets&rdquo;) from March 23, 2011, the date,
its parent company Ampio Pharmaceuticals, Inc. (&ldquo;Ampio&rdquo;) originally acquired the Vyrix Acquired Assets through its
merger with DMI BioSciences, Inc. (&ldquo;BioSciences&rdquo;) and the financial statements of Luoxis from its inception in January
2013, combined with the carve-out financial statements related to Luoxis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The carve-out financial statements present the statements of financial
position of Vyrix and Luoxis and the Vyrix Acquired Assets and the statements of operations and cash flows for purposes of presenting
complete comparative stand-alone financial statements in accordance with Regulation S-X, Article 3, General Instructions to Financial
Statements, and Staff Accounting Bulletin Topic 1-B1, Costs Reflected in Historical Financial Statements. Historically, financial
statements have not been prepared for Vyrix and Luoxis, as they were not held in a separate legal entities. Although Vyrix and
Luoxis have not been segregated as a separate legal entity, related revenues, direct costs and expenses, assets and liabilities
have historically been segregated on Ampio&rsquo;s books. In addition, the Company allocated corporate overhead costs based on
a review of specific labor and other overhead expenses and a reasonable estimate of activities related to Vyrix and Luoxis. Allocated
labor and other overhead totaled $264,000 in 2015 and $253,000 in 2014. The Company also prepared a calculation of income tax expense
and deferred income tax assets and liabilities on a &ldquo;separate return&rdquo; basis (see Note 4 &ndash; Income Taxes). These
financial statements do not include a carve-out for cash as the operations have historically been funded by Ampio. The historical
carve-out financial statements may not be indicative of the future results of Vyrix and Luoxis as a stand-alone entities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The &ldquo;Company&rdquo; as referred to in the notes to these financial
statements includes Vyrix and Luoxis, collectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company&rsquo;s activities, being primarily research and development,
have not generated significant revenue to date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As of June 30, 2015, Ampio is the majority shareholder of 81.5%
of Aytu&rsquo;s outstanding common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On June 8, 2015, in connection with the reincorporation as a Delaware
corporation, we effected a reverse stock split in which each common stock holder received one share of common stock for each every
12.174 shares then outstanding (the &ldquo;Reverse Stock Split&rdquo;). All share and per share amounts in this Registration Statement
have been adjusted to reflect the effect of the Reverse Stock Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Business Combination&mdash;ProstaScint</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In May 2015, Aytu entered into and closed on an asset purchase agreement
with Jazz Pharmaceuticals, Inc. (the &ldquo;Seller&rdquo;). Pursuant to the agreement, Aytu purchased assets related to the Seller&rsquo;s
product known as ProstaScint&reg; (capromab pendetide), including certain intellectual property and contracts, and the product
approvals, inventory and work in progress (together, the &ldquo;ProstaScint Business&rdquo;), and assumed certain of the Seller&rsquo;s
liabilities, including those related to product approvals and the sale and marketing of ProstaScint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The purchase price consists of the upfront payment of $1.0 million.
Aytu also agreed to pay an additional $500,000 payable within five days after transfer for the ProstaScint-related product inventory
and $227,000 payable on September 30, 2015 (which represents a portion of certain FDA fees). Aytu also will pay 8% as contingent
consideration on its net sales made after October 31, 2017, payable up to a maximum aggregate payment of an additional $2.5 million.
The contingent consideration was valued at $664,000 using a discounted cash flow. The total fair value consideration for the purchase
was $2.4 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company&rsquo;s allocation on consideration transferred for
ProstaScint as of the purchase date May 20, 2015 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Estimated<BR>
 Fair<BR> Value</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; font-family: Times New Roman, Times, Serif; text-align: left">Tangible assets</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">727,000</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Intangible assets</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">1,590,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">Goodwill</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">74,000</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total assets acquired</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">2,391,000</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The intangible assets will be amortized over a ten year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Future amortization from the year ended June 30, 2015 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; font-family: Times New Roman, Times, Serif">2016</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">159,000</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif">2017</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">159,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif">2018</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">159,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif">2019</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">159,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif">2020</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">159,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">Thereafter</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">775,000</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">1,570,000</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Pro Forma Information</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The unaudited pro-forma results presented below include the effects
of the ProstaScint acquisition as if it has been consummated as of July 1, 2013, with adjustments to give effect to pro forma events
that are directly attributable to the acquisition which includes adjustments related to the amortization of acquired intangible
assets. The unaudited pro forma results do not reflect any operating efficiency or potential cost savings which may result from
the consolidation of ProstaScint. Accordingly, these unaudited pro forma results are presented for informational purposes only
and are not necessarily indicative of what the actual results of operation of the combined company would have been if the acquisition
had occurred at the beginning of the period presented nor are they indicative of future results of operations and are not necessarily
indicative of either future results of operations or results that might have been achieved had the acquisition been consummated
as of July 1, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center">Years ended June 30,</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total revenue</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">1,371,106</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">1,736,139</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif">Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Cost of sales - ProstaScint</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">1,818,690</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">2,054,786</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Research and development</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">3,065,626</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">3,933,619</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Research and development - related party (Note 8)</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">156,988</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">125,587</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">General and administrative</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">4,417,884</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">2,388,665</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Amortization and impairment of intangible assets</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">131,989</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">100,000</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Loss from operations</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(8,220,071</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(6,866,518</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Interest (expense) income</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(114,994</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(45,553</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Net loss, before income tax</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(8,335,065</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(6,912,071</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Deferred income tax benefit</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">23,910</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">813,697</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(8,311,155</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(6,098,374</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 125; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Note 2 &ndash; Summary of Significant Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Cash and Cash Equivalents</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Aytu considers all highly liquid instruments purchased with an original
maturity of three months or less to be cash equivalents. Cash equivalents consist primarily of money market fund investments. Aytu&rsquo;s
investment policy is to preserve principal and maintain liquidity. The Company periodically monitors its positions with, and the
credit quality of the financial institutions with which it invests. Periodically, throughout the year, Aytu has maintained balances
in excess of federally insured limits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Revenue Recognition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>License Agreements and Royalties</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Payments received upon signing of license agreements are for the
right to use the license and are deferred and amortized over the lesser of the license term or patent life of the licensed drug.
Milestone payments relate to obtaining regulatory approval, cumulative sales targets, and other projected milestones and are recognized
at the time the milestones are achieved. Royalties will be recognized as revenue when earned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Product &amp; Service Sales</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Aytu recognizes revenue from product and service sales when there
is persuasive evidence that an arrangement exists, delivery has occurred or service has been rendered, the price is fixed or determinable
and collectability is reasonably assured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Estimated Sales Returns and Allowances</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Aytu records estimated reductions in revenue for potential returns
of products by customers. As a result, management must make estimates of potential future product returns and other allowances
related to current period product revenue. In making such estimates, management analyzes historical returns, current economic trends
and changes in customer demand and acceptance of our products. If management were to make different judgments or utilize different
estimates, material differences in the amount of the Company&rsquo;s reported revenue could result.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Accounts Receivable</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Accounts receivable are recorded at their net realized value. Aytu
evaluates collectability of accounts receivable on a quarterly basis and records a valuation allowance accordingly. As of June
30, 2015 and 2014, no allowance for doubtful accounts has been recorded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Inventories</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Inventories are recorded at the lower of cost or market, with cost
determined on a first-in, first-out basis. Aytu periodically reviews the composition of its inventories in order to identify obsolete,
slow-moving or otherwise unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory,
Aytu will record a write-down to net realizable value in the period that the impairment is first recognized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">When future commercialization is considered probable and the future
economic benefit is expected to be realized, based on management&rsquo;s judgment, Aytu capitalizes pre-launch inventory costs
prior to regulatory approval. A number of factors are taken into consideration, including the current status in the regulatory
approval process, potential impediments to the approval process, such as safety or efficacy, anticipated research and development
initiatives that could impact the indication in which the compound will be used, viability of commercialization and marketplace
trends. For product candidates that have not been approved by the FDA, inventory used in clinical trials is expensed at the time
of production and recorded as research and development expense. For products that have been approved by the FDA, inventory used
in clinical trials is expensed at the time the inventory is packaged for the clinical trial. Prior to receiving FDA approval, costs
related to purchases of the active pharmaceutical ingredient and the manufacturing of the product candidate are recorded as research
and development expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Fixed Assets</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Fixed assets are recorded at cost. After being placed in service,
the fixed assets are depreciated using the straight-line method over estimated useful lives. Fixed assets consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center">Estimated<BR>
Useful<BR>
 Lives in <BR> </TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center">June 30,</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">years</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; font-family: Times New Roman, Times, Serif; text-align: left">Lab equipment</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 12%; font-family: Times New Roman, Times, Serif; text-align: center">3 - 5</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">90,000</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">90,000</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less accumulated depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(60,000</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(33,000</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 2pt">Fixed assets, net</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">30,000</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">57,000</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Aytu recorded the following depreciation expense in the respective
periods:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Year Ended June 30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-family: Times New Roman, Times, Serif; text-align: left">Depreciation expense</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">27,000</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">27,000</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>In-Process Research and Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In-process research and development (&ldquo;IPRD&rdquo;) relates
to the Company&rsquo;s Zertane product and clinical trial data acquired in connection with the 2011 acquisition of BioSciences.
The $7,500,000 recorded was based on an independent, third party appraisal of the fair value of the assets acquired. IPRD is considered
an indefinite-lived intangible asset and its fair value will be assessed annually and written down if impaired. Once the Zertane
product obtains regulatory approval and commercial production begins, IPRD will be reclassified to an intangible that will be amortized
over its estimated useful life. If the Company decided to abandon the Zertane product, the IPRD would be expensed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Patents</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Costs of establishing patents, consisting of legal and filing fees
paid to third parties, are expensed as incurred. The fair value of the Zertane patents, determined by an independent third party
appraisal, is $500,000. The Zertane patents were acquired in connection with the 2011 acquisition of BioSciences and are being
amortized over the remaining U.S. patent lives of approximately 11 years which expires in March 2022. The cost of the Luoxis patents
was $380,000 when they were acquired in connection with the 2013 formation of Luoxis and is being amortized over the remaining
U.S. patent lives of approximately 15 years which expires in March 2028. Patents consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">June 30,</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-family: Times New Roman, Times, Serif">Patents</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">880,000</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">880,000</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less accumulated amortization</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(251,000</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(180,000</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 2pt">Patents, net</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">629,000</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">700,000</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Aytu recorded the following amortization expense in the respective
periods:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Year Ended June 30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-family: Times New Roman, Times, Serif; text-align: left">Amortization expense</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">71,000</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">70,000</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 127; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Future amortization from the year ended June 30, 2015 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">71,000</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">71,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">71,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">71,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">71,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">Thereafter</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">274,000</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">629,000</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Business Combinations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company accounts for its business acquisitions under the acquisition
method of accounting as indicated in the Financial Accounting Standards Board&rsquo;s (&ldquo;FASB&rdquo;) Accounting Standards
Codification (&ldquo;ASC&rdquo;) 805, &ldquo;Business Combinations&rdquo;, which requires the acquiring entity in a business combination
to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquire; and establishes
the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed
in business combinations, including contingent assets and liabilities and non-controlling interest in the acquiree, based on the
fair value estimates as of the date of acquisition. In accordance with ASC 805, the Company recognizes and measures goodwill as
of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets
acquired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Goodwill</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The ProstaScint purchase price allocation was based upon an analysis
of the fair value of the assets and liabilities acquired from Jazz Pharmaceuticals. The final purchase price may be adjusted up
to one year from the date of the acquisition. Identifying the fair value of the tangible and intangible assets and liabilities
acquired required the use of estimates by management, and were based upon currently available data, as noted below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company allocated the excess of purchase price over the identifiable
intangible and net tangible assets to goodwill. Such goodwill is not deductible for tax purposes and represents the value placed
on entering new markets and expanding market share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company tests its goodwill for impairment annually, or whenever
events or changes in circumstances indicate an impairment may have occurred, by comparing the carrying value to its implied fair
value. Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market
conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If the Company determines that
an impairment has occurred, it is required to record a write-down of the carrying value and charge the impairment as an operating
expense in the period the determination is made. In evaluating the recoverability of the carrying value of goodwill, the Company
must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the acquired assets.
Changes in strategy or market conditions could significantly impact those judgments in the future and require an adjustment to
the recorded balances. The goodwill was recorded as part of the acquisition of ProstaScint that occurred on May 20, 2015. There
was no impairment of goodwill for the year ended June 30, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Use of Estimates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The preparation of financial statements in accordance with Generally
Accepted Accounting Principles in the United States of America (&ldquo;GAAP&rdquo;) requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities as of the date of
the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant items subject
to such estimates and assumptions include valuation allowances, stock-based compensation, warrant valuation, purchase price allocation,
valuation of contingent consideration, sales returns and allowances, useful lives of fixed assets and assumptions in evaluating
impairment of definite and indefinite lived assets. Actual results could differ from these estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Income Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Aytu is included in the consolidated tax returns of Ampio. Aytu&rsquo;s
taxes are computed and reported on a &ldquo;separate return&rdquo; basis for these financial statements. Deferred taxes are provided
on an asset and liability method whereby deferred tax assets are recognized for deductible temporary differences and operating
loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences
are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced
by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred
tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates
on the date of enactment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The amount of income taxes and related income tax positions taken
would be subject to audits by federal and state tax authorities if Aytu filed these taxes on a separate basis. The Company has
adopted accounting guidance for uncertain tax positions which provides that in order to recognize an uncertain tax benefit, the
taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest
amount that is more than 50% likely to be realized upon settlement with the taxing authority. The Company believes that it has
no material uncertain tax positions. The Company&rsquo;s policy is to record a liability for the difference between the benefits
that are both recognized and measured pursuant to FASB ASC 740-10, &ldquo;Accounting for Uncertainty in Income Taxes&mdash;an interpretation
of FASB Statement No. 109&rdquo; (&ldquo;ASC 740-10&rdquo;) and tax position taken or expected to be taken on the tax return. Then,
to the extent that the assessment of such tax positions changes, the change in estimate is recorded in the period in which the
determination is made. The Company reports tax-related interest and penalties as a component of income tax expense. During the
periods reported, management of the Company has concluded that no significant tax position requires recognition under ASC 740-10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Stock-Based Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Aytu accounts for share based payments by recognizing compensation
expense based upon the estimated fair value of the awards on the date of grant. The Company determines the estimated grant fair
value using the Black-Scholes option pricing model and recognizes compensation costs ratably over the period of service using the
graded method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Research and Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Research and development costs are expensed as incurred with expenses
recorded in the respective period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Fair Value of Financial Instruments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The carrying amounts of financial instruments, including cash and
cash equivalents, accounts payable and other current assets and other liabilities are carried at cost which approximates fair value
due to the short maturity of these instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Impairment of Long-Lived Assets</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Aytu routinely performs an annual evaluation of the recoverability
of the carrying value of its long-lived assets to determine if facts and circumstances indicate that the carrying value of assets
or intangible assets may be impaired and if any adjustment is warranted. Based on its evaluation as of June 30, 2015 and 2014,
respectively, no impairment existed for long-lived assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Newly Issued Accounting Pronouncements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In June 2015, the FASB issued Accounting Standards Update (&ldquo;ASU&rdquo;)
2015-10, &ldquo;Technical Corrections and Improvements&rdquo;. The amendments represent changes to clarify the codification, correct
unintended application of guidance, or make minor improvements to the codification that are not expected to have a significant
effect on current accounting practice or create a significant administrative cost. In addition, some of the amendments will make
the codification easier to understand and easier to apply by eliminating inconsistencies, providing needed clarifications, and
improving the presentation of guidance in the codification. The amendments that require transition guidance are effective for all
entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is
permitted, including adoption in an interim period. All other amendments will be effective upon issuance. The Company is evaluating
the impact of ASU 2015-10 on its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In April 2015, the FASB issued ASU 2015-03, &ldquo;Interest - Imputation
of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs.&rdquo; The update requires debt issuance costs
related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of the
related debt liability instead of being presented as an asset. Debt disclosures will include the face amount of the debt liability
and the effective interest rate. The update requires retrospective application and represents a change in accounting principle.
The update is effective for fiscal years beginning after December 15, 2015. Early adoption is permitted for financial statements
that have not been previously issued. The Company is evaluating the impact of ASU 2015-03 on its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In January 2015, the FASB issued ASU 2015-01, &ldquo;Extraordinary
and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items.&rdquo;
The purpose of this amendment is to eliminate the concept of extraordinary items. As a result, an entity will no longer be required
to separately classify, present and disclose extraordinary events and transactions. The amendment is effective for annual reporting
periods beginning after December 15, 2015 and subsequent interim periods with early application permitted. The Company is evaluating
the impact the adoption of ASU 2015-01 will have on its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In August 2014, the FASB issued ASU No. 2014-15, &ldquo;Presentation
of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&rsquo;s Ability to Continue
as a Going Concern&rdquo; (&ldquo;ASU 2014-15&rdquo;). ASU 2014-15 is intended to define management&rsquo;s responsibility to evaluate
whether there is substantial doubt about an organization&rsquo;s ability to continue as a going concern and to provide related
footnote disclosures. The amendments in this ASU are effective for reporting periods beginning after December 15, 2016, with early
adoption permitted. The Company is evaluating the impact the adoption of ASU 2014-15 will have on its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In May 2014, the FASB issued ASU 2014-09 regarding ASC Topic 606,
&ldquo;Revenue from Contracts with Customers&rdquo;. The standard provides principles for recognizing revenue for the transfer
of promised goods or services to customers with the consideration to which the entity expects to be entitled in exchange for those
goods or services. The guidance will be effective for annual reporting periods beginning after December 15, 2017, with early adoption
permitted but not prior to the original public organization effective date of December 15, 2016. The Company is evaluating the
accounting, transition and disclosure requirements of the standard and cannot currently estimate the financial statement impact
of adoption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Note 3 &ndash; License Agreement/Revenue Recognition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">During 2011, Ampio entered into a license, development and commercialization
agreement with a major Korean pharmaceutical company which was assigned to Vyrix when it was formed in 2013. The agreement grants
the pharmaceutical company exclusive rights to market Zertane in South Korea for the treatment of premature ejaculation (&ldquo;PE&rdquo;)
and for a combination drug to be developed, utilizing Zertane and an erectile dysfunction drug. Upon signing of the agreement,
Ampio received a $500,000 upfront payment, the net proceeds of which were $418,000 after withholding of Korean tax. The upfront
payment has been deferred and is being recognized as license revenue over a ten year period. Milestone payments of $3,200,000 may
be earned and recognized contingent upon achievement of regulatory approvals and cumulative net sales targets, which may take several
years. In addition, Aytu may earn a royalty based on 25% of net sales, as defined, if the royalty exceeds the transfer price of
the Zertane product. No royalties have been earned to date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In April 2014, Vyrix entered into a Distribution and License Agreement
(the &ldquo;Paladin Agreement&rdquo;) with Endo Ventures Limited, which recently acquired Paladin Labs Inc. (&ldquo;Paladin&rdquo;),
whereby Paladin has exclusive rights to market, sell and distribute Zertane in Canada, the Republic of South Africa, certain countries
in Sub Saharan Africa, Colombia and Latin America. The Paladin Agreement expires on a country by country basis upon the later of
fifteen years after the first commercial sale of the product in that country or expiration of market exclusivity for Zertane in
that country. Paladin paid $250,000 to Vyrix upon signing the Paladin Agreement and is obligated to make milestone payments aggregating
up to $3,025,000 based upon achieving Canadian and South African product regulatory approval and achieving specific sales goals.
The upfront payment has been deferred and is being recognized as license revenue over a seven year period. In addition, the Paladin
Agreement provides that Paladin pay royalties based on sales volume.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Note 4 &ndash; Income Taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As previously discussed in Note 2 &ndash;Summary of Significant
Accounting Policies, the Company is included in Ampio&rsquo;s consolidated tax returns. For purposes of these financial statements,
the Company&rsquo;s taxes are computed and reported on a &ldquo;separate return&rdquo; basis. Ampio and Aytu do not have a tax
sharing agreement. Accordingly, certain tax attributes, e.g., net operating loss carryforwards, reflected in these financial statements,
may or may not be available to Aytu. In the event that Ampio&rsquo;s ownership interest in Aytu falls below 80% and Aytu is deconsolidated
from Ampio&rsquo;s consolidated income tax return, the net operating loss carryforwards originated prior to the incorporation of
Vyrix and Luoxis would no longer be available to Aytu and the related deferred income tax asset would be removed and recorded as
a deemed dividend to the parent, Ampio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Income tax benefit resulting from applying statutory rates in jurisdictions
in which Aytu is taxed (Federal and State of Colorado) differs from the income tax provision (benefit) in the Aytu&rsquo;s financial
statements. The following table reflects the reconciliation for the respective periods:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 130; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Years Ended June 30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-family: Times New Roman, Times, Serif; text-align: left">Benefit at federal statutory rate</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">(34.00</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">)%</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">(34.00</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">State, net of federal income tax benefit</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(2.79</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)%</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(2.89</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Stock-based compensation</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">5.51</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">1.84</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Change in valuation allowance</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">30.95</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">22.29</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">Other</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">0.03</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">0.03</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 2pt">Effective tax rate</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"></TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">(0.30</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">)%</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"></TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">(12.73</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">)%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Deferred income taxes arise from temporary differences in the recognition
of certain items for income tax and financial reporting purposes. The approximate tax effects of significant temporary differences
which comprise the deferred tax assets and liabilities are as follows for the respective periods:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Current deferred income tax asset:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; font-family: Times New Roman, Times, Serif; text-align: left">Deferred revenue short-term</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">32,000</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">32,000</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Accrued expenses</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">73,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Valuation allowance</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(64,000</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(13,000</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total current deferred income tax asset</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">41,000</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">19,000</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Long-term deferred income tax assets (liabilities):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Net operating loss carryforward</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">6,337,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">3,847,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Section 197 intangible</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">453,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">482,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Deferred revenue long-term</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">158,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">190,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Share-based compensation expense</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">80,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Acquired in-process research and development</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(2,779,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(2,779,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less: Valuation allowance</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(4,210,000</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(1,863,000</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total long-term deferred income tax assets (liabilities)</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(41,000</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(43,000</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total deferred income tax assets (liabilities)</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">(24,000</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Aytu has recorded income tax benefits in its statements of operations
since inception, stemming from its operating losses, and is expected to incur operating losses for the foreseeable future. During
the year ended June 30, 2015, the net deferred tax liability was reduced to zero based upon the operating losses, thus Aytu established
a valuation allowance offsetting any future net deferred tax asset. As such, Aytu would no longer record income tax benefits in
its results of operations after the year ended June 30, 2015 because management is currently unable to conclude that it is more
likely than not that a benefit will be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In assessing the realizability of deferred tax assets, management
considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate
realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which those temporary
differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable
income, carry back opportunities and tax planning strategies in making the assessment. The Company believes it is more likely than
not it will realize the benefits of these deductible differences, net of the valuation allowance provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has federal net operating loss carryforwards of approximately
$17.1 million and $10.4 million as of June 30, 2015 and June 30, 2014, respectively that, subject to limitation, may be available
in future tax years to offset taxable income. The available net operating losses, if not utilized to offset taxable income in future
periods, will begin to expire in 2031 through 2034. Net operating loss carryforwards are subject to examination in the year they
are utilized regardless of whether the tax year in which they are generated has been closed by statute. The amount subject to disallowance
is limited to the NOL utilized. Accordingly, the Company may be subject to examination for prior NOLs generated as such NOLs are
utilized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As of June 30, 2015 and 2014, the Company has no liability for gross
unrecognized tax benefits or related interest and penalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Aytu has made its best estimates of certain income tax amounts included
in the financial statements. Application of the Company&rsquo;s accounting policies and estimates, however, involves the exercise
of judgment and use of assumptions as to future uncertainties and, as a result, could differ from these estimates. In arriving
at its estimates, factors the Company considers include how accurate the estimates or assumptions have been in the past, how much
the estimates or assumptions have changed and how reasonably likely such changes may have a material impact. Aytu has been historically
included in the Ampio consolidated tax return. Under the general statute of limitations, the Company would not be subject to federal
or Colorado income tax examinations for years prior to 2011 and 2010, respectively. However, given the net operating losses generated
since inception, all tax years since inception are subject to examination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 131; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Note 5 &ndash; Commitments and Contingencies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Commitments and contingencies are described below and summarized
by the following table as of June 30, 2015:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Total</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2017</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2018</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2019</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2020</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Thereafter</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 23%; text-align: left">Management fee</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">1,800,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">360,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">360,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">360,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">360,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">360,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">ProstaScint Inventory Transfer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Sponsored research agreement with related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">350,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Clinical research and trial obligations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">329,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">329,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Manufacturing</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">133,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">133,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Office Lease</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">110,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">35,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">36,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">36,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,222,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,427,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">466,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">466,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">433,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">430,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Management Fee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In July 2015, Aytu entered into agreements with Ampio whereby Aytu
agreed to pay Ampio $30,000 per month for shared overhead which includes costs related to the shared facility, corporate staff,
and other miscellaneous overhead expenses. These agreements will be in effect until they are terminated in writing by both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>ProstaScint Inventory Transfer Fee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Aytu is obligated to pay $500,000 for the ProstaScint-related product
inventory upon the inventory transfer in July 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Sponsored Research Agreement with Related Party</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Aytu entered into a Sponsored Research Agreement with Trauma Research
LLC (&ldquo;TRLLC&rdquo;), a related party, in June 2013. Under the terms of the Sponsored Research Agreement, TRLLC agreed to
work collaboratively in advancing the RedoxSYS System diagnostic platform through research and development efforts. The Sponsored
Research Agreement may be terminated without cause by either party on 30 days&rsquo; notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Clinical Research and Trial Obligations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In connection with the Zertane clinical trials and RedoxSYS research
studies, the remaining commitment is $329,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Aytu Manufacturing and Commercial Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Aytu entered into agreements with manufacturing companies to build
its RedoxSYS system. The current remaining commitment is $133,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Office Lease</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In June 2015, Aytu entered into a 37 month operating lease. This
lease has initial base rent of $2,900 a month, with total base rent over the term of the lease of approximately $112,000. The Company
recognizes rental expense of the facility on a straight-line basis over the term of the lease. Differences between the straight-line
net expenses on rent payments are classified as liabilities between current deferred rent and long-term deferred rent. Rent expense
for the respective periods is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-family: Times New Roman, Times, Serif; text-align: center">Years Ended June 30,</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-family: Times New Roman, Times, Serif; text-align: left">Rent expense</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">51,000</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">11,000</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 132; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Note 6 &ndash; Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Capital Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">At June 30, 2015 and 2014, Aytu had 300 million shares of common
stock authorized with a par value of $0.0001 per share and 50 million shares of preferred stock authorized with a par value of
$0.0001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Note 7 &ndash; Equity Instruments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Options</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Prior to the Merger, Aytu had two approved stock option plans (Luoxis
2013 Stock Option Plan and Vyrix 2013 Stock Option Plan), pursuant to which Aytu had reserved a total of 1,718,828 million shares
of common stock, both of which were terminated on April 16, 2015 upon the closing of the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Luoxis options that were in the money and all outstanding Vyrix
options issued under the 2013 Option Plans were accelerated and cancelled in connection with the Merger. Option holders received
a cash payment per option share equal to the difference between the consideration payable per share of common stock pursuant to
the Merger and the exercise price of the option, if the consideration paid to holders of common stock was less than the exercise
price of such options, no amount was paid to the option holder in connection with the cancellation. The cash payment during the
period ended June 30, 2015 was $27,000. The company recognized compensation of $422,000 and $189,000 related to the Luoxis and
Vyrix options that had accelerated vesting as of the Merger date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Luoxis options that were not paid out were terminated pursuant
to the terms of the 2013 Luoxis Option Plan. The Company treated these options as pre-vesting forfeitures and $433,000 of previously
recognized compensation was reversed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the Luoxis 2013 Stock Option Plan, 1,102,761 shares
of its common stock were reserved for issuance. The fair value of the options was calculated using the Black-Scholes option pricing
model. In order to calculate the fair value of the options, certain assumptions are made regarding components of the model, including
the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected
option life. Changes to the assumptions could cause significant adjustments to valuation. Aytu estimates the expected term based
on the average of the vesting term and the contractual term of the options. The risk-free interest rate is based on the U.S. Treasury
yield in effect at the time of the grant for treasury securities of similar maturity. The assumptions are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Years Ended June 30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="width: 74%; font-family: Times New Roman, Times, Serif; text-align: left">Expected volatility</TD><TD NOWRAP STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">79% - 108%</FONT></TD><TD NOWRAP STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">79% - 82%</FONT></TD><TD NOWRAP STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Risk free interest rate</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.62% - 2.09%</FONT></TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.75% - 1.53%</FONT></TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Expected term (years)</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5 - 7.0</FONT></TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.0 - 6.5</FONT></TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Dividend yield</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center">0%</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center">0%</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 133; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Stock option activity is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center">Weighted</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center"></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center">Weighted</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center">Average</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center"></TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center">Average</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center">Remaining</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center">Aggregate</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number of</FONT></TD><TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center">Exercise</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center">Contractual</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center">Intrinsic</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Options</FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Price</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Life</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Value</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font-family: Times New Roman, Times, Serif">Outstanding June 30, 2013</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">396,994</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">4.53</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">9.96</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">1,272,000</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 2pt">Granted</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">33,083</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">4.53</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 2pt">Exercised</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 2pt">Forfeited/Cancelled</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif">Outstanding June 30, 2014</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">430,077</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">4.53</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">9.01</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">1,374,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 2pt">Granted</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">195,189</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">7.25</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 2pt">Exercised</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 2pt">Forfeited/Cancelled</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(625,266</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: right">5.40</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">Outstanding June 30, 2015</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">Exercisable at June 30, 2015</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Available for grant at June 30, 2015</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the Vyrix 2013 Stock Option Plan, 616,067 shares of
its common stock were reserved for issuance. The fair value of the options was calculated using the Black-Scholes option pricing
model. In order to calculate the fair value of the options, certain assumptions are made regarding components of the model, including
the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected
option life. Changes to the assumptions could cause significant adjustments to valuation. Aytu estimates the expected term based
on the average of the vesting term and the contractual term of the options. The risk-free interest rate is based on the U.S. Treasury
yield in effect at the time of the grant for treasury securities of similar maturity. In accordance with the Vyrix 2013 Stock Option
Plan, no additional options were granted during the year-ended June 30, 2015. The assumptions are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Year<BR> Ended June<BR> 30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="width: 87%; font-family: Times New Roman, Times, Serif; text-align: left">Expected volatility</TD><TD NOWRAP STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63% - 76%</FONT></TD><TD NOWRAP STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Risk free interest rate</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.90% - 2.02%</FONT></TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Expected term (years)</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.0 - 6.5</FONT></TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Dividend yield</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center">0%</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: left"></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 134; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Stock option activity is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center">Average</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center">Average</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center">Remaining</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center">Aggregate</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number of</FONT></TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center">Exercise</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center">Contractual</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center">Intrinsic</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Options</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Life</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Value</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif">Outstanding June 30, 2013</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; font-family: Times New Roman, Times, Serif; padding-left: 2pt">Granted</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">117,053</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">5.68</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 2pt">Exercised</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 2pt">Forfeited/Cancelled</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif">Outstanding June 30, 2014</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">117,053</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">5.68</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">9.54</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">417,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 2pt">Granted</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 2pt">Exercised</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 2pt">Forfeited/Cancelled</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(117,053</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: right">5.68</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">Outstanding June 30, 2015</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"></TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">Exercisable at June 30, 2015</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Available for grant at June 30, 2015</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Stock-based compensation expense related to the fair value of stock
options was included in the statements of operations as research and development expenses and general and administrative expenses
as set forth in the table below. Aytu determined the fair value as of the date of grant using the Black-Scholes option pricing
model and expenses the fair value ratably over the vesting period. The following table summarizes stock-based compensation expense
for the years ended June 30 2015 and 2014:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-family: Times New Roman, Times, Serif; text-align: center">Years Ended June 30,</TD><TD NOWRAP STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Research and development expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-family: Times New Roman, Times, Serif">Luoxis</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">427,000</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">206,000</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif">Vyrix</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">92,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">38,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">General and administrative expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif">Luoxis</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">316,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">152,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">Vyrix</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">183,000</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">104,000</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">1,018,000</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">500,000</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif">Unrecognized expense at June 30, 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif">Luoxis</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif">Vyrix</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Weighted average remaining years to vest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif">Luoxis</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif">Vyrix</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On June 1, 2015, Aytu&rsquo;s stockholders approved the 2015 Stock
Option and Incentive Plan (the &ldquo;2015 Plan&rdquo;), which provides for the award of stock options, stock appreciation rights,
restricted stock and other equity awards for up to an aggregate of 10,000,000 shares of common stock. The shares of common stock
underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied without any issuance of stock,
expire or are otherwise terminated (other than by exercise) under the 2015 Plan will be added back to the shares of common stock
available for issuance under the 2015 Plan. As of September 28, 2015, no grants have been made under the 2015 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 135; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Warrants </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu issued warrants in conjunction with its 2013 private placement.
A summary of all warrants is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.2in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Number of<BR> Warrants</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Weighted<BR> Average<BR> Exercise <BR>
Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Weighted<BR>
 Average<BR> Remaining<BR> Contractual<BR>
 Life</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%">Outstanding June 30, 2013</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">102,613</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">4.53</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">4.41</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Outstanding June 30, 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">102,613</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.53</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.92</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Outstanding June 30, 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">102,613</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.53</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.92</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These warrants were valued using the Black-Scholes option pricing
model. In order to calculate the fair value of the warrants, certain assumptions were made regarding components of the model, including
the closing price of the underlying common stock, risk-free interest rate, volatility, expected dividend yield, and expected life.
Changes to the assumptions could cause significant adjustments to valuation. The Company estimated a volatility factor utilizing
a weighted average of comparable published volatilities of peer companies. The risk-free interest rate is based on the U.S. Treasury
yield in effect at the time of the grant for treasury securities of similar maturity. The offering costs and the additional paid-in
capital for the warrants associated with the common stock offering were valued at $313,000 using the Black-Scholes valuation methodology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 8 &ndash; Related Party Transactions </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Ampio Loan Agreement </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In November 2013, Vyrix entered into a loan agreement with Ampio.
Pursuant to the loan agreement, Ampio agreed to lend Vyrix up to an aggregate amount of $3,000,000 through cash advances of up
to $500,000 each. Unpaid principal amounts under the loan agreement bear simple interest at the &ldquo;Applicable Federal Rate&rdquo;
for long-term obligations prescribed under Section 1274(d) of the Internal Revenue Code of 1986, as amended (or any successor provision
with similar applicability). The initial term of this loan agreement is for one year, subject to automatic extension of successive
one-year terms. Vyrix may repay any outstanding balance at any time without penalty. Ampio has an option of converting any balance
outstanding under the loan agreement into shares of Vyrix common stock at the fair market value per share of Vyrix common stock,
as determined by the Ampio board of directors, as of such conversion date. As of June 30, 2014, the amount advanced was $1,600,000
with interest rates from 3.11%-3.32%. On April 16, 2015, in connection with the closing of the Merger, Ampio released Vyrix from
its then outstanding obligation of $4,000,000 under the loan agreement as consideration of its share purchase, and the loan agreement
was terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In March 2014, Luoxis entered into a loan agreement with Ampio.
Pursuant to the loan agreement, Ampio agreed to lend Luoxis $3,000,000. Unpaid principal amounts under the loan agreement bear
simple interest at the &ldquo;Applicable Federal Rate&rdquo; for long-term obligations prescribed under Section 1274(d) of the
Internal Revenue Code of 1986, as amended (or any successor provision with similar applicability). The initial term of this loan
agreement is for one year, subject to automatic extension of successive one-year terms. Luoxis may repay any outstanding balance
at any time without penalty. Ampio has an option of converting any balance outstanding under the loan agreement into shares of
Luoxis common stock at the fair market value per share of Luoxis common stock, as determined by the Ampio board of directors, as
of such conversion date. As of June 30, 2014, the amount advanced was $3,000,000 with interest rates from 3.11% - 3.32%. On April
16, 2015, in connection with the closing of the Merger, Ampio released Luoxis from its then outstanding obligation of $8,000,000
under the loan agreement as consideration of its share purchase, and the loan agreement was terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 16, 2015, Ampio received 4,761,787 shares of common
stock of Aytu for (i) issuance to Aytu of a promissory note from Ampio in the principal amount of $10,000,000, maturing on the
first anniversary of the Merger, (ii) cancellation of indebtedness of Luoxis to Ampio in the amount of $8,000,000; and (iii) cancellation
of indebtedness of Vyrix to Ampio in the amount of $4,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 136; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Services Agreement </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has service agreements with Ampio which are described
in Note 5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Sponsored Research Agreement </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In June 2013, Luoxis entered into a sponsored research agreement
with TRLLC, an entity controlled by Ampio&rsquo;s director and Chief Scientific Officer, Dr. Bar-Or. The agreement, which was amended
in January 2015 and provides for Luoxis (now Aytu) to pay $6,000 per month to TRLLC in consideration for services related to research
and development of the Oxidation Reduction Potential platform. In March 2014, Luoxis also agreed to pay a sum of $615,000 which
is being amortized over the contractual term of 60.5 months and is divided between current and long-term on the balance sheet;
this amount has been paid in full. This agreement is set to expire March 2019 and cannot be terminated prior to March 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 9 &ndash; Litigation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of June 30, 2015, Aytu was not party to any legal matters
or claims, and none of its property is subject to any legal proceedings. In the future Aytu may become party to legal matters and
claims arising in the ordinary course of business, the resolution of which it does not anticipate would have a material adverse
impact on its financial position, results of operations or cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 10 &ndash; Employee Benefit Plan </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu allows its employees to participate in Ampio&rsquo;s 401(k)
plan. The plan allows participants to contribute a portion of their salary, subject to eligibility requirements and annual IRS
limits. Aytu does not match employee contributions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 11 &ndash; Subsequent Event </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During July and August 2015, Aytu closed on note purchase agreements
with institutional and high net worth individual investors for the purchase and sale of convertible promissory notes with an aggregate
principal amount of $5.2 million. The sale of the notes was pursuant to a private placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu intends to use the net proceeds of the offering to conduct
clinical studies for both Zertane&reg; and RedoxSYS&trade; and for working capital to begin commercializing FDA-approved ProstaScint&reg;,
as well as general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The notes are an unsecured obligation. Unless earlier converted,
the notes will mature 18 months from their respective dates of issuance which will be on January 22, February 11 and February 28,
2017, with an option to extend up to six months at our discretion (provided that in the event Aytu exercises such extension option,
the then applicable interest rate shall increase by 2% for such extension period). Aytu does not have the right to prepay the notes
prior to the maturity date. Interest will accrue on the notes in the following amounts: (i) 8% simple interest per annum for the
first six months and (ii) 12% simple interest per annum thereafter if not converted during the first six months. If there has not
been a registration statement on Form S-1 filed with the SEC for the registration of the shares of common stock underlying the
notes by the expiration of the first six-month period then (a) the interest rate will increase to 14% for the remainder of the
period in which the notes remain outstanding and (b) any notes held by officers and directors of the Company will be subordinated
to the remaining notes. Interest will accrue, is payable with the principal upon maturity, conversion or acceleration of the notes
and may be paid in kind or in cash, in Aytu&rsquo;s sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The notes are convertible at any time in a noteholder&rsquo;s
discretion into that number of shares of Aytu common stock equal in an amount equal to 120% of the number of shares of common stock
calculated by dividing the then outstanding principal and accrued interest by $4.63. A holder of notes will be obligated to convert
on the terms of Aytu&rsquo;s next public offering of its stock resulting in proceeds to it of at least $5,000,000 in gross proceeds
(excluding indebtedness converted in such financing) prior to the maturity date of the notes (a &ldquo;Qualified Financing&rdquo;).
The principal and accrued interest under the notes will automatically convert into a number of shares of such equity securities
of the Company sold in such financing equal to 120% of the principal and accrued interest under such note divided by the lesser
of (i) the lowest price paid by an investor in such financing or (ii) $4.63. In the event that Aytu sells equity securities to
investors at any time while the notes are outstanding in a financing transaction that is not a Qualified Financing, then the noteholders
will have the option to convert in whole the outstanding principal and accrued interest as of the closing of such financing into
a number of shares of Aytu capital stock in an amount equal to 120% of the number of such shares calculated by dividing the outstanding
principal and accrued interest by the lesser of (i) the lowest cash price per share paid by purchasers of shares in such financing,
or (ii) $4.63.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 137; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NewBridge Securities Corporation, Member FINRA/SIPC, through
LifeTech Capital, acted as sole placement agent for the institutional portion of the offering. Aytu sold the balance of the notes
to individuals and entities with whom Aytu has an established relationship. For notes sold by the placement agent, Aytu paid the
placement agent 8% of the gross proceeds of notes sold by the placement agent and a warrant to purchase shares of Aytu&rsquo;s
common stock equal to 8% of the gross proceeds of the notes sold by the placement agent divided by the price per share at which
equity securities are sold in Aytu&rsquo;s next equity financing, in addition to a previously paid non-refundable retainer fee
of $20,000. The placement agent warrant has a term of five years from the date of issuance of the related notes in July and August
2015, will have an exercise price equal to 100% of the price per share at which equity securities are sold in Aytu&rsquo;s next
equity financing, and provides for cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 19, 2015, Aytu entered into a 37-month non-cancellable
operating lease for new office space effective September 1, 2015. The new lease has initial base rent of $8,500 per month beginning
in October 2015, with the total base rent over the term of the lease of approximately $318,000 which includes rent abatements.
The Company recognizes rental expense of the facility on a straight-line basis over the term of the lease. Differences between
the straight-line net expenses on rent payments are classified as liabilities between current deferred rent and long-term deferred
rent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 138; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_025"></A>AYTU BIOSCIENCE, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">March 31,</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">June 30,</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">(unaudited)</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center">Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">8,665,835</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">7,353,061</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">84,274</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">157,058</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">621,352</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39,442</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Prepaid expenses, other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">943,126</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">370,888</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Prepaid research and development - related party (Note 11)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">121,983</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">121,983</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,436,570</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,042,432</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fixed assets, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">196,885</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,706</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Developed technology, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,201,153</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">780,125</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Customer contracts, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,405,125</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">711,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Trade names, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">202,306</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">79,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Goodwill</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">221,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">74,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">In-process research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Patents, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">575,686</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">628,776</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Long-term portion of prepaid research and development - related party (Note 11)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">243,967</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">335,454</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Deposits</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,888</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,886</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,549,010</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,142,947</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">21,985,580</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">18,185,379</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center">Liabilities and Stockholders' Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accounts payable and accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,177,049</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,195,368</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Primsol payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,154,616</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accrued compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">787,954</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">196,503</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Deferred revenue</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">85,714</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">85,714</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,205,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,477,585</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Convertible promissory notes, net of amortization discount of $1,040,203 (Note 8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,797</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Contingent consideration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">698,826</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">664,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Long-term deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">361,607</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">425,893</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Interest payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">66,131</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Deferred rent</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,009</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,449</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Warrant derivative liability</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">66,204</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,419,907</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,568,927</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Commitments and contingencies (Note 7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stockholders' equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Preferred Stock, par value $.0001; 50,000,000 shares authorized; none issued</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Common Stock, par value $.0001; 300,000,000 shares authorized; shares issued and outstanding 22,446,481 (unaudited) and 14,259,681, respectively as of March 31, 2016 and June 30, 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,245</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,426</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,827,395</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,996,367</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Ampio stock subscription</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,000,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(31,263,967</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(18,381,341</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total stockholders' equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,565,673</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">15,616,452</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders' equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">21,985,580</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">18,185,379</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 139; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_026"></A>AYTU BIOSCIENCE, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Statements of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center">Three Months Ended March 31,</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center">Nine Months Ended March 31,</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left">Product and service revenue</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">647,112</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,400</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,560,854</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">15,460</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">License revenue</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">21,429</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">21,429</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">64,286</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">64,286</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total revenue</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">668,541</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">23,829</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,625,140</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">79,746</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Cost of sales</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">340,796</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">622,222</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,143,676</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">694,180</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,308,009</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,418,125</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Research and development - related party (Note 11)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,998</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,998</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">143,994</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">155,994</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Sales, general and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,244,747</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,070,091</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,670,718</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,933,506</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Amortization of finite-lived intangible assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">118,697</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,697</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">284,633</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">53,091</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,895,914</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,829,966</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,029,576</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,560,716</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Loss from operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,227,373</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,806,137</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,404,436</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,480,970</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other (expense) income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Interest (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,074,668</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(36,052</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,428,136</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(110,900</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Derivative income (expense)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">27,983</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(50,054</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total other (expense)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,046,685</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(36,052</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,478,190</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(110,900</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss, before income tax</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,274,058</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,842,189</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,882,626</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,591,870</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Deferred income tax benefit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">23,910</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(7,274,058</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,842,189</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(12,882,626</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5,567,960</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Weighted average number of Aytu common shares outstanding</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">18,828,934</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,901,426</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">15,771,692</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,901,426</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Basic and diluted Aytu net loss per common share</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.39</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.23</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.82</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.70</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 140; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_027"></A>AYTU BIOSCIENCE, INC.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Statement of Stockholders&rsquo; Equity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common
    Stock</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional<BR>
    paid-in</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Ampio<BR>
    Stock</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total<BR>
    Stockholders'</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shares</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">capital</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Subscription</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deficit</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Equity</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balance - June 30, 2015</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">14,259,681</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,426</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">38,996,367</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,000,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(18,381,341</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">15,616,452</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Adjustment for rounding of shares due
    to conversion (unaudited)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">12</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Ampio stock subscription (unaudited)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,000,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,000,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock subscription (unaudited)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">307,692</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">31</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">199,969</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">200,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Conversion of convertible promissory
    notes to common stock, net of $29,754 conversion costs (unaudited)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,879,096</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">788</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,997,169</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,997,957</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issuance of warrants related to the
    convertible promissory notes (unaudited)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">86,781</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">86,781</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock-based compensation (unaudited)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">547,109</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">547,109</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss (unaudited)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">(12,882,626</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">(12,882,626</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balance &ndash; March&nbsp;&nbsp;31,
    2016 (unaudited)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">22,446,481</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,245</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">48,827,395</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(31,263,967</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">17,565,673</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 141; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_028"></A>AYTU BIOSCIENCE, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Statements of Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Nine Months Ended March 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash flows from operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(12,882,626</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(5,567,960</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stock-based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">547,109</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">749,810</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Depreciation, amortization and accretion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">433,471</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,746</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Amortization of debt issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">178,338</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Amortization of beneficial conversion feature</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,942,613</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Derivative expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,054</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Amortization of prepaid research and development - related party (Note 11)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">91,487</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">91,488</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Deferred taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(23,910</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Decrease (increase) in accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72,784</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,036</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(Increase) in inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(581,910</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,233</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">(Increase) decrease in prepaid expenses, other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(572,238</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">496,322</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(Increase) in prepaid research and development - related party (Note 11)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(150,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">(Decrease) in accounts payable and accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,319</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(103,158</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(Decrease) in related party payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(392,509</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Increase in accrued compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">591,451</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">98,949</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Increase (decrease) in interest payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">208,941</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(42,673</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Increase in deferred rent</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,560</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">(Decrease) in deferred revenue</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(64,286</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(64,286</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,992,571</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,846,450</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash flows used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Deposits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,998</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,998</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Purchases of fixed assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(203,577</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Purchase of Primsol business</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(540,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(741,579</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,998</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash flows from financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Proceeds from convertible note from Ampio converted to stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,700,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Proceeds from convertible promissory notes, net (Note 8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,175,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Debt issuance costs (Note 8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(298,322</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Ampio stock subscription payment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Sale of Stock subscription</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Costs related to the conversion of the convertible promissory notes to equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(29,754</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,046,924</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,700,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net change in cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,312,774</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,148,448</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cash and cash equivalents at beginning of period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,353,061</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,639,650</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents at end of period</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,665,835</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,491,202</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Non-cash transactions:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Warrant derivative liability related to the issuance of the convertible promissory notes (Note 8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">102,931</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Primsol business purchase included in primsol payable, $1,250,000 less future accretion of $173,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,077,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Conversion of convertible promissory notes and interest of $143,000 to common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,268,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Reclassification of liability based warrants to equity presentation related to the convertible promissory notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">87,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Beneficial conversion feature of $4,943,073 less $3,942,613 of accretion related to unconverted convertible promissory notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,001,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Debt issuance costs related to notes that converted to equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(183,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 142; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_029"></A>AYTU BIOSCIENCE, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 1 &ndash; Business, Acquisition of Assets and Basis
of Presentation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Business/Acquisition of Assets </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Aytu BioScience, Inc. (&ldquo;Aytu&rdquo;
or the &ldquo;Company&rdquo;) was incorporated as Rosewind Corporation on August&nbsp;9, 2002 in the State of Colorado. Aytu was
re-incorporated in the state of Delaware on June&nbsp;8, 2015. Aytu is a specialty healthcare company concentrating on acquiring,
developing and commercializing products focused primarily on the urological disorders market, specifically sexual dysfunction,
urological cancer, urinary tract infections and male infertility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Basis of Presentation </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">These unaudited financial statements represent
the financial statements of Aytu. These unaudited financial statements should be read in conjunction with Aytu&rsquo;s Annual Report
on Form 10-K for the year ended June 30, 2015, which included all disclosures required by generally accepted accounting principles
(&ldquo;GAAP&rdquo;). In the opinion of management, these unaudited financial statements contain all adjustments necessary to present
fairly the financial position of Aytu for the balance sheet and the results of operations and cash flows for the interim periods
presented. The results of operations for the period ended March 31, 2016 are not necessarily indicative of expected operating results
for the full year. The information presented throughout this report as of and for the period ended March 31, 2016 is unaudited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Aytu&rsquo;s current business was formed
through a reverse triangular merger (the &ldquo;Merger&rdquo;) in which Luoxis Diagnostics, Inc. (&ldquo;Luoxis&rdquo;) and Vyrix
Pharmaceuticals, Inc. (&ldquo;Vyrix&rdquo;) merged into Rosewind Corporation in a multi-step merger on April&nbsp;16, 2015. These
historical financial statements prior to April&nbsp;16, 2015 include the combined financial statements of Vyrix from its inception
in November 2013, combined with the carve-out financial statements related to Vyrix assets acquired in the Merger (the &ldquo;Vyrix
Acquired Assets&rdquo;) from March&nbsp;23, 2011, the date its parent company, Ampio Pharmaceuticals, Inc. (&ldquo;Ampio&rdquo;),
originally acquired the Vyrix Acquired Assets through its merger with DMI BioSciences, Inc. (&ldquo;BioSciences&rdquo;) and the
financial statements of Luoxis from its inception in January 2013, combined with the carve-out financial statements related to
Luoxis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On June&nbsp;8, 2015, in connection with
the reincorporation as a Delaware corporation, the Company effected a reverse stock split in which each common stock holder received
one share of common stock for every 12.174 shares then outstanding (the &ldquo;Reverse Stock Split&rdquo;). All share and per share
amounts in this Report have been adjusted to reflect the effect of the Reverse Stock Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Business Combination&mdash;ProstaScint </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In May 2015, Aytu entered into and closed
on an asset purchase agreement with Jazz Pharmaceuticals, Inc. (the &ldquo;Seller&rdquo;). Pursuant to the agreement, Aytu purchased
assets related to the Seller&rsquo;s product known as ProstaScint&reg; (capromab pendetide), including certain intellectual property
and contracts, and the product approvals, inventory and work in progress (together, the &ldquo;ProstaScint Business&rdquo;), and
assumed certain of the Seller&rsquo;s liabilities, including those related to product approvals and the sale and marketing of ProstaScint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The purchase price consisted of the upfront
payment of $1.0 million. Aytu also paid an additional $500,000 for the ProstaScint-related product inventory and $227,000 (which
represents a portion of certain FDA fees). Aytu also will pay 8% as contingent consideration on its net sales made after October&nbsp;31,
2017, payable up to a maximum aggregate payment of an additional $2.5 million. The contingent consideration was valued at $664,000
using a discounted cash flow estimate as of the acquisition date. The total fair value consideration for the purchase was $2.4
million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 143; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company&rsquo;s allocation on consideration
transferred for ProstaScint as of the purchase date of May&nbsp;20, 2015 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">Fair Value</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 82%; text-align: left">Tangible assets</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">727,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,590,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">Goodwill</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">74,000</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total assets acquired</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">2,391,000</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Included in the intangible assets is developed
technology of $790,000, customer contracts of $720,000 and trade names of $80,000, each of which will be amortized over a ten-year
period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of March 31, 2016 the contingent consideration
had increased to $699,000 due to accretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Business Combination&mdash;Primsol</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In October 2015, Aytu entered into and closed
on an Asset Purchase Agreement with FSC Laboratories, Inc. (the &ldquo;Seller&rdquo;). Pursuant to the agreement, Aytu purchased
assets related to the Seller&rsquo;s product known as Primsol&reg; (trimethoprim solution), including certain intellectual property
and contracts, inventory, work in progress and all marketing and sales assets and materials related solely to Primsol (together,
the &ldquo;Primsol Business&rdquo;), and assumed certain of the Seller&rsquo;s liabilities, including those related to the sale
and marketing of Primsol arising after the closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Aytu paid $500,000 at closing for the purchase
of the Primsol Business and paid an additional $142,000, of which $102,000 went to inventory and $40,000 towards the Primsol Business,
for the transfer of the Primsol-related product inventory. We also agreed to pay an additional (a) $500,000 which was paid on April
1, 2016, (b) $500,000 payable no later than June 30, 2016, and (c) $250,000 payable no later than September 30, 2016 (together,
the &ldquo;Installment Payments&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company&rsquo;s allocation on consideration
transferred for Primsol as of the purchase date of October 5, 2015 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Fair Value</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 82%; text-align: left">Tangible assets</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">182,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,470,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">Goodwill</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">147,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total assets acquired</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,799,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Included in tangible assets is $102,000
of inventory and $80,000 of work-in-process inventory. Included in the intangible assets is developed technology of $520,000, customer
contracts of $810,000 and trade names of $140,000, each of which will be amortized over a six-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of March 31, 2016, the accrued payable
adjusted for the present value was $1,155,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Adoption of Newly Issued Accounting
Pronouncements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In September 2015, the Financial Accounting
Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update (&ldquo;ASU&rdquo;) 2015-16, &ldquo;Business Combinations
(Topic 805): Simplifying the Accounting for Measurement-Period Adjustments,&rdquo; which requires that an acquirer recognize adjustments
to estimated amounts that are identified during the measurement period in the reporting period in which the adjustment amounts
are determined. The amendments require that the acquirer record, in the same period&rsquo;s financial statements, the effect on
earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the estimated
amounts, calculated as if the accounting had been completed at the acquisition date. The amendments also require an entity to present
separately on the face of the income statement or disclose in the notes the portion of the amount recorded in current-period earnings
by line item that would have been recorded in previous reporting periods if the adjustment to the estimated amounts had been recognized
as of the acquisition date. The amendment is effective for financial statements issued for fiscal years beginning after December
15, 2015 and early adoption is permitted. During the quarter ended September 30, 2015, the Company early adopted this standard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 144; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In April 2015, the FASB issued ASU 2015-03,&nbsp;&ldquo;Interest-Imputation
of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs&rdquo; to simplify the presentation of debt
issuance costs. The amendments in the update require that debt issuance costs related to a recognized debt liability be presented
in the balance sheet as a direct reduction of the carrying amount of the debt. Recognition and measurement of debt issuance costs
were not affected by this amendment. In August 2015, FASB issued ASU 2015-15,&nbsp;&ldquo;Presentation and Subsequent Measurement
of Debt Issuance Costs Associated with Line-of-Credit Arrangements &mdash; Amendments to SEC Paragraphs Pursuant to Staff Announcement
at June&nbsp;18, 2015 EITF Meeting&rdquo;&nbsp;which clarified that the SEC would not object to an entity deferring and presenting
debt issuance costs as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit
arrangement. The amendments are effective for financial statements issued for fiscal years beginning after December 15, 2015. During
the quarter ended March 31, 2015, the Company early adopted this standard and recorded debt issuance costs as a debt discount.
There was no impact related to this adoption as the Company did not have any debt issuance costs prior to adoption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In November 2015, the FASB issued ASU No.
2015-17 regarding ASC Topic 470 &quot;Income Taxes: Balance Sheet Classification of Deferred Taxes.&quot; The amendments in ASU
2015-17 eliminate the requirement to bifurcate deferred taxes between current and non-current on the balance sheet and requires
that deferred tax liabilities and assets be classified as noncurrent on the balance sheet. The amendments for ASU-2015-17 can be
applied retrospectively or prospectively and early adoption is permitted. Aytu early adopted ASU 2015-17 and there was no material
impact on its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Recently Issued Accounting Pronouncements,
Not Adopted as of March 31, 2016 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In March 2016, the FASB issued Accounting
Standards Update No. 2016-09, &ldquo;Compensation &ndash;Stock Compensation (Topic 718): Improvements to Employee Share Based Payment
Accounting&rdquo;. The standard includes multiple provisions intended to simplify various aspects of the accounting for share based
payments. The amendments are expected to significantly impact net income, EPS, and the statement of cash flows. Implementation
and administration may present challenges to companies with significant share based payment activities. The amendments are effective
for public entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption
is permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption.
The Company is currently evaluating the impact of this standard on its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In February 2016, the FASB issued Accounting
Standards Update 2016-02, &ldquo;Leases (Topic 842)&rdquo;. The new standard establishes a right-of-use (ROU) model that requires
a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases
will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income
statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those
fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at,
or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical
expedients available. The Company is currently evaluating the impact of its pending adoption of this standard on its financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In January 2016, the FASB issued ASU 2016-01,
&ldquo;Financial Instruments &ndash; Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities,&rdquo;
which requires that all equity investments be measured at fair value with changes in the fair value recognized through net income
(other than those accounted for under the equity method of accounting or those that result in consolidation of the investee). The
amendments in this update also require an entity to present separately in other comprehensive income the portion of the total change
in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to
measure the liability at fair value in accordance with the fair value option for financial instruments. In addition, the amendments
in this update eliminate the requirement to disclose the fair value of financial instruments measured at amortized cost for entities
that are not public business entities and the requirement to disclose the method(s) and significant assumptions used to estimate
the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet for public
business entities. The amendment is effective for financial statements issued for fiscal years beginning after December 15, 2017.
Early adoption is not permitted. The Company is currently evaluating the impact of this standard on its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 145; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In July&nbsp;2015, the FASB issued ASU
2015-11,&nbsp;&ldquo;Simplifying the Measurement of Inventory.&rdquo;&nbsp; ASU&nbsp;2015-11 clarifies that inventory should be
held at the lower of cost or net realizable value.&nbsp; Net realizable value is defined as the estimated selling price, less the
estimated costs to complete, dispose and transport such inventory.&nbsp; ASU 2015-11 will be effective for fiscal years and interim
periods beginning after December&nbsp;15, 2016. &nbsp;ASU 2015-11 is required to be applied prospectively and early adoption is
permitted.&nbsp; The adoption of ASU 2015-11 is not expected to have a material impact on the Company&rsquo;s financial position
or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In August 2014, the FASB issued ASU 2014-15,
&ldquo;Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&rsquo;s
Ability to Continue as a Going Concern&rdquo; (&ldquo;ASU 2014-15&rdquo;). ASU 2014-15 is intended to define management&rsquo;s
responsibility to evaluate whether there is substantial doubt about an organization&rsquo;s ability to continue as a going concern
and to provide related footnote disclosures. The amendments in this ASU are effective for reporting periods ending after December&nbsp;15,
2016, with early adoption permitted. The Company is evaluating the impact the adoption of ASU 2014-15 will have on its financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In May 2014, the FASB issued ASU 2014-09
regarding ASC Topic 606, &ldquo;Revenue from Contracts with Customers&rdquo;. The standard provides principles for recognizing
revenue for the transfer of promised goods or services to customers with the consideration to which the entity expects to be entitled
in exchange for those goods or services. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers: Deferral
of the Effective Date, which deferred the effective date of the new revenue standard for periods beginning after December 15, 2017,
with early adoption permitted. In March 2016, the FASB issued ASU 2016-08, which addresses principal versus agent considerations.
The Company is currently evaluating the effect that the updated standard will have on its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 2 &ndash; Fixed Assets </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Fixed assets are recorded at cost and, once
placed in service, are depreciated on the straight-line method over the estimated useful lives. Fixed assets consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Estimated</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">As of March 31,</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">As of June 30,</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Useful Lives in years</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left">Office equipment and furniture</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 - 5</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">154,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Lab equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 - 5</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Leasehold improvements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Manufacturing equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less accumulated depreciation and amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(97,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(60,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in">Fixed assets, net</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">197,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">30,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 3 &ndash; In-Process Research and Development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In-process research and development (&ldquo;IPRD&rdquo;)
relates to the Zertane product candidate. The $7.5 million recorded was based on an independent, third party appraisal of the fair
value of the assets acquired. IPRD is considered an indefinite-lived intangible asset and its fair value will be assessed annually
and written down if impaired. If the Zertane product candidate obtains regulatory approval and commercial production begins, IPRD
will be reclassified to an intangible that will be amortized over its estimated useful life. If the Company decides to abandon
the Zertane product, the IPRD would be expensed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 4 &ndash; Patents </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Costs of establishing patents, consisting
of legal and filing fees paid to third parties, are expensed as incurred. The fair value of the Zertane patents, determined by
an independent, third party appraisal to be $500,000, is being amortized over the remaining U.S. patent life since Aytu&rsquo;s
acquisition of approximately 11 years. The cost of the ORP related patents was $380,000 when they were acquired and is being amortized
over the remaining U.S. patent life since Aytu&rsquo;s acquisition of approximately 15 years. Patents consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 146; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">As of March 31,</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">As of June 30,</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%">Patents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">880,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">880,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less accumulated amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(304,000</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(251,000</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in">Patents, net</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">576,000</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">629,000</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 5 &ndash; Revenue Recognition </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The $647,000 and $2,000 product and service
revenue recognized during the three months ended March 31, 2016 and 2015, respectively, represents sales of the Company&rsquo;s
ProstaScint and Primsol products and the RedoxSYS System. The $1,561,000 and $15,000 product and service revenue recognized during
the nine months ended March 31, 2016 and 2015, respectively, represents sales of the Company&rsquo;s ProstaScint and Primsol products
and the RedoxSYS System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The license revenue of $21,000 and $64,000
recognized in the three and nine months ended March 31, 2016 and 2015 respectively, represents the amortization of the upfront
payments received from the Company&rsquo;s license agreements. The initial payment of $500,000 from the license agreement of Zertane
with a Korean pharmaceutical company was deferred and is being recognized over ten years. The initial payment of $250,000 from
the license agreement of Zertane with a Canadian-based supplier was deferred and is being recognized over seven years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 6 &ndash; Fair Value Considerations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Aytu&rsquo;s financial instruments include
cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, convertible promissory notes and warrant
derivative liability. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities
approximate their fair value due to their short maturities. The fair value of the convertible notes was approximately the face
value of the notes (see Note 8 for more information). The valuation policies are determined by the Chief Financial Officer and
approved by the Company&rsquo;s Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Authoritative guidance defines fair value
as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction
between market participants at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value
that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable
inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability
developed based on market data obtained from sources independent of Aytu. Unobservable inputs are inputs that reflect Aytu&rsquo;s
assumptions of what market participants would use in pricing the asset or liability developed based on the best information available
in the circumstances. The hierarchy is broken down into three levels based on reliability of the inputs as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.5in">
<TR>
    <TD STYLE="vertical-align: top; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&nbsp;1:</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 88%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&nbsp;2:</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&nbsp;3:</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable inputs that are supported by little or no market activity.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Aytu&rsquo;s assets and liabilities which
are measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair
value measurement. Aytu&rsquo;s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which
the event or change in circumstances caused the transfer. Aytu has consistently applied the valuation techniques discussed below
in all periods presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 147; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table presents Aytu&rsquo;s
financial liabilities that were accounted for at fair value on a recurring basis as of March 31, 2016, by level within the fair
value hierarchy:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Fair Value Measurements Using</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Level 1</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Level 2</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Level 3</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Total</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><U>March 31, 2016</U></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left">Warrant derivative liability</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">66,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">66,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The warrant derivative liability for the
warrants was valued using the Monte Carlo valuation methodology because that model embodies all of the relevant assumptions that
address the features underlying these instruments. Significant assumptions in valuing the warrant derivative liability, based on
estimates of the value of Aytu common stock and various factors regarding the warrants, were as follows as of March 31, 2016 and
at issuance:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">March 31, 2016</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">At Issuance</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: underline">Warrants:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; padding-left: 0.125in">Exercise price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">0.64</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.51 - $1.95</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in">Volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75.0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75.0</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Equivalent term (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.31 - 4.36</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.0 - 5.11</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Risk-free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.09% - 1.10%</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.54% - 1.74%</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in">Potential number of shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">159,000 - 228,000</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">139,000 - 224,000</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth a reconciliation
of changes in the fair value of financial liabilities classified as Level 3 in the fair valued hierarchy:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: center">Derivative Instruments</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Balance as of June 30, 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 82%; text-align: left; padding-left: 0.125in">Warrant issuances</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">103,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Reclassification of warrant liability to equity upon note conversion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(87,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Change in fair value included in earnings</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">50,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Balance as of March 31, 2016</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">66,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 7 &ndash; Commitments and Contingencies </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Commitments and contingencies are described
below and summarized by the following table for the designated fiscal years ending June 30, as of March 31, 2016:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Remaining</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Total</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2017</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2018</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2019</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: center">2020</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Thereafter</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 16%; text-align: left">Management fee</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">901,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">53,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">212,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">212,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">212,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">212,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Primsol business</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,250,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Manufacturing agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Office Lease</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">351,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">142,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">145,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Sponsored research agreement with related party</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">298,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">70,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">70,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">70,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">70,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,800,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,105,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">674,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">427,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">312,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">282,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Management Fee </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In July 2015, Aytu entered into an agreement
with Ampio whereby Aytu agreed to pay Ampio a set amount per month for shared overhead which includes costs related to the shared
facility, corporate staff, and other miscellaneous overhead expenses. This agreement was amended on November of 2015 and again
in April of 2016 resulting in an amount of $18,000 per month. These agreements will be in effect until they are terminated in writing
by both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 148; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Primsol Business</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In October 2015, Aytu entered into an agreement
with FSC Laboratories, Inc. for the purchase of Primsol (see Note 1).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Manufacturing Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In October 2015, Aytu entered into a Master
Services Agreement with Biovest International, Inc. (&ldquo;Biovest&rdquo;). The agreement provides that Aytu may engage Biovest
from time to time to provide services in accordance with mutually agreed upon project addendums and purchase orders. Aytu expects
to use the agreement from time to time for manufacturing services, including without limitation, the manufacturing, processing,
quality control testing, release or storage of its products for the ProstaScint product. Aytu is obligated to pay Biovest $1.0
million for time and materials as they develop a plan to reproduce the manufacturing process. Of this commitment, $500,000 was
paid on April 1, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Office Lease </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In June 2015, Aytu entered into a 37 month
operating lease for a space in Raleigh, North Carolina. This lease has initial base rent of $3,000 a month, with total base rent
over the term of the lease of approximately $112,000. In September 2015, the Company entered into a 37 month operating lease in
Englewood, Colorado. This lease has an initial base rent of $9,000 a month with a total base rent over the term of the lease of
approximately $318,000. The Company recognizes rental expense of the facilities on a straight-line basis over the term of the lease.
Differences between the straight-line net expenses on rent payments are classified as liabilities between current deferred rent
and long-term deferred rent. Rent expense for the respective periods is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center">Three Months Ended March 31,</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center">Nine Months Ended March 31,</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Rent expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">35,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">86,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">43,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Sponsored Research Agreement with Related Party </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Aytu entered into a Sponsored Research
Agreement with Trauma Research LLC (&ldquo;TRLLC&rdquo;), a related party, in June 2013. Under the terms of the Sponsored Research
Agreement, TRLLC agreed to work collaboratively in advancing the RedoxSYS System diagnostic platform through research and development
efforts. The Sponsored Research Agreement may be terminated without cause by either party on 30 days&rsquo; notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 8 &ndash; Convertible Promissory Notes </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>Convertible Promissory Notes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During July and August 2015, Aytu closed
on note purchase agreements with institutional and high net worth individual investors for the purchase and sale of convertible
promissory notes (&ldquo;Notes&rdquo;) with an aggregate principal amount of $5.2 million. The sale of the Notes was pursuant to
a private placement. Debt issuance costs totaled $401,000 which included the $103,000 fair value of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Notes are an unsecured obligation.
Unless earlier converted, the Notes will mature 18 months from their respective dates of issuance which will be on January&nbsp;22,
February 11 and February&nbsp;28, 2017, with an option to extend the maturity date up to six months at Aytu&rsquo;s discretion
(provided that in the event Aytu exercises such extension option, the then applicable interest rate shall increase by 2% for such
extension period). Aytu does not have the right to prepay the Notes prior to the maturity date. Interest will accrue on the Notes
in the following amounts: (i)&nbsp;8% simple interest per annum for the first six months and (ii)&nbsp;12% simple interest per
annum thereafter if not converted during the first nine months. Interest will accrue, is payable with the principal upon maturity,
conversion or acceleration of the Notes and may be paid in kind or in cash, in Aytu&rsquo;s sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.2pt">&nbsp;</P>


<!-- Field: Page; Sequence: 149; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Notes are convertible at any time at
the noteholder&rsquo;s discretion into that number of shares of Aytu common stock equal to 120% of the number of shares of common
stock calculated by dividing the then outstanding principal and accrued interest by $4.63. A holder of Notes will be obligated
to convert on the terms of Aytu&rsquo;s next public offering of its stock resulting in gross proceeds of at least $5.0 million
(excluding indebtedness converted in such financing) prior to the maturity date of the Notes (a &ldquo;Qualified Financing&rdquo;).
The principal and accrued interest under the Notes will automatically convert into a number of shares of such equity securities
of the Company sold in the Qualified Financing equal to 120% of the principal and accrued interest under such Note divided by the
lesser of (i)&nbsp;the lowest price paid by an investor in the Qualified Financing or (ii)&nbsp;$4.63. In the event that Aytu sells
equity securities to investors at any time while the Notes are outstanding in a financing transaction that is not a Qualified Financing,
then the noteholders will have the option to convert in whole the outstanding principal and accrued interest as of the closing
of such financing into a number of shares of Aytu capital stock in an amount equal to 120% of the number of such shares calculated
by dividing the outstanding principal and accrued interest by the lesser of (i)&nbsp;the lowest cash price per share paid by purchasers
of shares in such financing, or (ii)&nbsp;$4.63.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Placement agents for the offerings sold
the institutional portion of the offering of the Notes. Aytu sold the balance of the Notes to individuals and entities with whom
Aytu has an established relationship. For Notes sold by the placement agent, Aytu paid the placement agent 8% of the gross proceeds
of Notes sold by the placement agents and is obligated to issue warrants for an amount of shares to be equal to 8% of the gross
number of shares of the Company stock issuable upon conversion of the Notes issued to investors introduced to the Company by the
private placement agents in the private placement, in addition to a previously paid non-refundable retainer fee of $20,000. The
placement agent warrants have a term of five years from the date of issuance of the related notes in July and August 2015, will
have an exercise price equal to the conversion price per share at which the Notes are converted into common stock. Change in fair
value is recorded in earnings. Fair value at the grant date was recorded as a debt discount and amortized over the term of the
debt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The warrants were recorded at fair value
as long-term liabilities on the Balance Sheet (see Note 6).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Upon Aytu&rsquo;s adoption of ASU 2015-3,
the costs associated with the Notes were recorded as a long&ndash;term liability and are presented in the Balance Sheet as a direct
reduction of the carrying amount of the Notes on their inception date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Per the convertible promissory note agreements,
if Aytu sells equity securities at any time while the notes are outstanding in a financing transaction that is not a Qualified
Financing, the holders of the convertible promissory notes have the option, but not the obligation, to convert the outstanding
principal and accrued interest as of the as of the closing of such financings into a number of shares of Aytu capital stock in
an amount equal to 120% of the number of such shares calculated by dividing the outstanding principal and accrued interest by the
lesser of (a) the lowest cash price per share paid by purchasers of shares in such financing, or (b) $4.63. As a result of Aytu&rsquo;s
sale of common stock on January 20, 2016, the Company was obligated to provide notice to the above-referenced noteholders of such
stock sales. In accordance with the convertible note terms, for a period of ten business days (which was extended to 15 business
days by the Company, or February 10, 2016) following receipt of the notice, noteholders had the option to convert their entire
balance (inclusive of accrued but unpaid interest) into a number of shares of Aytu common stock equal to 120% of the number of
shares calculated by dividing such note balance by $0.65, which was the per share purchase price paid in the equity financing described
above. On February 10, 2015, the date of the conversion, an aggregate of $4,125,000 of principal and $143,000 of accrued interest
on the notes converted into an aggregate of 7,879,096 shares of Aytu&rsquo;s common stock. As of March 31, 2016 the convertible
notes had a remaining principal balance of $1,050,000 and interest payable of $66,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with the conversion of the
Aytu notes, Aytu was obligated to issue to the placement agents for the convertible note offering warrants for an amount of shares
equal to 8% of the number of shares of Aytu&rsquo;s common stock for the notes sold by the placement agents issued upon conversion
of the notes. As a result of the optional note conversion, on February 10, 2016, Aytu issued warrants to the placement agents to
purchase an aggregate of 267,052 shares of our common stock at an exercise price of $0.65 per share. These warrants are exercisable
for five years from the date of issuance of the related notes in July and August 2015. The warrants have a cashless exercise feature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Also in connection with the conversion
of the notes, Aytu recorded a beneficial conversion feature of $3.9 million which was recorded as a debt discount; this amount
represents that carry amount of the notes at the date of conversion. The&nbsp;beneficial conversion feature related to the notes
that converted was immediately expensed to interest expense and the remaining beneficial conversion feature will be amortized over
the remaining life of the notes. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of March 31, 2016, the carrying value
of the notes was $10,000 inclusive of an unamortized debt discount and beneficial conversion feature of $1,040,000. The beneficial
conversion feature is amortized over the expected term of the convertible notes (or the conversion date of the note, if sooner)
and is charged to interest expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A majority of the remaining noteholders
have signed lock-up agreements, which prohibit them from selling their stock until July 5, 2016. These noteholders received a 10%
premium upon conversion for this agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 150; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 9 &ndash; Common Stock </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>Capital Stock </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At March 31, 2016 and June 30, 2015, Aytu
had 22,446,481 and 14,259,681 common shares outstanding, respectively and no preferred shares outstanding at either March 31, 2016
or June 30, 2015. The Company has 300&nbsp;million shares of common stock authorized with a par value of $0.0001&nbsp;per share
and 50&nbsp;million shares of preferred stock authorized with a par value of $0.0001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Board of the Company had proposed the
reverse stock split in an effort to decrease the number of shares of common stock outstanding and increase the market price of
its shares. The Board is also seeking to reduce certain administrative burdens and costs relating to the large number of shares
that are currently issued and outstanding. The Board is asking its stockholders to approve a reverse split of the common stock
and grant to the Board the authority to set the ratio for the reverse split in the range of 1-for-4 and 1-for-12 or not to complete
the reverse stock split, as determined in the discretion of the Board at any time before November 24, 2016. The Board believes
that the reverse stock split will enhance the Company&rsquo;s ability to obtain an initial listing on a national securities exchange.
This proposal will be voted on by the Company&rsquo;s shareholders at the annual shareholders meeting on May 24, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Board of Directors has approved and
recommended a proposal to amend the Company&rsquo;s Certificate of Incorporation, to reduce the authorized shares of common stock
from 300,000,000 to 100,000,000 and preferred stock from 50,000,000 to 10,000,000. This decrease will result in a large tax savings
for the Company. This proposal will be voted on by the Company&rsquo;s shareholders at the annual shareholders meeting on May 24,
2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 10 &ndash; Equity Instruments </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Options </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Prior to the Merger, Aytu had two approved
stock option plans (Luoxis 2013 Stock Option Plan and Vyrix 2013 Stock Option Plan), pursuant to which Aytu had reserved a total
of 1,718,828&nbsp;million shares of common stock, both of which were terminated on April&nbsp;16, 2015 upon the closing of the
Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Luoxis options that were in the money
and all outstanding Vyrix options issued under the respective 2013 Option Plans were accelerated and cancelled in connection with
the Merger. Option holders received a cash payment per option share equal to the difference between the consideration payable per
share of common stock pursuant to the Merger and the exercise price of the option; if the consideration paid to holders of common
stock was less than the exercise price of such options, no amount was paid to the option holder in connection with the cancellation.
The cash payment during the period ended June&nbsp;30, 2015 was $27,000. The Company recognized non-cash compensation expense of
$422,000 and $189,000 related to the Luoxis and Vyrix options that had accelerated vesting as of the Merger date during the period
ended June 30, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Luoxis options that were not paid out
were terminated pursuant to the terms of the 2013 Luoxis Option Plan. The Company treated these options as pre-vesting forfeitures
and $433,000 of previously recognized non-cash compensation expense was reversed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On June&nbsp;1, 2015, Aytu&rsquo;s stockholders
approved the 2015 Stock Option and Incentive Plan (the &ldquo;2015 Plan&rdquo;), which provides for the award of stock options,
stock appreciation rights, restricted stock and other equity awards for up to an aggregate of 10.0 million shares of common stock.
The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied without
any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2015 Plan will be added back to the
shares of common stock available for issuance under the 2015 Plan. The fair value of the options are calculated using the Black-Scholes
option pricing model. In order to calculate the fair value of the options, certain assumptions are made regarding components of
the model, including the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend
yield and expected option life. Changes to the assumptions could cause significant adjustments to valuation. Aytu estimates the
expected term based on the average of the vesting term and the contractual term of the options. The risk-free interest rate is
based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. Aytu has computed
the fair value of all options granted during the nine months ended March 31, 2016 using the following assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 151; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; text-align: left">Expected volatility</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 25%; text-align: right">75.00%</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.21% - 1.90%</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected term (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.75 - 6.25</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Stock option activity is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Weighted</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Weighted Average</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Number of</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Average</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Remaining Contractual</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Exercise Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Life in Years</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Outstanding June 30, 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; padding-left: 0.125in">Granted</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3,717,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1.55</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 0.125in">Forfeited/Cancelled</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(50,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; text-align: right">1.51</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Outstanding March 31, 2016</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,667,500</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">1.55</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">9.55</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Exercisable at March 31, 2016</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,477,500</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">1.51</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">9.62</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Available for grant at March 31, 2016</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,332,500</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 152; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Stock-based compensation expense related to the fair
value of stock options was included in the statements of operations as research and development expenses and selling, general and
administrative expenses as set forth in the table below. Aytu determined the fair value as of the date of grant using the Black-Scholes
option pricing model and expenses the fair value ratably over the vesting period. The following table summarizes stock-based compensation
expense for the three and nine months ended March 31, 2016 and for the stock-based compensation expense related to the Luoxis and
Vyrix options for the three and nine months ended March 31, 2015:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center">Three Months Ended March 31,</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center">Nine Months Ended March 31,</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Research and development expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; text-align: left; padding-left: 9pt">Stock options</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">38,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">115,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">63,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">323,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Selling, general and administrative expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Stock options</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">258,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">157,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">484,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">427,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">296,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">272,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">547,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">750,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Unrecognized expense at March 31, 2016</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,554,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Weighted average remaining years to vest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.90</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Of the options that Aytu issued during the
nine months ended March 31, 2016, 1,447,500 were to Ampio board members and employees. This was recorded as a return of capital
to Ampio and Ampio will take a stock-based compensation expense equal to $1.3 million on their financial statements related to
these option grants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Warrants </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Aytu issued warrants in conjunction with
its 2013 private placement as well as to the placement agents in conjunction with the 2015 convertible promissory note financing
that converted to common stock (see Note 8). The 2015 warrants were previously classified as a liability and upon conversion of
the notes to common stock the associated warrants were assigned a value and moved to equity. A summary of these warrants is as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Weighted</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Weighted Average</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Number of</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Average</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Remaining Contractual</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Warrants</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Exercise Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Life in Years</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%">Outstanding June 30, 2015</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">102,613</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">4.53</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2.92</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Warrants issued to placement agents for convertible promissory notes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">267,052</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; text-align: right">0.65</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Outstanding March 31, 2016 (unaudited)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">369,665</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">1.73</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">3.78</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Significant assumptions in valuing the warrant
liability related to the placement agent warrants issued during the March 31, 2016 quarter were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; text-align: left">Expected volatility</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 25%; text-align: right">75%</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.36% - 1.37%</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Contractual term (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.6</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 153; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Warrant Obligation related to the Convertible Promissory
Notes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Aytu has the obligation to issue warrants
to the private placement agents for the 2015 convertible note financing as part of their fees for the financing. These warrants
are classified as a derivative warrant liability due to the fact that the number of shares and exercise price have not been set
as of March 31, 2016. The number of shares of Company stock that these warrants will convert into is equal to 8% of the gross
number of shares of the Company stock issuable upon conversion of the Notes issued to investors introduced to the Company by the
private placement agents pursuant to the private placement memorandum. The exercise price will be the conversion price per share
at which the first outstanding Note converts into Company common stock. The warrants have a term of five years from August 31,
2015 due to the conversion setting the price of these warrants (see Note 8). During the quarter ended March 31, 2016, a portion
of this warrant obligation converted into 267,052 warrants with an exercise price of $0.65 which were reclassified from liability
based warrants to equity presentation (see Note 12). This conversion increased additional paid-in capital by $87,000. The warrants
related to the convertible debt that did not convert are still classified as a liability until such time as the conversion price
is set.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 11 &ndash; Related Party Transactions </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Ampio Loan Agreement </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In November 2013, Vyrix entered into a loan
agreement with Ampio. Pursuant to the loan agreement, Ampio agreed to lend Vyrix up to an aggregate amount of $3.0 million through
cash advances of up to $500,000 each. Unpaid principal amounts under the loan agreement bear simple interest at the &ldquo;Applicable
Federal Rate&rdquo; for long-term obligations prescribed under Section&nbsp;1274(d) of the Internal Revenue Code of 1986, as amended
(or any successor provision with similar applicability). The initial term of this loan agreement is for one year, subject to automatic
extension of successive one-year terms. Vyrix may repay any outstanding balance at any time without penalty. Ampio had an option
of converting any balance outstanding under the loan agreement into shares of Vyrix common stock at the fair market value per share
of Vyrix common stock, as determined by the Ampio board of directors, as of such conversion date. As of June&nbsp;30, 2014, the
amount advanced was $1.6 million with interest rates from 3.11%-3.32%. On April&nbsp;16, 2015, in connection with the closing of
the Merger, Ampio released Vyrix from its then outstanding obligation of $4.0 million under the loan agreement as consideration
of its share purchase, and the loan agreement was terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In March 2014, Luoxis entered into a loan
agreement with Ampio. Pursuant to the loan agreement, Ampio agreed to lend Luoxis $3.0 million Unpaid principal amounts under the
loan agreement bear simple interest at the &ldquo;Applicable Federal Rate&rdquo; for long-term obligations prescribed under Section&nbsp;1274(d)
of the Internal Revenue Code of 1986, as amended (or any successor provision with similar applicability). The initial term of this
loan agreement is for one year, subject to automatic extension of successive one-year terms. Luoxis may repay any outstanding balance
at any time without penalty. Ampio had an option of converting any balance outstanding under the loan agreement into shares of
Luoxis common stock at the fair market value per share of Luoxis common stock, as determined by the Ampio board of directors, as
of such conversion date. As of June&nbsp;30, 2014, the amount advanced was $3.0 million with interest rates from 3.11%&mdash;3.32%.
On April&nbsp;16, 2015, in connection with the closing of the Merger, Ampio released Luoxis from its then outstanding obligation
of $8.0 million under the loan agreement as consideration of its share purchase, and the loan agreement was terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On April&nbsp;16, 2015, Ampio received 4,761,787
shares of common stock of Aytu for (i)&nbsp;issuance to Aytu of a promissory note from Ampio in the principal amount of $10.0 million,
maturing on the first anniversary of the Merger, (ii)&nbsp;cancellation of indebtedness of Luoxis to Ampio in the amount of $8.0
million; and (iii)&nbsp;cancellation of indebtedness of Vyrix to Ampio in the amount of $4.0 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Services Agreement </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company has entered into a service agreement
with Ampio which is described in Note 7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Sponsored Research Agreement </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In June 2013, Luoxis entered into a sponsored
research agreement with TRLLC, an entity controlled by Ampio&rsquo;s director and Chief Scientific Officer, Dr.&nbsp;Bar-Or. The
agreement, which was amended in January 2015 and provides for Luoxis (now Aytu) to pay $6,000 per month to TRLLC in consideration
for services related to research and development of the RedoxSYS platform. In March 2014, Luoxis also agreed to pay $615,000 which
is being amortized over the contractual term of 60.5 months and is divided between current and long-term assets on the balance
sheet; this amount has been paid in full. This agreement is set to expire March 2019 and cannot be terminated prior to March 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 154; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Convertible Promissory Notes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The convertible promissory notes (see Note
8) include $275,000 invested by relatives of senior management of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 12 &ndash; Subsequent Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In April 2016, the Company added a fourth
director. He will hold office until the Company&rsquo;s next annual meeting of stockholders. In April, the Board granted to each
of Aytu&rsquo;s two non-executive directors, including the new director, options to purchase 100,000 shares of Aytu common stock
for board fees in fiscal year 2016. The options vested upon grant and have an exercise price of $0.56 per share, which was the
closing price of Aytu common stock on the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On April 22, 2016, the Company entered into
and closed a license and supply agreement for the exclusive U.S. rights to Natesto&trade; (testosterone) nasal gel from Acerus
Pharmaceuticals Corporation (&ldquo;Acerus&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The license&rsquo;s term runs for the greater
of eight years or until the expiry of the latest to expire patent including claims covering Natesto and until the entry on the
market of at least one AB-rated generic product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Aytu paid Acerus an upfront fee of $2.0
million upon execution of the agreement. On September 5, 2016, Aytu will pay an additional $2.0 million (the &ldquo;Second Upfront&rdquo;).
On January 1, 2017, Aytu will pay an additional $4.0 million (the &ldquo;Third Upfront&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to the upfront payments, Aytu
must make the following one-time, non-refundable payments to Acerus within 45 days of the occurrence of the following event:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">$2.5 million if net sales during any four consecutive calendar quarter
period equal or exceed $25.0 million (the &ldquo;First Milestone&rdquo;);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">$5.0 million if net sales during any four consecutive calendar quarter
period equal or exceed $50.0 million;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">$7.5 million if net sales during any four consecutive calendar quarter
period equal or exceed $75.0 million;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">$10.0 million if net sales during any four consecutive calendar quarter
period equal or exceed $100.0 million; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">$12.5 million if net sales during any four consecutive calendar quarter
period equal or exceed $125.0 million.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company also agreed to purchase on
April 28, 2016, an aggregate of 12,245,411 shares of Acerus common stock for Cdn.$2,534,800 (approximately US$2.0 million), with
a purchase price per share of Cdn.$0.207. We cannot dispose of these shares until August 29, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the term of the agreement, Aytu
will purchase all of its Natesto product need from Acerus. Each month Aytu will provide Acerus with a two-year forecast of its
product needs, the first three months of which will be noncancelable. Pursuant to the agreement, Aytu will pay Acerus a supply
price per unit of the greater of 115% of Acerus&rsquo; cost of goods sold for Natesto, not to exceed a fixed ceiling price and
(ii) 10% of the net selling price for the first year of the agreement that increases to 16% in the second year and 25% in the third
year of the agreement and remains constant after that. Upon the expiration or invalidation of the last-to-expire (or be invalidated)
Acerus patent covered by the agreement, the supply price will be reduced to an amount equal to the sum of (A) 115% of Acerus&rsquo;
cost of goods sold (but not to exceed the fixed ceiling price) and (B) 50% of the difference between the supply price and 115%
of Acerus&rsquo; cost of goods sold (but not to exceed the fixed ceiling price); provided that the supply price will not be reduced
to an amount lower than 115% of Acerus&rsquo; cost of goods sold (but no to exceed the fixed ceiling price).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the event of any termination of the
agreement prior to the date on which the Second Upfront, Third Upfront and/or First Milestone is otherwise payable, all of those
amounts will, unless otherwise paid prior to the effective date of termination, be payable on the effective termination date. Following
the termination date, any further milestone amounts will be payable to Acerus in accordance with the agreement, even if the milestone
is met after the termination date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 155; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On May 2, 2016, the Company entered into
an underwriting agreement with Joseph Gunnar &amp; Co. as representative of the several underwriters named therein, relating to
an underwritten public offering of 18,750,000 shares of its common stock, par value $0.0001 per share, and warrants to purchase
up to an aggregate of 18,750,000 shares of common stock at a combined public offering price of $0.40 per share and related warrant.
Each warrant will be exercisable for five years from issuance and have an exercise price equal to $0.50.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company received net proceeds from
the sale of the shares of approximately $6.7 million, after deducting underwriting discounts and commissions and estimated offering
expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 2,812,500 shares
of common stock and/or 2,812,500 additional warrants. The Underwriters have already elected to exercise their over-allotment option
to purchase 2,049,250 warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with the public offering,
Aytu is obligated to issue to the placement agents&rsquo; warrants for an amount of shares equal to 7% of the number of shares
of our common stock issued in the offering. We issued warrants to the placement agents to purchase 1,312,500 shares of our common
stock at an exercise price of $0.50 per share. These warrants are exercisable for five years from the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the terms of the notes, the
notes (inclusive of accrued but unpaid interest) were automatically convertible due to the public offering, into securities of
the Company in an amount equal to 130% of the number of such shares issuable calculated by dividing the outstanding principal and
accrued interest by $0.40. On May 5, 2016, the date of the conversion, an aggregate of $1,050,000 of principal and $78,000 of accrued
interest on the notes converted into an aggregate of 3,666,698 shares of common stock and warrants to purchase 3,666,698 shares
of common stock with an exercise price of $0.50 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with the conversion, we were
obligated to issue to the placement agents for the convertible note offering warrants to purchase an aggregate of approximately
270,772 shares of our common stock at an exercise price of $0.40 per share. These warrants are exercisable for five years from
the date of issuance of the related notes in July and August 2015. The warrants have a cashless exercise feature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">After all of these transactions, the Company
has 44,863,179 common shares outstanding and 30,286,385 warrants and options with a weighted average exercise price of $0.64 as
of May 6, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 156; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tpg3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg3.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ /P"] P$1  (1 0,1 ?_$ ,    $#! ,!
M      D " H" P<+ 04&! $!   & P$               $" P<("00%"@80
M  $# P,"! ,% @<($P    $" P0%!@< $0@A$C$3"0I!42)A<105%C(7@9%"
M(R98&?"A4H*UEA@:P='A<F/3U"4V5F9VQE=G=Y<X.1$  0,"!0($ @<'!0$
M     0 " Q$$(1(%!@<Q"$%182(R$W&1H2,4%0F!L<'10E(S\&+2<R2$_]H
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M@I_B _OC1%!$][J ,7<(M@!_3^^QOMUV%N]!O]FB+/GLKO\ Z3<C_P#W[_\
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M4RH;!;:DGMW'@=$0<\,^V#],W .5+%S/C*FY:MG(&/*_!N2UZQ'R36T*BU.
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@N@?KA5(6S+6'4Q?SS\Z_*6VT%*GMNWZA]6GN]*HO_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tpg63.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg63.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!60%L P$1  (1 0,1 ?_$ ,4  0 !! ,! 0
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M41#R_1EB+<E62HS9M-=>IWR108 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M,50@'(8IB\E,4Q3 ("'@(9J55-IG;IUZ=/YGURI48 P!@# & , 8 P!@# &
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MC5%U6K2M!66,N=<:QD2VUPR?,Y)JBN\UK+PMD/:5GS^JV!B9%.=,NBS?,)5
MOHB9,YU MS5V?5E99''8UMNRGYDNM74V2R49'3D2]A9R.9RT3,12L5-0\LV1
M?L)*.?M#-GT7(M5_51>LW+=8R:I#=1% $>>>1$<BU#_=_)EJM?;J:7)R6H0N
MVOABI5TT?7O.W:!LN>TGL>/[0+O..YZ@6*$EIWM3N4Z\</IQG%59,B]J[?+)
M*NQ55FI*APJA)&MO53BY>5XBJ"PF5CC**<YRV$L>D\>M&M:ZZU/9_3'/X_*8
M<;+?ZUM*/B]*^\VIASFH@VXIOJ=8SG)%!@# & , 8 P!@# & , 8 P!@# &
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MN6U2W755T-H7;[MV-WUI35VXHEN5FSV-1X&T*L .8QH>6?LDPG8!;U !0KJ
MFDW#-8#<&*JB8! ! 0SBY1<)N'8CWNQ>CD6(WX])(F/*%T8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#H?D>D _\WCY?8/
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MN8)TPP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@'13D"B)2]1@Y$I>0#J, #TEY'RY'X_# -%_:+P;MOU@Y.8PO7[*R24T*@
M<*C8I*\6A_8B+A_^Y)-.%P.' <"4?MSL\!J6):2Z[$>">K;D7S-]=JNR,BQ
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MB3-=FJ=BR5V9SU=N\ :B[EUK((U?<.N71R"XK-H!L#A*6B%0 I)>A7)J'U&
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MVVJ/H-\N]G'J* 7I Y@+P  4#"!0 ! P 4 '@H 8 $ #P#C([8]PWS[V 4.
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MT+DP2& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M")I))EX(FBF0 *4@ !2E   . #,)12==:F_:3/3DBHP!@# & , 8 P!@# &
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MW'V??]P/M2_WMD< V'X P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@&O#^8G_<?9]_W ^U+_>V
M1P#8?@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & :\/YB?]Q]GW_<#[4O][9' -A^ , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8!KP_F*?W'V??]P/M2_WMD< V'X P!@# & , 8 P!@# & ,
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M5 ?G >,RWP6.DS6O_N!GTTBNG<2<E/\ >G$B52,[NHFPF*'@VV)VYZ^?M3B
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M$,51)0 .0Q3E*8+ER$9X]/Q$[>5+!N+*LNEVNO=1>'0N_LZW'<*3=3=H>W+
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M&QJ+UH37,7HNL4V_87_1-$T#6U<M-,K:=D-6+<24;K5N?M\_.QT)%397QY&
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M\D6CQ[)-H9-VVE8QI'.K9( N=)4AP2;-TB)_,7D3MN6CT1A/,Q[-U7:+:O\
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MPT2T=&4V37Y27"N2U%@V_P!+=IV.2C*V[>RP-D5T#IOD&8F-P(E-8NW7"5/
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MLI3W'AW)\)+C\F=M]4Z^\D\?ADC25KIW'8BBB?/IJ')U>!N@QB]0?8/2(<X
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MQD9%IJ)1<9&Q:2IR**I1K!I'IJJ)HIMDU%4VB*)%%$VR)$RF, B5,A2A\I0
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M# & , 8 P!@# & , 8 P!@# ->'\Q/\ N/L^_P"X'VI?[VR. ;#\ 8 P!@#
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M'\Q3^X^S_P#[@?:E_O;(X%4;#N0^T,%*HYP5& , 8 P!@# & , 8 P!@# &
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MDK+#7O;V=)@2YZ\D%9*O&D5[=M.??OXCUUC X; *1E2^'J%\LN+B/;T-7_\
M(4ZZXSVDRM-N=^,.0P)[$[7;P5+@4_S%IO8].?/.CE0Q'+RM;5G63<RP%Z 4
M39F!(3=0D/\ JY3]G?>R?_R#97_XY?,)WW[$J/[+?':U>XQF@0ONKSH"<8;T
MJH$^83/'55*VJ>V(]+TR"84D821,7P #'$0S7WN.R8HZ/!]8<3F42DD9KZ?W
MIJ3?E:"VZ?OM?O<(FJ+214AW?$G R1>?5A[1 .R-IZK3: E$%64@V;.DC (&
M3#,!QE![)?,CJ+=R-VVKMO6W)53\&2U@D, 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , A_=N\-:Z HS^_;1L/T"
M!0<-(N.2;M7DI/6:Q29C)0]3I]>C$UYBSVN:7+Z;1@S2475'DW $*<Q96[<K
MD]L>I9NWK-J+EDR4+2[6Z?>:L+=(;G[LU7,CO!Q9=1Z0<E%*N=L]6LRD7/6:
M+$W6E+]Q5XJ[AN_DY"12$HGJ40\3AV10]-ZL_5$WI])A\*W\=T\SYCUI*%V>
M+BZV=4I+M^TDNM5FN4R"CZO3Z]"5.LQ*!&T97ZY%LX6'8I% ."-H^/21;)AU
M (B;IZSF,(F$1'G-[]-8QK:\I14^UI)/[CSR_>NY%YWKDY23[&VT5WQ^\0'C
MD0 1X#[> #J$ \?(!\AXR.Z72KH6E\+K'1CQ#_P'GR$0$/#[!#*5?>2\R?>_
M><<B'Q_IYXJ^\IN?>SD!$! P>!@Y$!#SY'@1\?/QXRCUZZD8)6_\?P^S3^1#
MMSTC5+-9"[$KDC8M3[D;-@;QVYM62!:M?$R$Y%%E/J)(JP]_@ $"@K&3S609
M*$Y*!2\]08^3@8UZ'X5-ZO15.@XWG<SCI*;NW)07X7)M)=U&Z&0^B.\*R1EM
MKFCN[!&+K>Q)]RC":QW) -U8[4.^9 I1!"*0255<?NSVXY2)UJUI\N9!\(B>
M+<.2]2"/+Y>!+'G\-7!'JG >H<7EK>^Y)1R6VMOL\/$V/D.4_/2//2/ ^?@/
M'/ \_',"J?0Z:M?8=\%1@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MOF/>(W(7;<;L.C1?N , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8!P(\"'WCQY\#Y<^ ?' -*.MY)2_;-[F=W/@ [O8N\+12
MH$1\3--?:"75U+6&!!\133=3$'+RIR!P'JR9A\?/.MX>W&U:4WKN53Q3U[E3
MRLQX\&X^7-KOK0D&\6V)U]2[;?K#[O\ +]*K<S:YPS%N+IZ6'@&*\E**,VO4
MF+I=)DV.8J8& QQ#I#Q'-E<:A5]AR4$[DE"*^*B(]B-]T*4DUX%T:4K=@9DI
M[UU"VHD5".2P5\C965J]H:.5Y8\;+5^0;P;Q,RC-=PLBX:K)J)E%,PA:A>A*
MN[X:&6^/RXTFX=AZK3-Z#LC>'DKI.:QF6,FVDHR$<V&9@W,9(LS2+-S+,VQ'
MS@6+HB<O!HF. @<Y'30O'2<G 3<L>2^)U1.S+D4W&U;<&EUKU^XMAG6>UAVF
M+F.;ZE<HS[JR-DG#64BEB2,D_LR%UL_MW(/3=$HI<&R<HN=,Q5R/R J40,4!
MR*^E6L>I5WN6G/RY)[2ENVO:[,*OZ2:+H-F_-,4:N6.+]\S=)R%=OLA*NWR\
MVM(RR!I$M@E*DX,X6*HXD556?)NHJ7R2W6?S+W$U;Y"NJHCWSD_H+7:,!LAL
MUA9%Q8K0K0JW+04@QD07M,O$G92$6Q?RLZV@H>7DHJL%9K"*S=R[%N@V$5%%
M"$.W6?S(MQGERNNT>U"#[>1I=>J;J.J5?JU48$8Q-(D'H02M/2M<$$H[K,E%
M)R"3B.<2<&_'W3!83D524, E.4?&W^E^9%&^1K\C+VA]K:E?L6QX6_THT8FX
MEH1@+>8CF;45JHBJ6781J*RK<BR<*@R.!_1ZDR$1-P(@4>+BG:2IN1;>'ES>
M]Q^)ZE7KNP]?7!VHPJ5YJ5F?(M5'RK.!L$7+.DV23HC)5V=!BY66*W3=*$()
MA*  90@#X& <DFGK%U1;GC9-O64'0O(IA(8IN 'I$#>/ @/'P$H\@(#]@Y6,
MTI;6JIHI8KYGF1E1P52]OY<<BO#ZZV[I)42^QT!O>[TVIE PB=/7UT:PVX*4
MR,!A$03@H[89XM+CY028E O !P'&\C!0RI..B9[GZ7SGG\-;O-4:;76O0V(9
M@G0C & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MHEGK+AFX-X=+T6=.;*](!QZ*A!\\Y7D_^(;/9O0"E_T_%R_VDC9MFM.U& ,
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M>23:2KZ35['NT:1:ZFF1JHJ$ZHS;R1#G,WYX#*^=/N?N+7T6-WQ]Z+)GM_\
M<"$IL6,KNM'"*,!8'+2IRLQK&_N4I6.9P^W%UVX-F;A$C]7ZK281--VFMZ*Y
M)HHD#]HCE//GX^XR?I;/YH^\N#0VQ]K;*V[,3=UK5MHT$?4+=%6B2D#98N$K
M-R8[(G6Q/]J2R2<789V8IZC1X*[4I!*T7(D8!%(>,BPVY;GU*9EBS;QU*$HN
M6WL:,S^/++\]9:&@C679J6G?KO":THUOV'8U2HP=)KLO9I(##P=="(9JNB,V
MY>!,J[D%R%01('(G64*0/F,7+5ZX[=EUJDS.P,7ZK+C8DG5LS [(-8S&J.VG
M6D';&QF^P+/&O]H[.]5$Z3H=D;5EGE]M[=YZA2G%:(DYTS H#XD2:$+Y%#.'
MOW/,O29] \=C+$P;=E=4C+3+1F# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , Q"[RM!S&[M5>YH*S*.W=JN>:[2T=-/!(@
MV2O<$V<(JU27=>!RU;9$"Y=0$H41Z0:OQ5X$Z*?%VU<\JY&?B8?)8:SL.5CM
M:T,,=6[*@MKT]G:XA!Y$.DW+J#ME3F$A:62@7B%/[2U4*U1IP*O&6&M2@&;J
MIG  4#H5()DE4SF[>U?^HMJ[X4]QX!R>!^VYL\3NU_\ 5J>VZWV&HJ<&61;R
MTG)V:2>1-=@8%F1_,S3Z,A)*R22+!LJX:)*'904.Y<F 5"F,"720#',4HQN7
M?+:1:Q\6]D)NWT1 \GWGZAC@CCIM[[*A,PB]MAE(>L ^+*4]NSLCQ6UM% DT
MBGCDT*C)<I"(/.6W'H_M$^JU]2O R[?'9*?0]ZW=IK\KN-C6];V7(2<@ZF(T
MT:SK+91S&2<+>WFM',9)=4R1)-=6Y,@;$,D95+H635$P$$PDK]2O N/C<J:V
MI,\L5WCZKL+6$DJY%;+L$/83MT(V=CJ2]&",^-#*S\K&.9=VZ:L&TE78M ZC
MU$RG64I3"D"H%,(4^I7@1?#9:BY37P+J5R1[FZBP"KOU8ZSI0ML@)NR1'NX3
MTG5AB&#6E/XB:A'_ -6+&%B96/NS=0HN!*H8G7R"9D3 +ZA>!:7&1\2Q:EW@
MUZQ/IEZ=H8M1;HS]BKDBBT7:2$E1H+76KK\>;F74M+,(J"?1K78H$715,(&2
M1**0@<.D[ZE>!D_MZ[B9*1O.L[!L"-8B82]M)'Z(C+R*LS5'S&,K[U>'@["%
M8L,F4R[")M9H6QM7(,CGZC$.8"B)DSE#)B]T5+O,+(P593N$R@'(@'/']O\
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M_H;3_P#11S5Y'S2.JQ?DC['_ #+P)_HR_P!/MR%OI]A>?S'UR1 8 P!@# &
6, 8 P!@# & , 8 P!@# & , 8!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tpg67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg67.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ D #J P$1  (1 0,1 ?_$ +L    %!0$!
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M^QQ:U,7'*;;+] %M<9V0P\KC\QY#Z@(]9)IN4KU;MMYMC'_*?555[KL=C/\
M3]I">=/ZD.(3&5+M]WQT+X A+RTM*/$)*BA*G2A7$*J>@^W4_P#O%DLIG91U
MXY)C>X_ZJ%GLG*"UD%OA..-.-H>@1FW%U:0%K]-:227%]!3;4$^_PQ#3%D0M
MNU^WYE_EX T_5<]>YWZK.3W-4QBTWNX-Q0EU+;QG*44)(HA9:"E^HZYO4"@2
M=8LV_P SP3#\5TEGVE;VV,@&!Y+F=W-]V6<=S[B\F=>)TJ,XX?10'U("10HY
M \ME\!]^^N?NMSEN7!LM5U5E80PL/2I04JDC@4*_Y%D%KML8W&=<KQ,BV^WP
MAZKS\R7/DH:C,-A"5+=<==6$I%-R1J**TUNZ?%Y'X*2^OS#;NDX,:5[W/;W@
M$WMMV1[5X%=EJ7=,5P7'[5<N2N11<&8:53&N0.X8?6I W_AUZE81?3V,<)S:
M%\L[W="\W6:X;[7.P3OJCD_A1Q_W@:_>=M6UEJJ(R=Z"O3Q(_OT8E".8Z0-T
M^5-SN2?MT(IS1##!)-!U\S_]VEQ10HAB[_@_Z7_Y:2I0J?3+\* >%2*??4Z$
M(WH(*:* )\2":5ZUZZ$(BF $DC=6WPKO]M.FG,]P0,U:#*JUX?-Y\A_96G34
MS_:4I1O15UX?-Y\A_96FJZ1#TG/Y?WI_QT(7R2+CGSL%"+ZR3#,T)GP<W[:+
M7:Q)<C(*$R,NPN0]+@W%$8.%!=H]2J@5M^ A*C$.^=^QIEZXR)%MMCMZ0B0[
MDL *E]N\M>?V^CSK$/45"M]SFN"ADM>B\W4T><%!H0I68UWVE)9@6^^W-R#>
ME,*N$3&\DN\]BU+<#K+K;O;+NG;IWY_:H[ZGJ)ML\R$- <0TE%21">J#[B<T
MFSI=LM%TRBVSH2(ZY,"/^7V;N#&^K4&UI;:??9PSNE:7'' 0MIE,JE05$D$"
M$\F/=_L\ND--H8SVXR)UJ=7)N%@M=QFP[]/7]0E#:7NVN;W*U7VVR&D\D%=C
MNQ;+@JA*?E&A">WM!WO[I9UD;:SW/S"SX%AE\",D<9SG+XMSN\EA'KM8MC5X
MNLMR[6V.@JK.<#SP:4C@E?R@ZUMNVR.]8Z6X-(VJI<W<MI(UD J]_P"J]$>%
M^[2]0NU6.V5YZ=&?8@^H'[K?Y^0Y!+MBV_6B(N.0W%U<YY[T5<@I14YQ6$D[
M#6+?S11ROB@/\(-!Y+T#9.WYI8([V<?R2 $A,;GWNG1!$IP7$-)4-DE[U%))
M/(\CR))!&XKN=8;KHUS78-VL  4%1X**F4^[$S'*-3UL%8"JF00HI W*D!?
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M[##T)]3S+2G!3B=4;C=X;ISV]P;5:R.:"'.#*'2..HBF"W+6>[M'!UM=RL\
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MY>T+*=^NX:'2##,C#X$*2?MG]Q&3^SCN*[W+[:V+&\KSV99)5FM<?*F9<EN
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6]'5=X):HWTJ?^\'WC_#1U'>"2J__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tpg70a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg70a.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ =@(= P$1  (1 0,1 ?_$ (T  0 " P # 0$
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M#]=K1C<_1S!NBD1*<;,CT?FK[.C:TM",+<.$7D\0>'E\SE20(D)!V$Q.#23
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MNE]!$W;XE<H=+;K0FH;!HLZ:.[(TQF=*JWL5<\N3JTFJF<2A$%2B<'LPX@T
M @P:66(1><ASX@J[/^Q[7UF5E:$.E=]S$Z:V72VJ>NHK+1PN/$+F"H-2),SR
MZ&-:*/F.![<JE$Q?V%,>^N9AF FX!X$R=,'@258_:%@]HW/?=ZR:Y9-F;7%9
MFH5SQKT4192&ZKK-TT1E-E>O+4G$XFFR%HDC48J2O2%6,.3R58\$G$B" 6 V
M]=VE*#D6L%ZZV3-[D#^'8[9!UVKLVP4Q"5GD']W'2Q6*?%KXBE3FG@C+6SDQ
MU.U(2@GG'$HLF"$:,XP8\A[[([4-)3"ONX7 XC(WJML]Q5,SH[)=V=K;G3$&
M(;8.SPE9F#LZTPEN)/> MQS@>,[&<"7*<B%@82R\8"NUI]D&*6BFN\ITV3FS
M9F\*QTEK!Y$W5_%Q?)&_2!Y:'V$.;2!2YF>:NF2YJ_YH$[(P%EF9PG\O(<"X
M$.3W7K>]'O':UVU]4^OLPCINS=73*&1"VJ-DF%CZP1J$1&O5]P,EQPF?IZQC
MDM8HZX/IC6X/;2KE24.!IC,B"). (?T:D^'RP^#_ '?U8#_LP+./C\<_'@>W
M@. X#@. X#@. X#@.!XSGICKP.<%6]PJ)6)W#+VT051=?'G.NJHB5GUE-7$1
MR9!<*=.]O$7MU/%P'X"0N2US)0HT S",BR8H+6XSCPD8SD(7V [I;#%MD=2J
M9H <<L]EMK=)?I_=<@<(Y-"V.&R-EAKE)I0C@L]3900]^F406I$Z-R0A$M"G
M&IS@7A$6+& FY+W7]&ELJ30Q+:ST?(%EJV#121,75UHF)U5UUBW?-I94R->"
M'B1+Y^4WXR:E;2##3UP<?Y&!]<=0UAL[CE>6O;&BJ2@K'JQ_I[;,.P(1&2U@
MM)MLR2KJ79\^O8*S1IV$E@:I)$Y*C4E2)%(A)#BR @PF"88+@;M5W="TVO60
M,D)J"U#I',YG%+@DL"0.,!L1B02L5%N)K-:+8S+WF,MJ9X>(0Z P%P0I3#%8
M"\^((,]<<#0]2NY55=O5-0JJQ;%KR5W1;L%Q/UR'7J*VJ^P)/&7&VG6H8])T
MJ:3QX$T88RY2]$%MRI=4Y(0KBCQBR!.$)G Q=:=W[5"55C/KGG"Z:5'5,4VH
M==4&.:3> 39.U26=H7W$10"PH1L*LIO-=Y6C6I\IQYR:@***$L\@1V 8"4GO
MNEZ1QR())P^VPO:& V..\V=/FE?6&VO,3KUALT-..EBS2-N$72R*)P5-8Y@&
MW#DM2E$#,%@8<B*P(> @O:;NEP:GY[LQ1\'0!*L>@-20;,N-G6%#K'<J&CX9
M$J-(A IHYU\QN\A,@YZ)(H5N#FC#Y0/"$@D1BCS @"QAG<'UL@K+ D]L6S%F
MR5/=1T_;$W5QMLE2V%0B-W(O:XO"YI)G92V9-@T%F\Y</0,Q[WE*>/'ZC@@"
M T80]+EW-=,6>X'"B7.U52&R&>](WK8]-JJ#3PAE9+GFC&=(H5"W>6F1L,50
MJY@TIQ&-AHUGDJ^G0 \YX%C+CV$JNATT+%9$@,;G:R9>G@%;Q5J;E\@E\_FB
MAM<7G]N1&-LR=8Z/"],S-"M6HR ORDZ9.,PT80XQU#F==O<NDDDO72NC-)@5
MY816YE>6]9D5N><L%BOM7HFVK<MY(& T$-+;W9$K5+\K2'P\W.3(X).5A2GP
M([K@-G[EN\.QVB)U2VG!Z:8;UU\0I7Z5;7M[,2^@MFL:IC+U"&-_LVOL)W7Y
M7)43*IG!1RQ"H1^,E,GR9DS ,C$4$VP?>JJU[,^6^\VS '^A9O+*:B.M;S#6
M=Y5R2RGRY8:TR2,Q1(42ZNW[DESNYN@D:5$E1I#BQ)S,*  & > AI#_W6=:S
M))IVQ5GF;6VGW+G]DPJ$NT-A$L6)X[FG$#O_ '/!(T&6C#RCDL2D2 EN5-64
MV%2;)QB@[!:8G)@@F)P[C&G#.&=G/%U,#6V5W';-E3U(%Z-Z3QMT8Z6D[="+
M;5PY],;0M\T%7<T>$C2YEMHU R5RD!8<#ZYS@(YNGN8TI4RG6]"GC=IRMVV7
MO\J@HHT-E;3,IR:GIO9 RF4N3@VF,HG!8!NC&0J$)*,I0)UP:$:;(R &F@";
MXWO%K'*;8)I1FLU IG*R=R^J6L(VYW(CKS;%?QM#,)U5C1+#T((\Y6'$(PY%
M*W!K*4"4$!\P'3)A1H !ZI[LF!NVQJ74B&H$KG/)C6LOO2?N+@:HPW0:G(>]
M-$23K2TR49(W"4S>:OA2!N*$8$D@A*K4F8'Y("C I? >X5=\L-[L*-5458IG
MOMU/P6J&,B>=RGY98J%)3ZFVU3C)I0;%1JFY6L;\%%%)TS7@!)GB+&8+&?-P
M%W-&[[D&TFGNN.Q\J9&F.R*[*CA]E/$>CXEAC,S+94U$NAK6UC<#U"XU(DR?
MX "-&(8NG7/3KTP$&-/=GT6?'EJ8&BUGYP=7Z86M7#&G353:HPO=FTHGRKL6
MLV8_]F^G=9\RI B-"V)Q&*%!0<B*P(/3.0SF.Z-I$;7]=6:@N,MXBEH5=8=W
M1DQCBDP>7DBH*C5#;K1L611UN8U#Y&HS G0L:1P-6$%& 5 &66 P0!8P%@Y+
MM'1D.H4O9V53M#'J,41M@EB*=/*)V;27!EEAJ!/%3$+*L0$R%2NDRMU2DMZ0
M*3*I6<I* 67D0PXR% -PNZ;&*KK2LW;7UJ'8$\L/<>$Z9R5OD$-G!XJ2GC\I
M+')"K&AS4F;Y$&4M#4H3GMK,(U.8[X4A-3#-+ +J$Z;%[I'Z4U)K>Z;',&9?
M<-Y6O5M"?***C4R?(6JLR;+  ?%S&!Q3+9(F86UF1KEB%(H":YKS" IB0#,$
M(00E%9O7JVV3I=7;M:*!ED+4YO\ ''0UY:WML8FR9Q.M0W'*Z_7R-6W%LJ6P
M(Q5@LOB]G&=A<F1%C\8,&@$7@*[6QW8-<() J5G46;K+L=#?EUT[35>!CU<3
M0)+NHN)%^YF&4HSS64.7AE/@:54Y(@H,*3UYY.$A8,'8."4%AP;WZLBLP52F
MVBA1R\J<XJE5EP:WI!'F^WOV+BS3*A<I6J;RXZ@LY- \Y<CF8U2!645C)8PX
M/QDK@5_NCNO:PUIJI.]L8RHFEEP2*I8"9'OVW"92G2SH^UY,OA=:K6!Y7M2=
MM51:0R9O-)-<"QF 28+\)@<'C)),"P"_>77!BE,>@DEFBV-S)Z%6"):Q/L5E
M+0HB+_=)[NAJ*+3P3@TD%P:468XL"LAE;W0294L,+#C ,>:5D81%$N[)H3-8
M_*Y<QWB7B(06&S.<3*6NL(L%CC$::X#-TU<R5L<WYWBZ-L#+4TR6DHB68LTQ
MT5C.+R008$P&1!N4A[D.H,2827^466O8@?WU8=9W5D60:<F2R,WK*VU.\Q6M
MY3$D4>52)A?).TJR5#?D],%.K*-#DLP77IP/KC?<3U*F%7Q:VXO91SY'9K8<
MVJ:,,J&*2P<^=K*K4M^56%"RJ^,9BY<0^0IMC"]8Y%FI"PI$J81@Q8P('B#X
M8GNK!I)L32U7H'B/2BO-L:0?KOU:M&+JE)C7-4,%)CZJ=Q%S3G&&EY<BH]*4
M#XW*@8(R<DRJ(-) :DR(P*Q]Q?=':K2]94DBCS)1SU!KSW+H;5Z$-CZS397)
M6>,6JUID\@L)_=FJ8-B!0\-4J)6@1MA2,LD:(HL1I_C'GPAB+Y[@]T:=;)ZH
M5'L:S5@N@5W!W ?)U,JVBEE/$@:8+0D.)G%>R"+1)M=)6Z"=W]L59*>T REH
M4PDYAI)H2LX\(64E_=/T:A#-4[\]7/A2V7M3CW?5.&QR%3V6'V-6<<2IUCR[
M1E#&HRZ+ECD@(5 $8W"+ O#C.<Y*\(!Y"$C,>_&I\@E"J)([;:$JY*DL-1ER
M>4+PQ1I0JJ".,DOMUD1R5W;T;*JD-6QJ1HUC^A =E0VE#'@T.!D* E!O5)[3
MTOL8&4D5!*A/[K$FB&2!V9G%I>(V\D1RS(Z*55I*\-3\A;W R*SZ/XRK:UX2
M\DJ2@CZ9P,L80AS,<-S-ZV_?&(:$'MVL(9_*=(95M+^ZP1:R#&%MG[+, P]#
M6@BL6(6H51@U4<#SWC @*.F!" FZ9P'@2JU=S""UC-MKTFU-B53"H=K[9NN%
M2 (@D<M]\F$/G5X0-"YAC]I@/C2IH5YD4T&<5'EC%E2C,;1%"4F!-'C&0F&-
M]T?2J4S*+5^WV@[(Y?++U=-9TC._5Q8T=,9[W;49CB164L4/461)(G)WY 7D
M]L(7F$97%=!%=<9X&T.?<8TU9OWX>[W.Q-K;7<>LN5O;^N;WI/'G1BI>4-T(
MM=;#WP;;ANFG]O)L\)&IS V&*1D+E( 8P+&?%P)[B%ML5M0"0RZMU3@ERU&O
M30$4LBKXT&HGYL;25_@6,;H%F6KF\1*T@TLX@W!"HDS R3A!S@60X&5IWJKW
M0:.T%W"[UJVJ5-%V%LN]:\7#'*U%,&>:50WXLN35A&K285LA>G]LFK4%U8B3
MG5L.*0'E%J?^'.,\.<<#LL\[Y:LL5P-E&+;01CG[I9;52I)*-I>ES FN5_A?
M]Q8]5+G*4J R/M<\D$(_YBC0'J"QG$YQC&?'G ,AS6K[NIVG*+?TQ@Q9="V#
M%MF-HMWJ+FCW6;9;297"&K5]H.?XRC:T<U*:')38QB;):%_391*$(EH190F"
MP+&,!T\HG=;7C91AA4FI>7N<S89\_P!DQ5@<RHA+&PH$@J)0!%83:_$O#.A5
M1@^/N \)Q?,"TV#5&<%EY&+.,9"UH<^((1=,X\6,9Z9_KCKCKTS_ *^!YX#@
M.!X\(>G3ICI_HZ8Z?]G 8QC'],8Q_C\/A_7^O \\!P' <!P' <!P' <!P-3G
MB:9K(7*4E=.#"T3Q4Q.:>(.TH1K7&.M<A.2F%M;B\M[<<F7+V]"K$$TP@HPL
M1P0>#QAZ^+ <AK3[6,P77'H9LA15J--=7CJ4\.X; ?)BYVA8C);E?S= (JS:
MU1H':6X'%&68O"U:X^:1CPIE2G(L$"Z8Z!#43[-ML0*R*:%%[TKLVF:-[DUE
M=P2*M3Y"I4LL9UQ;#8ZDR&L'IY)DQ+$##&XOBK*%T+3B$<4(&3B B+R$P,K
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MR;69]IXF%O\ 6SK('!LLIPGC+,4=CAD3%*8RI=$9;>S!;@M[@!:E1A--4IR
MJ1X- &C;%]IBU+DF6TLMCEV5\Q#VR[=\,TCFR1ZA$C7!BC_"U+H-+8$5$BDQ
M&53.O)>SO,;UGB/ (H& GYP(0L!J]I]E=]LEAL^*XN6/M+1LKJOIQK/?ZO\
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M0)P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P'
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MIVZ04;"X/6+#?0_E$S$334P:DRF$VHM9,N23!,U.@:EM6+D.3T1Z5=A03@1
M@XR%8KP[9FW-CI=HIM'8Q%DSCL5OUHUL-'J@=;!8DR.NJXU::X>BG#RX/*-*
MNCQTSG'R(U.G1H,F &F3)?4'ASD02PZ2=UC52U]L]=JTB5,-<<<YO6FT^N6P
M'[9DSZ1'$DA9*HGJ5_D[ D?34BY A>%3489D@1P/3F#+\ A8P+KP*EL';UO
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M018"/KC ;X37<SJONK[!VPXM2E[B>TNEU:0RIEIAY2)O'9U$R2:#DM5Y=EF
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MC#I*6+7"OH-:6Q,H;G)(B+KB'6$[O*)A$A:ST9QTJ>DS'&W!\7) &I,)FE.
M>###CBR1!NTNVLBD8V)H;7E$S.TH>+N+FIYDH9CT/[8@9$5KIXL9H*D!YO\
MQ*MUFK2S'Y0)$^,F (+RH.R L16#0]A>S42=ML4VJC;''=U=!U%+[1=YW@23
M,/;UL(E5=L"ZO@EF>)6OE:8JQD#@IR7C!2$H10!YR<9D  W]_N%N;K4)J!@;
ME4FF*.!*+.E#<A-(+Q&H8)>N9(^I4B/R'U#S-)$W*4;6D\9>#L(E1PS  (SX
MPKU%MK[A?#]@XDLU.FZ2WJ2%7*AAK]LL2$/C%:*"TT[@ICORFRQDM$7C+DQE
M-"DQ^2KL=6LG!)H#%!2D@1@1Q'=^Y");EDMG78^E9^MV)CFL,90R>W(,_P 2
M=9T_5<?< @.5E11O<V=C3HV1,6C*29*4*5KTI(2% \P6?"$Y0K;V-R6,TM-7
MR-/$/BEV3AXJ=D=W(].>E:[0;)!)(\SLRHX!"<M?%K!6Q-4"//:?J0O,-2 \
MHO*LK@7$X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X'/&YZ/MF)[M
M5INU448(M%,"@9'J_<56AD#-&)1B$KIX@M&(V!7CC)5"&,N#S'Y.E5)7)L6J
MT'K$2PLPD_)A'E&![K_V(O.OG2FF=M;:TK%;<#Y;;2E)LD1TQ<8\BKRDIC93
M4Z.0(O*V)B,6.+Y%PIU*9,L/**2'@Z*,FYZ!"BSQW3[:8H,Z/#HKHL,L<=<X
M!LE"8^@0/V!N9$EU[LZV'BKP"<IJ0C6.3?(*[* %P,5)%1Z!?DE,WJ%@ >(+
MEP#;V:R;9R&5:^.]:(ZMM.$,DTKB3MJ)R4+'.7F5^CE$LUX6O GP31BS&1O>
M$<H3*0%! KC8QE83>I*,-"&-D%:2IBW&V[<'!I+D3+M)J'6<7JPA>8B(;'.8
M5)FWV675V>L=,@;$JI6DL1M="BC19">G.5&8QG"<WH'/Z8:K3&CZ!E#O9];Q
MZKZ[;.T%'-3;!7,%C1"*EGWPCE)"5I1*GYB3N&"F=0O>/)*?U:8U(1ZPSU 0
M$C/%P+":DQI\GURS1VD59*8_+Y[(J.LR[9JVS>C9C7KW'*0@G[4K*+1L%-26
M4$,[PYS-E2.:Q&X&A&H2E9,+Z$%@*"&-@.K&U\>LC65!+*BC$E(U[W>V/NZ0
MWV18<5 KLJL+K8;F!'GPIE7>.:$3=IQ8K>U.;<J"6G\MK+$0H-)\&"0FO3:)
M[::\UQ)JO>-="0+Y9M/L#8Q4U4VQ7*N),5?7/?LKL-"_.K:W.XI0L>&*(23J
M<VI4XO,7%>4$_P L7FA"9M2H>\'7[O?>V"QIX+=5R5VV5YD7C\I_;:8IV)UK
M))JB_2$HUL?)@@7(TIX/$%2G:P&A$(L8,\"^W <!P' <!P' <!P' <!P' <!
MP' <!P' <!P' <!P' IWO-7%E6O0HX95D83RR5#MBAI2%L4OS1'$X&*OKH@L
M_DBH;D\FE)<GELD9/P03CJ(Y0( /@'.1!"J6S&FUOSZ1[TMM?H&9;&^X!2%0
MU>]O[H\(D)E1R&$M\FKZ5/#TWF'95OC(LK:3 5(0-N%!PG5$,DT!91P3PAZ5
MG;_NJ+;"ZK3F"[(6"]5U6=I6].)LBD;%3I;HPH)?4#U!V9$V+00,+[)P+"\H
MF''JE!QK>T! (D18B0"P&R5?I#>%6;ATU:6-B9S8-102C;VB3X7*H_42!Y<)
M195DUA+RF1P%'84TO3LFDJAA6.R]V$;E:%:W$%^;@M0:#(;^W1B7UEOOLM8!
MS0.1-]^:TTMBI$IBY(U)WJ;40XVP5*ZQ*>W$.6]H<W)--VMP3Y.Z@$4J4G=/
M"F.Z!E]=J&D,0OR[]DBJ]?*617?7U>)YA2:^=M<PP_W%%5DG4/-GJQ,;\_0]
MD=EL<<6YA\Y$HQEP3H &J"R_++QD(PLO428V%KG6=4V/!(_:,9G-OO\ :>YU
M4!=&Y$LL4F>$S.2J6J,2A<N;R"CJ]L5U8SR!%+4!ZE Q@+3J2\X" P(VGE 6
MZCU2U6U,D,F<YE9:7:NF7R-/#NZD/LNB-!T?>Z6VFEQG$A0DD)WE]@%1Q5"Q
MJW0& @<'@T@&##!G^8,.RO <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!
MP' KA:NQK)7UH5S1<?CKO8=TVBTR651V#,2MM;2VF PPQL3RFPII('8P#?&H
MHW.3RD0DCR$]4O<%19"8@T6#<EAL->3=193G-66:54]0B05V^H&0Y-*_VX_(
M'Q,^1M \DR*&O#2>L3KXZJ N,1#,&!*IPH2'%FD \/Q"3112*#R7@<:CXQ%9
M)$3XF9N%DK*< R4^2^J;/@].4<( .G3P!%G&.F,YX'U_(V4ORA@:&P(TI^%B
M7(4*4.4ZLLG! %)&<%8P2I"0'!># ]!>#& ]>F.G BMHMN&RV7SB/(S$:EOJ
MB0-$9E,M7K&Y-'VVQEZ! ZEPQN-5F8RJD36T/J,Q4,&<!3F+BD^,C.\P!8;F
MKE=<O,=6N2Z2PQUB)QBUD<EZIX9%L9..P:- XLZ]6:H-:C30G8$2<G,%D6!=
M0"#U^' T%,[UG6IE<0NL(I%4B*QI2XMK8VUXACS,Q(4S5'G*0R"3J2&0@A":
ME;DK:42/P8\P9ZH@&,_KQP*N7WW$X31$DOEC-@[O8"'7[60[:"5/,+EL+6?,
MHR@F#E$GN)-R U> :.7M)K68?Y*XQ,6<7D(0"\6?@%R/W@_K:V3S<J%."U>L
MBY$C,@I"]K5.YY*I&6N&QHUH?^5KG42(P02P>())Q^,%^9@(O,X&0JZ=PNSH
M%$[!KMR2.T)E[ V/<:7HB\IR#6I21X4Y&48L!&WJ$.0"(.3B" :<XL10PX&
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M3[W!=;[2U[IQXLK,302)MN^:CD;A/9ZJ45N[RB.!:TDL+9"$2]L7+0^E2#"
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$C+__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tpg70b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg70b.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@"" %F P$1  (1 0,1 ?_$ *T  0 !! ,! 0$
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M\J-8IRTO1G9K!6I2TUINE 6%)>QL(AB\DG+:&!U%(INY51DP543:@(+'(43
M7CUP*'H_>G45P:,+*X='JE+D]<P]]9/K0WEXFSK'F9YY -H=O4G,020?G7>-
M?%!1J98%SF\2 /QP*TFNZO6:O1E<EY7:$8@SM366>Q/RHV;=N0;5]\G&SZLD
MR:1JSN&"">*E(\!V1$S;GE0"AZX%3;B[(Z]TM6*!<+'^=S,!LBZ56EUMW4(:
M0M!EW-N\S1LD9O#HNUS1HH%\_,I3"("  '(\8%L4>]>@H9%<-D76$HK\)NTL
M6K-<\M)!^35>81A74[*+MX=,L(@F[7(5P1R!/ICF IC<\\!7*?<#KFM5)2YI
M;-B#PL18$ZJ\X;2?YI^?K-OKF\<VA/H@EWBCB/ 7*9DD3D.V**H") \L"X$]
MN_5=9U_&;1F+G$(46;)'F@YY!11ZA.*2WI&M85NS37>2CUZ8!!-!%,ZIA 0
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M=:..L@1TB^3CQ0, FX %.>!XP,!.U7MG46PM7]UU\G*U.-J^EF] K^M-/42
M^L/9(VXQ5QC[4RBUW3".D_[_ (T <L# G]0F8?YT#<#@8\Z3]O/L/M><OF^;
MY=W6D]HN.PD=L[7[R>UK"D"5B&FO34*6/8M;-K NC!_F+)<YFB?Y@99!0GF;
MD#<8&5VJ_:RK]+8J1ETV2M=FC[K).]<I)PA66L+)&3L%GFK$]ML8]!T[4C77
M,P) 0(/CRGZF$!' O_TFZ9DZB0MFACV*J6I27:UZ'9S,%1U*A,O(.KH.6T4I
M;71Y^:+.S0HN>#K)E;IAQ^$GKQ@>;3^F=F9]NENU5VV57)"0BX"PUBO5VA:\
M:T%Q,QD\\*X(OLZ<:S$@XO$C#H)D2;'4(F4O FX 1XP+R[3ZT4_;FXM4;.N[
M* L41JV%MK)G3[! -)EF]F+$K$JL9Q-1X)TF;F&/&B).$C"8Q^>0XP,=K!T.
MFCWG8NQ*/MEG7+'LQ_L:.G49BD-K'#H4+8Z,:D_A8]B:4C_IIR*^@$R#WR,0
MWEXF3\0P+SZ/ZQN=#VZSNJW>?S/7-HJE*AGM4E(0!G4)FEUQ.K-I5I8TI I$
MFCYD3YBC?Z7DJH_A/Q@8X2GMR/YJOI4R4W""M0IT;=8S4S5M2VS29KR-^L+2
M?F5+7,A*K&M(MBM?IVY2IMP]?F&Y,&!?[MAU[VUOFJ4FFT#;T'KRM1,HT?7J
M"L%'4M\9LEG&D2%A 3I&\Y!N48 727S7#=-0 << 4P^/("%K[O[=>O=DS^M-
MDVV26:[>JMJU]8;K:*9)W2JUNV,:"11./K\73&EL4B*W&E1,4B((@840 1Y$
M1P+AONE5+1O#>V52<FXIF>C[8J4I%6"6GKNJY>;0CD6*LNQ?VJ8DEXU**^68
M2M$131.!N. P/4G>K\HZT?H[65=OB,+;]"2FO9ZJ6]U7RR<3(RU$2(V\)BN$
M?L_F,)1N)P,0C@IDS" @/IQ@6.=^WL^F8]Q5;!MXCJB18[7EZ0PCZ4V86*&M
MFWXQVSL$A,3WYLL,U$QKA\JHV:@DB8Y3E*HH/@ X%*6'VZMA7.\4V]73?D3-
M2%-CH9E&M@UQ\HD<6,ILQ25V< X6LKD(6*D&$F5RLFFD*BKI/DQO ?$ R>LG
M5^3D](:7U= WU*(LFDI6CSD#:GE?+(QTM(TU(S<4I2")(,S%9R:"IP,":Y3)
M&$#%$>.,#%V*]LT*_"7^OL+IKF80M?[1A#S%NU8YF;##IVZ84G)IH=Y^V:"(
M$9R:HK,5VZ:+A)4I#"81)ZA7#SH7;?GH.([?#M5TA':=E/S*QT].?E%]CZ30
M,VK5D>N%9I$KZ%DD%#E>,50,H;D!*MSZX'ZI=#)U2V5"]/=L1B5R;;/E=KWR
MUP-%_([%+S,N9%%_7:E(MIX0KE-DXMLFU>,5R/2.?$53#\P?0*%)[:;]27IL
MI);-J]I;TUE-4]I#V?7;AY%.]?2%J&VL&+INTM;(5+'&/E3D%SS\A<@AY) (
M>H7:;=))>MU^GJ4+9$9!WVA;.V??Z].RM';S%>58[32.SF:]+5P)1FJY!@S$
MH-7 .0,F8GJ!BF$,"E:I[=453Z5>*=&[#5=A<IW45C4DGM;:?/9RFM; ]L<D
M)$DW'@5M87[]3Y291 &9>"E\@# N%UZZ41F@-J6>],)N GX>0>7!_6@?5=VG
M>8$;S,$FI>-<6HT^Y:/8U)T @4J;%$ZA1#S'\/J'C272BRNH#9>NF>V6;+5]
MTO,CM6O1BM';.[36-@NYYC:&RSN?"40;6"O,IUG\P6J[8JBR)Q2%0I0 V!^E
M;Z22:&SF6Y[KLIE9-@OYFY3%P<QM.;P<%*#8J % AVL1$#(/QBBPK$A5U%3*
MJJNU1-Y" #@4_K3H=/ZGC)^J5;;[0U&V73&U1VM"2=%;NI&5%G'R\0$I49I*
M7;KUQ5Q%2WRCHJ$<)$.F"A  PX'PZ?\ ;R::OD=9R"]NJ\@OK"\0M@CY*+HZ
M\9-V2OUV FH**A[*_>V.6(J\3"7^;\Q!-)(ABF\2<''@/)>^W;,DAI& @MOL
MX^*LU"NFOK:@[I*3PSV)LFP)#84<M$G)*H%C7,=(/Q15\BJE53+R %$1P*@O
M70>4O6_X+<+_ &RC^S]==1JD54%Z:BYD8=DE0WU)F(>OV 98B</&2!'@O0(D
MU\A7$P',8,#PTO;VM:BE'EI#=;)Q9]25:H5S5<FC0$DV+$U$MLC8X![:8E6;
M63G06:2 MW*9#H@)@^800$ P*QKG0_\ *I"PV&7V(VEK+=:+NVNW!XC4V\?&
M.;'NEP@N]FH>(^N<IQD=")MB$3:^9Q6X$QS\C@>R\Z+UZ/HM1CZ-<9BO[*I\
MOK>QL[=,OK'::N\G-=&;?3?,H<G8?R>,CI(B!@.FQ^F$@F >1\>!"B">WNHX
M'8CB:V6TDWVPJIL: >&"HMTFC5_L.Y,+@ZD4T#O7!C(,G#+Y94?+\7ER)O3
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MK.F6$AK6G[7LUWF9RQ2H05M<:JL#:)6:ZW.@[34>(6)LX\DU%#*_2*@(&*H
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M8N&==<'^^6S)DX>1>JFVQ9*H(2S15W'N7E>"::Q#U8AS&;"Y$0!,QRE$Y!Y
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MR>K]?0)ZM2=?3#R78*.I)N=B /'RA 34%T;@IS%#D0S,_J_N8# 8# 8# 8#
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M],"6KVAXVV1W4!NM8U%#0DWN#=4]K1)4!*9#6<IL*:<5(J93)I^#11F(J(@
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MECC(?3_96)ZXZS;LB&G)6N:]873:DU*B=05$F#^S+A7(&+2)X@42HK+G'GD
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M('D6Z_RWR2+8O\\4"GY^W JOIG_HD=9O7G_R$ZL'T_33(<<#); 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8$-GNZ1B\3J<EMN
MMW<6/44_-5>C.^O;S07[Z8^U7*0=.CP4O%?LW,5_8D1)IJD,4ZL<Z**1 \N
M]1$+8>S[V^T=/1TYU9K.D&G7>X5V1FI*+KL70[Y3X6]*196X6:34/?'4O.I6
M9D99([AL\=J+ DH!BB)>,">$H\AS_5_$(X'. P+!]K/]%WLE_@#W#_D\L6!X
MO3+_ $1^LW^ G5G_ /1</@9+8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8'4YO HFX$>..>/NY]1_K8$3_O O#-.M-6&#@+?*[-
M=;@I;;3DU3MAP.JW-1V*HH[-"3LE>+.W>0,7&@F4Y#D<HJ$6$P%],"RGM6]4
M+;$NGG8'L1 V^'WQ!2UN8&4ENP5:W:PM,C=6T:%BOLNM3F+"&CYUVPC4&2*
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MN!]FZ8-OIS97C%RT_+;836(:]>:L2TZH9MX(!,EM:< 3\P]4P;F<C\H1\/7
MS8[.=4-52O02?UCM&O,-C$T5USNAJM(R0O6@-[+5=3S$<C8&Z3)TW$%5#-O(
MI%!.0 $.0$<##Z-,8\_[9!S#R8WMX=D!,/WB.G]1\B/Z1P) O;;_ - GJ3_@
M+H?_ ('1P,VL!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,#QY^:AZY$/YZP2K&"A(EJL]E)>3<HLF$<S1((JNGCMP<B#=ND \F,8P%#
M[1P-3?0L94%NY>H[;"SG78LU*=GK3(G[BU#?;^P;<WS$2[R9^DU/(:<;"=Y%
M,W!.&JCEUY1XIMB'2'UYP)+_ 'AMH:B4U,C0;)>:6A9]9W#7>W9[5FS(>Z.=
M:;*KX2#YM&5*Z/:M#2IRQDL\2'P+XJIE5( JE\<#U_98=T^>TEMN[4R4UY'Q
MEZV[)6,VJ-/M+4TU9J)5Q&LTC5JI?M9%Q#M<KGY?SW)FZ)&I53<% !YP)F1
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MQ^TX: =6>5J3N1%!VPAF+0[]ZX<NE$BQZ3AJP(*YVXK?4%1_'X>/K@4*7O\
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M;#!V:6CB@FQ<*S"!UDF1C*F03/\ RQ V!+E@,!@6$[5@'^:]V1#[/W";A#X
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M&)0E).G15H2N;&&!V4%VB"5D1C(=.1,=HH0YA!NGXF,)>!XYP+HX# 8# 8#
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ML'K[VGG>[M9[#HD:U;WXFV-7VR&/3'I3)%3"<6=,U58QR@N"GU+)R=+_ &/
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M8%K-H:/T[NB)/";9UA1MBQ9^?[TMU;BYH$Q, $^8W6>-E7#98H<>)TSE,40
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M52'.R:NI.3F'!3OF2+YT961F7;^1<&4<N#FY44-QSP'H&!> #"/P#[OM^_\
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MCCSM,<3,?8EJW)%0*DXBU)V**G'RID#$_P!N1*5,X#Z!@5W@, /KZ#\!P.
M ]0#CG YP&!U.(@41 >/AZ_=R(!S@1<RZ>_GGN<5+8B/6^W'TS :5L6C'.V?
MVKJH1:CB?M4/=T[<E BX_.3PC46!F2B7C\_YX@</P /(2C%Y\0\OC_5QS^GC
MXX'; 8$<_?Q1,EPZ" =0A!_SYM=&X,8I?PEUYM(!,/D(<% 1 !'X<B&!(MX@
M/]<?4!_2(_V\!X%_7_5^C [?PX&"7N;^(= NV'(  ?N=L?XC !_M;\!P8!\A
MY^'Z<#+R@B0:-2^?LJ-:_5ZPS/X<?HXP*P$ 'XX$=G?D "V=!N/M[UZW_CUU
MM7^Y@2)^(<\\>N!S@,!@,"$?WH*3HAIKS4FZ=R.-O-34?83!BP_=MN&9U+$F
M:J-9"1>+V!ZQ<)MUGI$V_@Q$A?JU%C@FF8.<"H_9BE:-*:;VJ>LZUM&O;$;9
M"4A<#VG:\_N61L!IB 82==?/+E8DTGQ95"!<)).F0ART4#QYX$,"97 8# L'
MVL_T7>R7^ /</^3RQ8&'_LM?^JBZ"_\ -KU[_P"#S8$GF P&!U A0^ ?;S\1
M^/\ 7P.V P&!U\"_=_&/]W Y H!\ P.<!@=1*4W/D'/(<#^H<#D"@ \@'K@
M  ^']D1_L_# YP& P& P&!P( (" AR _$!^ _KP'B'PX]!#CXC\,#GX?Q_Q^
MN P&!BKO_I7UQ[/6.IVW== &XS]&1*E5'PV&Q1(PIB.UGA'+1"'E&+<'I%G!
M^%A**@$.)?+Q],#)Z/8MXQBRCFA!3:L&C=DV3$YU!3;M4BH(D%10QU%#%3(
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M+@XVKU2O]R-EQT%7H9L5I%1#!.-@CD:1[0@_*;(%.<1 I0 .1^&!)V'IZ8#
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MX7\?P_-7(U\C<?:.!6^ P.IO@'_9$_[LN!'5T&]+=WJ_YZVS_P".+KXX$B^
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P B ?'^K_
M %<"+#:WN76G5^P;=1T^A_;RZ,JO//8-K=JU5ZN%5M(,N/\ OE774G863AXP
M7Y_ 82 (\#@9?,ML[%V3UT9[9U'K8C?85BK83-<U=M:5"KK%?%<F0<UZRRL5
M^9H1+XR:2A2JE^<D102^7(<A@0;ZGT'M?7NW6MMUCT+[JU38R5U?W)1OL#NQ
M'FZOH6>8?N'<I(.HF,D7@S%9%TN97Z).-1%0H@' &]<#8\AG,L2!CG5G3C64
MT$4U<3Z,>N<\2RD@:$4DTV3IT!%#Q[=P!P344 !%,H";C Q-E?<"ZI1E$MFR
MD]GMYVHTW9;W3\F^J<+.VYR]V)&H).9&NP$=7(^1?SR[%!7S5.V343(4AQ$?
MPX':)]P3J--WNI:YCMPPSBR7:HH76!,,?-(PAX=RP<RK=%_8%HXD/$S*T:R6
M6*Q<K).A(D;\'(<8%Q] ]I=(=H(NQRVE;A^U;.I31(6=!6'FH-TT<J *S)TF
MSG&$>Y=14FW(*C5VD4Z#A/\ $0PA@8W]!P,%O[U 8!*/^>KL[T'_ .*Z_P#?
MQ\<"1; 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M U8_>*M'5'<78UO3K;V-TXSO6E]4/G8ZEVO8MCU>MM[>SLR<B2,<RU/;"F22
MML.LHV,7Q.J4I$C$'\0X$V/MO$8H]%.M01;AJ]9%UHR69+-V<LQ9"F9R^620
M:I3A$Y;Z1OY@FFJN '5(7S_UV!$CUB[F]A-L=NX:"V)WAG( J^Y;-5G_ %4:
M]+;/&0*\9%2LC'QT*PW:^CCMS1SQD@FO^9F6 !'GCTP-DIPV;NVZ[-T@DX:.
MDE&SELL4%45VZQ#)K(*$, @J15,PE$!_E<X$/=SZ0]G*=I7L7K;K#9]*T>7W
M?V2DMBL%Y U@K[:HZCG(B)BYFNP$A!UV36K]TD"1ZJ/U;9N<J*"YQ*?S'G L
ML?VIMPO[U7V:4YJ6BZB?0M7FK,PK3VTRUAK=UJVO)BC-X"KJ2L>W_-ZU)'EQ
M=JO':R3H3 ;E/DW.!E7T^Z0;0UO6MRLM]6V&92^QZEK[5D4?1M@LM<<QE'UK
M#JP418F]B,A%S$-;YA)4%%3-?1L("!5#<^@8Z=2>PO6/H7$]LZEN;=0U9B7M
M]MB.I;O:-GFK-=+LM&QU>X9'GY%-](6"?<KN$T4_G*"NL<Y2AS@2 ]0>\%1[
MD)W=Y2-7;<I,/1I8:^_F]C5A. CG]@219.W4)''*\764D6;"2;N%"'(02I+%
M'XCQ@9MX# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8'
M _ ?U#@:]'NQQ[4O8'73R=0WE"4U345E>-K#U-U_6;IM64V<SFDB5YAL@'$=
M)R[;7[8H)?(463*T%P90IU"\8$IW5C9DI&]--,[$WY::K6IH==P:EOLTB_@(
M6 9O%CBPCU))RR63@&,@KYMTW"2)_ KPQB!ZAQ@0!]8[_)/?<"I%>9; G5-\
M$W?=G6Z=LR/;2F6S3NUM5/594T)2*)J)K9G:_P"<*-UVJ2#)".;N&"B)S',;
MG VQ"AP'Z_7X<<?HX^S YX#[@]/AZ?# YP.IO@'_ &1/^[+@:Z=U8L75<W<9
MVQ9NCE]ZK3!$S.6J"YB%6V;04E **B9A #D]#!\!#TP.\'L;M#K38FP([0E]
MUG4JMN3W6]GZ4G8VX4)Y9I!B\FZC69A*P1SIO*L4$6[1C F1^G\0$QU0-Y !
M>!#8A8D<D9M2/%4UG96Z)72R)!226<E3*"ZJ21C',FFHJ B4HB(E*(!R.!]6
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P ^GK@08]Y>
MNOM84[?AMS=N]TV_5=_VE6%V05YIN3:M;CIV/8. !>49P5*>JJ,&X*")%"@5
M-LJ<1'Q$P8&?-3U[J"]=+H77_5Y36UAU2\U^DUU YV!!OMA:X<D8.5',0]LL
M+.?*DYQDE+MQ45^:(+@L7S_E%# UG^E6RFTKW$TQ1[D/5EKL:M[^D65EO&H^
MALC!V.Y2QW4Z1JP9;S<0S>KQL&^^0;P?( D[,1OX>9C>0B&YF #R(\^@\\>O
MWCS@=L!@=3? /^R)_P!V7 UV;=_XN;P_Z[#27^4Z@8'V,?\ S@5[_KW+;_DN
M)@;#1/Y(?P_V1P.V P& P& P& P& P&!A[W'[7NNH=!C=CJZ7V!MZ <S<=!R
MX4)W MW%?=S<E'PT$:02G'K3YJ<K*R::)!2\O WJ;@/7 R;IDY(V6JU^P2U<
MDZA)3,2RD7U7FE6JTK NG2)%58M^JQ46:*.FAC>)Q3,8@F#T' J? 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8&N;[ML[:*1VMT];8RY[RUE#.])V"$5N.A=$5
MC=TQ(2!+09P6"M3.U-UF<;'$14!9HHC^,%!/Y>G&!,GU$E%Y[K)J&4<3%HLC
MF1IA%5)N\5*,HUIESG6>%%U/5"#!.+@WS@?51!$H% /7@!' @6ZK1VKWG8S3
M[_8O5ONSK>^5C>5W@*U,P47*MNJMF?!:;$ZJEDF'LK.KKNV<$D^<J-B^/*(J
MF(4HE  P-H</A_5]_P"H,#R)VP059C5Y>QS437HEKX?4RLW(LXF.;_,,!"?.
M?/ED&R0G./  8P"(^@8'G%N53&4C87]J:\,Q,,3RD1$A.1@R4K&)E RDE',0
M="Y>,"$$#"LF4Q.!YYP/I@[/7+0@Z<UJ?AK U9/E(]VYA)1C*H-7[90I'+)P
MJQ77(@Z0.'!DS"!@^[ U^K?_ .+6[_\ KK=)?Y4:#@?0Q_\ .#7O^O;MGV\?
M^B\N!)'K/M'O*Y]S=N]8IWK_ %RMTK5$! 6]SM=';A)A],UB[K6%O1G3>C$J
M+0[>0E%:VO\ 5H"^$&8"4?)3GC SZP& P& P& P& P& P([/=.(*O3FWH_,5
M1!Q?]*MQ50-X+I%5VW3R&41/\4UDP-Y$,'J4X /V8%M/;YI=KBMT=VE;'O7?
MVTH_6^^WFJ*37=H[(D+;7:]5DZ53+8F+&,=)$($DG(SBY"N3#\P&_BG\ YP)
M7@]0#[/T?=@,!@,!@,#XY%ZC&Q[Z1< N9NP:.'JY6K=9TY,BU1.NJ#=JW*==
MRL)$Q\4R%,<YN  !$>,"&79'O0ZKB+$RB-.Z=VMMJ*:7=CK:]VJ;@IG3L!K^
M]23DQ&==FGFRX:%2<.A9$,Z5^2)ODH>)C>ABB(23Z+[/:([',9)UIG:]!V4X
M@",B6MK1K1&V<M8D7:13FC9-S&JJ(IKI*B8GKP)O'GC O_@,!@,!@,!@,!@,
M!@,!@0 ^[%J"G]A-\:QU;_FIZ;[!;(2U'8YZ F]K]D;/H$U:CE)I2/.6)0A3
M$;VHC5X8KE4@"99, XX\1YP)(NM_7/\ 9;HYK?K;L5TV'Z358T^T.=7VF:8I
M-CN0<K./V3N3-VC.)+L15\$7I%BJ&4)Y>@#Q@:\70?2_AV3U/)5J(U5,ZMUY
MN^V,:[';/]Q&^6S<5<D(V:F(T9<>O+ATO6'-P((G4(W'U4!3SY\AP-O<H" >
MOW_>(\?H]?NP(TO=+U=;=FZ!@2TS7EDVM+538D)8#T*"@8JW,IUF9F_C%BV*
MG2S^-0L<2T^N!7Y150.BL0JH<^'&!#;5^CO<N&GM7UV;U3:)C;#FF:_=5;?"
M2\:UA-.4^L5"W1MDU7(3Z<J9]#OWKN7:) U0*JD[$@")A!,!P)"/;:Z[[EIE
M/[!L1HULZFMK=!:ZJD G*Q4(]FAV75H%>,OFUXV'^L?1<@WGI4_S4UUS%^N$
MWF<O(8&+\17['5-3;0KMNNK_ &/98CWGM(-)B\2D8PAG]D=DVC0CGD7,5&"$
M>Q5.4P!X(_@#CT^.!7C(!+L.N@/H/].Y;>0_5JX/M^&!(3J3_P!9CW$]>0#K
MSU8X#[ '\UV]SZ?#G\(8$BF P& P& P& P& P&!'?[I7^A]9_P#"-I'_ "NT
MW B_V6ONF N/:6S:>[!7O2JTO[G="U98&E1BJS)MYJ(V%1-:,7\@Z"PQKXZ3
M^.;)>*'RQ*7U$1 1P-CZ'9.8V*C(YW(N9ATQCVC1S+O02(\DW#9 B*KYT1 A
M$"N'9RBH?P I0,8>  ,#TL!@,!@,!@:Z\TBB[V#;FSA%)PW5]ZG7J:Z"Z9%4
M5TE*= @=)5)0#)J)G*' E, @(8$@'MD0L+$ZSWX:*AXN+.KW"[%(*FCH]HR%
M5)O:TQ;IJ"V23$Z:!3B!"CZ$^P P)*,!@,!@,!@,!@,!@,!@,#6-]]AI0UMU
M=;7FS]7U]S46\2Y:+[.F:7L2WN7Z+^>^FD:%$+TEX@A!JLDE"2"P*D,X>)F^
M6F)1#G FRZ*M73/IWH)NK13:Z63UW'_)I:_YL0(E,1<G9E%*=6<335*20$C@
M$7!S+(D5\!_DX&NUU6J]W2]RQPQD.L\?$[ +N]W8[))K]>Z1 4>K5-@6QIV=
M[3]F,4RNWT@S*O'/&[I)5>0<N%S%7\2EXP-N7^K[\!Q@=?$H!P   "/(@'P$
M?M$0^T1P.IBE#@> Y 2!S]O'F'IS]WK@:6WN8>X35^E],W144Z]-6#9]S]T2
M3VG33-6R80<2WTO*TRS+N9=TY,1!==V\^2FBW*/X@ PGX  Y#%7VC=]=Q=I=
M@*_!=G;8#MG-^XAK#<[>N3Z#9G9'%\O5.MCJP6.OHMT4"*5DT$HP1733$4VJ
MORB\!SZAM:P4[/5?O[WLL%9J3R]S\+U<ZT2D13HR2C8>1L\BU?;A6;PS.4F%
MVL7'KO3% A%'"A4BB/)A ,#(#IAVBL/;K5([=D-)6W2E>DI9]'U%M;[)4; ^
MM+.'D9"%EY5 E4DGY8QNSG(I=K\MP)%5!)\PI1((#@9A8# 8# 8# 8# 8# C
MP]TG_0^L_P#A'T?_ )8*6']C CAV('+SLR7[3>\7H$ Y] Y&H:Y^(_9@2P-N
M]VCG79=UU-2CMM_OA9^:SAL?3U^3JA(HJR[8EA_;8\,%;&MKNFQTDWWU'R#J
MAX@;GTP,S<!@,!@,!@:[DIZ;&L_Z?>MUUS^G_P"1\#@7^Z]=GJ/U-ZV]@-J;
M%K6R9ZHL>Z/8Y&7=:XI$K=W$ @-J; $G.-8DAU8^*\SE)\\WX/,X%^(X$M6L
MKZQVA0ZQ?XV#M=<C[5%H2S*&N\ [J]I9M7("9 LM OP*[CEU4N#@0X /@8!^
MW KO 8# 8# 8# 8# 8# X'X#^H<"$_W/>M7<OL%L'7D+I!>:=Z3E:HK$[':5
M_: :^DX)S&S8SS]9BV(B#F0E;>R:-H]L[163.Q AQ^!AY"2+JI3]C4+K=J6F
M[?DG#_8E>I+*.M+QU+C./D'"7SQ;-W<VH 'EGL:P,FBHZ-^)4Z0F$1^.!K==
M>+LVD^[>F=#(W>E6"@ZB[,[(O%0WC2=>;X7O^RK%;W+].:IMLMLJT2UXUCE5
MC%:/W2:RK9P#5,"\<#@;:0>7Q'T#[ONP.V P.IO@'_9$_P"[+@:EO<*FZYN;
MNO0FP*76;>A9/?ZUW3B)V"(;2 A$32*#B<BB+*D%1-A+-F(%<)<_+5 H 8H\
M!@1A^Z=H;L]"[NC>TVA+DWHM"U5[D&UM9L%ZMX1%EUU8W:.O)IK92MF21!DJ
MI%U^+=**(%Y*W10. $X' VQ>O;Q62[S]GY!>:;619_T^Z?O5K"S*!&D\JZ:[
M774F6Q  /%O*&.*Y ^PB@8%QO:S /\Q327_O^T?CZ_\ ICV /]G D%P& P&
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M,#\7+ANS;KNW2Z+9JU14<.7+A0B+=NW1(*BRZZRABII(HIE$QC&$ *4!$?3
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M58R/4=%Z/;"7*[48MC.BKI;IU^FFN#DR?SOFIE$2E-SR4/0! ,"2+ 8# 8#
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MSE6I4UC@0'"9%6JAA#Y:I^0P,N^I\@QE.L?7V0BWK218.=-:Z.U?,7"+MHX
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M'L>J;9UY3K7$O;S>*3(KMJ]K.Q50SZ285FPSQ))90#-72Q' !Y$ @%$HA.I
M=]-O$A(>0OWM[]NZO(/8B/>R;.#@:;=DF+YPV27<-4_V?M+AV8B9S& /,A5
M]"F*4_)0#UC>Y;J>,$Q+EI7M]K]4H>9B6KK!LY)$B7')%1>QD7(LP*KQP "?
MGG[,#ZF?NG=(55OIIC;KNFN *!CIW>@;!K ) )/,PKJR-9300*F;\)Q,< *?
MTP,;^_GNB]#ZWTM["R8]C:!/.)[5MHJM?K]<D%9*RSL_:X=W$P["-A2H$>JG
M5<K@8YA*!4DRF,<0 ,##O:WO1](Z5[27[34?82>U[;,]:F^KFNLZNU?DM439
M9RDKTAZI;2+,CMJQ&P,@J8[E5RH'D4I03 WF&!EM_P"S[;@I>V_:CZLI4J(G
M(='5]2/J:Q$FF)6I9"UTYRHWG)>+<IB9*1C))TL*B:H#Y!R)3  AZA*!MCKE
MH;>RD*ON745!V>M7_,()2ZUN.L!H@5E4UU#,/S!%;Z43+)E,(DX'D,"/:#ME
MM@O<WE),G73=4%J!CU]A]',-IJU%JRU?'R5=M\A832'YR:0*#>J)1*R9$W(D
MX\@XX  P+B^U?/P$OU\NZ$/.PTLJW[&]A5W"<7*L) Z"+O9\XHU66*S76,DD
MZ3_$F8W '*/(<A@>KN0/_P#I-TP !$"AIGLIR #P4P_)IO'(!Z"/.!C[[VW0
MC7W<;I)N-XH,=1]I:YJ4KL.L[+CXA$M@6;T^/=2KZG2TJT%"3=5NQ-4C)+('
M.HF!RD'P$ P+.^V[[8^YM#]+M&5NM>X1V/KC^1IL7<CP\"SUU.T""<VYFA,G
MAX&#O%0L$DG$L$7!4BD%T4HJ )RD+SQ@9REZV=Z8@W-?]P1Q+ 40\"WWK[K^
M8\@1X%O\W]GGE7\OFCS\_P ?#R#^3XX$%/6GKU[K,3[^NQ[7N3<E7M=/B]+.
M%[#>8]A&1E>E](SJJK"EPM.U^9Q*N:Y+,KHB*IFQU3E(=,YSJG*8.0V!NIG4
M>^=<K1NNPV_L)/;I:;LN+J_34-/TBKUQ".M3YNT8/7[5>&2!=9!>-8(H_(-_
M-<$\N.1P/*]Q#7FX+QU7V+JOKEJ"#V!<=FLDJXY9JV> H#.&:%=-G_YR[?2*
M::+XI#M?E@D7\0>7.!C#<I3M0Y[,](+H[Z7[)<Q.G*;;879$S7;[K"2@(>0V
M#5&=53)&N7=A8/Y9O75FWU#TY4"^2(^*0'-@3-%$1Y']/I^K@/[. ,4!Y'U]
M P(ZM/>GN1]RP#T =-=:OZYD[D C^O S5V+J;6.W8->M;1H-1V!!."^)XNW0
M,;.M2ASSR@5^W6,V. _ZY,2F_3@1_P!Y]OVPZPK=KF^B6]-H]>+V2&EW=3UX
M[LIK]H61L'TRJD?&/]?WPLVSK<:[= 1,3Q:K/Y/(' ! H@(0E^R';?>5I%>[
M0OMH:>JVZ*.IORZ)N8JT[&AM?VAEME*87'9CFD*$BGL7(5Y9]\L/EK*-42F$
MIDC" B7 G:_S];[4A,3='1GM?K\C;YGUTK4:O ;K@D")%Y,[(\UG-R[L[,P_
M 10*< _UN!:CL![L?1:N:!W1*6[<#BDOV.M[8V-4+O2KE3[@]?RD(]81\9'0
MD_!M%GL@X>N2)_*3,8P"/(\ '.!77L_=B=3]D/;\ZWV'4UC3GV='UM4]96YN
M9!9L]@+M3X!A'SL.^;KE*<ATEB@=,P<E42.4P#ZX$G. P.!#GC] \X&LWW1]
MJCW .W^Y;[*;(VYH?:77US=9&7UQIR\IVZ BH>N'$!C8^>-4&;=](O$.!$Z@
M.@\Q'U^S@)K=0:)L]!Z@U+0:,O%Z=M%<UR-2:3NH3OGL517R/U!FS^G_ +7"
M^?.6S$#%,4KPRAC^I1' UJ>GERF8SN7H/7]V[0]DMS1,/LB3>25F-2]:U&N*
MVV8F;0PH\1=I5C\W8,['6M&.655;&=JHMT_$3)%+X@ ;AA1$0Y$./4?O^'\(
M!@4M<Z+2]C0#NJW^IUVZUE^*0O8"TPT?.P[HR"@*HG6CY-NY:G.DH &*82\E
M$.0P/'2U'JQ&<K]F1UQ1DK'5(96NU>=3JD&G+5Z 6(5-6%AI C$'4=%G3+P*
M"1BI\<AQP(X'I5#7E#U\T?,*'3*O2V,G).)F2952!BZ^U?RSLXG=23Q"*:M4
MW+YP8PB=4X"<?OP(K/:U#C='NP!\>/<2OWQ]1'_Y!T<.1'[1],"83 #Z^F!T
M\ ^SGG[/Z@]<# J=ZG;BD^ZL!VPC>R:D36X*H&UL33W[J:J\9.-<2$I#V*Q0
M!KDNL6<)(2]BA4G)'H%^:V)RD4!*/.!GQ@,!@1S^XF1-2"Z@B8A% +WTZX>/
MF4I_$1<6@.2^0#P(\X$BW <^@CS\1#GGT$1^P>?01#  4 ^TP^O/XA$W]GX8
M'S.(]@[14;NV31T@L7P61<MD5TE2"/(E534(8BA1$.>! 0P(T_<_Z=];=^])
MNQ,+LC4E.D1A=;6RZP4U'0<;#62$M-8AGDO#R\9.QS5"1063=MP!0OF)%DS&
M(<! ?0+?:[ZJ=?=4>T-,ZIIFJZ>RI+[IO9IZ7BW$,R>FGI^0U;(61U-S3ET@
MHYD9(TX;ZDBJIC&34 OAX^)> R]Z%5&KTSI?U@@JC 1-9ADM(:W=DBX1BA'L
M@>2-5C'TB\,@W(0AW;]ZN=990W)U5#"8PB.!EV'IZ8'ES4)$V.(DH"=8(2D-
M,LG,=*1KLHJ-7S%VD=%RU<)\@!T5DCB4P?: X%I=/=;=#]?DYE'2FJJ;K)*P
MJ)+3:=1B4HLDHJB)C)J.RIB)55"F.(^7Q$1]<#'S;'3J][&[4:R[-Q'9^]T1
M/5D/*5^#UC$46B2E:=PUD%A^US.0EY9BK/'-8?RU$!.50#(>/\W@55W_ +G4
M:/TP[*2=SLT%4HMYIW8$(SD+!)-(MFXF):L2;.*BT%W2J::[^0=J%212*(G4
M.( 4!' J+I7=:9L#JMH>;H]J@;?$-]7TF'<2E<E&<LP1EHNN1K63CE7#-15-
M)ZP=%,FLD80.F<.!#G RC @ //K@1V5 "_TI6XC?Z[_,]UN7X_9^\J7'X?KP
M)%< (<@(#\!]!_AP../3CXA\/7[L  <!Q@!$/4/T?#[_ .# BVTV7?[3W$NQ
M5ULO6RY5K4>RJ?KVEUS:+JT4]Y%&4UBC8#'EG,,SDE)I)E83RA"MBBG\P@@/
MF !@2DAZ@ _HP/S$!\@#U'@0^(\CQZ<C^K CJ]M@!+J[??ER _YXW8X3>7W_
M +5M^1'G_P!P,"1CQYYY$WK^GCC]7'&!B;W>T!J3L;U<W9K7<5,B[E5)+7EJ
M?&:/4" Z8R43#O)2+E(M\0I7+"1CW[5-5-5,P#R7@>0$0$+ >T#UXU)UP]OG
MK=7-25=&M,KIK:J;*MBOSE'3^P7.XP3"3G)R2=JF,=9=RN?Q('\E-(A2@' 8
M$F> P& P/R6$2IG$"B<0*80)QSYB!1$"<>O/F(<? ?C@:DW5B0KC#W"ZE,P2
M&GGM^N_8>_&OG46&TM9H2Z]?$FZ<U&$W.]OCAP=BZ=JQZ1#E46(#90KTP-R%
M$!X#;<*(\B'' !SQZ<?;_6]<#M@,#H8PE'X?AY#UX'[> _5\1P(?O:Z$";G]
MU\W \&]Q&^<@/Q#FAT?D0^\.1P)@P'D.?7U^\.!P.<!@,!@,#@W/ \!R/W#@
M85]L>F43VR>ZU<3V[]YZL:ZOL\7>(&)U-8JU!QKV[0+I1U7[/+$FZK8'#J2A
M!75(@!3I)^"I@,4P\" 9CQK51DR:LU7+E\HT:MFQWSP2&=O3((D2.[=G3(FD
M=TY.43J"4I2^1AX ,#[L!@8K=TZMN*^];=H:\T=5JM:[QL.KS5'(TN%E5JT-
M&QEEB7\8]FS2"+)\JNXC/GE.1N! ^=SQY!Q@6.DX/L?7?;ID=92NE6-JWH;2
M$EIHNO->W>(7C5%Y"I.Z1'SZ5HLWY0Q%FW16(\=)B'S )Y%3 Y@ ,"\_2(FR
M8SJ_IVI[5U;,:DNM!H]<H4O5YJ<@;&LLM489A"FFFDE6W3N/-'2YVIED"&,"
MQ4S !R@8!P,LP^ 8# 8' AR'&!XD[6:[:8\\39X*(L<6HHFJI&SL:REF"BB)
MA,B<[1\@NW,=$P\E$2\E'X8',!6J[58\D36(*'KL6FHHJG&P<:SBF!%5C>2R
MI6;%%!N514WJ8P%Y,/Q$<#VAY /3U' C#I-SISGW6]PQ;:VUAS+'ZD4",+%-
M[#$KR(R3/8DJN[C_ ,O2=F=@]:HF ZB7AYD((&$  0P).2&,81Y /'CT$.?7
M[_7GC _3 8# X$H"(#Z^F!S@ ]/3 \J:C2S,5)Q)W3UB228NH\SV,<'9R+4C
MQ Z!G#%ZG_.M72('\DU"^I#@ _9@8J]7.F.M>HQ;DAK>V;4FV-[EW5@FV&Q=
M@2UR9$GG[L[Z5F8YO)?@9R,NY4\G*A?57Q#G R_P++]@X39MKTOL:K:?&DEV
M)9JQ(U^OJ;$6F6]/1--(C&OUY=6 ;/)4"H1KI8Z0))CY+%(!N"B(X%KNCNKM
MTZ1ZUZSTYO5UK21MFK:W#4.*EM5KV1: EZM68=A%1$D_)9V,>];3KOY"AG"2
M9!0+^'P$?7 RYP& P&!16QJ]+6NBVJNP-PEM?S4M"OF<7=H)%HYEZN]41-\B
M98M7Z:S)TLS.'E\M4IB'#D!# U5>H]V!KVZT%KJW=K>SFX&\/L.4D)*P.M:Z
MPJ-2?6B1EK-&4N)N5GCBA?9B-M9F;E8C7YJZ228%\R%*(  ;;P?;Z<<"/'ZO
MOP.<!@?BNF19%1%3U(L44E  PE$2*!X' #%$#%,)1'@0$! <"'#VQ.M6IM6;
M9[X7:F1<\QL"W;+9E57</[7/RS5Q%)H0+THKL)!\NT7? N<0^I.0R_R^"^?B
M'&!,F7^2']7P],#M@,!@,!@,#@0 ?B #Q\.0YXP.<!@,!@.,!@,!@,!@,!@,
M"QD5UFZ^P>RG.Y(?3U!C=JO'#IT[V SKS%"TN7#THD=K+RY$P=*G<%,(&$QA
MYP+YX# 8# 8# 8# X$ 'X@ _=R #@<X' E*/Q !_6 8'/ !\ XP& P& P/R7
M$024$$P5$"'X2'C^=_"/\WZ@(?SGP_AP-1KJ9L*'4]Q4]'C= T" MB_8EU8Y
MBB1>K]GQ4[0X]TSMT5(VAW=)I^XK+MQ7B)-78*D(DU/]<)&Z8"'E@;=("'^R
MY'[_ $_M8'.!3MOL"53JMDM#A%1PWKL%*SB[=$0*JX2BF*[XZ"9C>A3K%0$H
M#Z\".!%_T_\ <.M&X(G<$UO>F5VE1M!I59W%!N]=?M/;UC:RM[B03CF$S#DC
MW$NYMT=^7A\TC))4B@''P+Z#@8N]+O<<ZMU*U=S#SDULM ;+VROMKBTFVC]O
M2"YH.5C((6#AX@PIKE6,6<$3$P(N 26 H@;PX' SO+[IO4#@ _/]K<_\WW>
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F5O'U>+1! HJEY4,<! 1X' EEP& P& P& P& P& P& P& P&!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tpg79.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg79.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ LP"Y P$1  (1 0,1 ?_$ +0   $$ 04!
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M ;C3\VO HDV^+=7XL^W45"$;<?9%42Y+D<V@#0!H T : - &@#0!H T : -
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M^-#)NL91H3"?$IR)+QN%>,;2\M4-]QF\1H[J_P"$2S'#%[A,(55*7)L'8Z@
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MP8Z!UZ5/\/J2.E>FOB]SW/N>+<VUYGK+;[..+0J5CM[*5)2EEI*!^$!"4A(
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MVHPE#<$BOF-=>U'MNVMX6[<,.-%CXD>M<EZM4L?%B@R9SY0$+6I9!H%%140
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MKF5]OD=SON!MW+UI8RK*[S,XAY!LL6W8A=U35A*,\M[(=O>.9 MDMQV'+M%
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MUJJI:R5*)))U6=THR=+:$_A%*"@IX >- /"E=0Z<?PV=J;]22HJ(!KH#0!H
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M\%AJ+$98C16&TLQXT9EN/&CLHZ(:98:"6VVT#H   !K/&+BW5U.G9U,!H T
M: - &@#0!H T : - &@#0!H T : - &@#0$)/S6?IW]%\9]__1#?^LQO;?U$
M_FK^;:^^3ZO\O_RY_ _3]E/5]UTW;_3\U= )#\9_\I[L4_0?^@_WGI_\;^A?
MUJ_J;O\ 47O_ $W^I'_(?U??7?\ I_DI3;Y-NK.'$X6$$^(_R_IX>/X?I_V?
G=JLZ;D_F_#^(_A_]W^M]N@-V@#0!H T : - &@#0!H T : - ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tpg80.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg80.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 4P#R P$1  (1 0,1 ?_$ .(   $#!0$!
M      0" P<!!08)"@@  0  !@,!                 0(#! 4&!P@)$  !
M @,& @8%! P'!Q4    ! @,1! 4 (3$2!@=!$U%A(A4("7&!,A06D5(7-Z&Q
MP4)R@B,STR0E&-&B0S0G1V?P8I3$15:FX?&2LM+B@Y.SPT14=(34928V9H89
M$0 ! @,$!0@"# X" 04    !  (1 P0A$@4&,4%1$P=A<8&1H2(4"+$R\-%"
M4B,S4Y-4%A<8P>'Q8H*2LD-C<R0T9!6BHT1RTH,V"?_:  P# 0 "$0,1 #\
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MU.=.57OG*'*S=I1YBTGJM'.*2/D7**R@JY!O8A.8QD8]"N+7B$I+P<6AF2=
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M1[IQ%P'N#0O,)^B-E3[+,[7&#S22E4LM;2QD,7@I"5%0"C "TF^R9WG&WD3
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M<'H"\(\7868I-@7'X9^DQ]V5BZ@ZEQ;T3VEER!!@,RHG*, F_P"2P?/#GEK
MV,=B:?.F>K&Q/*?6KM%=Y3''[EG&3'AL'!L>9-$N-I)3B,RTA6>$<8G_ %;.
M";M#47>VE+4A+9;6D%R84HHRWE ;C$*C@;[)F339<#8QV(7W,UF)L188G)R8
M4TTTXX4)S)0QVE*1]\L)!O2C#KL]+:]XC=;'F0=43*<7YCA$:M:SBA[:ZOG
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MB4GY2 +-S)T^[:W6A8J&%\';B (%0((ZSQ%DRYU07!MU VV'0AGZ=*SZ0B8
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*_P!WXMH:K%__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
